<SEC-DOCUMENT>0001701541-20-000032.txt : 20201110
<SEC-HEADER>0001701541-20-000032.hdr.sgml : 20201110
<ACCEPTANCE-DATETIME>20201110071733
ACCESSION NUMBER:		0001701541-20-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201110
DATE AS OF CHANGE:		20201110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Black Diamond Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701541
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39200
		FILM NUMBER:		201299614

	BUSINESS ADDRESS:	
		STREET 1:		139 MAIN STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-417-5868

	MAIL ADDRESS:	
		STREET 1:		139 MAIN STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aset Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170321
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bdtx-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f,d:4b3a7974cf244e41b6ee41205c9d1597--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20200930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bdtx-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV8yLTEtMS0xLTA_84f3b50d-08e8-4df7-9d18-f76389f93140">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV8zLTEtMS0xLTA_a6337762-e9cf-4f46-b554-49a1a6b62ae2">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV80LTEtMS0xLTA_dc0c2e12-4177-4c3b-a340-20f4525c8140">2020</ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV81LTEtMS0xLTA_1e014cea-9a5e-4c5d-9efa-e7f032a08596">0001701541</ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV82LTEtMS0xLTA_96d1da06-96b6-4b40-8aa3-2d8fdff09561">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="icfadec1e666b4412980e25adc961a5c1_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNzQ0_ab6c24e2-8031-41b8-b38c-ee6a9db619f1">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if98ef25099314086a82b8992bf03ca26_I20200731" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfODUz_2dbf53ff-d133-4eb9-bc06-8e02afa3e25d">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bdtx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i922f12bc23d04883ba291d428df17336_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib0b08c5e6ad442e2b8cbbc86f2eb975c_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i784f5ca30047442983dcf65beeb93bee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a81c80297be401c9d24d2691c346ef2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21232485659451988f7d0eeb28e97ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b21f1f0f004ece96252d4ab23c11ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58633b5da934b49b8b50a4c4d972181_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7217cdda7640e7ae1b034817463336_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9f23bd51f0443f93921337df5f73f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad83db20b2549b4b55cf677334915d0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124cb79a827443e2813493747649bbc9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3dc3b2779764af18308733d70c4f62c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074869ac335a42f5a7f196856849e937_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54576d77d11f4bc98d78e4d4bec9b2b7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5a3ed127c341afad5d8cdcd796de26_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3505c54f434cd3bf526b9ed482b76d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0cfe23a39d04b45981404b0cafafc1e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492b70942c8c464bb7b030c69dcd3bd4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad6d2688d764b80aded6ed0d00e934f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b6d873955e48209a6a418f35b7fcd3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e65f12447a43acb33a821020f9863e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b38575d385a49a3b26c1c87ac517877_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8555adf1567478096f826df6313d2d6_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2357a6951c74f2696398526a038572d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66353e29adac49abbe387f172d904c62_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c0efe4132343138143e5551a0f9837_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife57cf6f9104422ea61f7f4857babf83_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b3f11fec2b49a0af040ad809ce33d8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a8909a627e42b38848dbf90108399f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36492d9410124470bd9c2fd1f4212068_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b4a20b72814524a27c1406bacbb3ef_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565b73dece054891910461129ca95434_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i207c218d1bd04cf780603f54f79e1863_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2476fa9c3754d8db2e83fb8bfd68fb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454902132c0642799fb3ab69cde52ed3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied582ee35a564838b1ea295d1176b312_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bcac3d2e867465e96341db5f2240c0c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd34c9b0a76740898aeb60ac87424dd3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81af7b765594d60a9350f6f9fedee1d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af9b7ab721f42c2bcba0cfa7c44b81a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9841212013b649f2b1befa1e22e66032_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648406fe2dd641c9affb2f4fc7fe5632_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf864a6a53647a3bd5644df4cb8cf9c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d47962149b433f8c6ea96b2b55b0d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd76357b0ab74e2fbe8275e5146d131b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fdc57f4648e450bbfed378e5fcdd3ca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib846e7133d394e7ca2eedbf3f8d57752_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b55a68c910849e8aa744b2a08ef3db2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab225aa474040e399399aa03538e02b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9728ed0168479192af535918a672e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida314bb8f6ce422595b08aa880542938_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9f2958722341e9b1508549506b903c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906e723b16b14714b27adf1a70d6337b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d945985182a46d29e60d5b0adecc88e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064d8550b5f14a5fb7683f439ba8a906_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c8de7312dd4239bea9f029a69bf4e5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae70735391d2461e94a96257903690ce_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366d53aa80e440bf8d38fbbdd6303468_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3553eae519643458d423ae9f2a413fd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49bf379564304e5d922780e8f420a712_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea11d544c35426496604cfa84c025e0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb0fe716bc64955bf8206a8eae54346_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dbfcd5ae7574f13a33d7c0efca4e952_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ec4550d4d24650a1470219051050e7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a424b1ba33e48f98265d6336718bb87_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd312051b8448829439a465edcd48dd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e90e33c2994557a44434862b43372d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d3a820d1414559b9b3240726cf7b3d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f321b23d52a4820b45efe5d1c94f118_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11983767b7d4dad85f031fb6de73cad_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897a00dbb83a405db5ed163d9aa4a3ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i802ddccf8c754eb68a0e9690f6a2f763_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b02127f61304cda9eba1d4bcae89e8f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2780cbca4e684d8989e0b46f32e55c05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9324e281d648bcb6c60d03c062a4e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a5f286773d44689501ab785a4633f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320d8fd71f63489eb502ae104503decd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cd387e3c1146338b053867f9d31021_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id054160055b645cf8264647b7eacebbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e7964618df467b897aff2a1719ffed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f8a8b906244beea5072e056d82cd69_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2796d34b9fe24cc0a43d330adcfe578d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib092073e7a104302a2a7a6e648beb09a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e7e3ae08f09416bac8565a02b39cc9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i654506ca5bb54d9ba365a4051bde05bf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475fec1b34ae4ddcb54ac9b6e28c06b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2614ce618414bc8b1620a813fef8f2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90f6ec00451a46b0808c3397c1657e45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761759e947174f6ab451d27b4f158f63_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d92be850134e31a71d7e87905cc175_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1021664df9e453ca21007fd9e2c51dc_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85cf12dce2d34ce8b9fb13d1c6a7cd12_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacebca6e78b94922a7d8f7456173f057_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a892af05d144f6950d2aaa62a4c297_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9413c1bf291b46ef9b03d54c13c6aee1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5948b654d548159e4cc0ad67cf5a7f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e014cca6184bdca2ca8de90a9a1b01_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088778d5e9cd4a59b544a5b80f5d24ba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995c252df7d4498e9caa9cfcdce34d17_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc2768ca441464d88c7b71c6c9bf982_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3791e4cc2d4bff830aac311516f572_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3abe3620951f41a29d7581f1d9a8baa5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dcb5e81a97143b0afa64625ea7745ff_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia99613d35727440abf965ec6cdb33b89_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db89b0e05b542d5acd609d84363f0fe_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4613097211945d588002788a6d88b08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b4a0d7d7f74e5980d1e7f53a4c1d3e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55196c9d5d44810bf624b67d74cf207_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978c35a69f6244fb9664243bcb241cbd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>bdtx:contract</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="icfadec1e666b4412980e25adc961a5c1_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bdtx:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if98ef25099314086a82b8992bf03ca26_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bdtx:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516d9585532d496ea7567f7c7e177c98_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bdtx:ServiceAgreementMonthlyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xMjY_6a83003e-bca9-4add-966b-985fda80231a">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6ZTQzMGI4M2FjZGIwNGY0ZGE1ZGJlYmNiNzAzZWQ5ZTcvdGFibGVyYW5nZTplNDMwYjgzYWNkYjA0ZjRkYTVkYmViY2I3MDNlZDllN18wLTAtMS0xLTA_c3b62874-018d-4819-8fbc-82b5b4647684">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8yMDY_7d51b7af-2096-43a1-b80f-f83250b73295">September&#160;30, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Y2QyODJjZjhkNjAxNGEwZGIxYWEwMDMzNGJkNzdhMjIvdGFibGVyYW5nZTpjZDI4MmNmOGQ2MDE0YTBkYjFhYTAwMzM0YmQ3N2EyMl8wLTAtMS0xLTA_ee4805db-6bd3-4f19-b9e8-6f7252f6a459">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM _ TO _</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8yNzU_76521fb1-d9f2-4b1c-a8c1-64b08e949699">001-38501</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8zMjI_bea529ed-0d32-46d6-b640-153c9dd235ac">BLACK DIAMOND THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> ________________________________________________________________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18wLTAtMS0xLTA_315495e5-363a-4b20-9213-7edecbb6ed22">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18wLTEtMS0xLTA_37791982-f19f-46e3-8b6b-23f82eed2108">81-4254660</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(State or other jurisdiction</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF81_0e10a185-8ef1-42e7-9327-c46324255bb3">139 Main Street</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF85_446dbac5-c330-4b4f-8fec-1f7d29bfdacc">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF8xMw_1722d17f-8d6f-4225-83a2-71c17be242fd">Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTEtMS0xLTAvdGV4dHJlZ2lvbjoxNDdjYTIwYTVmNGE0MGMwOTg4OWNjZWE1ZWQzZDdhOF81_45914b5b-d621-4eed-a5f6-508890ac328a">02142</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Zip Code)</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4M2IwNmVkNWJmNWE0MGVlOTc4MGUzMzUwNjg3MDVlZV81_70372194-7057-4ce2-a4bd-cb89f879a395">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4M2IwNmVkNWJmNWE0MGVlOTc4MGUzMzUwNjg3MDVlZV84_ed7b8541-9f44-4058-bb78-33566619fc8b">252-0848</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Registrant&#8217;s telephone number, including area code)</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTAtMS0xLTA_ba10a116-5530-4d10-9dd8-4a385bb143a4">Common stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTEtMS0xLTA_4d960b73-21c7-4d61-8a9a-b9a099ddf0a3">BDTX</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTItMS0xLTA_ac2c6a63-1aca-442f-a011-057d746177ab">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF84Nzc_1a5c778e-06b8-403a-b8d7-3dd8904ff0fe">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#61608;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xMjA0_398648fe-266f-40da-9661-2ba4842a5944">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#61608;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF8yLTAtMS0xLTA_a8ed2881-9379-45d9-87a6-96eebcf4cbdf">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF8yLTMtMS0xLTA_95f56237-2d91-42ed-bab3-a9f83134ec8a">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF80LTMtMS0xLTA_c07d3329-6b1b-4d9e-9688-5d8de36ee09f">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xODIw_eda93470-e188-4ecb-a516-80eb7169d4c3">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xOTQ1_390f42f6-5d96-4b79-97b2-59b30977da15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;2, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="ib0b08c5e6ad442e2b8cbbc86f2eb975c_I20201102" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xOTg2_184f6a50-45c6-45a8-b95a-8a68d8a42464">35,995,660</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_546"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of the Material and Other Risks Associated with Our Business </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We are very early in our development efforts and are substantially dependent on our lead product candidate, BDTX-189. If we are unable to advance BDTX-189 or any of our other product candidates through clinical development, obtain regulatory approval and ultimately commercialize BDTX-189 or any of our other product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our open-label Phase 1/2 clinical trial for BDTX-189 with the genetic mutations that BDTX-189 is designed to target. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Our discovery and preclinical development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to marketable products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our MAP platform to build a pipeline of product candidates with commercial value.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Business or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We have incurred significant losses since inception, and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We have not generated any revenue from our product candidates and may never be profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We will need substantial additional funding. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We do not currently own or in-license any issued patents relating to our product candidates or technology, including BDTX-189. If we are unable to obtain and maintain patent and other intellectual property protection for BDTX-189, our MAP platform and our other product candidates and technology, or any other product candidates or technology we may develop, or if the scope of intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize BDTX-189 or any other product candidates or technology may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We plan to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The price of our stock is volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The material and other risks summarized above should be read together with the text of the full risk factors below and in the other information set forth in this Quarterly Report, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_7"></div><div style="margin-top:15pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;), contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and investigational new drug applications, or IND, and other regulatory submissions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to obtain and maintain regulatory approval for BDTX-189 or any of our other current or future product candidates that we may identify or develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our need to raise additional funding before we can expect to generate any revenues from product sales; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to identify future product candidates for treatment of additional disease indications; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to develop our current product candidates for the treatment of various cancers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the effects of competition with respect to BDTX-189 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the implementation of our strategic plans for our business, any product candidates we may develop, and our MAP platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to successfully develop companion diagnostics for use with our current or future product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to use the proceeds of our initial public offering in ways that increase the value of your investment; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP platform;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our financial performance and our ability to effectively manage our anticipated growth; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our estimates regarding the market opportunities for our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to remediate our existing material weaknesses and to maintain an effective system of internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other material risks and uncertainties, including those discussed in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item&#160;1A, &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">5</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_13">PART I</a> - FINANCIAL INFORMATION</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_13">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_13">Item 1. Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_13">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_16">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_19">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_22">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_25">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_28">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_70">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_97">Item 3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_97">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_100">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_100">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_103">PART II</a> - OTHER INFORMATION</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_103">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_106">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_106">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_109">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_109">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_112">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_112">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_115">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_115">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_118">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_118">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_121">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_121">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_124">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_124">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:66pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4b3a7974cf244e41b6ee41205c9d1597_127">104</a></span></div></td></tr></table></div><div style="margin-top:21pt"><span><br/></span></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the &#174;, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part I - FINANCIAL INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item I. Condensed Consolidated Financial Statements (Unaudited)</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNC0xLTEtMS0w_e56dc0d0-eb56-4661-aecc-699ef4bea9da">56,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNC0zLTEtMS0w_fb028563-c2d8-4108-9f2d-2ade7225dee5">154,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNS0xLTEtMS0w_4c04bc65-0038-4701-9c27-092d1d650007">276,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNS0zLTEtMS0w_875deb27-aceb-4c7f-8a58-c3888db77e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNi0xLTEtMS0w_8dcae985-4e58-4fb2-b2d9-a255a905e9f4">3,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNi0zLTEtMS0w_8c633f64-d48a-40a5-9e5b-b22f375269c6">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNy0xLTEtMS0w_22a5fc8e-1825-414e-a171-4c550a41cb16">336,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNy0zLTEtMS0w_429c5539-7e7a-4be9-bcf2-b68dd39fa295">155,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOC0xLTEtMS0w_8b5ca9d4-8d05-4864-80f6-ba3ed58e745f">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOC0zLTEtMS0w_c0b9390e-000b-470a-a723-8cc3d37c0413">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOS0xLTEtMS0w_49e3f606-f5b7-40c8-83cc-07d6945ec233">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOS0zLTEtMS0w_b78c1adb-3ea1-4cc8-844a-75c8741e5758">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTAtMS0xLTEtMA_ec4d08e8-0b25-4ac0-82e9-bc7cdc396fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTAtMy0xLTEtMA_acd2069b-ad31-4f4c-af2c-e19ec0227ff0">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTEtMS0xLTEtMA_01a423ca-2cfb-4901-8131-0ea116394399">8,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTMtMS0xLTEtMA_fe5ff0c1-31d9-447a-b310-6bbafb5ba0b5">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTMtMy0xLTEtMA_21bb7362-b19b-456b-b801-2cded5ce3d01">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTQtMS0xLTEtMA_3f85d60e-4df2-4b96-a7e9-a804916c95c2">346,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTQtMy0xLTEtMA_7fe07f19-0761-40d0-8729-fabca8946bab">158,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTctMS0xLTEtMA_2bb55bb4-e431-4c15-af7b-b5fcbfba79af">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTctMy0xLTEtMA_fde09411-e599-4d9e-bfe1-0b7fa8698cf9">1,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts due to related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTgtMS0xLTEtMA_fa1a4c15-4db8-4a68-911e-ab39d1291034">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTgtMy0xLTEtMA_0fae3891-94e4-4542-a776-d666e72d0873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTktMS0xLTEtMA_007a3f0b-f259-446a-90ed-3df8ad7cb922">8,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTktMy0xLTEtMA_9a5e22b5-2aaf-49af-8771-4839f91409b3">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjAtMS0xLTEtMA_fca478be-d84f-4fd9-ba76-e99c9c4d54b8">11,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjAtMy0xLTEtMA_79ab6ffa-51c9-4e78-ab5a-6f40319c46a6">4,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjEtMS0xLTEtMA_19f25aaa-8efb-48d4-bf2e-43782de33d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjEtMy0xLTEtMA_1b599247-bd3c-4ab4-9b2f-257f939d8de4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-current operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjItMS0xLTEtMA_1578405f-6299-4714-8ea1-d2efc8fe6a46">7,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjMtMS0xLTEtMA_747102d1-cbb2-401e-b6d6-08bb7b84b373">19,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjMtMy0xLTEtMA_3473c184-d672-442b-95aa-33c8dc1a54a8">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commitments and contingencies (Note&#160;11)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjQtMS0xLTEtMA_b6e76a0b-4ff6-4163-a93c-9a235671560f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjQtMy0xLTEtMA_016da72c-4731-4594-b214-2827868fa60f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Convertible preferred stock (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjUtMS0xLTEtMA_09face2a-1a14-4ab1-9abc-0b02b2b463e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjUtMy0xLTEtMA_bccbfecb-3478-48e9-9e29-08134c31bc24">200,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzE5_2866c6d1-5eef-4668-a3e7-491c6ed3a1ac"><ix:nonFraction unitRef="usdPerShare" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzE5_fb8c9da0-61ca-4556-8f7d-175043bb3695">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzMz_9884e0d2-f207-41d2-878e-5cd7d5843edb">500,000,000</ix:nonFraction> shares authorized at September&#160;30, 2020 and <ix:nonFraction unitRef="shares" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzY0_b4c165fb-5fd6-43f4-982b-195fafab0ef5">80,000,000</ix:nonFraction> shares authorized at December&#160;31, 2019; <ix:nonFraction unitRef="shares" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzky_ecd1adef-1e4f-4d57-ac8d-5b9701eb7070"><ix:nonFraction unitRef="shares" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzky_f40252ef-d3c2-4704-be80-bb67b9dd737a">35,963,447</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2020 and <ix:nonFraction unitRef="shares" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzEzNQ_0aa13540-58ba-46db-9890-2e89515db2de"><ix:nonFraction unitRef="shares" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzEzNQ_5ebbc3d7-fa46-45c8-b724-f9affda1cf4c">2,236,672</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMS0xLTEtMA_adc66d9c-b577-4c38-b181-a1f3dc2a6ce7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMy0xLTEtMA_6dd636d2-8167-4e46-bd96-6130e24a04f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjgtMS0xLTEtMA_64683e29-208b-4b40-b26a-7782242bfeca">422,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjgtMy0xLTEtMA_7d039435-bd96-426f-9f76-a16e854bf758">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjktMS0xLTEtMA_ab788d5c-65c6-4888-9606-ab60142308e2">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjktMy0xLTEtMA_e703aa6f-be05-4a58-b4ac-36aae97653cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzAtMS0xLTEtMA_a3cef8c3-4cbd-4679-93e3-35828d7c6ce2">95,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzAtMy0xLTEtMA_ba79a5df-8cad-4509-a6ca-5d3f34cb4ef9">50,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total stockholders' equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzEtMS0xLTEtMA_c1eb7677-243e-4b47-a0e9-5ef8f8522bf9">327,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzEtMy0xLTEtMA_196be1d9-baaa-4d7d-9948-08195e9b9cc1">47,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzItMS0xLTEtMA_0bdc6bfa-1379-484c-88e3-b340653ec397">346,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzItMy0xLTEtMA_86f00c17-31af-48b7-9dba-8f7169c8c88f">158,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">7</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development (inclusive of $<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNDM_035c2cb0-a895-45ca-a146-f077f69590e3">190</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNDc_5ed1943e-fc2a-4f4e-a646-cefc5004b961">3,480</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNTE_b3b8ee6f-a51e-4f7c-b25a-c72d3200a501">2,293</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNTg_fd04aaca-ccae-49c3-b2b3-6c6b24bcd93f">8,497</ix:nonFraction> respectively, with a related party)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0xLTEtMS0w_e873b9bf-cbea-406d-b084-76b95d7cfb40">12,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0zLTEtMS0w_7ea780cc-29e1-4108-bc54-45bbc314d8f6">5,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy01LTEtMS0w_93b5ca04-f789-41f4-adbe-b786ded17cc1">30,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy03LTEtMS0w_22c94ff2-0a52-482e-a25c-63688b5d0a23">14,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative (inclusive of $<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNDU_01afddf3-90af-4d34-abe4-92c341bedd05">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNDk_fb6e8fb6-d034-41cc-bb35-4ccd7431a979">176</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNTM_f43431d4-3908-4a73-93f6-29f86cd772e4">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNjA_39452ecf-17a3-4338-b349-f76a49e718af">357</ix:nonFraction> respectively, with a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0xLTEtMS0w_dcb77505-bcb0-42fe-b8f3-255894b49763">5,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0zLTEtMS0w_b317218c-c57b-4c51-840d-677794f01aa7">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC01LTEtMS0w_dbdc63e3-4bf8-4143-8a6d-a4e7fcd3fc5b">15,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC03LTEtMS0w_47a48eb4-5718-4a91-b664-d8e88f80229f">4,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS0xLTEtMS0w_e918eea9-e99e-4082-8162-0d86ce42a352">18,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS0zLTEtMS0w_ac85ea4a-14cb-49bd-9664-e4804d40b241">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS01LTEtMS0w_1cc782b7-b36e-4f27-afcb-9f4370668abe">46,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS03LTEtMS0w_621a4907-bda8-42af-af86-d1b45df7d971">18,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi0xLTEtMS0w_5adc7aab-e295-41cf-beb7-eae959b21761">18,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi0zLTEtMS0w_1c1dc70e-9f36-444b-a754-b7922e8be0a1">8,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi01LTEtMS0w_57d48783-1a0e-4d1d-9270-8558335cc461">46,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi03LTEtMS0w_571700dc-e513-4b3b-a84d-91dde423e885">18,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC0xLTEtMS0w_1a576122-bebe-472b-a0df-cda533864abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC0zLTEtMS0w_7d274b12-b4fb-4af1-8bed-49a8665f7af7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC01LTEtMS0w_6c3ce32a-3336-440e-98df-58bbadeb05ed">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC03LTEtMS0w_bf2ca670-1b34-47b5-958b-74275ea7bcb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS0xLTEtMS0w_d1d6aaa2-8440-4c18-a0da-aad3a7294b1e">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS0zLTEtMS0w_3d535d8d-1aad-4bf4-a0b4-c9ff8ed61370">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS01LTEtMS0w_506453c1-07ae-4d10-97d7-ea22e7f60af0">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS03LTEtMS0w_69c7f02f-9aa5-4e8d-99b4-3b6078f699b5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtMS0xLTEtMA_19415489-9e2c-4a64-a1c6-074ce5bd1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtMy0xLTEtMA_08e8cfc9-18eb-43fa-b5af-0323cef48b3b">1,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtNS0xLTEtMA_a64e42de-bb1b-4acd-9fe9-8f767c9b7091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtNy0xLTEtMA_790f57aa-cd1f-4349-94e0-b9083b9ed486">6,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtMS0xLTEtMA_304515c7-1dc4-424a-9800-14b00f670535">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtMy0xLTEtMA_833f4719-bdf0-470c-b170-0699a7c7ee65">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtNS0xLTEtMA_57f0a169-affd-4350-9b98-8bba4b63a9f1">1,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtNy0xLTEtMA_c40d8e9f-9ded-4cc6-8100-e8d839d9a3f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItMS0xLTEtMA_bcf6cfeb-151d-4ec5-bc16-7d56d20f993a">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItMy0xLTEtMA_0f1cc754-c8fa-40f1-8ab4-b407a3e417ff">1,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItNS0xLTEtMA_f338202e-5168-4e75-8e6d-f66828014d0e">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItNy0xLTEtMA_c5e46040-b970-4c37-b120-004e2d946c78">6,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtMS0xLTEtMA_2886df3f-ca93-4420-b4f6-379158f2b4c3">17,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtMy0xLTEtMA_6f958e42-c364-4cac-818b-ad0e53f0a647">9,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtNS0xLTEtMA_4131c25a-06d6-4efb-b5d2-fc7025717bd5">44,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtNy0xLTEtMA_62466c99-5cd0-4ba7-8078-cf77f15f2b0b">25,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtMS0xLTEtMA_7f7f676c-a6f9-43ce-a36d-2a3444e365a5">0.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtMy0xLTEtMA_6ca40f0b-2073-43a8-8292-b3e4bc704ec6">4.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtNS0xLTEtMA_42f6a046-a155-4adc-a9dd-b14481934808">1.42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtNy0xLTEtMA_d33a7341-eb73-4bcf-8df2-83974ec45d10">12.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtMS0xLTEtMA_4f6c69d6-5a03-40cf-b870-5b1dd81c57d0">35,927,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtMy0xLTEtMA_fcad5661-727f-4195-a725-d41a666d19f3">2,065,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtNS0xLTEtMA_80ace4ef-aa45-4b10-b1a8-d502382d91c1">31,860,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtNy0xLTEtMA_40f845c1-14f2-4bf3-bb11-f8bc5bc5d336">2,054,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtMS0xLTEtMA_1153429d-b9d9-4805-88bc-e4619285b846">17,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtMy0xLTEtMA_666468ea-cefa-446b-ad04-3cd89cf985b9">9,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtNS0xLTEtMA_3e82a2d7-35b3-4fa9-ac52-0d79b92a72e6">44,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtNy0xLTEtMA_033fbddd-b8c3-4d35-ab08-8f6050081067">25,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtMS0xLTEtMA_4908e453-9691-437c-9bf5-da8d10817c2f">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtMy0xLTEtMA_4f5370e8-8fe2-4814-a6f1-1c06d26603ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtNS0xLTEtMA_26efb099-4590-4316-8a4d-9b51d434cf00">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtNy0xLTEtMA_e7d4cebe-8389-495f-b430-7c3d4220f820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtMS0xLTEtMA_fa04628b-4d43-4806-9845-8f4683a6bf6e">18,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtMy0xLTEtMA_39f023c2-b426-4d8e-a84e-7ca363d92c09">9,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtNS0xLTEtMA_1104fe48-0223-4517-bd93-5def537094c3">43,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtNy0xLTEtMA_df780a97-a247-4c85-9b60-1cde37920129">25,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_22"></div><hr style="page-break-after:always"/><div style="min-height:13.5pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:73.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMy0xLTEtMS0w_b5bab496-f13c-4239-8439-188935b26d25">44,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMy0zLTEtMS0w_b63bcf5b-8370-4317-b849-ea6d416a1d61">25,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNS0xLTEtMS0w_677fd0dc-97da-41b4-aaed-ad9a160ce4b2">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNS0zLTEtMS0w_019ab72b-e699-4f79-a3f5-a183cdf22692">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNi0xLTEtMS0w_4aceec0d-7989-457d-b07a-3fe84b2ac55d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNi0zLTEtMS0w_fc0c35d6-f2b7-4894-8fa4-ef40f0be4ce6">6,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNy0xLTEtMS0w_6f94f07d-46aa-4df5-885c-5852c2c30136">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNy0zLTEtMS0w_9719559e-cc41-464f-9c8e-2a5e3f43cbc5">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accretion of discount on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfOS0xLTEtMS0w_7d45ec03-db8e-4f57-91a3-53b30b6a8c7d">990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfOS0zLTEtMS0w_77aebf43-d199-4010-85c0-97f693f927db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Noncash rent expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTAtMS0xLTEtMA_842ff830-4713-4e3f-a3ac-e6e386692364">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTAtMy0xLTEtMA_6e59befe-101b-4583-8fed-0d3ea19de336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in current assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTItMS0xLTEtMA_5820d570-ae08-472e-88b9-c82c157393f4">2,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTItMy0xLTEtMA_d07f5b51-01aa-42fb-91d8-58438fcb9b24">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTMtMS0xLTEtMA_04e23f09-8c56-4207-aeca-b7edbb38bbdf">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTMtMy0xLTEtMA_84a89833-0ee5-405c-b2f3-552f921c1b59">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTQtMS0xLTEtMA_0d1183e9-cdbb-47cf-89e3-5445b78a0abd">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTQtMy0xLTEtMA_c5a2ab14-3d74-45e6-b5ef-4bb962ec4b7c">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts due to related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTUtMS0xLTEtMA_3214c3db-d605-4957-94cb-b9ca50c8ca46">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTUtMy0xLTEtMA_7f71b356-d48e-44ff-9d08-740554a6429b">453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTYtMS0xLTEtMA_9f7d4d31-c524-419a-b8a3-a1563f4a2648">4,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTYtMy0xLTEtMA_88584c40-b4b2-4302-8e6a-7865608455c0">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-current operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" name="bdtx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTctMS0xLTEtMA_bd0a990f-2624-4143-b6e3-abe80b6a3cbe">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTgtMS0xLTEtMA_9d36c416-67ae-42bc-937c-5ad056df6498">36,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTgtMy0xLTEtMA_26fb6d81-e712-49cb-a87d-fdc6ecc5db15">17,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjEtMS0xLTEtMA_5fe16bfc-95ba-4193-b23b-98814c24f37a">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjEtMy0xLTEtMA_6f235ad3-6aef-4eda-876b-e01cb1db630f">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMS0xLTEtOTM5_77b3bd50-3327-4c22-9084-9ba1be5e533b">17,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMy0xLTEtOTM5_add776a0-44ca-4d82-b542-052da28146f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMS0xLTEtMA_c5a139e1-d1b1-4bbe-bc40-0b3cbd6a91eb">292,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMy0xLTEtMA_02c21f77-bb93-4d0b-a7ec-19c576456ae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjMtMS0xLTEtMA_70dd9b5c-08e0-47dd-88ed-54716c77a0c1">275,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjMtMy0xLTEtMA_48f281f1-46fa-4a00-b98b-1739c8ee3d1d">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from issuance of convertible preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjYtMS0xLTEtMA_8195a22b-f76a-4f69-914c-068525a714f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjYtMy0xLTEtMA_f4892df4-9941-452c-bc5c-b904249fc436">44,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMS0xLTEtNzk_89c60de5-0cc9-4fe2-94e0-94f30ccd35a0">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMy0xLTEtNzk_b05de4b3-742d-4f35-9386-edac6e791dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from initial public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU4MzljMWY2ZDVhMTQxMmI4NWE4MGFmNDZmZjFkNzBhXzY4_5b669f2f-a234-4086-873e-9d5bb2a69670">1,275</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMS0xLTEtMA_5700fc19-e6e6-42f2-b6c4-0e097021361d">213,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMy0xLTEtMA_40837560-4036-44b0-8405-ba184767187b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payment of deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjgtMS0xLTEtMA_37dc642c-c190-4809-8292-b7b21c9a817e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjgtMy0xLTEtMA_ed128d4c-4861-428d-b263-59baf834cb8c">408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjktMS0xLTEtMA_505f9d7e-ad52-43c5-8d60-0eb629a0a056">214,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjktMy0xLTEtMA_e9983867-721c-4be5-a6a3-522559cc38fa">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzAtMS0xLTEtMA_499c0726-d6dd-4252-a9b6-db7cf8454642">97,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzAtMy0xLTEtMA_a2791ff4-a9ac-40b5-b23e-ff0b1d44ed94">27,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzEtMS0xLTEtMA_473507e2-1955-4e7f-b9e4-9cfe4fef4ede">154,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzEtMy0xLTEtMA_7dd89c69-54b5-48cf-8ceb-4f3fc5216a0f">51,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzItMS0xLTEtMA_d79d8329-08d0-47f0-ad8f-dd491c6499e2">57,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzItMy0xLTEtMA_7789c2d8-5af6-4c45-8935-5f5e9c149b81">78,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzQtMS0xLTEtMA_9216f64f-78f1-40c6-8e85-84ef35a99b2b">56,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzQtMy0xLTEtMA_c6912d81-b097-4013-8edf-52bd2910b6d9">78,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzUtMS0xLTEtMA_748d393b-566c-4007-8830-47e1a5f1b3ff">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzUtMy0xLTEtMA_78a6fc7b-ddb0-48ac-9a8c-2ce570ef593d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzYtMS0xLTEtMA_b5de4655-c892-406f-b01a-d0092f32be14">57,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzYtMy0xLTEtMA_8b875c79-42a2-43c3-8eb5-146a0eb43112">78,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deferred offering and stock issuance costs included in accounts payable and accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="bdtx:DeferredOfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDAtMS0xLTEtMA_b6f566bc-7f72-4948-9f5f-ab07098ef6c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:DeferredOfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDAtMy0xLTEtMA_c60d9f49-1864-4876-8f98-fdb375ab274d">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Conversion of preferred stock into common stock upon closing of initial public offering</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDItMS0xLTEtMA_6491fcd9-0c26-4a16-acd2-eae58c5d2c97">200,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDItMy0xLTEtMA_9fd8dbe0-ea76-4b35-ac7c-a5542f0d6a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease obligation </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDUtMS0xLTEtMjI1_3a850a22-cb64-4a8b-bc38-f610a0a72445">8,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exercise of series B convertible preferred stock tranche right</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b21f1f0f004ece96252d4ab23c11ea_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDQtMS0xLTEtMA_3ebbfde3-851f-44fb-a360-4b4dfb00a7ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58633b5da934b49b8b50a4c4d972181_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDQtMy0xLTEtMA_bf514ae2-2db5-41e7-ad8c-f97e840fe7a8">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Line of credit for operating lease obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDctMS0xLTEtNDI4_d4ab5fd5-88ac-4155-a7fc-2aeb30e48b36">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:LineOfCreditAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDctMy0xLTEtNDI4_91b683da-547a-46e5-9208-aeb8fbd8c98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:11.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">9</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_25"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.158%"></td><td style="width:0.1%"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Additional</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">paid-in capital</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">stockholders&#8217;</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">equity (deficit)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xLTEtMS0w_0b13a0d2-bc2b-43d1-b6d7-afb589fd1fc9">33,668,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0zLTEtMS0w_e6706b8e-3d3d-4b48-a78c-c9a3807b1dcb">60,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7217cdda7640e7ae1b034817463336_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi02LTEtMS0w_45a03fa7-44d7-4fd9-a018-30340e472fa1">2,173,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7217cdda7640e7ae1b034817463336_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi04LTEtMS0w_5f5a67fd-94e4-485b-ac1f-072c7876e744">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9f23bd51f0443f93921337df5f73f3_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xMC0xLTEtMA_a0917fe2-cf09-42a4-bfb7-4ba26db8427b">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad83db20b2549b4b55cf677334915d0_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xMi0xLTEtMA_8994b80b-d632-461c-ad34-601e594b5068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i124cb79a827443e2813493747649bbc9_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xNC0xLTEtMA_4ca624d5-ddb9-42fe-a709-f4d7378b3143">15,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xNi0xLTEtMA_2e633528-6dab-4117-952c-1ce5f7a58178">15,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant of restricted common stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3dc3b2779764af18308733d70c4f62c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMy02LTEtMS0w_a70f2b3c-7ec1-422b-9498-4e495018af03">46,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMy0xNi0xLTEtMA_eb288c30-a1a8-4287-b944-4bdc81696b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54576d77d11f4bc98d78e4d4bec9b2b7_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNC0xMC0xLTEtMA_2a49dd9b-9567-43a0-aab2-3b313b17379d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNC0xNi0xLTEtMA_a63e56e3-2681-4895-9a64-5087782adf1b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd5a3ed127c341afad5d8cdcd796de26_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNS0xNC0xLTEtMA_8a67d60c-59e3-4744-ab99-6599bc483bd7">3,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNS0xNi0xLTEtMA_3305d845-c268-4386-b232-6ff6d6121c79">3,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xLTEtMS0w_76307930-e017-459d-b424-8345409549d4">33,668,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0zLTEtMS0w_ded41b1b-8a74-4c0b-8059-b0d0eae15f7b">60,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c3505c54f434cd3bf526b9ed482b76d_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi02LTEtMS0w_e5e5860c-5bba-44db-b32b-ac96ec46ddae">2,220,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3505c54f434cd3bf526b9ed482b76d_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi04LTEtMS0w_a61124cb-0700-4843-b6c6-ac41a991fa6e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cfe23a39d04b45981404b0cafafc1e_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xMC0xLTEtMA_9c002978-d91c-4816-a4cf-1f621a285bf5">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492b70942c8c464bb7b030c69dcd3bd4_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xMi0xLTEtMA_3043feb4-1a5f-4c4f-8df4-925bf3e1b6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ad6d2688d764b80aded6ed0d00e934f_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xNC0xLTEtMA_2bdd6ecd-4c79-45a9-9710-36d554df4682">19,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xNi0xLTEtMA_18a91458-2a64-4c48-9208-24bf0eaa61c8">19,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b6d873955e48209a6a418f35b7fcd3_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOC0xMC0xLTEtMA_6d7eec74-f25a-466f-af7d-038d122fbb0b">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOC0xNi0xLTEtMA_c561155e-40ea-4792-bf90-997b88dfd1c8">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59e65f12447a43acb33a821020f9863e_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOS0xNC0xLTEtMA_f663ab94-9c2a-4d02-8b93-506eca573107">12,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOS0xNi0xLTEtMA_67dd4ce5-4575-405c-b718-2ab6b461334f">12,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMS0xLTEtMA_93749ed8-1b6f-4156-bdb4-89c9ffdc6844">33,668,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMy0xLTEtMA_8cd1da7d-c167-45c8-9562-20de88db875a">60,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8555adf1567478096f826df6313d2d6_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtNi0xLTEtMA_c51bd6f1-e71e-486e-ae52-49d82a00aee5">2,220,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8555adf1567478096f826df6313d2d6_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtOC0xLTEtMA_ef4e5d9a-7ec8-4534-8ff3-011b69ee1296">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2357a6951c74f2696398526a038572d_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTAtMS0xLTA_3d8e654e-6e00-4eae-85c1-064f8b78ed04">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66353e29adac49abbe387f172d904c62_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTItMS0xLTA_1ed88791-1275-440e-a6ad-bebe5bcf7a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8c0efe4132343138143e5551a0f9837_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTQtMS0xLTA_86c4666a-eb92-451f-ae74-c37e2da69be7">31,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTYtMS0xLTA_20afb3ea-c27e-466a-8e4f-a7840e0f405a">31,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of series B convertible preferred stock, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="bdtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMS0xLTEtMzE3_a03b49d4-f2b0-4c17-a393-7b55179b6468">11,751,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMy0xLTEtMzE3_609fa4ba-9145-4b84-baea-9c87ec125777">55,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife57cf6f9104422ea61f7f4857babf83_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTAtMS0xLTQ4_f18eac4a-1e26-4845-a3d7-308136232cbb">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTYtMS0xLTQ0_f8ee3b63-3dab-4a74-ab38-9d90db865db0">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b3f11fec2b49a0af040ad809ce33d8_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTQtMS0xLTUy_ec1582bc-585b-4bb2-b7a2-e4117c4f6685">9,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTYtMS0xLTQ0_52d4c1e8-a05f-4e87-befd-3d3f94c19ce9">9,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMS0xLTEtNDQ_2fabc085-6644-4cfc-8c21-9421ca838830">45,419,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMy0xLTEtNDQ_d1ddd1bd-cb10-433d-afa3-726e2496495f">115,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37a8909a627e42b38848dbf90108399f_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtNi0xLTEtNDQ_1178761b-6e3b-49a0-af70-4d89408fa012">2,220,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a8909a627e42b38848dbf90108399f_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtOC0xLTEtNDQ_72aa1abf-690c-417c-ae28-fdb80dfa0a0c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36492d9410124470bd9c2fd1f4212068_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTAtMS0xLTQ0_9e865918-b923-49fc-bde6-26459d3ed482">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b4a20b72814524a27c1406bacbb3ef_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTItMS0xLTQ0_b4fe2bb1-8e56-46a5-b279-26534d945e96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i565b73dece054891910461129ca95434_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTQtMS0xLTQ0_00df11fd-5dc6-422e-915b-2da7dcf9aecc">41,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id21232485659451988f7d0eeb28e97ba_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTYtMS0xLTQ0_6c7c74d2-bd6c-4313-b136-bd0fad3573d8">39,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMS0xLTEtMA_de06fa1d-4109-4b0d-937e-aee117335185">64,839,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMy0xLTEtMA_faefaaea-d303-4f92-9b90-693ec71e83b6">200,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItNi0xLTEtMA_ea257c8f-0ce4-42b1-894e-9380e4d08e9d">2,236,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItOC0xLTEtMA_44ae2801-a383-4505-8df6-ef0e1b3d58ff">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i207c218d1bd04cf780603f54f79e1863_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTAtMS0xLTA_087451bc-bd79-408b-ae8d-57c291415bc0">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2476fa9c3754d8db2e83fb8bfd68fb2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTItMS0xLTA_1b009ccc-f65e-41bf-a4d5-87f1e4722b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i454902132c0642799fb3ab69cde52ed3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTQtMS0xLTA_42427f8f-4e87-403d-bac5-deba3c818014">50,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTYtMS0xLTA_c9caa250-a913-43c2-b887-8facfbddb21e">47,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock upon closing of the initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="bdtx:ReclassificationsOfTemporaryToPermanentEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMS0xLTEtMA_4158e109-041b-460e-9d1c-a776b20ea2de">64,839,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMy0xLTEtMA_007dafef-1084-4e0a-af38-716caae626c5">200,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtNi0xLTEtMA_66c77359-4b08-4074-9db9-35f6e4d9e9fa">21,499,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtOC0xLTEtMA_7c2ad85a-b4a5-4d20-a5be-aa8757096f8c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTAtMS0xLTA_242086ff-dbd1-4fed-9e73-f0100d561644">200,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTYtMS0xLTA_c3d0ee65-d3a5-47cc-b8c6-c446db6ade17">200,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtNi0xLTEtMA_092d1b7d-99ec-414a-bfbe-c4d13f67940b">12,174,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtOC0xLTEtMA_71d38bcf-01c3-40f9-a519-0b15ebb5e72d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTAtMS0xLTA_5e8a6f79-9ec0-4a6e-9cf8-bee6ceb42155">212,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTYtMS0xLTA_ed82175d-c0e5-4af2-850c-c4a1c621c6bc">212,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrants to additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTUtMTAtMS0xLTA_33f63800-8fba-442c-abf4-1d5080cf7bb2">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTUtMTYtMS0xLTA_0fe77df3-be4b-45d4-aaa0-e2aa168b2e36">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTYtMTAtMS0xLTA_a2900481-6bcb-4aff-8620-9d7b31e44720">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTYtMTYtMS0xLTA_0891c737-a8e9-4025-a5ae-1f314fa3ae4d">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied582ee35a564838b1ea295d1176b312_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTctMTQtMS0xLTA_24f552b3-0723-4208-8408-e012212f6892">12,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTctMTYtMS0xLTA_56f5704f-0d8b-425c-9877-49fe357d4071">12,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMS0xLTEtMA_b85f2a33-e71c-41c7-ad80-8a333bec65c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMy0xLTEtMA_e697e09d-d8a3-4b5e-90ee-46872d14b2ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bcac3d2e867465e96341db5f2240c0c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtNi0xLTEtMA_10eb8180-6c64-4eef-ae38-e51d96029042">35,910,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcac3d2e867465e96341db5f2240c0c_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtOC0xLTEtMA_3dbb362c-f04b-4136-81b8-3136fb3b9c4d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd34c9b0a76740898aeb60ac87424dd3_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTAtMS0xLTA_5f5a720e-b566-47e9-8b3c-c078e2decc22">418,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81af7b765594d60a9350f6f9fedee1d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTItMS0xLTA_43c8c14a-e353-4a03-ba38-b358e5370242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af9b7ab721f42c2bcba0cfa7c44b81a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTQtMS0xLTA_54c7d153-5a1e-49fe-b569-3aaa4e78bada">63,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTYtMS0xLTA_a58f8d84-83fc-4663-a5b9-74b01392e532">355,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9841212013b649f2b1befa1e22e66032_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTktMTAtMS0xLTA_f20ecc20-3616-4674-a47f-7f46d9a3cea6">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTktMTYtMS0xLTA_b4520cbb-ba3b-4911-9d50-3c46677051a5">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648406fe2dd641c9affb2f4fc7fe5632_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjAtMTItMS0xLTA_dd1d3907-2afb-4e29-b617-4d65e7a98c0f">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjAtMTYtMS0xLTA_dc0c202b-9610-4407-8a25-924fe12da189">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf864a6a53647a3bd5644df4cb8cf9c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjEtMTQtMS0xLTA_0a868d3c-b256-4d1e-b8bc-712efddc89a7">14,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjEtMTYtMS0xLTA_b4648180-3325-4776-9019-c92c45656c26">14,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMS0xLTEtNzA_8594192b-d34c-483c-aa09-626aa30b7dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMy0xLTEtNzA_509ea7e4-efa9-4e34-bac8-1dc2ee88c01a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd76357b0ab74e2fbe8275e5146d131b_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtNi0xLTEtNzA_11f20f0b-2378-485a-9db1-8f39060ad42b">35,910,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd76357b0ab74e2fbe8275e5146d131b_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtOC0xLTEtNzA_292c31d0-2119-4e00-b8b6-a496a45a3d70">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fdc57f4648e450bbfed378e5fcdd3ca_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTAtMS0xLTcw_0f143734-7f94-4edc-a2ef-032f1c883981">419,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib846e7133d394e7ca2eedbf3f8d57752_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTItMS0xLTcw_23830033-380d-4c7b-acb4-63658bee3f54">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b55a68c910849e8aa744b2a08ef3db2_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTQtMS0xLTcw_d67bd985-b4dd-4f54-ac87-88bbe5fac0bd">77,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTYtMS0xLTcw_8768c49b-5a26-48ef-bd7c-e11b5bf14f95">343,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctNi0xLTEtNzA_6fc7835b-7e14-4a40-aaad-f9ba813bb3dc">51,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab225aa474040e399399aa03538e02b_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctMTAtMS0xLTcw_0643c788-c218-425e-828c-83ddc5ad70db">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctMTYtMS0xLTcw_6ed224ea-64dd-410c-b315-4f3b1da810e1">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktNi0xLTEtMzc1_9126bfd6-1a5a-46bc-bf95-a61992b5e66d">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTYtMS0xLTM3NQ_24892caa-5404-49bb-9dd6-485fb233cf03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab225aa474040e399399aa03538e02b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjgtMTAtMS0xLTcw_1fb1d8a0-7083-4c1d-b8cc-6e482e2d896c">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjgtMTYtMS0xLTcw_489e9632-b1f7-4448-b161-4750d1fa7ceb">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9728ed0168479192af535918a672e8_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTItMS0xLTcw_29646563-d141-4b9d-bbbc-53359889b195">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTYtMS0xLTcw_4bb3e641-083f-458f-bb4f-2e9081bcb82a">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida314bb8f6ce422595b08aa880542938_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMzAtMTQtMS0xLTcw_005659b0-0424-41c8-81b9-8a26c11b7385">17,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMzAtMTYtMS0xLTcw_5c7c0ac4-467c-433a-9bc6-3f0d699cfcfe">17,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCE - September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMS0xLTEtMA_32ed8db9-69ef-46d5-bb66-ca3b23365d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMy0xLTEtMA_2583c2ff-0968-454d-990c-0f9ffa485347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItNi0xLTEtMA_c4bde409-63ca-48ed-baf7-28d7b7996bec">35,963,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItOC0xLTEtMA_792b5c62-b34f-49f1-b012-b11653da886a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9f2958722341e9b1508549506b903c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTAtMS0xLTA_b6f3ec3f-ddab-451f-b2c0-f400caf472d8">422,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906e723b16b14714b27adf1a70d6337b_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTItMS0xLTA_9e008451-8818-4b23-8fda-c25770c0af4d">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d945985182a46d29e60d5b0adecc88e_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTQtMS0xLTA_fc310d9d-4d46-4438-98cb-53f0f2820e28">95,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTYtMS0xLTA_571dc507-1dd3-4dcd-9ee2-659ec3ef2339">327,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">10</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfNjk4Ng_48508508-5949-4056-9a63-0580267332ce" continuedAt="ibeb1462e199b4306a7ab9c20ef1c550e" escape="true">NATURE OF BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ibeb1462e199b4306a7ab9c20ef1c550e" continuedAt="id0782085666d43de86b828efa11eab4b"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfNjk4Nw_8ad3e397-7277-4397-89b0-03677e77182f" continuedAt="i59b1f1bc71ac4991afe540550d9a9971" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of BDTX-189 and its earlier-stage pipeline programs as well as its mutation, allostery, and pharmacology computational and discovery platform. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers including a related party Ridgeline Therapeutics GmbH (&#8220;Ridgeline&#8221;). Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 21, 2020, the Company effected a 1-for-<ix:nonFraction unitRef="number" contextRef="i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMTgyNQ_afca3e09-f5e9-45d6-8dca-1d9043e33f19">3.01581</ix:nonFraction> reverse stock split of the Company&#8217;s common stock. All shares, stock options, warrants and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, the Company completed an initial public offering (the &#8220;IPO&#8221;) of <ix:nonFraction unitRef="shares" contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjI1OQ_f514283e-0bcf-4159-bee8-28f54c812123">12,174,263</ix:nonFraction> shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjM3NQ_de458481-c653-4e8d-aaf4-e8c8c93a2fd4">1,587,947</ix:nonFraction> additional shares of common stock, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjQ0NQ_a81952d7-a85a-4ffc-8917-2af18b0dac7f">231,311</ix:nonFraction> and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#8220;BDTX.&#8221; The Company received $<ix:nonFraction unitRef="usd" contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjU2Nw_7b89f620-f3a9-468c-b3e9-613e7bd9c952">212,101</ix:nonFraction> in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Upon closing of the IPO, all of the Company's outstanding shares of convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjgyOA_a6a273c3-5fac-4715-b753-27bdd1d55186">21,499,770</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of convertible preferred stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of November&#160;10, 2020, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital requirements into 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="id0782085666d43de86b828efa11eab4b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing global outbreak of the novel coronavirus disease (&#8220;COVID-19&#8221;), which began in December 2019, was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries worldwide. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &#8220;essential,&#8221; work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of the Company&#8217;s business, including how it has and will continue to impact the Company&#8217;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#8217;s third party service providers have also experienced shutdowns or other business disruptions. The Company does not yet know the full extent of potential delays or impacts on the Company&#8217;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company&#8217;s business, results of operations or financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain the pandemic or treat its impact, among others. In addition, a recurrence or &#8220;additional waves&#8221; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. While states and jurisdictions have rolled back &#8220;stay at home&#8221; and quarantine orders and reopened in phases, it is difficult to predict what the lasting impact of the pandemic will be, and any prolonged material disruption to the Company&#8217;s employees or third party service providers could negatively impact the Company&#8217;s ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Company&#8217;s business, results of operations and financial condition.</span></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODA_a6f03cab-864e-4d77-bf34-b3462746e466" continuedAt="icb628a8497e94a31a03c269e508c9255" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i59b1f1bc71ac4991afe540550d9a9971" continuedAt="if398cf697b134afdbc29194781a9d0b7"><ix:continuation id="icb628a8497e94a31a03c269e508c9255" continuedAt="i589bb5efd81c4307bb709586d3f2728a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzA_8a4494a3-7aba-4eed-81b3-9cf6077d5e1c" continuedAt="ib7602549b4c64dfe8b5f8a86d6bba55e" escape="true">Principles of consolidation </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="ib7602549b4c64dfe8b5f8a86d6bba55e">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</ix:continuation> </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="i589bb5efd81c4307bb709586d3f2728a" continuedAt="id04d4443dbc14b069410fb689e7b2b71"><ix:continuation id="if398cf697b134afdbc29194781a9d0b7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March 24, 2020. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODE_147545bc-31bb-447d-be6c-bf60bb189f47" continuedAt="i7e1318b372e14b7da663bf5cdb0a2032" escape="true">Use of estimates </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i7e1318b372e14b7da663bf5cdb0a2032">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzI_be8e0838-5010-4bf2-8e2f-5c91211470ae" continuedAt="i7e5d3067f44146a3ba810d81da61c875" escape="true">Deferred offering costs</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i7e5d3067f44146a3ba810d81da61c875">As of December&#160;31, 2019, the Company recorded deferred offering costs of $<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMzM2MA_392302db-dda5-4c62-9844-d79b1141494e">2,303</ix:nonFraction>. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. After consummation of the IPO, which closed on February 3, 2020, these costs were recorded in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</ix:continuation> </span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="id04d4443dbc14b069410fb689e7b2b71" continuedAt="i8aa6e2ab94394025b65c86c20fcb1d36"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODI_61bc4bf3-767a-4294-85f3-2d1cc0c0e139" continuedAt="i753a2ee106c44c4191b99b8833bac0ef" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments consist of marketable securities with original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders&#8217; equity. Amortization and accretion of premiums and discounts are recorded in other income (expense). Realized gains or losses on debt securities are included in interest income or interest expense, respectively.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i753a2ee106c44c4191b99b8833bac0ef">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company&#8217;s statement of operations and comprehensive income (loss).</ix:continuation> </span></div><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTA5OTUxMTY0OTIwMQ_b78ce543-9405-44b4-99f1-46c099d5ee54" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. Restricted cash includes amounts held as security deposits in the form of letters of credit for the Company&#8217;s leased facilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzQ_76f69c4b-ed01-4f7f-9cf5-e9e0bcdb4dea" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzU_b94ec207-cad9-4686-9b7f-f2d1e9e5e726" continuedAt="if99a17fd729845bf83e82f59fec8e864" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-02&#8221; or &#8220;ASC 842&#8221;), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases (&#8220;ASC 840&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company has elected not to recognize leases with an original term of one year or less on the condensed consolidated balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="i8aa6e2ab94394025b65c86c20fcb1d36"><ix:continuation id="if99a17fd729845bf83e82f59fec8e864"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></div></ix:continuation><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzM_7ed68c97-6c66-477d-94bb-1be76db7a54b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on our financial condition and results of operations.</span></div></ix:nonNumeric></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxMQ_cb4880ce-e9f1-432a-8f3b-953a5ec54bd5" continuedAt="i6d2c579cd417485282730e6a703f3525" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i6d2c579cd417485282730e6a703f3525" continuedAt="iae74b2d5eac14970aa00af23bd43dcf2"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxMg_bf1d2f93-1c04-4e57-ab78-c368da3bc712" continuedAt="i2434226b290c4c4e96181c185533cdb6" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at September 30, 2020 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064d8550b5f14a5fb7683f439ba8a906_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC0xLTEtMS0w_524da71e-7354-4e18-b552-baa068fc58d1">52,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c8de7312dd4239bea9f029a69bf4e5_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC0zLTEtMS0w_6d547194-3940-452b-a6cd-5460c046deb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae70735391d2461e94a96257903690ce_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC01LTEtMS0w_5b96bf16-c0e6-4096-9d16-e5f3585bd531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366d53aa80e440bf8d38fbbdd6303468_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC03LTEtMS0w_b6ed09c5-3448-4fa3-9b77-46245a5b0c71">52,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3553eae519643458d423ae9f2a413fd_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi0xLTEtMS0w_bbff8ea2-abb8-4259-9bf0-aa4441235f6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bf379564304e5d922780e8f420a712_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi0zLTEtMS0w_536c30da-56bf-4976-8687-a459d46d7120">69,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea11d544c35426496604cfa84c025e0_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi01LTEtMS0w_529f83da-c86c-470f-9504-ef9eec793114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb0fe716bc64955bf8206a8eae54346_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi03LTEtMS0w_5ca87db5-40d4-4960-8efd-8a473fe58676">69,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbfcd5ae7574f13a33d7c0efca4e952_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy0xLTEtMS0w_df34cd64-f82d-4f11-8c1b-f123748bc62b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ec4550d4d24650a1470219051050e7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy0zLTEtMS0w_9f3684bf-70db-4a9d-8958-82ac75f3f1e1">186,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a424b1ba33e48f98265d6336718bb87_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy01LTEtMS0w_1b06177b-70ce-4059-b6e4-bd687ecd325a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd312051b8448829439a465edcd48dd_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy03LTEtMS0w_7bef29ef-366f-446b-92ed-7191776ec712">186,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e90e33c2994557a44434862b43372d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC0xLTEtMS0w_28b252db-6dc9-4291-9797-b3721e817527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d3a820d1414559b9b3240726cf7b3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC0zLTEtMS0w_9573e2ce-a97d-4bc4-a89a-ae7f9a13bed5">20,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f321b23d52a4820b45efe5d1c94f118_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC01LTEtMS0w_61edfbc5-eeb1-46a3-a226-b1a2a26ce762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11983767b7d4dad85f031fb6de73cad_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC03LTEtMS0w_7cafec1f-0e76-46d2-8a00-0375452469b5">20,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897a00dbb83a405db5ed163d9aa4a3ef_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS0xLTEtMS0w_6ce1126f-da54-4e3c-bc48-215dff06d2bb">52,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i802ddccf8c754eb68a0e9690f6a2f763_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS0zLTEtMS0w_4f5c1f66-02b0-4199-ba4c-e0d7c9ab1705">276,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b02127f61304cda9eba1d4bcae89e8f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS01LTEtMS0w_29d20f28-21ee-4c5b-a398-f11cf8dbced0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS03LTEtMS0w_9cf3c884-04ab-4029-a1fe-a37c748e79dc">328,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="iae74b2d5eac14970aa00af23bd43dcf2"><div style="margin-top:12pt"><ix:continuation id="i2434226b290c4c4e96181c185533cdb6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at December 31, 2019 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2780cbca4e684d8989e0b46f32e55c05_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy0xLTEtMS0w_b61ffe4b-c270-49a0-8d92-2adb71105810">24,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9324e281d648bcb6c60d03c062a4e3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy0zLTEtMS0w_071da8c7-a504-474f-abb2-ba35743ccf9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a5f286773d44689501ab785a4633f5_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy01LTEtMS0w_c90e0594-426d-4974-b6e0-0130f68aa283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320d8fd71f63489eb502ae104503decd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy03LTEtMS0w_e417241a-a22e-4fbd-ad19-ec10490ff2a4">24,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cd387e3c1146338b053867f9d31021_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC0xLTEtMS0w_1c32132d-8b6f-4eb6-9e98-2bec7070f3d8">24,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC0zLTEtMS0w_c55fe759-1967-4198-9dff-380a59427074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id054160055b645cf8264647b7eacebbc_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC01LTEtMS0w_d70302ae-d632-49d9-a969-7d78b7424721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e7964618df467b897aff2a1719ffed_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC03LTEtMS0w_65bc3e4f-f20d-44a3-9849-1c8171ca82f3">24,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cd387e3c1146338b053867f9d31021_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi0xLTEtMS0w_fc97c51b-9b45-44a6-8b4c-7ff08e38bce7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi0zLTEtMS0w_be4b3ea6-e929-41aa-8390-fb331803b3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id054160055b645cf8264647b7eacebbc_I20191231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi01LTEtMS0w_318314f6-96db-433c-8b31-ec1478ae687c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e7964618df467b897aff2a1719ffed_I20191231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi03LTEtMS0w_f8361202-821c-4051-bab8-ea6cf3f0aebf">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cd387e3c1146338b053867f9d31021_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy0xLTEtMS0w_b999ce12-92a5-431c-90be-9a9e9774307b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy0zLTEtMS0w_9f290f69-d1ed-4227-a420-4b3a79ca58d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id054160055b645cf8264647b7eacebbc_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy01LTEtMS0w_72fa931a-92a6-45a7-82df-aac25e1f6e0f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e7964618df467b897aff2a1719ffed_I20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy03LTEtMS0w_9380c81d-c037-4e70-b6bd-4fa8b3702222">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Valuation of derivative liabilities </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of the derivative liabilities related to the warrants to purchase series A convertible preferred stock is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon completion of the IPO in February 2020, the warrants to purchase series A convertible preferred stock converted to warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ie6f8a8b906244beea5072e056d82cd69_I20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTYzNA_acd5499e-bb15-4fe5-b530-f8c8c40b0602">10,757</ix:nonFraction> shares of common stock and the fair value of the derivative liability was reclassified to additional paid-in capital. As a result, we will no longer remeasure the fair value of the warrant liability at each reporting date. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxNA_b6163775-d254-4bda-a82b-d67e8917142c" continuedAt="i00d6e63164554dd3aeece823e23c28dc" escape="true">Derivative liabilities consisted of the following:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i00d6e63164554dd3aeece823e23c28dc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfMS0xLTEtMS0w_0d1d08df-7e0d-49d1-bf69-af1a681a7fac">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reclassification to additional paid-in capital in connection with IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfMy0xLTEtMS0w_29096ec7-cca2-4037-bb44-3ab212da2d9c">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfNC0xLTEtMS0w_95b4d1e0-ea9a-4f47-a022-4b7f114792bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjI1_423b3c42-c5d9-45df-9012-63d45064e1ba" continuedAt="i267ea4bce3044ffbaba22d0cae30d20d" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i267ea4bce3044ffbaba22d0cae30d20d"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjI3_79fa7622-5647-4f91-9566-d5828e29c3c4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, investments were comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS0xLTEtMS0w_92c8ffe6-4a9c-44de-9be9-d1d3f59b0c88">69,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS0zLTEtMS0w_32df8cd1-477e-4065-8755-e28b2b25ad6e">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS01LTEtMS0w_e61d5468-9ffa-41f5-88a9-61524705a234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS03LTEtMS0w_f94ffb1d-491e-4b5b-bedd-f03bf1358dea">69,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi0xLTEtMS0w_832b582d-58f1-486a-93b1-843c749a1343">186,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi0zLTEtMS0w_96e9b11d-ee10-4011-a664-9b4b4c744d76">765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi01LTEtMS0w_2d6b958c-6098-46ac-a180-45303d923511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi03LTEtMS0w_3b7e66ca-bda9-4519-8615-1467204ac692">186,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy0xLTEtMS0w_2358e26d-3138-4dcd-a2d8-7c155990d84d">20,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy0zLTEtMS0w_44a3c05e-ff83-467c-bef6-50e04e2856ef">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy01LTEtMS0w_8b330697-b6e3-4456-a62d-542da55af490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy03LTEtMS0w_1ba9222a-6cbb-427c-a679-03b10ef2b02f">20,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC0xLTEtMS0w_641a9d1b-1527-4e73-aebc-08dede16f255">276,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC0zLTEtMS0w_2546a0f1-213f-4aba-932c-e8cfd329a726">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC01LTEtMS0w_1aecd954-0b56-4b30-8612-1263ab4cb1be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC03LTEtMS0w_9e087bab-f234-4963-bcf9-50381a23b538">276,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company did <ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjAx_4609f413-6632-45fc-975b-901047b0c65d">no</ix:nonFraction>t hold any investments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">16</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTU5_3fc7686d-7152-4b6c-b89c-33c4e161cb05" continuedAt="i2258cc15ada64384b5ece0ca71e4b6c1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i2258cc15ada64384b5ece0ca71e4b6c1"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTYw_87f5e057-efaa-42f5-a545-3eb029901445" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equipment, net consisted of the following:</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib092073e7a104302a2a7a6e648beb09a_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMS0xLTEtMS0w_954db7ef-79c8-45c0-9db8-92072bc47a98">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7e3ae08f09416bac8565a02b39cc9d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMS0zLTEtMS0w_f36e74d4-86c4-4dae-9c17-f0c9808af18d">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654506ca5bb54d9ba365a4051bde05bf_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMy0xLTEtMS0w_ea4f3608-c043-4b13-b134-0efe978ae874">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475fec1b34ae4ddcb54ac9b6e28c06b2_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMy0zLTEtMS0w_34020679-ab16-4649-be5f-5358ae1afa28">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2614ce618414bc8b1620a813fef8f2d_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0xLTEtMS0yMTA_c8326cb4-319a-4507-bfb5-7a5ae2722749">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90f6ec00451a46b0808c3397c1657e45_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0zLTEtMS0yMTQ_1c120dc0-96ad-41aa-a878-9e01aee72c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0xLTEtMS0w_9f9ceebc-225c-4438-9ed4-e55422086d83">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0zLTEtMS0w_695f080b-ed07-413c-b9fc-05095cb3781c">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNS0xLTEtMS0w_3ea834e0-5558-438e-8ba2-641ed268f3bc">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNS0zLTEtMS0w_99d80051-5be3-4e67-b5a6-869a6e03fd88">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNi0xLTEtMS0w_50b7b555-9f98-4d8c-baf2-fd01f5b7d538">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNi0zLTEtMS0w_324f5509-8f2d-4815-8a7a-44bae0039127">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTM2_69c55c78-38f0-4cdb-b909-38308218b910">37</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTQz_6ebbba3a-9f82-4d43-aa82-a31724f4ebf1">38</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RleHRyZWdpb246ZDVlYzFlNTk2YmFjNDdhNjkyZDJjNjY5ZGRiMTFlY2ZfMTMy_aea2c839-b62a-4c1c-b5e3-5964621b4451" continuedAt="i681d1688a6f641fda3eea48f86188213" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </ix:nonNumeric></span></div><ix:continuation id="i681d1688a6f641fda3eea48f86188213"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RleHRyZWdpb246ZDVlYzFlNTk2YmFjNDdhNjkyZDJjNjY5ZGRiMTFlY2ZfMTMz_df176717-fa0e-4dc9-8170-43cd62548be9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:AccruedContractResearchServiceFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMS0xLTEtMS0w_899d94ec-6e17-43a5-b02a-ef017b4c6679">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="bdtx:AccruedContractResearchServiceFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMS0zLTEtMS0w_784a39a1-31ed-4e3c-832c-c484d9cd52b2">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMi0xLTEtMS0w_c3460246-a354-44ed-8a56-1fa8049f766c">2,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMi0zLTEtMS0w_e49dde01-8b68-447f-86fb-ca59d21ffc6d">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMy0xLTEtMS0w_941e33e2-e24c-41cd-8758-b79b7bb0526d">3,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMy0zLTEtMS0w_8e5bc619-47a1-4cb8-b531-b72bb239365d">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="bdtx:AccruedLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNC0xLTEtMS0w_696140c6-ec03-4328-977f-84fd265a3fa9">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="bdtx:AccruedLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNC0zLTEtMS0w_3564029c-7c77-4a38-a861-a839a9bccda4">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNS0xLTEtMS0w_59b20c37-7ca7-4a9c-9c10-c4b865047398">937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNi0xLTEtMS0w_9574b6c8-39f5-4e55-bf1f-9b196443682c">8,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNi0zLTEtMS0w_33164e66-e7f7-4645-8f3d-25c54a330a59">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfODIy_88467691-b252-4e7e-ac18-213237c5b2f3" continuedAt="if02e37a263224706b04fb856ef3c15bb" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="if02e37a263224706b04fb856ef3c15bb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon closing of the IPO on February 3, 2020, all of the preferred stock converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i761759e947174f6ab451d27b4f158f63_D20200203-20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfMzU5_6cbc0c8d-c952-4100-89b7-c520d78b4aae">21,499,770</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, in connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to <ix:nonFraction unitRef="shares" contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203" decimals="INF" format="ixt:numdotdecimal" name="bdtx:SharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNjE3_ba1a30f1-504e-4abf-a97b-e71ebe45870a">510,000,000</ix:nonFraction> shares, of which (i) <ix:nonFraction unitRef="shares" contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNjQx_96fbc022-be37-4fdf-951d-3f15cc1c318b">500,000,000</ix:nonFraction> shares shall be a class designated as common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNzA2_51625d01-7b10-44c5-9bb6-80a8d9bc23ff">0.0001</ix:nonFraction> per share, and (ii) <ix:nonFraction unitRef="shares" contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNzI5_ac6a6844-2ef9-48e3-8019-ab9f2aef83ad">10,000,000</ix:nonFraction> shares shall be a class designated as undesignated preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfODEw_4ce6000b-ea5f-425d-a99d-b3f6d583aa16">0.0001</ix:nonFraction> per share.</span></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTA5OTUxMTYzMjQ1OQ_4a5c8b37-aedc-4f50-876c-fae7ff4bbe58" continuedAt="i55874400be3640e3a6bae6ad1568e4b3" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i55874400be3640e3a6bae6ad1568e4b3" continuedAt="i4a23e9102ffb47179b2cb846a6fd04e6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2017 Plan&#8221;), provided for the Company to grant qualified incentive options, nonqualified options, stock grants and other stock-based awards to employees and non-employees to purchase the Company&#8217;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), no further issuances were made under the 2017 Plan. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="i4a23e9102ffb47179b2cb846a6fd04e6" continuedAt="i8ad5991fbf054e5ea8d699228522731f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by our board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2020 Plan is <ix:nonFraction unitRef="shares" contextRef="i12d92be850134e31a71d7e87905cc175_I20200114" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTIyMA_f913fe8c-7a7e-4d9b-8e17-0472b8ec13bc">6,665,891</ix:nonFraction>, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by <ix:nonFraction unitRef="number" contextRef="i12d92be850134e31a71d7e87905cc175_I20200114" decimals="INF" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTMxNA_5c83eabd-1d51-4d91-a457-a5df9b25d0ff">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation, nomination, and corporate governance committee of the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and our stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. A total of <ix:nonFraction unitRef="shares" contextRef="ia1021664df9e453ca21007fd9e2c51dc_I20200114" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTk1Mg_bcb8e5bc-23fe-4a39-b61c-32d07fb13e28">326,364</ix:nonFraction> shares of common stock were initially reserved for issuance under this plan, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by <ix:nonFraction unitRef="number" contextRef="ia1021664df9e453ca21007fd9e2c51dc_I20200114" decimals="INF" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjEyMg_cfa3e68e-befc-4a22-a793-04d9e556b0a0">1</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation, nomination and corporate governance committee of the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzE3Mw_80f8fa07-afd3-4d5d-a231-5dc94327dfc8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cf12dce2d34ce8b9fb13d1c6a7cd12_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi0xLTEtMS0w_6ebb0721-fad8-407b-a486-d7b4eadd44f4">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacebca6e78b94922a7d8f7456173f057_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi0zLTEtMS0w_012d38b3-95a3-44ab-97ad-9f3d85e3031c">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a892af05d144f6950d2aaa62a4c297_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi01LTEtMS0w_acf9af4f-4020-475f-b425-9fa6a3433b6a">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9413c1bf291b46ef9b03d54c13c6aee1_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi03LTEtMS0w_c7f642a0-442e-4518-a938-77dfac512f5d">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab5948b654d548159e4cc0ad67cf5a7f_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy0xLTEtMS0w_301cd060-4f3b-416b-ba33-eb74b3bb8e4f">955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e014cca6184bdca2ca8de90a9a1b01_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy0zLTEtMS0w_484de958-50e2-47b6-b081-060f77107a4f">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088778d5e9cd4a59b544a5b80f5d24ba_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy01LTEtMS0w_b754554e-2386-4a07-a9f9-58572d62ea82">3,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995c252df7d4498e9caa9cfcdce34d17_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy03LTEtMS0w_675d1568-1d53-4fb8-b647-fcfb8e5d37b1">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC0xLTEtMS0w_16bc5469-7278-4917-a702-6617ec22b416">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC0zLTEtMS0w_0cec7634-b19d-4423-b51b-c0376c3c770e">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC01LTEtMS0w_9ae0b935-69fb-42e5-8ffc-d5dd0904f5de">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC03LTEtMS0w_4ab58354-9b38-4581-809e-22fd7263d555">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted options to purchase <ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjY4Ng_bc89d2ea-358b-499a-ba71-48e3d87a2674">1,351,593</ix:nonFraction> shares of common stock. The total fair value of options vested during the nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjc4Ng_d0ed14a3-067d-4259-b24b-cbe6d287c501">2,043</ix:nonFraction>. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjgxMQ_e83add27-7708-4d6b-810f-a51fc84dcb8a">3,639,228</ix:nonFraction> options outstanding, <ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjgzNQ_5be2a62f-54bc-44fd-8e7e-18d823e652f2">39,763</ix:nonFraction> options were forfeited and <ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NDg0Ng_f28d6df4-7285-464a-bad5-b343ea8dae32">51,076</ix:nonFraction> options were exercised during the period. The weighted-average grant-date fair value per share of options granted during the nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjk4Ng_38cc90e8-1603-4d2f-9ab1-2775bebce751">14.47</ix:nonFraction>. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested stock-options was $<ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzA5OA_b886ec0a-9720-4a56-8007-023b48a6386d">26,283</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i6fc2768ca441464d88c7b71c6c9bf982_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzE3MQ_88a054b0-f7d1-4081-bc7a-e927e5c7cd27">3.0</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="i8ad5991fbf054e5ea8d699228522731f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company&#8217;s stock on the date of the grant. Under terms of the restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. During the nine months ended September&#160;30, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NjIyNw_feb2e514-0133-4395-a6dd-1ce2fe0d0bdc">61,000</ix:nonFraction> restricted stock units during the period. The total fair value of restricted stock units vested during the nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzc4Mw_627f0ba1-4b4e-42cc-87c8-be4a02146b7a">50</ix:nonFraction>. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i4d3791e4cc2d4bff830aac311516f572_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzk2OA_58559df2-be5f-42fd-82b2-82948af999c2">59,334</ix:nonFraction> restricted stock units outstanding and <ix:nonFraction unitRef="shares" contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzk3Mg_d6ebcf8c-43a5-447b-8ee2-82c9b08a05f3">1,666</ix:nonFraction> units were vested during the period. The weighted-average grant-date fair value per share of restricted stock units granted during the nine months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NjM0NA_38939a91-46a6-4723-8720-9639d60eef4d">29.65</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i4d3791e4cc2d4bff830aac311516f572_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1NzY1NA_def57d8c-1aed-4315-9988-6c5c278ac9f3">1,631</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1NzY1OA_7a90b12f-e940-48e7-91ac-d6dca84414d4">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMwOA_c6246e69-7375-4366-997c-e80dd2ef02da" continuedAt="i92627ea2cb124a80a77175233b575d0d" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i92627ea2cb124a80a77175233b575d0d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMxMA_a8ec5633-c734-494a-b193-6fc3582394a0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi0xLTEtMS0w_ba39c338-ea8c-4e30-8b8c-e8b5e004468a">17,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi0zLTEtMS0w_3c577418-2a36-41cd-a60a-c5c837109016">9,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi01LTEtMS0w_f9c8c92f-bdac-4687-865c-c7ef6ea936a0">44,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi03LTEtMS0w_aaea5f0f-3eaf-44b9-8128-9ae44e547388">25,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy0xLTEtMS0w_9847e8e9-dbf7-4ac4-94fa-38edfc9dcf5a">35,927,485</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy0zLTEtMS0w_5a1585fc-6194-402e-9f6d-f925177ec642">2,065,676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy01LTEtMS0w_12fcf720-6621-4e6e-98a5-5b2a9c63106a">31,860,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy03LTEtMS0w_cbbd73ba-7dbb-428f-88f8-e9f21e6de41e">2,054,115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC0xLTEtMS0w_1838f4b5-4ca6-44fa-b0f9-959373d0b72a">0.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC0zLTEtMS0w_8ebe27b5-257c-4fa9-9ece-cc7927979842">4.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC01LTEtMS0w_da2412c6-24b7-4767-bbed-7b6e958918ac">1.42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC03LTEtMS0w_10379daa-0d6f-41f3-8a1d-703b77d35c9d">12.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock, convertible preferred stock and warrants to purchase convertible preferred stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMxMQ_950a4015-e2f4-4a94-82d8-f60c06773238" continuedAt="i182024e8808b426383c5d383cab959a9" escape="true">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i182024e8808b426383c5d383cab959a9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3abe3620951f41a29d7581f1d9a8baa5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMi0xLTEtMS0w_8c4e0bbb-2ee3-4511-a81e-f661758b85ab">3,639,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dcb5e81a97143b0afa64625ea7745ff_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMi0zLTEtMS0w_48d078ce-68da-4793-bafe-d620137c5d0e">1,608,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia99613d35727440abf965ec6cdb33b89_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMy0xLTEtMS0w_7c474a4f-2226-488a-9417-73b9ef47ac74">59,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0db89b0e05b542d5acd609d84363f0fe_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMy0zLTEtMS0w_1a66896d-1274-4f15-9a71-328e90f0f790">125,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4613097211945d588002788a6d88b08_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNC0xLTEtMS0w_fcb15c5b-48a9-4b5d-9418-4d63dc5ff406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62b4a0d7d7f74e5980d1e7f53a4c1d3e_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNC0zLTEtMS0w_26cc359d-ed50-4bd1-8e98-f37d58eda5eb">15,060,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warrants to purchase shares of series A preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie55196c9d5d44810bf624b67d74cf207_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNS0xLTEtMS0w_54226051-af8f-4978-83d7-5c75fc62ac31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i978c35a69f6244fb9664243bcb241cbd_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNS0zLTEtMS0w_2fa1a56f-e2f4-41d6-92ee-6f0d0d4908e0">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNi0xLTEtMS0w_b2c839c0-c4ea-44be-9f8f-7468a00a55d4">3,698,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNi0zLTEtMS0w_2a0c5ac8-6f6c-481f-981d-dcdd88eb0aa7">16,805,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">19</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTA5OTUxMTYzMDI0Mw_c6fcb21c-a11f-4849-a4ea-ce594b5729d3" continuedAt="ie7ae0150b52d4db5a9d3dbcc2bb03bfa" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ie7ae0150b52d4db5a9d3dbcc2bb03bfa" continuedAt="i523f32428fb445428f7b2793ea7b51f1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of September&#160;30, 2020, the Company had <ix:nonFraction unitRef="contract" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bdtx:LesseeOperatingLeaseNumberOfContracts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTIz_a694d3e3-3f40-43c3-8fa8-6be3e2e5280d">two</ix:nonFraction> operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In February 2019, the Company entered into an agreement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="icfadec1e666b4412980e25adc961a5c1_I20190228" decimals="0" format="ixt:numdotdecimal" name="bdtx:LesseeOperatingLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNTcw_bc56e300-5756-4896-9214-5018e59167a9">2,357</ix:nonFraction> square feet of office space for its principal office, which is located in Cambridge, MA. The lease expires on April 30, 2022, subject to an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNzQ0_ab6c24e2-8031-41b8-b38c-ee6a9db619f1">three</span> additional years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a <ix:nonNumeric contextRef="if98ef25099314086a82b8992bf03ca26_I20200731" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Ng_99309740-1ca0-4fda-a5c8-7b643f1b8979">seven-year</ix:nonNumeric> agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfODUz_2dbf53ff-d133-4eb9-bc06-8e02afa3e25d">five</span> additional years to lease two floors totaling approximately <ix:nonFraction unitRef="sqft" contextRef="if98ef25099314086a82b8992bf03ca26_I20200731" decimals="0" format="ixt:numdotdecimal" name="bdtx:LesseeOperatingLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfOTE2_a7339453-173b-4f26-a3e4-04636e654664">25,578</ix:nonFraction> square feet of office space in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the Company currently expects the lease of the second floor to commence in the fourth quarter 2020 when the landlord delivers the space in accordance with the lease terms. The Company recognizes the respective lease balances on the condensed consolidated balance sheets when the lease of each floor has commenced. Under the terms of the lease, the Company is required to make up to $<ix:nonFraction unitRef="usd" contextRef="if98ef25099314086a82b8992bf03ca26_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTQ4Nw_6f17066c-30c4-4265-b141-11d49ae3f376">17,048</ix:nonFraction> in total minimum payments during the term and is required to issue a $<ix:nonFraction unitRef="usd" contextRef="if98ef25099314086a82b8992bf03ca26_I20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTU1OQ_4f2c312b-35d7-4c7f-8bee-e2d64b9bbe47">1,168</ix:nonFraction> letter of credit as security for the lease.</span></div><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2MQ_6fc12780-c98a-4cea-903a-f5889c09de93" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three and nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMi0xLTEtMS0w_cffb0f9d-4fa6-49f0-b824-fe75bf81f988">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMi0zLTEtMS0w_3ac7d197-bc38-40c2-be06-cf9bb0b49deb">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMy0xLTEtMS0w_0d6214a9-16dd-4f28-9ed8-61620ec57aaa">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMy0zLTEtMS0w_6577bb7b-1998-4e9b-9168-acff55ffd415">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNC0xLTEtMS0w_236256bb-c250-4410-9116-da7998042fcf">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNC0zLTEtMS0w_17ea9123-f7c7-498d-92bc-86be2306efdc">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNS0xLTEtMS0w_0126e95c-5a0d-48e8-8554-845da8c6f999">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNS0zLTEtMS0w_bfc68c90-ba51-49fa-84a0-575769eb6392">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMS0xLTEtMS0w_b8728de7-f5c1-4f69-b774-a74b3cb28ea0">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMi0xLTEtMS0w_d40814f7-5690-4a2f-a012-1a026107d55d">7.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMy0xLTEtMS0w_472e7e9f-e1ca-4745-8b2c-73456843d726">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three and nine months ended September&#160;30, 2020 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="i523f32428fb445428f7b2793ea7b51f1"><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Mg_d4d74193-11c2-4a1b-98f2-39f7bb16f036" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of September&#160;30, 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September&#160;30, 2020)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMS0xLTEtMS0w_fa4ce2c7-077b-48ce-a79b-f347275daaf4">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMi0xLTEtMS0w_bd7ae29c-204c-4b35-aabe-3234ef5c7757">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMy0xLTEtMS0w_2d8b1a9b-1ed6-41a1-94c5-48e728507ae3">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNC0xLTEtMS0w_2c434f02-d6f7-4b62-8f31-37205af8569b">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNS0xLTEtMS0w_49032c50-3d34-4f80-8004-861090c2332a">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNi0xLTEtMS0w_e277be6d-d9c8-425b-a80d-acf5182650f5">4,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNy0xLTEtMS0w_e8dced25-f373-47d8-82c1-51986ce339c1">10,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfOC0xLTEtMS0w_238359b8-684a-43ad-a100-30359b8cd90a">1,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfOS0xLTEtMS0w_01e2941a-0f09-48bf-8b00-5ea2ac34e2ee">8,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Mw_cf3774ea-3953-4fe1-9fa1-917185345b82" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2019, future minimum lease payments under the Company&#8217;s lease obligations under ASC 840 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMS0xLTEtMS0w_f31f94e9-a167-4925-a22e-2918f422753d">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMi0xLTEtMS0w_046b433c-94cf-4918-a592-2530e9364165">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMy0xLTEtMS0w_477fec9c-b5ca-461f-a538-f5c4ff76a72d">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfNC0xLTEtMS0w_ad460aac-d0a7-4e06-ae41-e385aa2d0960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfNS0xLTEtMS0w_20eb6756-cc11-4fcb-80f4-b3c9b589b7b1">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182MS9mcmFnOmE3ODBlZGUxOGI2MzQ1OTNiZTY5Y2I3NTY4ZmI0OTdiL3RleHRyZWdpb246YTc4MGVkZTE4YjYzNDU5M2JlNjljYjc1NjhmYjQ5N2JfMjI1MQ_caf09ef2-cd79-4f75-8a15-9f020959a54a" continuedAt="if439ce9b642e4e8084b1ffbfa47b74ea" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="if439ce9b642e4e8084b1ffbfa47b74ea" continuedAt="iefdfdbcb5cea4bbcb2e85408b5ba0d69"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September&#160;30, 2020 or December&#160;31, 2019. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><ix:continuation id="iefdfdbcb5cea4bbcb2e85408b5ba0d69"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div></ix:continuation><div id="i4b3a7974cf244e41b6ee41205c9d1597_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDcw_bebc474b-8c45-4cd7-82b7-b203d79bc023" continuedAt="i255178bc72664daaad67d85ca568cea1" escape="true">BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i255178bc72664daaad67d85ca568cea1">In 2018 the Company established a Simplified Employee Pension (&#8220;SEP&#8221;) defined-contribution savings plan. This plan covers substantially all employees who meet minimum age and service requirements. The Company provides contributions of <ix:nonFraction unitRef="number" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMjU4_f9c154c6-c81d-4554-bcfe-f7d1b35bbef2">6</ix:nonFraction>% of each participant&#8217;s salary. Employees are immediately and fully vested in the Company&#8217;s contribution. During the three and nine months ended September&#160;30, 2020 and 2019, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMTY0OTI2NzQ0MjE0MQ_e41871df-0f6c-4618-b27c-72f714834a93">161</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDMx_8b7dd4b7-5437-4bd0-9ab1-c425516b7cbf">428</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMTY0OTI2NzQ0MjEzNw_0c17ff62-27ee-4b4e-a18e-9e70d4219243">64</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDQy_5e3b2de5-315d-4881-bdb4-c0cdf41269b3">125</ix:nonFraction> to the plan, respectively.</ix:continuation></span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTExNA_e2c6ee71-467d-4ee2-bfc1-6cee3db0872d" continuedAt="i209b5ff1ec8f4ff7b1c730262ea5c8c5" escape="true">RELATED-PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i209b5ff1ec8f4ff7b1c730262ea5c8c5">The Company is party to a services agreement, which was entered into in March 2017 and amended in November 2017 and March 2020, with Ridgeline. Ridgeline is an entity owned by one of the Company&#8217;s investors, whereby an individual who is a Company director and was executive officer until September 2019 and other employees of Ridgeline provide the Company with scientific consulting services. The services agreement is effective until December 31, 2020. Under the November 2017 amended services agreement the Company paid Ridgeline $<ix:nonFraction unitRef="usd" contextRef="i516d9585532d496ea7567f7c7e177c98_D20171101-20171130" decimals="INF" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfNTU5_1aa914f8-5c93-401e-830c-67f06e6ea0c1">950</ix:nonFraction> per month, which was reconciled on a quarterly basis with the actual expenses incurred by Ridgeline on its behalf. In connection with the March 2020 amendment to the services agreement, the Company transitioned to a more limited consulting arrangement whereby Ridgeline invoices the Company for services performed on an ongoing monthly basis. Total amounts due to related party were $<ix:nonFraction unitRef="usd" contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfOTM3_1346d97d-0bd2-457e-9ccb-6525380a55ce">190</ix:nonFraction> as of September&#160;30, 2020. Total prepaids with Ridgeline were $<ix:nonFraction unitRef="usd" contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231" decimals="-3" name="bdtx:PrepaidExpenseRelatedPartyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfOTg5_e8f16d75-1ac1-4c5b-8622-af46f528f91c">916</ix:nonFraction> as of December&#160;31, 2019. Total service fees incurred were $<ix:nonFraction unitRef="usd" contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTAzNQ_35330ab0-c9c0-4f9e-9425-8cfdd898ed3c">190</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTAzOQ_717b4d2f-40dc-411d-bba5-b6f2b5880a67">2,293</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTA0Mw_43959ce5-a1ea-4ff6-a5ba-aa8ce2ab44a6">3,656</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTA1MA_84cd6780-e8c9-4730-8b21-ea61cfe666a1">8,854</ix:nonFraction>, for the three and nine months ended September&#160;30, 2020 and 2019, respectively.</ix:continuation></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* * * * * *</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2019 included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 24, 2020. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Part II, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report. You should carefully read the &#8220;Risk Factors&#8221; section of this Quarterly Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. We target undrugged oncogenic driver mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with a single small molecule therapy in a tumor-agnostic manner. We have designed our lead product candidate, BDTX-189, to potently and selectively inhibit a family of oncogenic proteins defined by mutations which occur outside the adenosine triphosphate, or ATP, site, and which we refer to as non-canonical mutations. Non-canonical mutations occur across a range of tumor types that affect both the epidermal growth factor receptor, or EGFR, and the tyrosine-protein kinase ErbB-2, or HER2. We have designed BDTX-189 to bind to the active site of these mutant kinases and inhibit their function. BDTX-189 is also designed to spare normal, or wild type, EGFR, which we believe will improve upon the toxicity profiles of current ErbB kinase inhibitors. We are also leveraging our MAP platform to identify other families of non-canonical mutations in validated oncogenes beyond ErbB, which has the potential to expand the reach of targeted therapies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities. Through September&#160;30, 2020, we have received net proceeds of $200.6 million and $212.4 million from sales of our preferred and common stock, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We submitted our IND for BDTX-189 in November 2019, which was allowed by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on December 13, 2019. We have since begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy and expect to complete the Phase 1 portion of the trial by the first half of 2021. In July 2020, we were granted Fast Track designation for BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation or an epidermal growth factor receptor (EGFR) or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since inception we have incurred significant operating losses. Our net losses were $44.6 million and $25.4 million for the nine months ended September&#160;30, 2020 and 2019, respectively. As of September&#160;30, 2020, we had an accumulated deficit of $95.6 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue preclinical studies and initiate or advance clinical trials for BDTX-189, our glioblastoma (GBM) program and other product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance the development of our product candidate pipeline; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue to develop and expand our proprietary MAP platform to identify additional product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, scientific and commercial personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">acquire or in-license additional product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expand our infrastructure and facilities to accommodate our growing employee base; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our transition to operating as a public company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash, cash equivalents and investments of $333.1 million, which we believe will fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and capital resources.&#8221; To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COVID-19 Considerations </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease (&#8220;COVID-19&#8221;), was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries worldwide. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, which continues to spread throughout the U.S. and around the world. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &#8220;essential,&#8221; work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events. Although some states have relaxed quarantines and similar restrictions, the regulations vary on a state by state basis and the impact of loosening of those restrictions is not yet known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in our labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of our third party service providers have also experienced shutdowns or other business disruptions. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy and we cannot presently predict the scope and severity of any potential business shutdowns or disruptions. In particular, our ability to conduct our MasterKey-01 trial in a timely manner that meets our current projected timelines could be adversely impacted. While the Phase 1 portion of the trial currently remains on track to complete by the first half of 2021, potential COVID-19-associated risks include delays in patient recruitment and principal investigator availability, clinical trial site shutdowns or other interruptions and potential limitations on the quality, completeness and interpretability of data we are able to collect. Additionally, our drug product supply chain, early stage research &amp; development programs and activities and other aspects of our business operations could be negatively impacted by the pandemic and COVID-19-related delays or disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Beyond the impact on our pipeline, the extent to which COVID-19 ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain COVID-19 or treat its impact, among others. In addition, a recurrence or &#8220;additional waves&#8221; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of our results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses (inclusive of amounts with a related party) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">payments made in cash or equity securities under third-party licensing, acquisition and option agreements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred under our services agreement with Ridgeline Therapeutics GmbH, or Ridgeline; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">costs related to compliance with regulatory requirements; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">allocated facilities-related costs, depreciation and other expenses, which include rent and utilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not track our research and development expenses on a program-by-program basis. Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-189, as well as conduct other preclinical and clinical development, including submitting regulatory filings for our other product candidates. Historically, many of our research and development activities were conducted pursuant to our services agreement with Ridgeline, a related party, and we have transitioned many of these activities internally as we&#8217;ve increased our internal capacity. While the service fee we have historically paid under our Ridgeline Services Agreement has been reduced significantly as a result of this transition, we expect that we will incur increased personnel and overhead costs associated with moving those functions in-house, which we expect will offset that reduction in Ridgeline services fees. In addition, we expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing an appropriate safety and efficacy profile with IND enabling studies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful patient enrollment in and the initiation and completion of clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">significant and changing government regulation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses (inclusive of amounts with a related party) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, realized and unrealized foreign currency transaction gains and losses, and changes in fair value of derivative liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our issuance of Series B preferred stock provided investors the right to participate in subsequent offerings of Series B preferred stock, in the event specified developmental and regulatory milestones were achieved. We classified the tranche right as a derivative liability on our condensed consolidated balance sheets. We remeasured the derivative liability associated with tranche right to fair value at each reporting date, and recognized change in the fair value of the derivative liability in the condensed consolidated statements of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">three months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ended September&#160;30, 2020 and 2019</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development (inclusive of $190 and $3,480 respectively, with a related party)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative (inclusive of $0 and $176, respectively, with a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,480&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18,480)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8,148)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17,912)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8,644)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development (inclusive of amounts with a related party)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $12.9 million for the three months ended September&#160;30, 2020, compared to $5.6 million for the three months ended September&#160;30, 2019. The increase of $7.3 million was primarily due to an increase in headcount expenses of $2.3 million and external fees of $4.2 million related to the continued development of our MAP platform and our product candidates, including BDTX-189. We do not currently track expenses on a program-by-program basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative (inclusive of amounts with a related party)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $5.6 million for the three months ended September&#160;30, 2020, compared to $2.5 million for the three months ended September&#160;30, 2019. The increase of $3.0 million was primarily a result of higher personnel-related costs due to additional headcount and higher legal and other professional fees due to operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income was $0.6 million for the three months ended September&#160;30, 2020, compared to other expense of $1.1 million for the three months ended September&#160;30, 2019. The increase was primarily attributable to no derivative liability in 2020 as well as interest income on investments and accretion of discount on investments in 2020 and none in 2019.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ended September&#160;30, 2020 and 2019</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development (inclusive of $2,293 and $8,497 respectively, with a related party)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative (inclusive of $0 and $357, respectively, with a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(46,387)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(27,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6,395)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25,383)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(19,245)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development (inclusive of amounts with a related party)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $30.5 million for the nine months ended September&#160;30, 2020, compared to $14.3 million for the nine months ended September&#160;30, 2019. The increase of $16.2 million was primarily due to an increase in headcount of $5.8 million and external fees of $8.4 million related to the continued development of our MAP platform and our product candidates, including BDTX-189. We do not currently track expenses on a program-by-program basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative (inclusive of amounts with a related party)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $15.9 million for the nine months ended September&#160;30, 2020, compared to $4.7 million for the nine months ended September&#160;30, 2019. The increase of $11.2 million was primarily a result of higher personnel-related costs due to additional headcount and higher legal and other professional fees due to preparing to operate as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income was $1.8 million for the nine months ended September&#160;30, 2020, compared to other expense of $6.4 million for the nine months ended September&#160;30, 2019. The increase was primarily attributable to no derivative liability in 2020 as well as interest income on investments and accretion of discount on investments in 2020 and none in 2019.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">30</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred stock. On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3&#160;million. We received $212.1&#160;million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through September&#160;30, 2020, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of September&#160;30, 2020, we had cash, cash equivalents and investments of $333.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:71.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(36,372)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17,188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(275,043)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">214,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(97,301)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,054&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we used cash in operating activities of $36.4&#160;million, primarily resulting from our net loss of $44.6&#160;million, partially offset by the non-cash charge related to stock compensation expense of $5.3&#160;million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, we used cash in operating activities of $17.2&#160;million, primarily resulting from our net loss of $25.4&#160;million, partially offset by a increase in accrued expenses and prepaid expenses as well as the change in fair value of derivative liabilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates, and the timing of vendor invoicing and payments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we had cash used in investing activities of $275.0&#160;million for the purchase of investments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, we used cash in investing activities of less than $0.1 million, consisting solely of purchases of equipment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we had cash provided by financing activities of $214.1&#160;million, consisting primarily of proceeds from the IPO. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2019, we had cash provided by financing activities of $44.3&#160;million consisting of proceeds from issuance of convertible preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance BDTX-189 through clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance preclinical development of our early stage programs, including in GBM;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, quality control and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash, cash equivalents and investments of $333.1 million, which we believe will fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for BDTX-189 or our other product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ability to receive additional non-dilutive funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish and maintain collaborations on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Off-balance sheet arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and use of estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Critical Accounting Policies and Use of Estimates&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 24, 2020. During the three and nine months ended September&#160;30, 2020, there were no material changes to our critical accounting policies from those previously disclosed.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">33</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Emerging growth company and smaller reporting company status </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not &#8220;opt out&#8221; of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. </span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report were not effective at a reasonable assurance level due to the material weaknesses in internal control over financial reporting described below. The Company&#8217;s disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In preparation of our financial statements to meet the requirements of our IPO, we determined that material weaknesses in our internal control over financial reporting existed during fiscal 2017 and remain unremediated as of September&#160;30, 2020. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The material weaknesses we identified are related to the design and maintenance of an effective control environment commensurate with our financial reporting requirements. Specifically, we lacked a sufficient complement of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately and we did not design and maintain controls to ensure adequate segregation of duties within our financial reporting function including the preparation and review of journal entries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The material weaknesses contributed to the restatement of our previously issued 2017 annual financial statements. Specifically, the material weaknesses resulted in errors in our accounting for and reporting of derivative liabilities, loss on extinguishment of convertible promissory notes and expense classification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Remediation Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Management has been actively engaged in remediating the above described material weaknesses. The following remedial actions have been taken during the quarter ended September&#160;30, 2020:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">strengthened our internal policies, processes and reviews, including drafting of related documentation thereof;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">implemented an enterprise resource planning system to support key financial processes and controls; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">completed the design and implementation of internal controls to address the relevant risks and continued to engage with outside consultants to finalize the related documentation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process of implementing an effective financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a financial reporting system that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over financial reporting, we may take additional actions to address control deficiencies or modify certain of the remediation measures described above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe the above actions will be effective in remediating the material weaknesses described above and we will continue to devote significant time and attention to these remedial efforts. The material weaknesses cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded that these controls are operating effectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The items described in &#8220;Remediation Activities&#8221; above are considered a change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the third quarter of 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">35</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report and in other documents that we file with the SEC, in evaluating the Company and our business. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks and uncertainties summarized and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this Quarterly Report are forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to the development of our product candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to clinical development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts and are substantially dependent on our lead product candidate, BDTX-189. If we are unable to advance BDTX-189 or any of our other product candidates through clinical development, obtain regulatory approval and ultimately commercialize BDTX-189 or any of our other product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are very early in our development efforts. Most of our product candidates are still in preclinical development and have never been tested in human subjects. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of BDTX-189 and one or more of our other product candidates. In addition, our drug development programs contemplate the development of companion diagnostics, which are assays or tests to identify an appropriate patient population. Companion diagnostics are subject to regulation as medical devices and must themselves be approved for marketing by the FDA or certain other foreign regulatory agencies before we may commercialize our product candidates. The success of our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful completion of preclinical studies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">approval of INDs for our planned clinical trials or future clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FDA acceptance of our tumor-agnostic development strategy; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful initiation of clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful patient enrollment in and completion of clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful development of companion diagnostics for use with our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">safety, tolerability and efficacy profiles for our product candidates that are satisfactory to the FDA or any foreign regulatory authority for marketing approval; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">receipt of marketing approvals for our product candidates and any companion diagnostics from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates, if any product candidates are approved; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">effectively competing with other cancer therapies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining and maintaining third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">maintaining a continued acceptable safety profile of our products following approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is no guarantee that the results obtained in current preclinical studies or our open-label Phase 1/2 clinical trial of BDTX-189 will be sufficient to obtain regulatory approval or marketing authorization for such product candidate. Negative results in the development of our lead product candidate may also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes because, although other product candidates may target different indications, the underlying technology platform, manufacturing process and development process is the same for all of our product candidates. Accordingly, a failure in any one program may affect the ability to obtain regulatory approval to continue or conduct clinical programs for other product candidates. For example, although we believe based on our preclinical studies that the conformational change to the active site receptor is similar for all of the genetic mutations we are targeting and therefore the chemical structure of BDTX-189 will suffice to bind adequately to such receptor for all such mutations, this may not prove true in clinical testing of BDTX-189 for all or any of the targeted mutations. Moreover, anti-tumor activity may be different in each of the different tumor types we plan on evaluating in the clinical trial. Therefore, even though we plan on pursuing tumor-agnostic clinical development of BDTX-189, the tumor response may be low in patients with some cancers compared to others. This may result in discontinuation of development of BDTX-189 for patients with these tumor types and/or mutations due to insufficient clinical benefit while continuing development for a more limited population of patients more likely to benefit. As a consequence, we may have to negotiate with the FDA to reach agreement on defining the optimal patient population, study design and size in order to obtain regulatory approval, any of which may require significant additional resources and delay the timing of our clinical trials and ultimately the approval, if any, of any of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, because we have limited financial and personnel resources and are placing significant focus on the development of our lead product candidate, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in our open-label Phase&#160;1/2 clinical trial for BDTX-189 with the genetic mutations that BDTX-189 is designed to target. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of completion of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because we are focused on patients with specific genetic mutations, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. For example, with respect to BDTX-189, we cannot be certain how many patients will have each of the genetic mutations that BDTX-189 is designed to target or that the number of patients enrolled for each mutation will suffice for regulatory approval and inclusion of each such mutation in the approved label. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the potentially small populations, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their disease is either severe enough or not too advanced to include them in a study. Additionally, the process of finding and diagnosing patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical study sites for prospective patients, the availability of genetic sequencing information for patient tumors so that we can identify patients with the targeted genetic mutations, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We intend to engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, furthering the difficulty in identifying patients with the targeted genetic mutations for our clinical trials. Further, if we are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in FDA&#8217;s expedited review and development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise seek to accelerate clinical development and regulatory timelines. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The enrollment of patients further depends on many factors, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the proximity of patients to clinical trial sites; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the design of the clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to obtain and maintain patient consents; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">reporting of the preliminary results of any of our clinical trials; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment and because most of our product candidates have not been tested in humans before, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any future clinical trial. Additionally, because our clinical trials are in patients with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial and requiring additional patient enrollment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have no experience as a company in conducting clinical trials. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have no experience as a company in conducting clinical trials. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies will be completed on time or if the planned preclinical studies and clinical trials will begin or be completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and reliance on third-party clinical investigators, contract research organizations, or CROs, and consultants. Relying on third-party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. For our lead product candidate, BDTX-189, we entered in to a master services agreement with a CRO to lead our first-in-human open-label Phase&#160;1/2 clinical trial. There can be no assurance that we will be able to negotiate and enter into any additional master services agreement with other CROs, as necessary, on terms that are acceptable to us on a timely basis or at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of our product candidates, including BDTX-189, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency, purity and efficacy profile despite having progressed through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency, purity and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in safety, potency, purity or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. As is the case with all oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. For example, other EGFR inhibitors have experienced dose limiting toxicities due to rash in patients and, although we have designed BDTX-189 to be &#8220;wild-type&#8221; sparing to limit the risk of similar toxicities, clinical results may differ and patients may also experience similar or different toxicities that limit the dose and/or efficacy of BDTX-189. If on-target toxicity is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We submitted an IND for BDTX-189 in November 2019, which was allowed by the FDA on December 13, 2019, but we may not be able to file INDs for our other product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our product candidates could harm our drug development strategy and operational results. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As one of the central elements of our business strategy and approach, we seek to screen and identify subsets of patients with a genetic alteration who may derive meaningful benefit from our development product candidates. To achieve this, our product development program is dependent on the development and commercialization of a companion diagnostic by us or by third party collaborators. Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices. Each agency that approves a product candidate will independently need to approve the companion diagnostic before or concurrently with its approval of the product candidate, and before a product can be commercialized. The approval of a companion diagnostic as part of the product label will also limit the use of the product candidate to only those patients who express the specific genetic alteration it was developed to detect. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. To date, the FDA has required premarket approval of all companion diagnostics for cancer therapies. We and our third-party collaborators may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third- party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of our related product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Since the number of patients that we plan to dose in our open-label Phase 1/2 clinical trial of BDTX-189 is small, the results from such a clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In our open-label Phase 1/2 clinical trial of BDTX-189, we are evaluating the safety profile of BDTX-189 and establishing the recommended Phase 2 dose in patients with bladder cancer, endometrial cancer, breast cancer, gastric cancer, colon cancer and non-small cell lung cancer, or NSCLC, and other solid tumors. The Phase 1 portion of the trial is expected to enroll up to 100 patients with solid tumors that have alterations likely to be associated with anti-tumor activity based on preclinical studies as well as some patients with the targeted genetic mutations and is designed to establish the recommended dose for the Phase 2 portion of the trial. The Phase 1 portion may have to evaluate different dosing schedules if the pharmacokinetic or safety data suggest once daily dosing is suboptimal. This may delay initiation of the Phase&#160;2 portion. The open-label Phase 2 portion of the trial is expected to enroll up to 100 patients with the targeted mutations to evaluate efficacy as determined by objective response rate, or ORR, a measure of tumor response and tumor duration response, or DOR. This portion may need to be expanded to provide additional safety and efficacy data to support an application for accelerated approval even if tumor response and duration is adequate. The preliminary results of clinical trials with smaller sample sizes, such as our ongoing open-label Phase 1/2 clinical trial of BDTX-189, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of BDTX-189, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our initial open-label Phase 1/2 clinical trial. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">regulatory authorities may withdraw or limit their approval of such product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">regulatory authorities may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may be subject to regulatory investigations and government enforcement actions; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may decide to remove such product candidates from the marketplace; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our reputation may suffer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future clinical trial results. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on the expected timelines, if at all. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All of our lead product candidates are in preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our preclinical studies and future clinical trials may not be successful. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We cannot be certain that our preclinical study and clinical trial results will be sufficient to support regulatory approval of our product candidates. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Failure or delay can occur at any time during the clinical trial process. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, some of the clinical trials we conduct may be open-label in study design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our Phase 1/2 clinical trial of&#160;BDTX-189&#160;includes an open-label dosing design, the results from this clinical trial may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment with a placebo or active control. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may experience delays in obtaining the FDA&#8217;s authorization to initiate clinical trials under future INDs, completing ongoing preclinical studies of our other product candidates, and initiating our planned preclinical studies and clinical trials. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time, or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities disagreeing with our tumor-agnostic development strategy; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">delays in obtaining regulatory approval to commence a clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining IRB approval at each clinical trial site; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">recruiting an adequate number of suitable patients to participate in a clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">having subjects complete a clinical trial or return for post-treatment follow-up; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">addressing subject safety concerns that arise during the course of a clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">adding a sufficient number of clinical trial sites; or </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining sufficient product supply of product candidate for use in preclinical studies or clinical trials from third-party suppliers. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our research efforts for our other product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">clinical trials of our product candidates may not produce differentiated or clinically significant results across tumor types or indications; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the cost of clinical trials of our product candidates may be greater than we anticipate, for example, if we experiences delays or challenges in identifying patients with the mutations required for our clinical trials, we may have to reimburse sites for genetic sequencing costs in order to encourage sequencing of additional patients; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate, and any transfer of manufacturing activities may require unforeseen manufacturing or formulation changes; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, principal investigators for our future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our preclinical studies or clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, our entire pipeline and MAP platform could have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may in the future conduct clinical trials for product candidates outside the United&#160;States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may in the future choose to conduct one or more clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to our approach</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our discovery and preclinical development is focused on the development of precision medicines for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to marketable products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The discovery and development of precision medicines for patients with genetically defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, that the mutations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain mutations or certain tumor types. The patient populations for our product candidates are limited to those with specific target mutations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with the targeted mutations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific genetic alterations respond to our product candidates and developing companion diagnostics to identify such genetic alterations. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and commercialize our products and achieve profitability. In addition, even if our approach is successful in showing clinical benefit for tumors harboring the targeted mutations affecting the ErbB proteins EGFR and HER2, we may never successfully identify additional oncogenic mutations for other receptor tyrosine kinases. Therefore, we do not know if our approach of treating patients with genetically defined cancers will be successful, and if our approach is unsuccessful, our business will suffer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, we are pursuing a tumor-agnostic development strategy (i.e., pursuing approval based on a biomarker rather than a specific cancer indication). There is currently a limited number of approved tumor-agnostic therapies. We may not receive approval for a tumor-agnostic indication or may be delayed in receiving tumor-agnostic approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our MAP platform to build a pipeline of product candidates with commercial value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our MAP platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers. Although our research and development efforts to date have resulted in our discovery and preclinical development of BDTX-189, BDTX-189 may not be safe or effective as a cancer treatment, and we may not be able to develop any other product candidates. Our MAP platform is evolving and may not reach a state at which building a pipeline of product candidates is possible. For example, we may not be successful in identifying additional genetic mutations which are oncogenic and which can be &#8220;basketed&#8221; into a group that is large enough to present a sufficient commercial opportunity or that is druggable with one chemical compound. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second or third line therapy, for use in patients with relapsed or refractory metastatic cancer. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a second or third or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our projections of both the number of people who have the cancers we are targeting, who may have their tumors genetically sequenced, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to the COVID-19 pandemic</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Business or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Broad-based business or economic disruptions could adversely affect our ongoing or planned research and development activities. For example, in December 2019, an outbreak of a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries worldwide. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed restrictions on travel between the United States, Europe and certain other countries. Almost all U.S. states and many local jurisdictions have issued &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders, restrictions, and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &#8220;essential,&#8221; work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, as well as record declines in stock prices, among other effects. There is a risk that government actions will not be effective at containing COVID-19 or other infectious diseases, and that government actions, including the orders and restrictions described above, that are intended to contain the spread of COVID-19 will have a devastating negative impact on the world economy at large, in which case the risks to our sales, operating results and financial condition described herein would be elevated significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The continued spread of COVID-19 or other global health matters, such as pandemics, could also impact our target patient populations as well as the hospitals and clinical sites in which we conduct any of our clinical trials, which could lead to delays in completing enrollment of our clinical trials. For instance, the COVID-19 outbreak may continue to impair our ability to recruit and retain patients and engage principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography or due to prioritization of hospital resources toward the outbreak and restrictions on travel. Furthermore, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. COVID-19 already has affected and may further negatively affect the operations of third party contract research organizations that we rely upon to carry out our discovery work, clinical trials or the operations of our third party manufacturers, which could result in delays or disruptions in the supply of our product candidates and the conduct of experiments and studies. Any negative impact COVID-19 has to patient enrollment or treatment or the timing and execution of our preclinical studies or clinical trials could cause costly delays to our development programs, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our business and financial results. COVID-19 has also caused, and may continue to cause for an extended period, volatility in the global financial markets and threatened a slowdown in the global economy, reducing our ability to access capital, which would negatively affect our liquidity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although some states are starting to relax &#8220;shelter-in-place&#8221; orders, quarantines and similar restrictions, the regulations vary on a state by state basis and the impact of loosening of those restrictions is not yet known. While our lab-based employees have returned to our labs with enhanced safety measures, our office-based employees continue to work primarily from home and this may continue for an extended period despite the loosening of restrictions, due to the complexities of re-entering the workplace and concerns of individual employees. Furthermore, there has been a resurgence of COVID-19 cases, which could prompt a reinstatement of &#8220;shelter-in-place&#8221; orders and restrictions at the state and local levels impacting our reentry to the workplace and causing hospital and clinical sites to suspend our clinical trials or could deter patients from continuing to participate in our trials.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, duration of the outbreak, travel restrictions, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken in the United States and other countries to contain COVID-19 or treat its impact, among others. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical trial sites, service providers, regulators and other third parties with whom we conduct business, were to experience prolonged business shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to manufacturing and supply</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to manufacture our clinical product supplies, and we may rely on third parties to produce and process our product candidates, if approved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical scale manufacturing facility and expect to rely on outside vendors to manufacture supplies of our product candidates. We will need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMPs and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing our product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply of our product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process of manufacturing of our product candidates is complex and highly regulated. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We rely on third parties for the manufacture of our product candidates. These third-party manufacturers may incorporate their own proprietary processes into our product candidate manufacturing processes. We have limited control and oversight of a third party&#8217;s proprietary process, and a third party may elect to modify its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost of and significantly delay the manufacture of our product candidates. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As our product candidates progress through preclinical studies and clinical trials towards approval and commercialization, it is expected that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. Such changes may require amendments to be made to regulatory applications which may further delay the timeframes under which modified manufacturing processes can be used for any of our product candidates and additional bridging studies or trials may be required. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not have our own clinical-scale manufacturing facility and are currently reliant on a limited number of manufacturers for our product candidates. These third-party manufacturing providers may not be able to provide adequate resources or capacity to meet our needs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to sales, marketing, and competition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing, and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain such arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">differing regulatory requirements in foreign countries, for example, no country other than the United States has a pathway for accelerated drug approval and so obtaining regulatory approvals outside of the United States will take longer and be more costly than obtaining approval in the United States; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">difficulties staffing and managing foreign operations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">business interruptions resulting from geo-political actions, including war and terrorism. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and on specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future discovery and preclinical development programs and product candidates for specific indications may not yield any commercially viable products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The use of precision medicines as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates are accepted in the market, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the clinical indications for which our product candidates are licensed; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the potential and perceived advantages of our product candidates over alternative treatments; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to demonstrate the advantages of our product candidates over other cancer medicines; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the prevalence and severity of any side effects; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the prevalence and severity of any side effects for other precision medicines and public perception of other precision medicines; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">limitations or warnings contained in the labeling approved by the FDA; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the timing of market introduction of our product candidates as well as competitive products; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the cost of treatment in relation to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the effectiveness of our sales and marketing efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, although our product candidates differ in certain ways from other precision medicine approaches, serious adverse events or deaths in other clinical trials involving precision medicines, even if not ultimately attributable to our product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of our product candidates, stricter labeling requirements for those product candidates that are licensed, and a decrease in demand for any such product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies, academic institutions and government agencies, and public and private research institutes that conduct research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, regulatory approvals and product marketing than we do. Our competitors may compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Specifically for BDTX-189, we expect competition primarily in the EGFR and HER2 Exon 20 insertion NSCLC patient populations, including: mobocertinib (TAK-788), which is under development by Takeda Pharmaceutical Company Ltd; amivantamab (JNJ-61186372), which is under development by Janssen Research &amp; Development, LLC; trastuzumab deruxtecan (DS-8201), marketed by Daiichi Sankyo Company Ltd. and AstraZeneca plc under the trade name Enhertu, which is currently approved for HER2+ breast cancer, but under development for HER2 mutan t solid tumors; poziotinib, which is under development by Spectrum Pharmaceuticals, Inc; CLN-081 (formerly TAS6417), which is under development by Cullinan Oncology, LLC; and DZD9008, which is under development by Dizal Pharmaceutical Co., Ltd. In addition, there are other small molecule and precision oncology-focused companies with whom we may eventually compete, including Loxo Oncology, Inc. (recently acquired by Eli Lilly and Company), Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., and Mirati Therapeutics, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If our drug candidates, including BDTX-189, are approved for the indications for which we are currently planning clinical trials, they will likely compete with the competitor drugs mentioned above and with other drugs that are currently in development. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information regarding our competition, see &#8220;Business&#8212;Competition.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to our financial position and capital requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to past financial condition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a biotechnology company with a limited operating history. We commenced operations in December 2014, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. Most of our product candidates are still in preclinical development. We have not yet demonstrated our ability to successfully conduct or complete any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment in biopharmaceutical product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We are still in the early stages of development of our product candidates. We have begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We have financed our operations primarily through private placements of our preferred stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have incurred significant net losses in each period since we commenced operations in December 2014. For the nine months ended September&#160;30, 2020, we reported a net loss of $44.6 million. As of September&#160;30, 2020, we had an accumulated deficit of $95.6 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue our research and development efforts and submit INDs for our lead product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">conduct preclinical studies and clinical trials for our current and future product candidates based on our Mutation&#8212;Allostery&#8212;Pharmacology, or MAP, platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities, whether alone or with third parties, to commercialize any product candidates for which we may obtain regulatory approval, if any; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, expand, maintain, enforce and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, regulatory and scientific personnel; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">operate as a public company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have not generated any revenue from our product candidates and may never be profitable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from any of our product candidates. We do not expect to generate significant revenue unless or until we successfully complete clinical development and obtain regulatory approval of, and then successfully commercialize, at least one of our product candidates. Most of our product candidates are in the preclinical stages of development and will require additional preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We have begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy. Our other product candidates are in various stages of preclinical development. We face significant translational risk as our product candidates in preclinical development advance to the clinical stage, as promising results in preclinical studies may not be replicated in subsequent clinical trials and testing on animals may not accurately predict human experience. Our ability to generate revenue depends on a number of factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to complete IND-enabling studies and successfully submit INDs or comparable applications; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">whether we are required by the U.S. Food and Drug Administration, or the FDA, or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, potency, purity, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates and such regulatory authorities&#8217; acceptance of our tumor-agnostic development strategy (i.e., our pursuit of approval based on a biomarker rather than a specific cancer indication); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates over alternative or more conventional therapies, such as chemotherapy, to treat solid tumors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the actual and perceived availability, cost, risk profile and side effects and efficacy of our product candidates, if approved, relative to existing and future alternative cancer therapies and competitive product candidates and technologies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">patient demand for our product candidates and any future product candidates, if approved; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercializing our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to future financial condition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we would be compelled to delay, reduce or eliminate our product development programs or commercialization efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our expenses to increase in parallel with our ongoing activities, particularly as we continue our discovery and preclinical development activities to identify new product candidates and initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. However, we have estimated our current additional funding needs based on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our discovery and preclinical development programs or any future commercialization efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We had cash, cash equivalents and investments of $333.1 million as of September&#160;30, 2020. Our net proceeds from our initial public offering were $212.1 million, based the initial public offering price of $19.00 per share, after deducting underwriting discounts and commissions and offering expenses payable by us. We believe that, based upon our current operating plan, our existing capital resources, including net proceeds from our initial public offering will be sufficient to fund our anticipated operations into 2023, including the Phase&#160;1/2 clinical trial of BDTX-189 and the identification of a lead product candidate and IND-enabling studies in our glioblastoma program, with additional resources for continued development of our MAP platform. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, results and costs of discovery, preclinical development and clinical trials for our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent to which we enter into collaboration arrangements with regard to product discovery or acquire or in-license products or technologies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish discovery collaborations on favorable terms, if at all; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing and protecting our intellectual property rights and defending intellectual property-related claims. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to government regulation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts. Most of our product candidates are still in preclinical development. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are very early in our development efforts, and most of our product candidates are still in preclinical development. We have invested substantially all of our efforts and financial resources in the identification and preclinical development of our product candidates, including the development of our initial product candidate, BDTX-189. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend on the successful development, approval and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a marketable product. The success of our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">approval of INDs for our planned clinical trials or future clinical trials;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FDA acceptance of our tumor-agnostic development strategy; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful enrollment in future clinical trials;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">positive results from future clinical trials that are supportive of safety and efficacy in the intended patient populations; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful development of companion diagnostics for use with certain of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">receipt of regulatory approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">effectively competing with other therapies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining and maintaining third-party insurance coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining, enforcing and defending intellectual property rights and claims; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">maintaining a continued acceptable safety profile of the product candidates following approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. Depending on results from our open-label Phase 1/2 clinical trial for BDTX-189, we expect, subject to discussions with FDA, to either expand the Phase 2 portion of the trial or initiate a second Phase 2 trial in order to seek accelerated approval from the FDA for the treatment of patients with advanced solid tumors that harbor one or more of the targeted genetic mutations detected by an NGS test requiring contemporaneous FDA clearance or approval, who have progressed or relapsed following prior treatment and who have no satisfactory treatment options. Whether the results from our open-label Phase 1/2 clinical trial and other trials will suffice to obtain accelerated approval will be a review issue and the FDA may not grant accelerated approval and may require that we conduct one or more controlled, randomized Phase&#160;3 clinical trials to obtain approval. In addition, because there is limited experience of the FDA with the approval of tumor-agnostic cancer treatments and since we will need to show that there is no available therapy for each of the tumors tested in our open-label Phase 1/2 clinical trial, we may experience challenges in obtaining accelerated approval across all such tumor types. To date, we have had no interactions with regulatory authorities outside of the United States. We intend to engage with the EMA following the results of the Phase&#160;2 portion of the planned trial regarding regulatory requirements for registration in the EU. There is limited experience of regulatory authorities outside of the United States with the approval of tumor-agnostic precision cancer medicines. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted IND, NDA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including our Phase 1/2 clinical trial design for BDTX-189; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities may disagree with our tumor-agnostic development strategy; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any of our product candidates, including BDTX-189 and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective in humans. Our product candidates may fail to demonstrate efficacy in humans, and particularly across tumor types. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications, patient population and regulatory agency. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA, the EMA or other comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA, the EMA, or other comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA, the EMA or other comparable foreign regulatory authorities will view our product candidates as having sufficient efficacy to support a tumor-agnostic indication even if positive results are observed in clinical trials. To the extent that the results of the trials are not satisfactory to the FDA, the EMA or other comparable foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Additionally, any safety or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">efficacy concerns observed in any tumor-specific subgroup of our clinical trials could limit the prospects for regulatory approval of our product candidates for a tumor-agnostic indication, which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may in the future seek orphan drug status for BDTX-189 and some of our other future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may seek orphan drug designation for BDTX-189 and some or all of our other future product candidates in additional orphan indications in which there is a medically plausible basis for the use of these products. Even when we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive such designations. For example, the FDA has expressed concerns regarding the regulatory considerations for orphan drug designation as applied to tissue agnostic therapies, and the FDA may interpret the FD&amp;C Act and regulations promulgated thereunder in a way that limits or blocks our ability to obtain orphan drug designation or orphan drug exclusivity, if our product candidates are approved, for our targeted indications. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August&#160;3, 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may seek Breakthrough Therapy designation for BDTX-189 and some or all of our future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to candidate products considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for BDTX-189 and some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy designation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We have been granted Fast Track designation for BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation or an epidermal growth factor receptor (EGFR) or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options. We may seek Fast Track designation for other indications or for certain of our future product candidates, but there is no assurance that the FDA will grant this status to any of our other proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accelerated approval by the FDA, even if granted for BDTX-189 or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We plan to seek approval of BDTX-189 and may seek approval of future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our drug candidates that are required or experience significant delays in doing so, we may not realize the full commercial potential of these drug candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the clinical development of our drug candidates for certain indications, we intend to engage third parties to develop or obtain access to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our drug candidates. Such companion diagnostics would be used during our clinical trials as well as in connection with the FDA approval of our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA regulates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> companion diagnostics as medical devices and, under that regulatory framework, will require the test to be analytically validated and used for patient selection in the clinical trial, which we expect will require separate regulatory clearance or approval prior to commercialization if not already approved. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic drug candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic drug candidates, or experience delays in doing so, the development of these therapeutic drug candidates may be adversely affected, these therapeutic drug candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to ongoing regulatory obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with applicable cGMP, GLP and GCP requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">imposition of a REMS, which may include distribution or use restrictions; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">fines, warning letters or holds on clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The insurance coverage and reimbursement status of newly-approved products is uncertain. Our product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a covered benefit under its health plan; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">safe, effective and medically necessary; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">appropriate for the specific patient; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">cost-effective; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">neither experimental nor investigational. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates third-party payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, we may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, may be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. Even if we obtain regulatory approval or clearance for such companion diagnostics, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. Medicare reimbursement methodologies, whether under Part A, Part B, or clinical laboratory fee schedule may be amended from time to time, and we cannot predict what effect any change to these methodologies would have on any product candidate or companion diagnostic for which we receive approval. Our inability to promptly obtain coverage and adequate reimbursement from both third-party payors for the companion diagnostic tests that we develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, administrative, executive and Congressional legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example. various portions of the ACA are currently undergoing constitutional challenges in the Fifth Circuit Court and the United States Supreme Court, and the Trump Administration has issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Additionally, Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended, and we cannot predict what affect further changes to the ACA would have on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Members of the U.S. Congress and the Trump administration have expressed an intent to pass legislation or adopt executive orders to fundamentally change or repeal parts of the Affordable Care Act. While Congress has not passed repeal legislation to date, the Tax Cuts and Jobs Act of 2017, or TCJA, repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December 14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The Trump Administration and CMS have both stated that the ruling will have no immediate effect, and on December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, and remanded the case to the lower court to reconsider its earlier invalidation of the full ACA. Pending review, the ACA remains in effect, but it is unclear at this time what effect the latest ruling will have on the status of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. We will continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. The Trump administration has concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the ACA have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those appropriations are made. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. The loss of the cost share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Further, on June 14, 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay to third-party payors more than $12 billion in ACA risk corridor payments that they argued were owed to them. On December 10, 2019, the U.S. Supreme Court heard arguments in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Moda Health Plan, Inc. v. United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which will determine whether the government must make risk corridor payments. The U.S. Supreme Court&#8217;s decision will be released in the coming months, but we cannot predict how the U.S. Supreme Court will rule. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business, are not yet known. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. However, on December 20, 2019, President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">taxes could be instated in the future. The Bipartisan Budget Act of 2018, also amended the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has recently published a final rule that would give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, or ATRA, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#8217;s budget for fiscal year 2020 contains further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low- income patients. Additionally, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, in December 2019, the FDA issued a notice of proposed rulemaking that, if finalized, would allow for the importation of certain prescription drugs from Canada. FDA also issued a Draft Guidance document outlining a potential pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The regulatory and market implications of the notice of proposed rulemaking and Draft Guidance are unknown at this time, but legislation, regulations or policies allowing the reimportation of drugs, if enacted and implemented, could decrease the price we receive for our products and adversely affect our future revenues and prospects for profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the Affordable Care Act. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the demand for our product candidates, if we obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to set a price that we believe is fair for our products; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to obtain coverage and reimbursement approval for a product; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to generate revenue and achieve or maintain profitability; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the level of taxes that we are required to pay; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the availability of capital. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For example, over the last several years, including beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA and other similar foreign regulatory authorities, provide true, complete and accurate information to the FDA and other similar foreign regulatory authorities, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The laws that may affect our ability to operate include, but are not limited to: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which impose criminal and civil penalties, including through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the federal Physician Payment Sunshine Act, created under the Affordable Care Act and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and we may be required to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010, or the Bribery Act. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Risks related to our intellectual property </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to protecting our intellectual property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We do not currently own or in-license any issued patents relating to our product candidates or technology, including BDTX-189. If we are unable to obtain and maintain patent and other intellectual property protection for BDTX-189, our MAP platform and our other product candidates and technology, or any other product candidates or technology we may develop, or if the scope of intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize BDTX-189 or any other product candidates or technology may be adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our product candidates, including BDTX-189, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment and development that are important to our business, as well as successfully defending these patents against third-party challenges. If we do not adequately protect our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We intend to rely upon a combination of patent applications, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our product candidates and technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to establish our patent position. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To protect our proprietary position, we plan to file patent applications in the United States and abroad relating to our product candidates and MAP platform that are important to our business; we may in the future also license or purchase patents or patent applications owned by others. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. If we are unable to secure or maintain patent protection with respect to BDTX-189, our MAP platform or any other proprietary products and technology we develop, our business, financial condition, results of operations, and prospects would be materially harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not currently own or in-license any issued patents relating to BDTX-189, including its composition of matter, and we do not currently own or in-license any issued patents relating to any of our other product candidates or technology. We own one Patent Cooperation Treaty, or PCT, patent application that covers the composition of matter for BDTX-189, as well as methods of using and making BDTX-189. This PCT application may never result in an issued patent. This pending PCT patent application is not eligible to become an issued patent until, among other things, we file a national stage patent application within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent application and any patent protection on the inventions disclosed in such PCT patent application. While we intend to timely file a national stage patent application relating to our PCT patent application, we cannot predict whether any of our future patent applications for BDTX-189 or any of our other product candidates will result in the issuance of patents that effectively protect BDTX-189 or our other product candidates. If we do not successfully obtain patent protection, or, even if we do obtain patent protection, if the scope of the patent protection we or our potential licensors obtain with respect to BDTX-189 or our other product candidates and technology is not sufficiently broad, we will be unable to prevent others from using our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection with respect to BDTX-189 and our other product candidates would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any patents we may own or in-license in the future will have, or that any of our patent applications that mature into issued patents will include, claims with a scope sufficient to protect our current and future product candidates or otherwise provide any competitive advantage. In addition, to the extent that we license intellectual property in the future, we cannot assure you that those licenses will remain in force. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan, and the term of any patents we may own or in-license in the future may be inadequate to protect our competitive position of our product candidates or technology for an adequate amount of time. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if they are unchallenged, our patent applications, if issued, and any patents we may own or in-license in the future, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent any patents we may own or in-license in the future by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but that uses a formulation and/or a device that falls outside the scope of any patent protection we may have in the future. If the patent protection provided by our patent applications or any patents we may pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. Although we currently own our patent applications, similar risks would apply to any patents or patent applications that we may own or in-license in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patent positions of life sciences companies can be uncertain and involve complex factual and legal questions. Changes in either the patent laws or their interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of our patent applications or any patents we may own or in-license in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patent prosecution process is complex, expensive, time-consuming and inconsistent across jurisdictions. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is possible that we will fail to identify important patentable aspects of our research and development efforts in time to obtain appropriate or any patent protection. While we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development efforts, including for example, our employees, corporate collaborators, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose results before a patent application is filed, thereby endangering our ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Consequently, we cannot be certain that we were the first to file for patent protection on the inventions claimed in our patent applications. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is possible that defects of form in the preparation or filing of our patent applications, or any patents we may own or in-license in the future, may exist or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patent applications or patents </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">we may own or in-license in the future, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, we cannot be certain that the claims in our patent applications covering composition of matter of our product candidates or technology will be considered patentable by the USPTO, or by patent offices in foreign countries, or that the claims in any issued patents we may own or in-license in the future will be considered patentable by courts in the United States or foreign countries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Method of use patents protect the use of a product for the specified method. These types of patents do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may induce or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain unresolved. In recent years, patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any rights we may have from our patent applications are highly uncertain. Our patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Moreover, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art, including our own previously filed patent applications and scientific publications, allow our inventions to be patentable over the prior art. Even if our patent applications issue as patents, third parties could challenge the validity of such patents based on such scientific publications and we could potentially lose valuable patent rights. Further, the scope of the invention claimed in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance. Even where patent applications we currently own or that we may license in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with a competitive advantage. Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by valid and enforceable patent rights. Our competitors or other third parties may be able to evade any rights we may have from our patent applications by developing new compounds or alternative technologies or products in a non-infringing manner. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The issuance or grant of a patent is not irrefutable as to its inventorship, scope, validity or enforceability, and any patents we may own or in-license in the future may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the patent claims of any patents we may own or in-license being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We may in the future, become subject to a third-party pre-issuance submission of prior art or opposition, derivation, revocation, re-examination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">review, or interference proceeding and other similar proceedings challenging any rights we may have from our patent applications or the patent rights of others in the U.S. Patent and Trademark Office, or USPTO, or other foreign patent office, or in declaratory judgment actions or counterclaims. An unfavorable determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, any rights we may have from our patent applications, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or extinguish our ability to manufacture or commercialize products without infringing third-party patent rights. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, some of our intellectual property, including any patents we may own or in-license in the future, may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such intellectual property, including patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our future licensors may need the cooperation of any such co-owners of our owned and in-licensed intellectual property, including patents and patent applications, in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us or our future licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our future licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in any future agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the future, we may be party to license or collaboration agreements with third parties to advance our research or allow commercialization of product candidates. Such future agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our future licensors might conclude that we have materially breached our future license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disputes may also arise between us and our future licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the priority of invention of any patented technology; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the agreements under which we may license intellectual property or technology from third parties in the future are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license in the future prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents we may own or in-license in the future, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes, including our MAP platform that involve proprietary know-how, information, or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our MAP platform, including aspects of oncogenicity computational algorithms, in vivo experiments to validate mechanisms and pharmacology, drug design, and related processes, are based on unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Presently we own one PCT patent application related to BDTX-189. Because additional product candidates may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. Similarly, efficient production or delivery of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Moreover, the molecules that will be used with our product candidates may be covered by the intellectual property rights of others. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program and allowing third parties to compete with us. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Any issued patents we may own or in-license in the future covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we or our future licensors or strategic partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or in-license in the future in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we may own or in-license in the future, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or priority of invention or other features of patentability with respect to our patent applications and any patents we may own or in-license. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not be able to pursue generic coverage of our product candidates or MAP platform outside of the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of any patents we may own or in-license in the future or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our patent applications or any patents we may own or in-license in the future in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we may own or in-license in the future at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license in the future that are relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates we may develop, our business may be materially harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any of our current or future product candidates we may develop, one or more U.S. patents we may own or in-license in the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following expiration of any patents that issue from our patent applications, and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">patent applications that we own or may in-license in the future may not lead to issued patents; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">patents, should they issue, that we may own or in-license in the future, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license in the future, should any patents issue;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license in the future;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may not develop or in-license additional proprietary technologies that are patentable; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the patents of others may have an adverse effect on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to intellectual property litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement, misappropriation or other violations may be costly and time consuming and may prevent or delay our product discovery and development efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The intellectual property landscape around precision medicine is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> review, and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business and may impact our reputation; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, including BDTX-189, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">redesigning our product candidates or processes so they do not infringe, misappropriate or violate third party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> re-exam, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications can take many years to issue. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have not filed patent applications covering our product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patent applications or any patents we may own or in-license in the future is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our intellectual property rights, including any patents we may own or in-license in the future, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competitors may infringe any patents we may own or in-license in the future. In addition, any patents we may own or in-license also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or in-license in the future is not valid or is unenforceable or that the other party&#8217;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that any patents we may own or in-license in the future do not cover the technology in question or that such third party&#8217;s activities do not infringe our patent applications or any patents we may own or in-license in the future. An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or in-license in the future at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may own or in-license in the future. These proceedings are expensive and an unfavorable outcome could result in a loss our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the European Patent Office, or EPO, or similar proceedings in other foreign patent offices, where either our foreign patents are challenged. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may not be able to detect infringement against any patents we may own or in-license in the future. Even if we detect infringement by a third party of any patents we may own or in-license in the future, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third party. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may own or in-license in the future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in any patents we may own or in-license in the future, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. Litigation may be necessary to defend against these and other claims challenging inventorship of any patents we may own or in-license in the future, trade secrets or other intellectual property. If we were unsuccessful, in addition to paying monetary damages, we could lose valuable rights in intellectual property that we regard as our own, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are party to a services agreement with Ridgeline Therapeutics GmbH, or the Ridgeline Services Agreement, pursuant to which Ridgeline provides certain drug discovery and development services. Pursuant to the Ridgeline Services Agreement, we own all rights in and to all patent, copyright and other intellectual property rights generated by Ridgeline in the course of performing the specified services. If it is unclear whether certain intellectual property generated by Ridgeline is our property, we may be subject to conflicting claims of ownership. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, as is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, in some cases until recently. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information or trade secrets of these third parties or our employees&#8217; former employers or our consultants&#8217; or contractors&#8217; current or former clients or customers. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims and possible aftermath could result in substantial cost and be a distraction to our management and employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We plan to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We plan to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract manufacturing organizations, or CMOs, and strategic partners to conduct and support our preclinical studies and clinical trials under agreements with us. For example, we contract with Ridgeline for services related to our drug discovery and preclinical work, but we are continuing to build our internal chemistry, manufacturing and controls, biology and preclinical development capabilities to assume activities conducted by Ridgeline on our behalf. We have transitioned from our old service model to a more limited consulting arrangement with Ridgeline. As part of this transition, we may incur additional costs or experience delays in engaging directly with other third-party CROs and CMOs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with pharmaceutical product produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing, clinical and non-clinical product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Switching or adding third parties to conduct our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or third parties to manufacture our product candidates. Our business could be harmed if we are unable to use third-party manufacturing suites or if the third party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our anticipated reliance on a limited number of third-party manufacturers exposes us to a number of risks, including the following: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must inspect any manufacturers for current cGMP compliance as part of our marketing application; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards and we have no control over third-party manufacturers&#8217; compliance with these regulations and standards; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our third-party manufacturers could breach or terminate their agreements with us; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or man-made disasters; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to commercially produce our products either at our own facility or at a third party&#8217;s facility, we will need to comply with the FDA&#8217;s cGMP regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our precision medicines as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our precision medicines for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant non-compliance could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation and our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to managing growth and employee matters </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to our employee matters</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our President and Chief Executive Officer, our Chief Financial Officer, Chief Scientific Officer, Chief Medical Officer, Executive Vice President of Discovery and Translational Sciences, and our Senior Vice President, Non-Clinical Development. Our Senior Vice President, Non-Clinical Development, Karsten Witt, M.D., is not our employee and provides services under a consulting agreement. We have transitioned from our old service model with Ridgeline to a more limited consulting arrangement. While we have engaged in an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties relating to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. In addition, the loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We conduct our operations at our facilities in Cambridge, MA, New York, NY, Stony Brook, NY, and Toronto, Canada. The Massachusetts region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to our business operations and growth</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had 58 full-time employees. We intend to hire new employees to conduct our research and development activities in the future. Any delay in hiring such new employees could result in delays in our research and development activities and would harm our business. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">improving our operational, financial and management controls, reporting systems and procedures. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of regulatory approval, clinical trial management and manufacturing. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of data from completed or future preclinical studies and clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">decreased demand for our product candidates or products that we may develop; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">injury to our reputation; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">initiation of investigations by regulators; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">costs to defend the related litigation; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">loss of revenue; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">exhaustion of any available insurance and our capital resources; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the inability to commercialize any product candidate; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a decline in our share price. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to tax</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership by 5% stockholders over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income may be limited. As a result of our most recent private placements and other transactions that have occurred over the past three years, we may have experienced, and may experience, an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December&#160;31, 2019, we had U.S. federal and state net operating loss carryforwards of $39,596 and U.S. federal research and development tax credit carryforwards of $1,014, each of which will begin to expire at various dates through 2039 and which could be limited if we experience an &#8220;ownership change.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks related to ownership of our common stock </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to investments in our securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock is volatile, and you could lose all or part of your investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Similar to the trading prices of the common stock of other biopharmaceutical companies, the trading price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report, these factors include: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development programs; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">adverse results or delays in preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">adverse developments concerning our manufacturers or our manufacturing plans; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our inability to establish collaborations if needed; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our failure to commercialize our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">additions or departures of key scientific or management personnel; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">unanticipated serious safety concerns related to the use of our product candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">introduction of new products or services offered by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to effectively manage our growth; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the size and growth of our initial cancer target markets; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to successfully treat additional types of cancers or at different stages; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">actual or anticipated variations in quarterly operating results; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our cash position; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">changes in the market valuations of similar companies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">overall performance of the equity markets; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">sales of our common stock by us or our stockholders in the future; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">trading volume of our common stock; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">changes in accounting practices; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">ineffectiveness of our internal controls; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">significant lawsuits, including intellectual property or stockholder litigation; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">general political and economic conditions; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other events or factors, many of which are beyond our control. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, financial condition, results of operation and future prospects. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our management will have broad discretion in the application of our existing cash, cash equivalents and marketable securities. Because of the number and variability of factors that will determine our use of the net proceeds from our IPO, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase or maintain the value of your investment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Based upon our common stock outstanding as of September&#160;30, 2020, our executive officers, directors, and their affiliates beneficially owned over a majority of our outstanding voting stock. These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval. For example, these stockholders are able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this Quarterly Report and our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in which we complete our IPO, although circumstances could cause us to lose that status earlier. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&#160;million as of the prior June 30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and (2)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to not &#8220;opt out&#8221; of this exemption from complying with new or revised accounting standards and, therefore, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an emerging growth company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this Quarterly Report and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the Securities and Exchange Commission, or SEC, annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and other legal restrictions on resale discussed in this Quarterly Report lapse, the trading price of our common stock could decline.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our 2020 Plan and our 2020 Employee Stock Purchase Plan, each of which became effective upon the effectiveness of the registration statement of which this Quarterly Report forms a part, will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to our charter and bylaws</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Our bylaws designate a certain court as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. In addition, our amended and restated bylaws will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clause in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Risks related to internal control over financial reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In preparation of our financial statements to meet the requirements of our initial public offering, we determined that material weaknesses in our internal control over financial reporting existed during fiscal 2017 and remained unremediated as of September&#160;30, 2020. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual and interim financial statements will not be detected or prevented on a timely basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The material weaknesses we identified are related to the design and maintenance of an effective control environment commensurate with our financial reporting requirements. Specifically, we lacked a sufficient complement of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately and we did not design and maintain controls to ensure </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">adequate segregation of duties within our financial reporting function including the preparation and review of journal entries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The material weaknesses contributed to the restatement of our previously issued 2017 annual financial statements. Specifically, the material weaknesses resulted in errors in our accounting for and reporting of derivative liabilities, loss on extinguishment of convertible promissory notes and expense classification. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are in the process of building a finance organization and implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to these material weaknesses, including hiring additional finance and accounting personnel, implementing a new enterprise resource planning system, and the establishment of controls to account for and disclose complex transactions. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and applicable Nasdaq Global Select Market listing requirements, investors may lose confidence in our financial reporting, and our share price may decline as a result. In addition, we could become subject to investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional financial and management resources. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adequate internal control over financial reporting are necessary for us to provide reliable financial reports and, together with effective disclosure controls and procedures, are designed to prevent or detect material misstatements due to fraud or error. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing conducted by us in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General risk factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for violations of the GDPR, including potential fines of up to &#8364;20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA went into effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended on September 23, 2018, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future. For example, in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Assoc. for Molecular Pathology v. Myriad Genetics, Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. Any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce any rights we may have in our patent applications or any patents we may own or in-license in the future. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could also increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents we may own or in-license in the future. The United States has enacted and implemented wide-ranging patent reform legislation. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or America Invents Act, was signed into law, which includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, establish a new post-grant review system and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patent applications or any patents we may own or in-license. These changes also allow third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents we may own or in-license in the future, all of which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our MAP platform and product discovery efforts, we may collect and use a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware,&#160;denial-of-service,&#160;social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, state breach notification laws), federal (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, HIPAA, as amended by HITECH), and international law (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the computer systems of various third parties on which we rely, including our CROs and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. </span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Set forth below is information regarding shares of equity securities sold, and options granted, by us during the nine months ended September&#160;30, 2020 that were not registered under the Securities Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, upon the closing of our IPO all 64,839,353 shares of our then-outstanding redeemable convertible preferred stock automatically converted into 21,499,770 shares of common stock. The issuance of such common stock was exempt from the registration requirements of the Securities Act, pursuant to Section 3(a)(9) of the Securities Act, involving an exchange of securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. No underwriters were involved in this issuance of shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we issued to certain of our employees and advisors, options to purchase an aggregate of 1,351,593 shares of our common stock at an exercise price ranging from $19.00-$43.05 per share and restricted stock units of 61,000. We deemed these issuances to be exempt from registration under the Securities Act either in reliance on Rule 701 of the Securities Act as sales and offers under compensatory benefit.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from IPO of Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus dated January 30, 2020.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_124"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">No.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Index</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit311q32020.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit312q32020.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit321q32020.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101INS</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101SCH</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101CAL</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101LAB</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101PRE</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101DEF</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">103</span></div></div></div><div id="i4b3a7974cf244e41b6ee41205c9d1597_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i4b3a7974cf244e41b6ee41205c9d1597_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date: November 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ David M. Epstein</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">David M. Epstein</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">President and Chief Executive Officer</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date: November 10, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Thomas Leggett</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Thomas Leggett</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Chief Financial Officer </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">104</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q32020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6f52b799259547c8ab799ef01c05f6e9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, David M. Epstein, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2020 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238&#47;34-47986 and 33-8392&#47;34-49313)&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:43.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; November 10, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q32020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i75e13d699ede4e4b894518adb8d4acab_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Thomas Leggett, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2020 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238&#47;34-47986 and 33-8392&#47;34-49313)&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:52.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; November 10, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Leggett</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thomas Leggett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q32020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4b292742be024f4ca4fac7540852aa6e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Chief Executive Officer, and Thomas Leggett, the Chief Financial Officer, of Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;), hereby certify, that, to their knowledge&#58; </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:4.02pt">the Quarterly Report on Form 10-Q for the period ended September 30, 2020 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November 10, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November 10, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Leggett</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Thomas Leggett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bdtx-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.blackdiamondtherapeutics.com/20200930">
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATION" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
        <link:definition>2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2106103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2307301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails">
        <link:definition>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS">
        <link:definition>2111104 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables">
        <link:definition>2312302 - Disclosure - INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSScheduleofMarketableSecuritiesDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails">
        <link:definition>2413406 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>2114105 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>2315303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails">
        <link:definition>2416407 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>2117106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2318304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>2419408 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2120107 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>2421409 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2122108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2323305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2424410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
        <link:definition>2425411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE">
        <link:definition>2126109 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables">
        <link:definition>2327306 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails">
        <link:definition>2428412 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
        <link:definition>2429413 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES">
        <link:definition>2130110 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables">
        <link:definition>2331307 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails">
        <link:definition>2432414 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails">
        <link:definition>2433415 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>2434416 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2434416 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2135111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANS" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS">
        <link:definition>2136112 - Disclosure - BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANSDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails">
        <link:definition>2437417 - Disclosure - BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2138113 - Disclosure - RELATED-PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2439418 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bdtx_OperatingLeasePrincipalOfficeTwoMember" abstract="true" name="OperatingLeasePrincipalOfficeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_OperatingLeasePrincipalOfficeOneMember" abstract="true" name="OperatingLeasePrincipalOfficeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" abstract="false" name="ReclassificationsOfTemporaryToPermanentEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bdtx_SharesAuthorized" abstract="false" name="SharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bdtx_A2020PlanMember" abstract="true" name="A2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_LeaseOtherInformationAbstract" abstract="true" name="LeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bdtx_DeferredOfferingCostsIncurredButNotYetPaid" abstract="false" name="DeferredOfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_LeaseContractualTermDomain" abstract="true" name="LeaseContractualTermDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseArea" abstract="false" name="LesseeOperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" abstract="false" name="RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_LeaseContractualTermAxis" abstract="true" name="LeaseContractualTermAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bdtx_AccruedContractResearchServiceFeesCurrent" abstract="false" name="AccruedContractResearchServiceFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ServiceAgreementMonthlyMember" abstract="true" name="ServiceAgreementMonthlyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_PrepaidExpenseRelatedPartyCurrent" abstract="false" name="PrepaidExpenseRelatedPartyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_RentExpense" abstract="false" name="RentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>bdtx-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8db13a3a-6dfa-44b6-b1d1-2d515446f9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b43cf0ca-b489-4ad9-ab9d-5c517d3847d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8db13a3a-6dfa-44b6-b1d1-2d515446f9c0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b43cf0ca-b489-4ad9-ab9d-5c517d3847d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_d1f678be-80c9-465f-aec8-376ab2d3f3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8db13a3a-6dfa-44b6-b1d1-2d515446f9c0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_d1f678be-80c9-465f-aec8-376ab2d3f3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac71c61e-cec1-4b49-9f4c-feb2b362d149" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8db13a3a-6dfa-44b6-b1d1-2d515446f9c0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac71c61e-cec1-4b49-9f4c-feb2b362d149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ee349e8f-8c0f-4901-a7aa-19109ad33c27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6fa519dc-c0ab-497e-a2da-4199b55f5bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee349e8f-8c0f-4901-a7aa-19109ad33c27" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6fa519dc-c0ab-497e-a2da-4199b55f5bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04337d11-13e7-4b9e-874f-7337549145b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee349e8f-8c0f-4901-a7aa-19109ad33c27" xlink:to="loc_us-gaap_LiabilitiesCurrent_04337d11-13e7-4b9e-874f-7337549145b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61ef3bec-85f3-4f86-874c-1c3a2d9f2184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ee349e8f-8c0f-4901-a7aa-19109ad33c27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_61ef3bec-85f3-4f86-874c-1c3a2d9f2184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a63fbd29-24ff-4c3d-82ba-4c126b8cd240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc1c730-dbe5-439d-b66a-5a1e77c9f915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a63fbd29-24ff-4c3d-82ba-4c126b8cd240" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fc1c730-dbe5-439d-b66a-5a1e77c9f915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0a9b6d1-50a5-4db0-918e-ea62c46c166d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a63fbd29-24ff-4c3d-82ba-4c126b8cd240" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0a9b6d1-50a5-4db0-918e-ea62c46c166d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143d65aa-999d-4821-a256-8ce11c5c0ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a63fbd29-24ff-4c3d-82ba-4c126b8cd240" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_143d65aa-999d-4821-a256-8ce11c5c0ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d73cd2a-fddb-4eb7-99a1-d95cd6174d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8d25926-3e67-4308-858d-38c5ec77e0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d73cd2a-fddb-4eb7-99a1-d95cd6174d5a" xlink:to="loc_us-gaap_StockholdersEquity_c8d25926-3e67-4308-858d-38c5ec77e0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_daf276ae-2c92-4f60-985d-29bdc89726d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d73cd2a-fddb-4eb7-99a1-d95cd6174d5a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_daf276ae-2c92-4f60-985d-29bdc89726d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9ea6549f-f0be-49bd-9883-baadf4916e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d73cd2a-fddb-4eb7-99a1-d95cd6174d5a" xlink:to="loc_us-gaap_Liabilities_9ea6549f-f0be-49bd-9883-baadf4916e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6df44ff7-e743-4180-8e6f-552d9e31a768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d73cd2a-fddb-4eb7-99a1-d95cd6174d5a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6df44ff7-e743-4180-8e6f-552d9e31a768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_735a6c5a-2053-4241-b377-5349a7dc7faa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4fb43398-a046-4513-8687-cab3667c0f10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735a6c5a-2053-4241-b377-5349a7dc7faa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4fb43398-a046-4513-8687-cab3667c0f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1a2c23e3-17fe-4023-a0ce-294cd27e906b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735a6c5a-2053-4241-b377-5349a7dc7faa" xlink:to="loc_us-gaap_CommonStockValue_1a2c23e3-17fe-4023-a0ce-294cd27e906b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1dabedcc-b923-47f4-93fc-bbd344de0357" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735a6c5a-2053-4241-b377-5349a7dc7faa" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1dabedcc-b923-47f4-93fc-bbd344de0357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0ba580ae-2fa9-4cc7-a517-8641e16ef4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735a6c5a-2053-4241-b377-5349a7dc7faa" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0ba580ae-2fa9-4cc7-a517-8641e16ef4b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_689bd8bd-081a-4330-84e3-ac89ce0bac35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_AssetsCurrent_689bd8bd-081a-4330-84e3-ac89ce0bac35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_efdd9c4e-65ac-46d8-aea5-c6b23ada5055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_efdd9c4e-65ac-46d8-aea5-c6b23ada5055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5654d130-4199-4928-b4e4-aadac7e8ad0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5654d130-4199-4928-b4e4-aadac7e8ad0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b7479245-ec8a-42a9-9f11-f7cdd622392c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b7479245-ec8a-42a9-9f11-f7cdd622392c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_2aac2635-080a-4949-b856-60cbd2b9ff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_DeferredCosts_2aac2635-080a-4949-b856-60cbd2b9ff6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c996ee9-db77-41d7-ae23-1912ebd8b14a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e003e9a7-0b22-4f43-9092-f2fb10acdd9b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c996ee9-db77-41d7-ae23-1912ebd8b14a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_91646392-1863-4739-b3ce-2ddc9df08d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_34e8ba4c-1a35-42a9-9a7e-a2596e1c785a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_91646392-1863-4739-b3ce-2ddc9df08d5d" xlink:to="loc_us-gaap_OperatingExpenses_34e8ba4c-1a35-42a9-9a7e-a2596e1c785a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b3489f2f-f806-4b82-8197-06b7f3038ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2dcfe8cf-9267-429a-b6d6-ad235a5811a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b3489f2f-f806-4b82-8197-06b7f3038ec1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2dcfe8cf-9267-429a-b6d6-ad235a5811a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c047f480-e991-431d-8072-da2732e47a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b3489f2f-f806-4b82-8197-06b7f3038ec1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c047f480-e991-431d-8072-da2732e47a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1ee599ea-f8d8-40be-92a4-9b19002480cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1de5eb6e-79c5-45b5-ab06-a2757bb77a00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1ee599ea-f8d8-40be-92a4-9b19002480cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1de5eb6e-79c5-45b5-ab06-a2757bb77a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_888c0edc-b28e-48c0-8c4c-2d4886eb4ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1ee599ea-f8d8-40be-92a4-9b19002480cf" xlink:to="loc_us-gaap_NetIncomeLoss_888c0edc-b28e-48c0-8c4c-2d4886eb4ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f7541a9-9779-4a46-9310-c8514bd7a329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e7d95cba-a698-4829-9112-a0a2db36bee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0f7541a9-9779-4a46-9310-c8514bd7a329" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e7d95cba-a698-4829-9112-a0a2db36bee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e966db0e-dfcc-4e8a-a909-56b4d76d143e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0f7541a9-9779-4a46-9310-c8514bd7a329" xlink:to="loc_us-gaap_OperatingIncomeLoss_e966db0e-dfcc-4e8a-a909-56b4d76d143e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6df0779e-edb4-4f2f-9b09-66b7eeeda96b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fbe7e890-f79f-41ac-a581-42c669865080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6df0779e-edb4-4f2f-9b09-66b7eeeda96b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fbe7e890-f79f-41ac-a581-42c669865080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_216a4463-108c-4923-bb06-2197ec654fad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6df0779e-edb4-4f2f-9b09-66b7eeeda96b" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_216a4463-108c-4923-bb06-2197ec654fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_fb9e40f7-7334-4b6d-bb7a-92a7b8373f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6df0779e-edb4-4f2f-9b09-66b7eeeda96b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_fb9e40f7-7334-4b6d-bb7a-92a7b8373f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d13f71d9-8af3-40ce-8b84-0e60b05f6e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6df0779e-edb4-4f2f-9b09-66b7eeeda96b" xlink:to="loc_us-gaap_InterestExpense_d13f71d9-8af3-40ce-8b84-0e60b05f6e41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1204505-fa47-4900-ba74-f264dd0f30ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc508004-e998-4892-afe2-2bf497eef8aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1204505-fa47-4900-ba74-f264dd0f30ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc508004-e998-4892-afe2-2bf497eef8aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89b0056e-1700-40fb-9545-e5760b2af571" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1204505-fa47-4900-ba74-f264dd0f30ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89b0056e-1700-40fb-9545-e5760b2af571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28780294-208c-4d7a-9892-844bb44f06dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1204505-fa47-4900-ba74-f264dd0f30ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28780294-208c-4d7a-9892-844bb44f06dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0364ffb9-c3cc-496b-bda6-e6f3dea3e86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f5ce637-9a55-4bb2-8802-da0480766f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0364ffb9-c3cc-496b-bda6-e6f3dea3e86d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f5ce637-9a55-4bb2-8802-da0480766f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_749e6cfa-d6c5-4751-a2f1-23bbc03ab118" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0364ffb9-c3cc-496b-bda6-e6f3dea3e86d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_749e6cfa-d6c5-4751-a2f1-23bbc03ab118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04c75302-8c13-4bc2-991b-679f72908f04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_e942ebdc-df35-4236-8ad9-96bef12a0e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04c75302-8c13-4bc2-991b-679f72908f04" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_e942ebdc-df35-4236-8ad9-96bef12a0e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_13c41163-1cbc-4633-98ab-5bfe8d675e88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04c75302-8c13-4bc2-991b-679f72908f04" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_13c41163-1cbc-4633-98ab-5bfe8d675e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c18c5819-345e-4394-9f1b-0177a75d912e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04c75302-8c13-4bc2-991b-679f72908f04" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c18c5819-345e-4394-9f1b-0177a75d912e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7f7a68ee-bbb8-4da4-be68-1a0c7613ee08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_04c75302-8c13-4bc2-991b-679f72908f04" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7f7a68ee-bbb8-4da4-be68-1a0c7613ee08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1df0902d-7cd3-45dd-a867-a300c573ab7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_99552c14-5179-4357-b2d9-c3e50dc6c59f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1df0902d-7cd3-45dd-a867-a300c573ab7c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_99552c14-5179-4357-b2d9-c3e50dc6c59f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27e443ca-f2db-4a3f-8c2e-7741f5dfd34b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1df0902d-7cd3-45dd-a867-a300c573ab7c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_27e443ca-f2db-4a3f-8c2e-7741f5dfd34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6260dd74-d7d0-42af-b288-5c592a836f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1df0902d-7cd3-45dd-a867-a300c573ab7c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6260dd74-d7d0-42af-b288-5c592a836f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_aa190c49-7cea-48c6-83fb-334968fd13df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_aa190c49-7cea-48c6-83fb-334968fd13df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_4faa7255-7493-4b32-864f-5b5c4cf67e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_4faa7255-7493-4b32-864f-5b5c4cf67e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02cf0441-57b2-4560-8b35-fbb15620e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_NetIncomeLoss_02cf0441-57b2-4560-8b35-fbb15620e55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7dc5c23-aea9-4ad0-a999-b467336ce240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_ShareBasedCompensation_a7dc5c23-aea9-4ad0-a999-b467336ce240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_3df02f47-55a3-4865-98f6-0b7dda762e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_3df02f47-55a3-4865-98f6-0b7dda762e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b557c9a5-7948-47c9-9b44-e438b660b908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_Depreciation_b557c9a5-7948-47c9-9b44-e438b660b908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f13520f-3019-46f1-9bda-b9abbd5670fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f13520f-3019-46f1-9bda-b9abbd5670fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_22754b6c-708c-49be-82c9-a704f76241a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_22754b6c-708c-49be-82c9-a704f76241a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_8982e5c7-55ec-4c22-8962-7bc2903a8b15" xlink:href="bdtx-20200930.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_8982e5c7-55ec-4c22-8962-7bc2903a8b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_c66a741c-9711-461d-b878-b4ec8cfd6b4c" xlink:href="bdtx-20200930.xsd#bdtx_RentExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_bdtx_RentExpense_c66a741c-9711-461d-b878-b4ec8cfd6b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3868b4ad-acb7-42d3-8ebb-f713baf52ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3868b4ad-acb7-42d3-8ebb-f713baf52ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_c32143ff-2901-4264-a517-111319b064a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3951738-a2a2-4315-a8ce-5d89c1cd3676" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_c32143ff-2901-4264-a517-111319b064a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_84dcc676-90f2-4505-9472-e88c82800e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f5b106fb-6e0b-409e-8de4-c34f978e293e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_84dcc676-90f2-4505-9472-e88c82800e8e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f5b106fb-6e0b-409e-8de4-c34f978e293e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62303697-0a2f-44d4-8aa5-d105dafca24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_84dcc676-90f2-4505-9472-e88c82800e8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62303697-0a2f-44d4-8aa5-d105dafca24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2764cf3d-0798-4099-85fe-9d3d13ab4695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_615762ac-dc2e-4376-be3d-c1f9fa77e394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_2764cf3d-0798-4099-85fe-9d3d13ab4695" xlink:to="loc_us-gaap_DerivativeLiabilities_615762ac-dc2e-4376-be3d-c1f9fa77e394" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTS"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0a03b06-6089-4e7c-bcb2-62a606afbdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_31c5e726-fb02-4cef-837b-45b66169a85d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0a03b06-6089-4e7c-bcb2-62a606afbdfd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_31c5e726-fb02-4cef-837b-45b66169a85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62e3e72e-f0a8-4dba-99cf-5f20622ebf0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0a03b06-6089-4e7c-bcb2-62a606afbdfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62e3e72e-f0a8-4dba-99cf-5f20622ebf0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6578dcf5-eb2d-47bb-8114-9eda2a2f20b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0a03b06-6089-4e7c-bcb2-62a606afbdfd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6578dcf5-eb2d-47bb-8114-9eda2a2f20b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENT"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_36db0e4f-0435-42f5-9be9-67338e83be6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba354d6b-3ea9-4982-917b-724ba682b202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_36db0e4f-0435-42f5-9be9-67338e83be6f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba354d6b-3ea9-4982-917b-724ba682b202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_818da24f-c1f1-4df3-9b14-1b7b490644fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_36db0e4f-0435-42f5-9be9-67338e83be6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_818da24f-c1f1-4df3-9b14-1b7b490644fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedLegalFeesCurrent_1a6b7fa8-3155-410c-aecc-8a3d5f976bfb" xlink:href="bdtx-20200930.xsd#bdtx_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:to="loc_bdtx_AccruedLegalFeesCurrent_1a6b7fa8-3155-410c-aecc-8a3d5f976bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9467da97-e974-4da7-9d3c-029b8cfd9aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9467da97-e974-4da7-9d3c-029b8cfd9aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d2f8accd-ac30-4b0f-87ab-7723782bf25d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d2f8accd-ac30-4b0f-87ab-7723782bf25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_8c4e2eb2-7b81-4a52-9bd9-14afb50c90ca" xlink:href="bdtx-20200930.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_8c4e2eb2-7b81-4a52-9bd9-14afb50c90ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_432ca191-c336-4476-b2f1-fcb2789fd897" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_72057f86-ca75-4893-bf28-f41407a169dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_432ca191-c336-4476-b2f1-fcb2789fd897" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARETables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASES"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESTables"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_68d7029c-e01e-457a-8186-4a21283ec83a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_76788703-9edf-41bb-8bf1-dc3735977434" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_68d7029c-e01e-457a-8186-4a21283ec83a" xlink:to="loc_us-gaap_OperatingLeaseCost_76788703-9edf-41bb-8bf1-dc3735977434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_6a9b9120-1a2a-49ec-96f3-398f3cb1fb38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_68d7029c-e01e-457a-8186-4a21283ec83a" xlink:to="loc_us-gaap_ShortTermLeaseCost_6a9b9120-1a2a-49ec-96f3-398f3cb1fb38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_bd82f87a-0a2e-4a00-bbfe-e5119899c76a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_68d7029c-e01e-457a-8186-4a21283ec83a" xlink:to="loc_us-gaap_VariableLeaseCost_bd82f87a-0a2e-4a00-bbfe-e5119899c76a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f62794f6-461c-4a3e-bd37-2c65329a872c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4b937f73-59d9-4491-93fc-de27f22a3ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f62794f6-461c-4a3e-bd37-2c65329a872c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4b937f73-59d9-4491-93fc-de27f22a3ecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c2756178-5d7e-4876-8156-7a30fc1c8292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f62794f6-461c-4a3e-bd37-2c65329a872c" xlink:to="loc_us-gaap_OperatingLeaseLiability_c2756178-5d7e-4876-8156-7a30fc1c8292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cb5f9075-e822-4adf-9e1f-8e508e184765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c109e9e6-867c-4597-9f34-490574ff2169" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cb5f9075-e822-4adf-9e1f-8e508e184765" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c109e9e6-867c-4597-9f34-490574ff2169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_50565540-4345-4f7f-9b4d-0137efa58091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cb5f9075-e822-4adf-9e1f-8e508e184765" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_50565540-4345-4f7f-9b4d-0137efa58091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e40dec20-f3f6-4416-80d4-4fe8ccf34f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cb5f9075-e822-4adf-9e1f-8e508e184765" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e40dec20-f3f6-4416-80d4-4fe8ccf34f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_277f648a-473e-4eab-a353-ea6bf06f636b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cb5f9075-e822-4adf-9e1f-8e508e184765" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_277f648a-473e-4eab-a353-ea6bf06f636b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f9bc0b6c-0fb8-426d-ad31-dc36c68fe293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f9bc0b6c-0fb8-426d-ad31-dc36c68fe293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_87799b6e-3d69-4156-944b-bc705505e119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_87799b6e-3d69-4156-944b-bc705505e119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_67045bde-8cb6-46ad-a3da-3d09c2257c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_67045bde-8cb6-46ad-a3da-3d09c2257c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_ad5a3bbb-ab90-45e0-bae0-3b99e430d1c5" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_ad5a3bbb-ab90-45e0-bae0-3b99e430d1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7300fd79-b9a8-4edc-897f-ffd52c905632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7300fd79-b9a8-4edc-897f-ffd52c905632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_78ffd7e4-db86-4488-95ae-61db463544ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5a66c5a6-3ea5-476b-acf0-fc8bf4572411" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_78ffd7e4-db86-4488-95ae-61db463544ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANS"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANSDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>bdtx-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended" id="i3706a10ee3d948eda85f79d32ffe9ef9_CoverPage"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i2209bfd2371f483183e4c3d3aea68c17_CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="i14f38ae9038f4762919a9980c69d5166_CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="ie4db942f89d649838323d51f7c8e2105_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="extended" id="i7250e1dbd17a494badd3aedeb6ce12db_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="iaf0a494bc7da4e5a9733ccb708b8ad2b_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4fa89960-62e7-4990-8c5e-209a5cdd3381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_NetIncomeLoss_4fa89960-62e7-4990-8c5e-209a5cdd3381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a0df109-8cd3-488c-804c-b6e798919a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_ShareBasedCompensation_9a0df109-8cd3-488c-804c-b6e798919a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_96ec8607-b79f-4f6f-b2b4-af2744cd2111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_96ec8607-b79f-4f6f-b2b4-af2744cd2111" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cb27f6b3-470b-46d5-a436-9f9333ff604b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_Depreciation_cb27f6b3-470b-46d5-a436-9f9333ff604b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_3d3996ba-6211-4a75-a89a-95c3ad46c162" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_3d3996ba-6211-4a75-a89a-95c3ad46c162" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_f67239e2-41e1-41d6-9572-ce8ae84b4b26" xlink:href="bdtx-20200930.xsd#bdtx_RentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_bdtx_RentExpense_f67239e2-41e1-41d6-9572-ce8ae84b4b26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_458106bc-f01f-4e0a-aeeb-50705d988a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_458106bc-f01f-4e0a-aeeb-50705d988a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_da18be76-f073-4a2e-9f6a-01b07352cd17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_da18be76-f073-4a2e-9f6a-01b07352cd17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_162bace1-368d-47ff-976a-3f6fa60097d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_162bace1-368d-47ff-976a-3f6fa60097d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_1d4e9531-8903-4285-ac14-db2deba6e4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_1d4e9531-8903-4285-ac14-db2deba6e4b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_79bb4dc2-449d-44ca-ae6d-eaa58cbaff8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_79bb4dc2-449d-44ca-ae6d-eaa58cbaff8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_df72d656-1b9a-4567-83e6-dc8aebaa67be" xlink:href="bdtx-20200930.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_df72d656-1b9a-4567-83e6-dc8aebaa67be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d75a26a6-110d-4f22-a29d-2ae387ca74b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d75a26a6-110d-4f22-a29d-2ae387ca74b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d23674cc-b552-490b-a453-44bab0829605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d23674cc-b552-490b-a453-44bab0829605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5c91eecb-2e5f-46d1-8ba0-655f09f5bcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5c91eecb-2e5f-46d1-8ba0-655f09f5bcdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641ba917-67c3-474c-8031-f6d45fd38fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_641ba917-67c3-474c-8031-f6d45fd38fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc18158c-83da-4730-b669-1ed6a1eeb60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc18158c-83da-4730-b669-1ed6a1eeb60d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_fbf883b6-5dd0-419d-9701-480622356090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_fbf883b6-5dd0-419d-9701-480622356090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ad63d1a2-d39e-41f1-b825-c1b8a298d517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ad63d1a2-d39e-41f1-b825-c1b8a298d517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0c6da217-011a-429e-90dc-05ca10e70583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0c6da217-011a-429e-90dc-05ca10e70583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7eee4551-29a7-46ff-8624-68dfacd957ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7eee4551-29a7-46ff-8624-68dfacd957ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7138a1d0-d5d8-48d3-99b0-d4aed3b6a4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7138a1d0-d5d8-48d3-99b0-d4aed3b6a4c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf2b5dc-6eaa-4619-b2a1-b9501f2bad40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf2b5dc-6eaa-4619-b2a1-b9501f2bad40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c13a5a17-5e86-4da0-b53a-b76ced5ad284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c13a5a17-5e86-4da0-b53a-b76ced5ad284" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee4b16d4-228c-4a36-82b2-597d86f40a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b96ea9b-8c11-457f-ba08-8010327f8323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b96ea9b-8c11-457f-ba08-8010327f8323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c3dc26b9-2a06-4b89-8c5e-3f4034e0c59d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c3dc26b9-2a06-4b89-8c5e-3f4034e0c59d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aba699bf-af46-494f-a747-0a4830df77e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_019923ce-2b4e-433e-9356-476ce87fa010" xlink:href="bdtx-20200930.xsd#bdtx_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_019923ce-2b4e-433e-9356-476ce87fa010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_f7771779-acce-401f-b2d6-3ab3d4eb5606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_f7771779-acce-401f-b2d6-3ab3d4eb5606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0fd7c139-c59c-467d-bd84-ab7071ea01fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0fd7c139-c59c-467d-bd84-ab7071ea01fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditAssumed1_c7b05c94-a1f6-42d8-866e-4b1f104907f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_LineOfCreditAssumed1_c7b05c94-a1f6-42d8-866e-4b1f104907f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:to="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_de754b09-2731-4e18-9b84-549a58d7ab44_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:to="loc_us-gaap_ClassOfStockDomain_de754b09-2731-4e18-9b84-549a58d7ab44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:to="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8635bed0-33af-4ee5-8ce8-2b40560d40fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8635bed0-33af-4ee5-8ce8-2b40560d40fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="extended" id="ic9a3b5d3f9734cdba1cdcf096345aa75_CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="i428b6ebe3c6c47f0aef49fe8a4cb1cb2_CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2be7cd97-d4bd-4dcf-b5a4-05e57a771c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2be7cd97-d4bd-4dcf-b5a4-05e57a771c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_74282277-8a94-4348-a752-77641f33c1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_74282277-8a94-4348-a752-77641f33c1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3a30ef0c-63c5-4e47-a735-653be1639f0c" xlink:href="bdtx-20200930.xsd#bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3a30ef0c-63c5-4e47-a735-653be1639f0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_25319d22-9ab0-4a05-b796-7723deb2c543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_25319d22-9ab0-4a05-b796-7723deb2c543" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_ea3f024f-f42f-47f8-86bb-38e4a49c8d6a" xlink:href="bdtx-20200930.xsd#bdtx_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_ea3f024f-f42f-47f8-86bb-38e4a49c8d6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_1b34ff15-4929-409a-a004-f34813216299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_1b34ff15-4929-409a-a004-f34813216299" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_e586d6bb-cd3e-401a-b198-7f2c53213f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0797e39e-b8d4-4abb-abd0-b7ddb170b71d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64873152-8228-43a8-9902-5c3aa5a3926b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64873152-8228-43a8-9902-5c3aa5a3926b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_571a426a-b02c-4529-bb22-5d36bdd30d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockholdersEquity_571a426a-b02c-4529-bb22-5d36bdd30d5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_83535188-65de-4546-b742-601fbce501d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_83535188-65de-4546-b742-601fbce501d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_79dd9d8f-74cc-4f59-bb5f-c949b354abc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_79dd9d8f-74cc-4f59-bb5f-c949b354abc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9b95fa2c-dab5-4b50-8539-4705b9282e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9b95fa2c-dab5-4b50-8539-4705b9282e9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_61a88ce0-f928-4a92-a642-782795d1ca66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_61a88ce0-f928-4a92-a642-782795d1ca66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c70f1ff-28d4-4af0-ab67-b16a9a5bf161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c70f1ff-28d4-4af0-ab67-b16a9a5bf161" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_57760039-ace4-4615-9a6b-9463554b7de8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_57760039-ace4-4615-9a6b-9463554b7de8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f85a0a0-d51c-456f-b4ca-63ed69a6021b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f85a0a0-d51c-456f-b4ca-63ed69a6021b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2e546-76e9-4ede-8c41-4757d6a83197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2e546-76e9-4ede-8c41-4757d6a83197" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_261d0c1b-5101-4c08-9fd1-dc18ce2dfc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_261d0c1b-5101-4c08-9fd1-dc18ce2dfc1c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_71db0928-3d83-42a8-bedd-fd7ddd92cb68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_71db0928-3d83-42a8-bedd-fd7ddd92cb68" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_416e04d6-ff5d-4842-806f-d03159d6b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_416e04d6-ff5d-4842-806f-d03159d6b93c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e270af0e-2277-41e5-973f-be896e043c70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e270af0e-2277-41e5-973f-be896e043c70" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_782fb4a5-6515-430a-aec8-982596069c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_782fb4a5-6515-430a-aec8-982596069c71" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81abb371-263e-4093-879e-05522008e895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_NetIncomeLoss_81abb371-263e-4093-879e-05522008e895" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a496daa7-d644-444f-a1ee-aee950e9fd79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b020f6b3-608d-4dba-9b37-b1a2ead77e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:to="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42bc9a94-8a5c-4c27-9e47-b10c27643e68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:to="loc_us-gaap_EquityComponentDomain_42bc9a94-8a5c-4c27-9e47-b10c27643e68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:to="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cb26cd54-122a-4c36-b157-fd421f3c152a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_CommonStockMember_cb26cd54-122a-4c36-b157-fd421f3c152a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5f0ed13d-075c-4542-85cd-59f86fb66806" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5f0ed13d-075c-4542-85cd-59f86fb66806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb29fa51-8eef-4b6b-850f-8894aa59bcdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb29fa51-8eef-4b6b-850f-8894aa59bcdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c1fa1a50-902d-4208-9528-d7b350e97990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_RetainedEarningsMember_c1fa1a50-902d-4208-9528-d7b350e97990" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:to="loc_us-gaap_ClassOfStockDomain_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:to="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_426a6f90-dace-4cbf-9f69-623ef914f221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_426a6f90-dace-4cbf-9f69-623ef914f221" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended" id="ie4f7431a5d9d454abc5cfa50967a8ee2_NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended" id="i845337356ede4919801cf54f3ff36344_NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_aefad231-a961-4659-ba6d-56300bf82a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_aefad231-a961-4659-ba6d-56300bf82a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_08fa687c-a76f-483c-9de4-46e5f0dd7643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_08fa687c-a76f-483c-9de4-46e5f0dd7643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d79c1385-4ca3-417f-b749-0d0140db78ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d79c1385-4ca3-417f-b749-0d0140db78ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_88c9578e-910c-4951-a4ac-d875bc19612d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_88c9578e-910c-4951-a4ac-d875bc19612d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a0c99b73-faae-4c5c-891d-010ae7627bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a0c99b73-faae-4c5c-891d-010ae7627bb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_81d38dc1-07c1-4cbd-a8fe-5d12239d7196" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_81d38dc1-07c1-4cbd-a8fe-5d12239d7196" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_15f5afc9-db47-4105-b4dc-efaa657a9667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:to="loc_us-gaap_IPOMember_15f5afc9-db47-4105-b4dc-efaa657a9667" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i464bcd44378e48008d2d6a692a987922_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="ideea64875e6047739cb317cc3d2d55b9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="ibc9de1f69c70429b85d0c97635fdb975_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="i0969d206ba6f4ceda01528f6a1fd9b82_FAIRVALUEMEASUREMENTS"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="icc5a8f3efce74330a621001403552a6f_FAIRVALUEMEASUREMENTSTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i9a7bd18b8d3a402d9036b2bedbaf8936_FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_630036c1-1ecd-4179-8b2f-110a09d9118e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_630036c1-1ecd-4179-8b2f-110a09d9118e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a00a1ddb-1e34-487a-a461-3c0b347c17f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a00a1ddb-1e34-487a-a461-3c0b347c17f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90ad49f0-aefb-4b1a-ba94-1fad0d21d0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_90ad49f0-aefb-4b1a-ba94-1fad0d21d0f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_79c4f18f-f854-4584-a870-0da7a0d4be75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:to="loc_us-gaap_DerivativeLiabilities_79c4f18f-f854-4584-a870-0da7a0d4be75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40a8d900-040b-4308-8910-77e7e77d56e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40a8d900-040b-4308-8910-77e7e77d56e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c38e59ec-90a1-48dc-b717-af88cd3e6b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c38e59ec-90a1-48dc-b717-af88cd3e6b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fe9c43d-2256-4911-966b-4bd060b1403f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fe9c43d-2256-4911-966b-4bd060b1403f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c70d3d25-0f4a-467a-a3ea-cf9b1bd99a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c70d3d25-0f4a-467a-a3ea-cf9b1bd99a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_da0c01e1-5fd9-4e13-a340-3ddddd05b519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_da0c01e1-5fd9-4e13-a340-3ddddd05b519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8328dc3d-5d00-472d-a98c-7c882aa0e8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8328dc3d-5d00-472d-a98c-7c882aa0e8a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a0babaa-6763-4046-beca-be5a043ca2e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a0babaa-6763-4046-beca-be5a043ca2e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cb5f1023-ba4b-4f45-9d4e-5334a5caab3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cb5f1023-ba4b-4f45-9d4e-5334a5caab3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a689b255-3e33-4abd-ba95-6b25c0a24fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a689b255-3e33-4abd-ba95-6b25c0a24fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_73050156-b8ef-40eb-9e16-07d6cbe899fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_73050156-b8ef-40eb-9e16-07d6cbe899fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f24f5a1-3134-42ea-a4bd-7e19ace7ceeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f24f5a1-3134-42ea-a4bd-7e19ace7ceeb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended" id="iaacfb2f4d11842b79338b5551adadb00_FAIRVALUEMEASUREMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23877028-1806-47da-bb72-3525133aea85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23877028-1806-47da-bb72-3525133aea85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_407c9205-2dc1-471e-ad45-53534127b7c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:to="loc_us-gaap_EquityComponentDomain_407c9205-2dc1-471e-ad45-53534127b7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:to="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_982fca69-b299-487d-9a88-40144c90fb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:to="loc_us-gaap_CommonStockMember_982fca69-b299-487d-9a88-40144c90fb2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="extended" id="i22a78bd7c81e4630b012b4655c8e85d5_FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTS"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="extended" id="if8de8a71c9db4c379f5e72967e613e3b_INVESTMENTS"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="extended" id="ia0d641b9609345d6a44ea365123b774d_INVESTMENTSTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended" id="ia80afaf2f9234f5c9966225144d356a5_INVESTMENTSScheduleofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ae202fc-d33f-42d7-af23-016e75b39a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ae202fc-d33f-42d7-af23-016e75b39a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2e268cae-e8ed-4c62-b333-1ba02ba40471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2e268cae-e8ed-4c62-b333-1ba02ba40471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6af6aa86-6bf1-4916-9253-f162e1715323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6af6aa86-6bf1-4916-9253-f162e1715323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5376d157-5bd8-40eb-97ff-4628c2ee1fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5376d157-5bd8-40eb-97ff-4628c2ee1fb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78c4d4d0-ce26-40ee-af47-839c841c5c25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78c4d4d0-ce26-40ee-af47-839c841c5c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f3877670-e85e-4745-bdb9-cc50bde4a804" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f3877670-e85e-4745-bdb9-cc50bde4a804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ae024e07-d34b-41fa-a5ff-46d436bb4727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ae024e07-d34b-41fa-a5ff-46d436bb4727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d080e134-cd1d-4e64-856c-e020b20b41ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d080e134-cd1d-4e64-856c-e020b20b41ed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENT"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended" id="i4412c955557e47219e36769cd40ca063_PROPERTYANDEQUIPMENT"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended" id="i9c6b70b257e748edac1db069c5fcf2af_PROPERTYANDEQUIPMENTTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended" id="ic59514c25f0b47ba8a2ca628ddfe95a6_PROPERTYANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_98339f5d-85c3-42e7-ab76-cc9c2583256a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_98339f5d-85c3-42e7-ab76-cc9c2583256a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562d8bfc-1759-4d09-a0ce-5ab672f030d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562d8bfc-1759-4d09-a0ce-5ab672f030d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3b9721ca-df9a-4b76-95fa-0af35cc05dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3b9721ca-df9a-4b76-95fa-0af35cc05dc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_30b7899f-3728-4044-8895-564d3901b891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_Depreciation_30b7899f-3728-4044-8895-564d3901b891" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe90e60-144a-4e6b-aa13-738ae6b90220_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe90e60-144a-4e6b-aa13-738ae6b90220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_19795511-ba25-4b1e-84cb-8ac64d7c0a55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_EquipmentMember_19795511-ba25-4b1e-84cb-8ac64d7c0a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ee0e13b8-b308-4e5e-95e9-595a97b6e1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_OfficeEquipmentMember_ee0e13b8-b308-4e5e-95e9-595a97b6e1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f2cd3c88-afdc-4df1-9488-20e2e5f7cdc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_ConstructionInProgressMember_f2cd3c88-afdc-4df1-9488-20e2e5f7cdc0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended" id="ice6277cac2e44d7e9d4801c520b2b4dd_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended" id="i303b6df11c1a40a8b36b706e67363e6d_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended" id="i8ce402fd15374810b0c8f2c0a448e2e3_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="i1c262ff0d7bd413784aae68bd80f9961_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended" id="i0c7df06f543049dd89315772f1e6622a_STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_61883345-8ede-4807-b7e0-12b82c7aa296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_61883345-8ede-4807-b7e0-12b82c7aa296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SharesAuthorized_b1ceda10-68d4-4dd0-99c3-f4cf7c5e7789" xlink:href="bdtx-20200930.xsd#bdtx_SharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_bdtx_SharesAuthorized_b1ceda10-68d4-4dd0-99c3-f4cf7c5e7789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c4443b3c-d16b-4275-afcf-d4d124f205e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c4443b3c-d16b-4275-afcf-d4d124f205e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ff3bdd3-9c5d-4024-84b6-9da736226a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ff3bdd3-9c5d-4024-84b6-9da736226a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45922ec0-5d3a-44c8-ba92-b07c3f67ff5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45922ec0-5d3a-44c8-ba92-b07c3f67ff5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b188c68-8ccf-4005-ac19-d866aa886b12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b188c68-8ccf-4005-ac19-d866aa886b12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4574a20-54bf-433f-b1c0-767c5ec82882_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:to="loc_us-gaap_EquityComponentDomain_f4574a20-54bf-433f-b1c0-767c5ec82882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:to="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4a43bbd-0a0a-4049-ba97-9adbcedabb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:to="loc_us-gaap_CommonStockMember_a4a43bbd-0a0a-4049-ba97-9adbcedabb0b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i12e62ebc874f46fe90a688918555284f_STOCKBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="i35f06931d49a4271a0f664e7852815e0_STOCKBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ib4bf45ee86194a5d9ca127d097f434ba_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ff0f21c6-07a7-4ff7-8fb7-b43b6e1e7d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ff0f21c6-07a7-4ff7-8fb7-b43b6e1e7d6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_d1c0093c-2800-4ef3-be45-06d3fac182d4" xlink:href="bdtx-20200930.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_d1c0093c-2800-4ef3-be45-06d3fac182d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a62cf128-a500-4fb9-9d47-d2b979e10a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a62cf128-a500-4fb9-9d47-d2b979e10a2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d58f082a-b015-4719-8bd2-ded2b6d4ebe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d58f082a-b015-4719-8bd2-ded2b6d4ebe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5adfc58e-eb18-4023-9240-b23e9472967f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5adfc58e-eb18-4023-9240-b23e9472967f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d8b436d2-df95-4f9d-b2c9-f3529282ba4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d8b436d2-df95-4f9d-b2c9-f3529282ba4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_009cc487-b32d-4022-a391-177ae405fc61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_009cc487-b32d-4022-a391-177ae405fc61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1eead00d-aab4-4b1c-9c01-7598b2e23f81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1eead00d-aab4-4b1c-9c01-7598b2e23f81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_adb19674-33d0-48d7-b705-5fafc3708ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_adb19674-33d0-48d7-b705-5fafc3708ede" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ad80029-afb8-4ece-ae6e-7da9e1954390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ad80029-afb8-4ece-ae6e-7da9e1954390" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2c824bad-ea17-485c-899d-90500e2cbcc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2c824bad-ea17-485c-899d-90500e2cbcc3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dad81d71-a043-41c5-a6a3-054cb2d8b182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dad81d71-a043-41c5-a6a3-054cb2d8b182" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd51ec3f-2850-41f7-954d-9a786b08f181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd51ec3f-2850-41f7-954d-9a786b08f181" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f43e7e8b-3c69-4395-9e65-3e1771628da4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f43e7e8b-3c69-4395-9e65-3e1771628da4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e66e2cd-e00c-4749-9560-9f23891e4d79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e66e2cd-e00c-4749-9560-9f23891e4d79" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3f90465a-2043-4451-9ec8-fe81dfeb2209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3f90465a-2043-4451-9ec8-fe81dfeb2209" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:to="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a20ecee4-80aa-4ede-a031-524a2cdc533c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a20ecee4-80aa-4ede-a031-524a2cdc533c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_383f49c1-858f-47c3-93fe-cf243889e159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_383f49c1-858f-47c3-93fe-cf243889e159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7eb78af0-86da-4aac-a776-7c865a24c680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7eb78af0-86da-4aac-a776-7c865a24c680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:to="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_769fa9c6-8928-4f0e-a6f2-8eee40837e14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:to="loc_us-gaap_PlanNameDomain_769fa9c6-8928-4f0e-a6f2-8eee40837e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:to="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020PlanMember_18a1f1fb-14f7-48fe-b0ba-a107e8ab64f8" xlink:href="bdtx-20200930.xsd#bdtx_A2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:to="loc_bdtx_A2020PlanMember_18a1f1fb-14f7-48fe-b0ba-a107e8ab64f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_c893c976-850c-4f5d-bc93-8432b5679ce6" xlink:href="bdtx-20200930.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_c893c976-850c-4f5d-bc93-8432b5679ce6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended" id="i5a9a9ac2092743ed9648e7beffbf54d8_STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9909d8a8-ce3e-4af9-947b-8c24de3a6428" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9909d8a8-ce3e-4af9-947b-8c24de3a6428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4b445400-f741-4196-a90f-527ce2793a6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4b445400-f741-4196-a90f-527ce2793a6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a5b82e0-8175-4fa9-87d7-d08d4c3788fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a5b82e0-8175-4fa9-87d7-d08d4c3788fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8df48c34-2b84-4e82-b1aa-03032248c198" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8df48c34-2b84-4e82-b1aa-03032248c198" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended" id="ic5676fa77f6b4c9499072fce7849751b_NETLOSSPERSHARE"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARETables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended" id="i9ca1534690c74b5ca3078d007cd0f059_NETLOSSPERSHARETables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="extended" id="i91d3e1f7c3374599b84b051d16c5479c_NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended" id="ic61cc17f36b949ea92d3056c101f4d4d_NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e9231596-b8e4-4194-8c64-64f3d58c82b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e9231596-b8e4-4194-8c64-64f3d58c82b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_68369942-f889-4dfa-90e2-bc338da0a43f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_68369942-f889-4dfa-90e2-bc338da0a43f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_914a1a2f-3fe5-4bec-a1f4-765b61ee304b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_914a1a2f-3fe5-4bec-a1f4-765b61ee304b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_cbf04268-e3be-4625-ac86-1f0247eade29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_RestrictedStockMember_cbf04268-e3be-4625-ac86-1f0247eade29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_81849657-d2b8-42e8-8ebb-6a5c636b3041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_81849657-d2b8-42e8-8ebb-6a5c636b3041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_babd99ee-eac7-4578-bc35-df223efa05db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_WarrantMember_babd99ee-eac7-4578-bc35-df223efa05db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASES"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="extended" id="ic1d4319d51644ed08781dcc92d70b5d7_LEASES"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESTables"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="extended" id="i7ad68afafd0c4c6b8b1eb66ad6427bc0_LEASESTables"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i59935682ec6f4b0ca4a614779f04703f_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_5c64b325-5d9c-440a-8d1d-69cdba504234" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_5c64b325-5d9c-440a-8d1d-69cdba504234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_749c5707-65f7-4f61-9d27-1fe3a6c08ae8" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_749c5707-65f7-4f61-9d27-1fe3a6c08ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fbd9b1aa-d715-46f4-9aeb-ada1889c60a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fbd9b1aa-d715-46f4-9aeb-ada1889c60a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5398f4a3-6f10-4255-be80-cca47a724444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5398f4a3-6f10-4255-be80-cca47a724444" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ebc80b6-f227-40d7-8598-e8f853874ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ebc80b6-f227-40d7-8598-e8f853874ae4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_00150213-bd7b-4065-be99-7a315463e867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_00150213-bd7b-4065-be99-7a315463e867" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:to="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermDomain_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a_default" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:to="loc_bdtx_LeaseContractualTermDomain_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:to="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_c8c71ace-93af-45fa-8ed7-ff2243815771" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_c8c71ace-93af-45fa-8ed7-ff2243815771" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_2150bcef-c8a3-44cc-958c-1d3c083038f2" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_2150bcef-c8a3-44cc-958c-1d3c083038f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended" id="i4a3e433bd7a84e948d721c68ae477d10_LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="ibb724cb4d49b480982766004aa3c47c5_LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="id47b5e4ac3124663bd2b1fe229b1bfaf_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANS"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="extended" id="i333cabc8227d43459ea97e0982d9c783_BENEFITPLANS"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="extended" id="id6f1af9d122147f9a46d25368589adad_BENEFITPLANSDetails"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="idc32f7560f9342db946890e7f68db729_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="ib30ed8efa43843c49e8e8776a412a583_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_59c360d9-b4ee-4b63-89a3-a1e8d22d4526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_59c360d9-b4ee-4b63-89a3-a1e8d22d4526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2059be46-9ff8-4077-a378-2e0d7589d53b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2059be46-9ff8-4077-a378-2e0d7589d53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PrepaidExpenseRelatedPartyCurrent_a6ea7c58-3070-410d-8fda-7a59d9b5d700" xlink:href="bdtx-20200930.xsd#bdtx_PrepaidExpenseRelatedPartyCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_bdtx_PrepaidExpenseRelatedPartyCurrent_a6ea7c58-3070-410d-8fda-7a59d9b5d700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa100b87-5031-4952-a82e-7bcec0d3fd28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa100b87-5031-4952-a82e-7bcec0d3fd28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a655aa3d-82c9-4fe2-89f2-be677764a6b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:to="loc_us-gaap_RelatedPartyDomain_a655aa3d-82c9-4fe2-89f2-be677764a6b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:to="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_5dd1cb85-25ef-4dc3-bb88-4a64178a7706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:to="loc_us-gaap_InvestorMember_5dd1cb85-25ef-4dc3-bb88-4a64178a7706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ServiceAgreementMonthlyMember_c309de9d-aafe-4c02-9eee-f6218f364a0d" xlink:href="bdtx-20200930.xsd#bdtx_ServiceAgreementMonthlyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:to="loc_bdtx_ServiceAgreementMonthlyMember_c309de9d-aafe-4c02-9eee-f6218f364a0d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bdtx-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_45f97f62-bee2-4b8d-9384-33c409216244_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant of restricted common stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_174a7f70-964b-4c4f-b479-27d0e955f02e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e0d73aaf-5ff6-4378-9622-e8ea722c6ebd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5a9a85a1-298c-42d4-8ac8-4bd5fa4d7d89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9e782b19-2467-4b02-8c58-499b610baf30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_f9135da6-baa0-4075-857c-4d3e3291000c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeline</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_6671c718-2299-4688-8cad-4e2c51a466f1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_344b8841-9a13-4068-a938-17073a463c20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c18caa5e-83a8-4926-b392-b5e7157263ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1bcb816c-9483-4238-833a-b3fe5d2bf7ed_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_81b87706-44d6-4095-a8da-bf70d975ef28_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aad5c64c-dd69-45df-9b76-fa522a36c60d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_f380891c-6e6b-4740-bab3-5699c5d7a4fd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_751c5dc6-931b-4c2a-8ad2-0c35cfbf9aee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares reserved</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_016acea4-9915-4ba8-9f2f-f86ff7ef4a62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de362b4b-e8af-48b2-bb93-eb0a9b0873cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d1284bca-5539-44d5-bf69-4732fc451bd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_12b9fc5a-7b59-45d3-8cf9-043d09dba527_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LeaseContractualTermDomain_333ea94f-7c35-472f-87c7-553bb147d06a_terseLabel_en-US" xlink:label="lab_bdtx_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_bdtx_LeaseContractualTermDomain_label_en-US" xlink:label="lab_bdtx_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_bdtx_LeaseContractualTermDomain_documentation_en-US" xlink:label="lab_bdtx_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermDomain" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LeaseContractualTermDomain" xlink:to="lab_bdtx_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_524b208e-1876-42f8-9bed-b40a72054b12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_97fdc366-ec8e-4ba0-8136-83cb2bfb319f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78eb059b-da1f-4531-ae64-6d2e67a6de81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4d51dcca-0bbd-4279-9aca-8603ad6ce1a4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40c35a58-dfd1-42a3-a418-202667ad91f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ed6b05b7-97e3-4abf-bf75-8b9e35ec9c93_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_759cac61-fd4e-4d2c-bae6-0d80b9315986_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution, percent of each participant's salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_89aea72b-3e85-4127-accd-06bdbf8884d5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_87bb53ed-2e76-4d91-a9d9-f2208e9b2056_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7de579b-cbbc-4449-9369-74d8837f386c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e0312cd1-130b-428e-96e1-5b219977f9cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to additional paid-in capital in connection with IPO</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e298f207-de4a-4252-a8b4-8a746f8bf6bf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_26624737-c40e-4452-8e2f-b60436d5a3b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_c967a35c-af35-45a3-810e-ea26c7329b8c_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (square feet)</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseArea" xlink:to="lab_bdtx_LesseeOperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_685b3fc4-90ee-4876-9225-61abecd74ce2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_addcc637-6e67-42a0-a1ae-f06f44a52556_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a8e9d441-42cd-41f5-b5fd-3d482ba0185c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_173f1e89-2e78-4218-903c-a12caa51786b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4dfca82a-d88d-4a59-9e74-690bcade848a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_43c6dabd-f97d-4848-aaec-4a65af6fa1c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ceaf1b7c-dc19-4891-84ce-166a7f7b21ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2e7efbd3-d0e7-43e2-9a0f-eb8c5c011188_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_017ca35b-2b42-4a06-bd4f-81f6f4750bab_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2dad7fd5-3747-413d-88d1-5ecd04394227_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7983df80-c100-49c4-899f-56899abc2da3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d7f26393-da62-4fde-81db-78b1693b96da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a8693e60-9b11-4b20-8bd2-f32a3c1ca112_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_09380b01-9498-4515-b494-81e63ab4aeb2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7df9d823-ae41-462d-bfd5-3cc786cf9b34_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e27564d7-960a-4531-a185-3026bd658ff4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_05a99f16-da20-406b-a986-e0d828e28ddc_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_086f572c-1cb5-4e0b-b47a-7aaaef0dc971_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0eab4e6c-30cc-4a54-ba96-b4352c3cce53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8705865-74fb-4349-b7b7-f3629adc49f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_84b8828c-83c6-4e01-83c1-3d4c8d27d1fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, net of issuance costs of $1,275</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1cdf0e7f-ed5b-403b-9819-eb197c3ffab0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9e361ff5-3a2e-417d-ad5d-9f7e82a17eae_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a04ca01-7bdc-4f26-92e7-9009d81b3ca1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3d8bb571-1e7d-49ef-9beb-cd5dd4589aba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_ef3b388a-ca04-4923-99de-63e7861278e9_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal office, lease one</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_label_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, One [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeOneMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:to="lab_bdtx_OperatingLeasePrincipalOfficeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c85832e4-e269-4171-8079-b3b71e215017_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8b0dd1fe-1461-4c61-851c-6cb5df96d8bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_93388a15-3765-4e74-84d5-d8391c6d106c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9e26655d-1ef0-4355-a16a-5c00bc785cf6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9955d470-5724-42de-9c61-c6e9bd07b3ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_87f06396-4af4-45cf-8582-9c32733cc3bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f02b2b6d-e305-4f7d-9bbf-8a6febd067f0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_d219cc39-bda0-41b4-8c67-6c166fab6272_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_539f051a-4181-4263-af49-55bb2dce7180_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_045915d3-a08a-4391-a006-5ccd14102404_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_7d33c3f5-9f8a-4906-8672-a027b7024d73_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ae905ac-a48d-4ca6-bc59-9fd03672196e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_84e8f9d9-1094-4b94-904c-3f6d0aef9e41_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f49d1140-6f44-4f6b-bb7d-6a43ab732c54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c0401d39-7201-4705-9a8b-d9611e512962_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_36dc77b2-586a-4834-947c-0869e694c189_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_75a270f7-6f30-4e9e-a914-c3d91a7c1c34_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party expense, service fees</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020PlanMember_04570052-7ace-4196-9044-9208f67e5fdc_terseLabel_en-US" xlink:label="lab_bdtx_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_bdtx_A2020PlanMember_label_en-US" xlink:label="lab_bdtx_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020PlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020PlanMember" xlink:href="bdtx-20200930.xsd#bdtx_A2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020PlanMember" xlink:to="lab_bdtx_A2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed26020d-4838-4254-91b1-dcbd003e84c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0fecfa00-9bf0-4248-a0a1-6b97661237bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8dd41eb-1ba9-49e3-b7e5-862ee3af90a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dff1dbd9-d014-4dde-a600-18b447c10b91_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1b9eb216-4e3f-4cfb-875a-6e275cceec89_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation and unaudited interim financial information</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9c135374-0050-4b80-875a-8b558b54ea94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_RentExpense_a341980b-bab7-41be-b499-6134c98bd077_terseLabel_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash rent expense</link:label>
    <link:label id="lab_bdtx_RentExpense_label_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:label id="lab_bdtx_RentExpense_documentation_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense" xlink:href="bdtx-20200930.xsd#bdtx_RentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_RentExpense" xlink:to="lab_bdtx_RentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_SharesAuthorized_c335d70c-48b9-42e5-8319-83767d615d2c_terseLabel_en-US" xlink:label="lab_bdtx_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares authorized</link:label>
    <link:label id="lab_bdtx_SharesAuthorized_label_en-US" xlink:label="lab_bdtx_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Authorized</link:label>
    <link:label id="lab_bdtx_SharesAuthorized_documentation_en-US" xlink:label="lab_bdtx_SharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SharesAuthorized" xlink:href="bdtx-20200930.xsd#bdtx_SharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_SharesAuthorized" xlink:to="lab_bdtx_SharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_19a37451-72be-475e-bbd1-b42aa5051404_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1f3ae257-85f7-486d-8f9b-eb945da1b60f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note&#160;11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a798b5f7-14bc-4a95-b80a-8d25cbf2bc6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e85a8746-8ec3-474b-921c-1e781d06bdaa_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be34171c-9f8b-4fca-b698-ff322fbc7fc2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_bf7fb05a-3873-4771-9bcd-e699afd5df3e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb0d6396-aedd-47d7-837f-d1eeeb27d18c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_cf901845-6fd2-4231-a3c6-a76a28ce5b32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1eed31e2-f747-40fa-ab9b-27c851e9a4e4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_55ed8692-7301-46c5-b7d6-9348bf9d28dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ebddfc91-5f05-492f-bd47-c6270f3cd345_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_2a3be150-b7f1-4eab-a357-4db66a57a801_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_52a5bf72-127e-43d3-b925-94b563627f86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant of restricted common stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9d9a9236-d9c5-44df-b5f9-7d71b6281cb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_94d6859d-cac9-4a63-90a6-0fe85b22531d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8b904c97-6a28-473b-b7c3-da8d1a951a36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2efb222f-9161-4151-ae3c-f4311a40d4ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 840</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_2cbd1192-0625-4d17-a346-bb3246cd5e07_terseLabel_en-US" xlink:label="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering and stock issuance costs included in accounts payable and accrued expenses and other current liabilities</link:label>
    <link:label id="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:href="bdtx-20200930.xsd#bdtx_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lab_bdtx_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_50f07160-f37f-4849-bc33-554081514301_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_21b08773-35bd-4d40-9505-5b80ff07ff4a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_896bf0a6-372e-4abe-8186-57f34d37567d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_25ba60e7-ef48-4e95-a5d0-61b457ec9455_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b39490c4-e690-43e7-b0da-85d5e361102d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1deef09c-d3fe-45cb-97c7-424fefca29e2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fbe379fd-355d-44c2-9bae-8614202164d9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9a2342f4-9579-40f6-8a24-e16e6ca7641a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dca1fc02-772b-4f19-b95a-8848e6c3c451_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_7519897b-0961-4804-8660-c92e32817b46_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_86c2ba74-7ae3-4d2d-b99d-4e71496287d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_963834cd-c745-49b7-96e3-fcbcbd05a9ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83d02e37-ad90-4566-bfcd-7276d503a5c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_fe283acb-db6c-4ac6-aa14-75b4ddcce8c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b1cea6d7-81c3-4002-9287-a022e1b5f4c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September&#160;30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ed9c88b0-1409-42ea-9a0f-1a8935df1440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_299dfb22-90e7-47d5-945d-8529f1482c98_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_9131dc37-f592-4f3b-96bc-311d2d2a8587_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of authorized shares, percent of common stock outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:href="bdtx-20200930.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c6d523e9-c9ab-4cef-acee-f1ff1b4baa7d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1d97b773-1dd4-40dd-918d-6e2dc4e436b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03c994c4-b901-46e4-b4fb-2ddf949d1397_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8446961f-c49f-4caf-a63f-4bf97b351a35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_d98d3a8c-de52-4105-8120-327bdcac6f2b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_e1b3b84b-77e8-4d64-b846-33c4016ea5f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_3a73c2c5-45ca-4f6d-8146-335cd06fcb46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8e278ee8-0094-4086-b534-309f160ee0d5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_11155ac1-2cc8-42d9-bf38-e066661c32aa_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4bc47e58-0dc4-4ee7-b3b7-18c24645069c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_bba303cb-b662-4b01-bd16-ad75e90d788a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase shares of series A preferred stock (as converted to common stock)</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4ba591eb-69b1-4b89-bc3f-f5d08580653a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fe8faac1-480d-4800-9023-fe40e4e94314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_8ba16f25-ff45-44f6-bd7a-1c5d32707c47_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e853ce0-0499-447b-a204-c831570a486a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_638773d5-7de5-43e7-8e90-c81bec02c302_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_03651eb4-a6f5-4711-8a11-854f6be9d9e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_df0a8276-1f70-4b28-81c2-0fbfe9df3635_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4c7bfd13-3050-47d1-807c-650eac79d9ce_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7e3f1dab-01d9-4a89-8c9a-05d18ad4e362_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_25fb3478-10fe-4f6d-821e-9ca65190e5b9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19365c96-c819-4a9d-a469-a805dd6fdc51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4bdc4ac-124c-4890-93e5-77016a9f3112_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe7de267-5d10-463b-a353-757427836775_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cad818b1-e1da-4ede-88d5-69447e6138f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2502fd4b-12dc-4aa3-a8dd-30550ee586e5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f59531be-f005-43d2-bf31-d1a098353d24_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in current assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8a6423ba-9136-49d2-865b-c107d7c3cc51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3e966bd-b8cd-4905-a3bc-8f77be9cea8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_affd6f33-3fe3-4a5e-89bf-40a77ae30cbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b43e92a5-c07e-480c-acda-3fffbb6c69a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bb7e52cb-1ec6-4a33-961a-27e8e909e245_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_22011087-d45e-4f36-88e7-e48ceccefecc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5151908-2e16-4369-9b93-ad0ec8ecb492_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_86f9ff60-c374-4c24-bb8a-4a5da72bf3be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c0993e15-e8b3-40a2-8cd0-201c9311fb49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f483ac92-fe7e-4587-8e3c-dbea89b51d4c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8e52da9-e21f-47af-a320-b84d0ac9205f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6ced739a-f95f-4950-8fde-5fad6b6db4ab_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b816b782-aba4-4d5a-954a-9587524037a7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0b821e32-dca5-4f2f-a2b7-2fd41a98fe8b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4700b7c1-b85d-4c05-92e2-d73f01df8500_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_AccruedLegalFeesCurrent_c5c3bb40-98fe-497c-baa6-4b3dbfee9b67_terseLabel_en-US" xlink:label="lab_bdtx_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_bdtx_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_bdtx_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_bdtx_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_bdtx_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedLegalFeesCurrent" xlink:href="bdtx-20200930.xsd#bdtx_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_AccruedLegalFeesCurrent" xlink:to="lab_bdtx_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_76e2d9aa-1f11-4f86-8ab1-1a5ec45c31df_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_a4265b0c-a7f0-46d0-91df-313be1c49d36_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_880c6d18-defd-4c39-ad0f-ddbfa05e94a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f9323e2-fb24-4191-b03f-57b38bbd4f35_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum lease payments due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2bc282f1-cc20-47f2-8e75-3972b8fc4d63_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3d826b14-9a56-4045-b999-c583322fafeb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_530eb841-59ac-40c6-9542-92e72967571a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_9221f673-60a0-4524-857b-c2c6278d0632_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LeaseContractualTermAxis_742ad7f1-ef7f-4495-884b-73aee7360343_terseLabel_en-US" xlink:label="lab_bdtx_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_bdtx_LeaseContractualTermAxis_label_en-US" xlink:label="lab_bdtx_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_bdtx_LeaseContractualTermAxis_documentation_en-US" xlink:label="lab_bdtx_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermAxis" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LeaseContractualTermAxis" xlink:to="lab_bdtx_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_a8a2377a-59fe-4b06-81c4-daab796ddef4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2fc3760b-7541-4892-b296-c84339cf8d59_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_727282a5-cd18-423e-9be9-d66e3ab3c33d_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_19400a6a-bf16-4048-b358-aaffe69106bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_08a64b03-4d0c-4aea-b652-e9cd7561a167_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_888af03c-1d5d-4ada-95c2-ba60da236b51_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c3c6b0e7-9253-4e80-86ad-4c3e7b54f5eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8f796f77-ceee-46a1-ab91-076eb6d6cb57_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_365d3eb5-add2-4e3a-9cf7-e8de5a7c65b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_3786949a-18a4-4fba-ace8-92a97cea9d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_605eba2b-148c-4571-ba76-620c559ac99e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2a4d37b-107a-4253-8efd-f511789c5d27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3bacbdb0-b7d7-486c-8bf6-560f031a7e82_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6586232d-ea1e-4be7-aa07-148a71a87211_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bffd410d-b5fe-419f-87eb-af7446f5258b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d000148a-cde4-4e06-b375-352965f78f38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a865f3ba-37b6-4c4a-b3e4-aa328c82eced_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f35f24b3-a92e-423b-8135-10096180dfef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_d6f12d5c-9197-450b-9c6c-310571b36da2_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4b05db68-c4ac-4f6d-ad88-68099f4df064_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term, optional extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b27e906e-ee9f-48f9-bfe7-a8a6b7d125c6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_308718b8-4c34-40c0-83ca-e252f4de6d56_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_855b5145-3d10-4c87-a3ac-2f028f459148_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_acef9da1-3858-46be-a99b-ac8131e3326e_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4acfe417-c700-42db-8fd7-a9e2a9759748_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_99471845-030a-4a21-b472-6fce4728e76d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrants to additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8aefe367-630b-4771-a6b3-70c58b3eaaae_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94bc9ed0-9b82-4428-a3a3-4133579e70c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_PrepaidExpenseRelatedPartyCurrent_f6f53c94-d6a2-4007-8eb7-dc8e4be99369_terseLabel_en-US" xlink:label="lab_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids with related party</link:label>
    <link:label id="lab_bdtx_PrepaidExpenseRelatedPartyCurrent_label_en-US" xlink:label="lab_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Related Party, Current</link:label>
    <link:label id="lab_bdtx_PrepaidExpenseRelatedPartyCurrent_documentation_en-US" xlink:label="lab_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Related Party, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:href="bdtx-20200930.xsd#bdtx_PrepaidExpenseRelatedPartyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:to="lab_bdtx_PrepaidExpenseRelatedPartyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d536d579-64ac-493f-bfdd-3566bfb935c5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cf7b6dae-7feb-4479-8530-a66b2d0cfd45_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dc9bd23d-8278-4c2e-87dc-004c0b4d10d9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8a543731-189a-4353-b30e-bca164611853_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_fe53ff36-841d-4a87-b3db-411f2275a3dd_negatedTerseLabel_en-US" xlink:label="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)</link:label>
    <link:label id="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_label_en-US" xlink:label="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity, Shares</link:label>
    <link:label id="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_documentation_en-US" xlink:label="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:href="bdtx-20200930.xsd#bdtx_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="lab_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cc5b682c-8034-4cea-8636-1ac3048e8e89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_507f12e4-625d-43f0-af6a-d53b1d6e9147_terseLabel_en-US" xlink:label="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of series B convertible preferred stock, net (in shares)</link:label>
    <link:label id="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="bdtx-20200930.xsd#bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5ddce6db-e1bf-4137-bad9-f6e90a1b783d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_830aa0ed-07f9-492f-81ed-f5728752fa03_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c67bf07f-91e7-4d74-bdbd-067f51dad0fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9e7ecc4b-897d-4079-9d73-491cfc19c592_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2c6eb403-1bae-417c-b42a-57700edad09b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_018b6f34-fa05-4daf-8822-71ca4334e858_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1a0d60f6-f08c-4390-b508-c161a30d62e2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_343a918d-d3e7-47f7-9c4e-bde98eeb9a76_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8c777028-8ffc-49d5-9a07-55d5b6d10d5b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative (inclusive of $0, $176, $0 and $357 respectively, with a related party)</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ec1a986f-8381-487c-b2a4-1bbba4452531_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74a021a-83c7-4d7a-9296-e0ac018ba2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_fd874f88-530a-4859-b04f-4c764367f544_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_8de5c674-1bbc-450d-8450-cdaa03d1a626_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a7a4ea1-0f0a-4f06-bd9c-e123756af3c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_a03ccae9-21f8-463c-80d6-8eb26a61ea93_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6a3f93ad-66cd-452f-8209-5027e070946a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_53511284-6ff2-4c4b-aaa1-8b00b57418b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a6c59497-b0e7-4a68-b38b-eb61f10fa4fd_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5e7f4e53-690c-4a19-aab9-90f83aacb7fd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative, related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_c35fd443-9e96-4f5a-b087-fe62e9307374_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon closing of the initial public offering</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_dc91a2f1-c3be-4734-905d-6cc0feef4e0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_27034b65-e3b9-4aae-84d2-fbc2b5141a6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized (loss) gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_aabcaf6e-476f-4ca5-935b-41d62abf4ea6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_29cfddfd-fd71-4260-baa8-12554f3126a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8f82c572-d169-4e3d-a28f-844ee420a654_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_54e7d760-184d-434e-8105-9cc74bd3e55c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c48ed3a-2a76-4e01-99ed-a57d07f19001_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_4020e1f2-34b2-4e15-a6d4-0edc3bac884f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_eaa5f809-1d2e-4f32-a426-80280f74eb7b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7f8cb8a3-bc73-4ddd-9a24-3146f783d693_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5b396b4d-e146-419a-9c03-19cfee199123_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued upon conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7dae029c-ccff-4d27-8027-c4b15bc892f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Fair Value Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_18ca102c-a66f-468d-8bef-f37f18428699_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty_a7e435b8-8ac1-4dfd-b29a-68a4633232d9_terseLabel_en-US" xlink:label="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, related party</link:label>
    <link:label id="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Research and Development Expenses from Transactions with Related Party</link:label>
    <link:label id="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty_documentation_en-US" xlink:label="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Research and Development Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:href="bdtx-20200930.xsd#bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:to="lab_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fc83a510-309c-42e4-aaca-6b8e3d365f34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fc1e2e20-976e-49ed-bfd1-0f688db7975e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0451dc5f-d91b-4b66-9ea4-fe7f5cda6b7c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_a8c8cb32-7f10-4375-b5cd-0549741c79f3_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1231898f-1694-4844-8fd4-ac067ec4cb6a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c34e6d45-0a25-4997-b793-7f232a9b4ecc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e82aa46-f977-4806-be7e-32c8073791be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8dbeda87-d7c3-470e-8b07-d0591aa5e505_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f172bfe-e98e-49f6-80cb-800c2b7cd66a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_046277d1-9484-40c8-8412-42a22bc7f926_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee4983d-a3ca-4017-be51-925636e851fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_afc00da0-e5d4-4c8c-8d7e-4df10f18efee_terseLabel_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracted research services</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_label_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_documentation_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:href="bdtx-20200930.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:to="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9c4b2f1f-20df-4e5d-b85a-bfefd4201465_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1e72615-bfb2-4411-a078-23c17205e910_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock issuance, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_de50a84d-c8e2-4d56-92e3-a0775a087d70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCosts_5d7dbdf3-2ee2-41db-a4e8-caccaa333b27_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredCosts_label_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8a5d3639-775b-4dca-84cb-9fdcb8844e91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4c36a945-8d6d-4cb2-a8c7-def4573f9496_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b68a27c1-e3da-40fe-a953-63e393a00f7a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, monthly transaction amount</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8a446c49-d6a6-474f-8491-dea33baf7eaa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_89d40be5-302d-47eb-89b2-2edd4c697243_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_dd5ce9c0-adad-4ba6-96b7-a5fb844d92ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_0628ded0-d757-4b84-a902-652cb1ed46f3_terseLabel_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 ESPP</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:href="bdtx-20200930.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d0ca8544-fbbb-40dd-89f2-d3583d60a444_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_2c447de8-2c59-4e60-ac21-4180b13e6f37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ServiceAgreementMonthlyMember_69186e79-a6b6-4e38-900d-d79cec6e9d5c_terseLabel_en-US" xlink:label="lab_bdtx_ServiceAgreementMonthlyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly service agreement</link:label>
    <link:label id="lab_bdtx_ServiceAgreementMonthlyMember_label_en-US" xlink:label="lab_bdtx_ServiceAgreementMonthlyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Monthly [Member]</link:label>
    <link:label id="lab_bdtx_ServiceAgreementMonthlyMember_documentation_en-US" xlink:label="lab_bdtx_ServiceAgreementMonthlyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Monthly</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ServiceAgreementMonthlyMember" xlink:href="bdtx-20200930.xsd#bdtx_ServiceAgreementMonthlyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ServiceAgreementMonthlyMember" xlink:to="lab_bdtx_ServiceAgreementMonthlyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9c027916-5ee6-46bf-a6a3-5231cf88953f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which the warrant may be converted</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_75a85821-a2ca-4e6b-a8b3-067fb529b439_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_91271afc-3ffd-49be-ba60-ba2b62b405fe_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_207624e8-8522-49d9-933e-f8d0a878fe73_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditAssumed1_d606cb3f-aa73-45fa-a721-7fd3fe8c0e9e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_LineOfCreditAssumed1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditAssumed1" xlink:to="lab_us-gaap_LineOfCreditAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0ff9945b-b193-467e-9970-c2d4bc3760d3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_84ccebde-a8fe-4201-97f1-fdb24dcbc638_terseLabel_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Lease Information</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_label_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract" xlink:href="bdtx-20200930.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LeaseOtherInformationAbstract" xlink:to="lab_bdtx_LeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_225ebce8-2387-4508-b5ec-501baadca829_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b8d1d187-5883-498a-8d0d-97f1b762d956_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_804cef05-0b4c-4e3e-87e3-1c0c1efe189c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.0001 par value; 500,000,000 shares authorized at September&#160;30, 2020 and 80,000,000 shares authorized at December&#160;31, 2019; 35,963,447 shares issued and outstanding at September&#160;30, 2020 and 2,236,672 shares issued and outstanding at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_af2a210d-5848-4838-8ea1-d59d537956a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9ee5119d-4946-41aa-8c63-e3d89202ae4c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (inclusive of $190, $3,480, $2,293 and $8,497 respectively, with a related party)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3a028943-f25d-47f9-9ab9-d5727f9edb7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_cca28e3d-9442-424a-b44a-15034fbefddc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cc45d92a-d7aa-47d2-be8a-bd524a2aabde_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED-PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_f27f4c7b-d0fb-4cf4-952e-a410b6e8f7ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b120f416-bce9-4c59-8dd7-affd8fcaeabb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a161bb12-6978-4ae8-9d93-9f5d4f030474_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a55111a2-2b5a-4227-822f-002ed08c29b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e2b475a-dbee-46d4-b0cc-f263c5ab6d00_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_392753af-3601-4bd3-b960-9e721a689350_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_8bc54282-77ad-4e59-a5ee-fc6d9256e30d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of series B convertible preferred stock, net</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fdfc6650-36c9-4be3-85bc-0978923bc703_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e93942de-b759-4d43-924f-968b44132308_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d556f250-f849-4892-b754-17070cb79dad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5acaaace-de5a-4f01-87dd-fba94eb470f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_503a91dc-6fb4-489b-8d49-59bd7c534474_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_05f429ee-1408-41b3-a2ab-0ce8862c06bd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5cb5d236-15b8-475c-9791-7ead0ba6a96c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_76c76d67-42d8-45bd-9c52-bf589b5731ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5154b1a1-aa94-4945-8217-2cba6ea87dc6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_099fc543-942b-49b8-a08e-3360fde2e199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of units vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_203ec29b-1a19-4851-85b5-ac96f3c7489e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c599ebc3-b6b5-4122-a5f5-7e39002c0d15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fc9a36be-91b4-47e6-95d9-b3fc9a94e46f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188491d-bb5e-44b0-88b2-ec7c62bb8bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_aa01956f-18d0-436e-9a40-d28c35ac5769_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_bd951193-ac9d-446a-a6ac-e8ca36310b33_terseLabel_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liability</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="bdtx-20200930.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_80acebae-c528-446d-b682-682c8285de58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d1c656e2-cb6d-44e1-b668-ed901ede582e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_552a4e2b-5b17-4065-9fde-3a4a25693c4c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b8283b7d-ddc3-4964-866a-5485aa0e34d0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Cost and Other Operating Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f42f1ec0-9fd6-4561-b8a5-dc91296bc596_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f8c11d56-0696-4a92-9b8e-7a9947402c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8817b586-d442-44d8-82e3-e354508858fa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fa06d505-93e2-4cc1-a4a7-9d980f85fbe4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon closing of the initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4e77eab0-fd4f-49d1-99c7-6d4e1535dd3e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock (Note 7)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_43484315-f618-4083-b50e-ac904d53e5de_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f8c77941-0e93-47b5-ae8e-2b04ccbdb423_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_5988e157-93d3-4042-96bd-937ae77f009d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e9ff1d27-b50d-412e-8602-e3df52f86c8c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_52babc13-ddd3-4b34-884f-d6e6eb677821_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_6535215c-a999-447e-b59b-619403bc7dce_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4a6e3082-edcd-4e74-95c8-0cdd0c46411f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_3cdd0205-7b3c-445d-88a9-e9e71558d92f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock (as converted to common stock)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ccb5ec6a-e954-4121-a4f9-be7984792002_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bae2b29b-9daa-42fc-94b2-0b25539839a8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_937db1a2-5e7d-4eda-a088-355fc17ee861_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_36b0f12f-bd59-462c-8bfa-935655b8c708_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_0a6be3bf-9dcb-42c4-a0a1-5908ba3f86a3_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_734fbdad-066c-41a5-99a0-63cd39a15025_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0bec4370-7b17-46a5-9d5b-8abae5b03294_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_15f4188a-cd58-4cfb-81ed-2bb67f9a5815_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e18277a7-e8a2-4875-97aa-4c69a2bdff9d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ff27cc80-60b3-4e06-a8a8-8cfab09a1927_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_11d232b1-7705-4ac0-a910-d077aec9af91_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_055c1566-fd3b-44bc-ad16-3b958e2921c2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8434c64b-fa2c-48c9-ab30-a7cd794ed103_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_4fbe0025-8d86-4029-9fab-47fbfffac595_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_390d18e9-d772-454b-ab04-9a92d6acdea2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cf96b77d-066c-4a6d-8043-b42a925a8dd8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_b75ba25b-9c1b-4c29-ae86-11368e3fdd0f_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_bb66d66d-eb36-44e1-a106-057252e94908_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1082991c-bf4d-478f-aa05-ae45c119458d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_dd9acf12-91aa-4b26-89e5-8e2dc5adef6b_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal office, lease two</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_label_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:to="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_876f75e0-b4c8-4805-aac0-2e4c28ef3285_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57d28ebb-87c4-4d79-8729-3c967378a642_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5708c8cf-d6c7-41aa-83aa-3c10664306a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_abe9f1ec-a2c2-408b-9c17-d778db285f6f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_459af232-a29a-4e52-830c-a43567982fda_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_eece889c-a0a9-4f1b-8a96-06ff1c54df48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bcb25906-768c-424e-996b-1b8a6ffa1d7d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a16b2777-aaaa-47e5-a5e5-ac07cb82fa89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c944f502-b9c6-47c9-a6d1-91726f0ccfce_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and consulting fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_d322bae4-00ef-4656-9747-700fb5635aba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bdtx-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a4819f0a-49c2-4676-9d84-b9b8a0a56ee8,g:ea093899-5abb-4018-bf2f-9bb1ffdc808f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b3c05679-42e3-4f60-8650-9afb67236f42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentType_b3c05679-42e3-4f60-8650-9afb67236f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7c666042-919e-458a-8fb0-2959e18dce0a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityRegistrantName_7c666042-919e-458a-8fb0-2959e18dce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bb0c49fd-7cf2-4b70-937e-6aaa5590cb61" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentQuarterlyReport_bb0c49fd-7cf2-4b70-937e-6aaa5590cb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f4b85923-6ba7-4754-9928-ebac7e2d99b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentTransitionReport_f4b85923-6ba7-4754-9928-ebac7e2d99b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_12260b1a-ef5c-45f7-8ba8-e5fa347d2fc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentPeriodEndDate_12260b1a-ef5c-45f7-8ba8-e5fa347d2fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_84bfbf7c-7417-43b6-ba58-22867e4f46ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentFiscalYearFocus_84bfbf7c-7417-43b6-ba58-22867e4f46ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3f2cdd8a-fc38-4ad7-bdce-4f2e76bcf018" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_CurrentFiscalYearEndDate_3f2cdd8a-fc38-4ad7-bdce-4f2e76bcf018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_577d86bf-0658-4ab4-823d-1916e2a10495" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_577d86bf-0658-4ab4-823d-1916e2a10495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_033712f2-ea03-47ef-8f1b-3e655120fd8b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityFileNumber_033712f2-ea03-47ef-8f1b-3e655120fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2063ada6-f62c-4ca6-aaa1-633501e7fefc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityCentralIndexKey_2063ada6-f62c-4ca6-aaa1-633501e7fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_673c10ca-2851-4097-8b16-57d12ada890b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_673c10ca-2851-4097-8b16-57d12ada890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0cc81511-6ac6-410e-a160-bf07e8b5e61e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityTaxIdentificationNumber_0cc81511-6ac6-410e-a160-bf07e8b5e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_aa95f3c9-84ef-465c-b922-6c19932288d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityAddressAddressLine1_aa95f3c9-84ef-465c-b922-6c19932288d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7c8a5fcd-0c00-4fd5-b12a-79533a37b3ca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityAddressCityOrTown_7c8a5fcd-0c00-4fd5-b12a-79533a37b3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9c2beedd-8d4d-42be-9ab5-f090d9207b94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityAddressStateOrProvince_9c2beedd-8d4d-42be-9ab5-f090d9207b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_98987838-ea18-4895-ae75-3c9f181e381d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityAddressPostalZipCode_98987838-ea18-4895-ae75-3c9f181e381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_de449160-2f3d-4252-b879-148d8ad96f81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_CityAreaCode_de449160-2f3d-4252-b879-148d8ad96f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2d3b42b6-3a4f-44dd-909a-36124ce1d128" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_LocalPhoneNumber_2d3b42b6-3a4f-44dd-909a-36124ce1d128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_868653b7-a319-42d2-ab1e-f379e1beb440" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_Security12bTitle_868653b7-a319-42d2-ab1e-f379e1beb440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9b70d8a6-97c7-496c-a432-cd510dc67c99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_TradingSymbol_9b70d8a6-97c7-496c-a432-cd510dc67c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2a87ab68-40db-4f8a-b27d-820f7f13f2d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_SecurityExchangeName_2a87ab68-40db-4f8a-b27d-820f7f13f2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_29bc1fc8-a694-4348-b4c9-1274b28387c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityCurrentReportingStatus_29bc1fc8-a694-4348-b4c9-1274b28387c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9d961ca5-0bed-4b49-b056-b06efc340b18" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityInteractiveDataCurrent_9d961ca5-0bed-4b49-b056-b06efc340b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0ba47bf8-6cca-454e-a8eb-9c01203c0ca1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_AmendmentFlag_0ba47bf8-6cca-454e-a8eb-9c01203c0ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f483991e-9c6e-4ef0-a247-f409e7307575" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityFilerCategory_f483991e-9c6e-4ef0-a247-f409e7307575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5d3941dc-6dc8-4787-96ed-69cea090e972" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntitySmallBusiness_5d3941dc-6dc8-4787-96ed-69cea090e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ab52e124-6f2f-4ad1-b8e7-e0309671dde1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityEmergingGrowthCompany_ab52e124-6f2f-4ad1-b8e7-e0309671dde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_1f5afacc-9446-4388-8441-a47dd4a512a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityExTransitionPeriod_1f5afacc-9446-4388-8441-a47dd4a512a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d6ecdcfa-2e83-461c-9d78-9560dce053bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityShellCompany_d6ecdcfa-2e83-461c-9d78-9560dce053bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ac5cbdcc-9ac1-4422-a0f8-dd8e99507ebc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a2551684-d505-422d-a864-5d4ae79de7d1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ac5cbdcc-9ac1-4422-a0f8-dd8e99507ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_52c23682-b13f-4720-978d-c6b0c482b72b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52c23682-b13f-4720-978d-c6b0c482b72b" xlink:to="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd1e9497-6ac1-4f1e-bdfb-2674744eb97a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd1e9497-6ac1-4f1e-bdfb-2674744eb97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcce433-98a2-4984-a313-78d233a09bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_efcce433-98a2-4984-a313-78d233a09bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2383407e-7abe-4957-8cc5-b092ecbe3716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2383407e-7abe-4957-8cc5-b092ecbe3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2fc2d262-2236-4f3d-8358-029e7ed7e4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dd2c1d16-98ce-4d80-b885-0a61cff53d19" xlink:to="loc_us-gaap_AssetsCurrent_2fc2d262-2236-4f3d-8358-029e7ed7e4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_208491aa-b4f4-4f6d-b2a7-9610c0f8ba61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_208491aa-b4f4-4f6d-b2a7-9610c0f8ba61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9b0e5a30-7268-466d-a6a7-cf133f75143e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9b0e5a30-7268-466d-a6a7-cf133f75143e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_444eec5f-c19b-4ae3-ab0f-abfa5a4ea3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_DeferredCosts_444eec5f-c19b-4ae3-ab0f-abfa5a4ea3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cf26c976-fe58-41ca-a52b-14c9bd67704c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cf26c976-fe58-41ca-a52b-14c9bd67704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_31de73c1-3648-4f32-a331-729df3a6811e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_31de73c1-3648-4f32-a331-729df3a6811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_501d2fb5-b55d-413d-a391-656f60b34781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab42981c-4b53-4f0e-a114-d5202c4117f2" xlink:to="loc_us-gaap_Assets_501d2fb5-b55d-413d-a391-656f60b34781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52c23682-b13f-4720-978d-c6b0c482b72b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a7e92c0f-d6e2-468f-9310-e8a2e0d1fb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:to="loc_us-gaap_AccountsPayableCurrent_a7e92c0f-d6e2-468f-9310-e8a2e0d1fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_460dd919-8442-4bbd-8957-90d63f1b1d28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_460dd919-8442-4bbd-8957-90d63f1b1d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b93e5dc9-b03d-4381-9070-7a193a288af9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b93e5dc9-b03d-4381-9070-7a193a288af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e09a1e28-45e8-4d1a-991d-e3bb1e42b479" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_33a076c9-7f21-4bc1-ac6c-b891b9bf0d72" xlink:to="loc_us-gaap_LiabilitiesCurrent_e09a1e28-45e8-4d1a-991d-e3bb1e42b479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_146db986-352b-4c74-99db-aa19c4797123" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_146db986-352b-4c74-99db-aa19c4797123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_998be4bb-e429-4fd0-8eba-f5a1878f787b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_998be4bb-e429-4fd0-8eba-f5a1878f787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_679a1f9d-edba-4a5b-8508-b4fa75a7d2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_Liabilities_679a1f9d-edba-4a5b-8508-b4fa75a7d2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed1df6ba-de5c-485a-8046-7ad684e4b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed1df6ba-de5c-485a-8046-7ad684e4b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_67236fe3-9409-4e5f-aeb1-9c9a9eae2d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_67236fe3-9409-4e5f-aeb1-9c9a9eae2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3af9ef1e-15f9-42fd-94dc-23ddeb5ea378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:to="loc_us-gaap_CommonStockValue_3af9ef1e-15f9-42fd-94dc-23ddeb5ea378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8166e04c-845d-4686-86d0-83c364bfba89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8166e04c-845d-4686-86d0-83c364bfba89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe85abf4-9271-42f2-9c63-a2b641a6ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe85abf4-9271-42f2-9c63-a2b641a6ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb09e5a6-100a-4692-8a41-a83848b0eab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb09e5a6-100a-4692-8a41-a83848b0eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_afcc3e21-f046-4208-b413-96632030de96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_022479d4-82d3-4cbf-bf74-86f6dc5789ef" xlink:to="loc_us-gaap_StockholdersEquity_afcc3e21-f046-4208-b413-96632030de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_da52e6bd-3538-47b1-bcf6-e957287c7240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05c18735-9bf8-467d-8d1b-b3a50401a2dc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_da52e6bd-3538-47b1-bcf6-e957287c7240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8d21e3f2-90a8-42e5-81c6-b8f2158ad4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa3e8990-b974-4003-a1a8-bd1009933fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d21e3f2-90a8-42e5-81c6-b8f2158ad4fd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fa3e8990-b974-4003-a1a8-bd1009933fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b228af16-ef67-42d3-89ad-b409034e73b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d21e3f2-90a8-42e5-81c6-b8f2158ad4fd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b228af16-ef67-42d3-89ad-b409034e73b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bfec4c45-6175-44f2-a44c-efba6b00b500" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d21e3f2-90a8-42e5-81c6-b8f2158ad4fd" xlink:to="loc_us-gaap_CommonStockSharesIssued_bfec4c45-6175-44f2-a44c-efba6b00b500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8642abfd-87eb-4331-a771-821b4a8a6796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8d21e3f2-90a8-42e5-81c6-b8f2158ad4fd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8642abfd-87eb-4331-a771-821b4a8a6796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8c244423-9ca6-4a48-91b7-c1cce73ebaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8c244423-9ca6-4a48-91b7-c1cce73ebaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2f3d0970-810d-4d4d-96b1-176689ce68eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8c244423-9ca6-4a48-91b7-c1cce73ebaaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2f3d0970-810d-4d4d-96b1-176689ce68eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0f6d00a3-bbbf-4200-ae0b-a96ae66e1308" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8c244423-9ca6-4a48-91b7-c1cce73ebaaf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0f6d00a3-bbbf-4200-ae0b-a96ae66e1308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b5fcdc9f-414b-498f-b92f-d51db894ea5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8c244423-9ca6-4a48-91b7-c1cce73ebaaf" xlink:to="loc_us-gaap_OperatingExpenses_b5fcdc9f-414b-498f-b92f-d51db894ea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_591da6b9-f6ad-4c24-983c-ab6927ef7111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_OperatingIncomeLoss_591da6b9-f6ad-4c24-983c-ab6927ef7111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_350a7d98-1387-4d2b-9ccc-c86d2713673c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:to="loc_us-gaap_InterestExpense_350a7d98-1387-4d2b-9ccc-c86d2713673c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_e768e776-f97b-4c5c-87b5-c9f8cbaf8ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_e768e776-f97b-4c5c-87b5-c9f8cbaf8ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e77bd7b-8199-44ab-b5d0-0138879c3b25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e77bd7b-8199-44ab-b5d0-0138879c3b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c5ce431-72b4-452e-be65-28bcf37d1e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c5ce431-72b4-452e-be65-28bcf37d1e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_84c1e224-6f04-4d7d-afe2-d39c059f7032" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e9f4b49-fad6-4f13-80f4-3d0c8b9cdff8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_84c1e224-6f04-4d7d-afe2-d39c059f7032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f02f5f60-2083-4c76-81cb-68c4db9d97b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_NetIncomeLoss_f02f5f60-2083-4c76-81cb-68c4db9d97b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_feaa9952-1069-4fc1-a3d7-457e7a094105" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_feaa9952-1069-4fc1-a3d7-457e7a094105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_886481de-2970-4f22-98d5-f25c91f78195" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_886481de-2970-4f22-98d5-f25c91f78195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_cdb8d9db-ed2f-400b-aa68-988d95baaa68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e9df3eb3-e70e-421f-9224-b9f30c465c26" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_cdb8d9db-ed2f-400b-aa68-988d95baaa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80d0b4ed-3927-47a6-8ffc-502ed7429cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_cdb8d9db-ed2f-400b-aa68-988d95baaa68" xlink:to="loc_us-gaap_NetIncomeLoss_80d0b4ed-3927-47a6-8ffc-502ed7429cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47766221-9137-40ac-9b11-2d0215760712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_cdb8d9db-ed2f-400b-aa68-988d95baaa68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47766221-9137-40ac-9b11-2d0215760712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_5ed9417f-a0c9-4eb2-9daa-942c6e51d70c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47766221-9137-40ac-9b11-2d0215760712" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_5ed9417f-a0c9-4eb2-9daa-942c6e51d70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_351b182e-844d-4db6-9f4d-4c7917717c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_cdb8d9db-ed2f-400b-aa68-988d95baaa68" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_351b182e-844d-4db6-9f4d-4c7917717c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a2405bd5-f6a0-4f4a-9527-be65e81466b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty_ddb13abb-fb2a-4190-aa70-51f16a9ded26" xlink:href="bdtx-20200930.xsd#bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a2405bd5-f6a0-4f4a-9527-be65e81466b6" xlink:to="loc_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty_ddb13abb-fb2a-4190-aa70-51f16a9ded26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_3a4be4f3-ea1d-4c4a-968f-ef86993659a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a2405bd5-f6a0-4f4a-9527-be65e81466b6" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_3a4be4f3-ea1d-4c4a-968f-ef86993659a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_df49529d-6e73-45c1-8b6d-a507d8581bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_df49529d-6e73-45c1-8b6d-a507d8581bf2" xlink:to="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:to="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_de754b09-2731-4e18-9b84-549a58d7ab44" xlink:to="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8635bed0-33af-4ee5-8ce8-2b40560d40fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3a77e9a4-242a-4a0c-8e08-21d72f389f13" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8635bed0-33af-4ee5-8ce8-2b40560d40fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c5b36dbd-68fc-4300-9fa7-2fe1df6e4337" xlink:to="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4fa89960-62e7-4990-8c5e-209a5cdd3381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_NetIncomeLoss_4fa89960-62e7-4990-8c5e-209a5cdd3381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a0df109-8cd3-488c-804c-b6e798919a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_ShareBasedCompensation_9a0df109-8cd3-488c-804c-b6e798919a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_96ec8607-b79f-4f6f-b2b4-af2744cd2111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_96ec8607-b79f-4f6f-b2b4-af2744cd2111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cb27f6b3-470b-46d5-a436-9f9333ff604b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_Depreciation_cb27f6b3-470b-46d5-a436-9f9333ff604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_3d3996ba-6211-4a75-a89a-95c3ad46c162" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfDiscount_3d3996ba-6211-4a75-a89a-95c3ad46c162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_f67239e2-41e1-41d6-9572-ce8ae84b4b26" xlink:href="bdtx-20200930.xsd#bdtx_RentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_bdtx_RentExpense_f67239e2-41e1-41d6-9572-ce8ae84b4b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_87647fb3-ab18-42f3-948f-7ea11ae62a6b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_458106bc-f01f-4e0a-aeeb-50705d988a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_458106bc-f01f-4e0a-aeeb-50705d988a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_da18be76-f073-4a2e-9f6a-01b07352cd17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_da18be76-f073-4a2e-9f6a-01b07352cd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_162bace1-368d-47ff-976a-3f6fa60097d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_162bace1-368d-47ff-976a-3f6fa60097d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_1d4e9531-8903-4285-ac14-db2deba6e4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_1d4e9531-8903-4285-ac14-db2deba6e4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_79bb4dc2-449d-44ca-ae6d-eaa58cbaff8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_79bb4dc2-449d-44ca-ae6d-eaa58cbaff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_df72d656-1b9a-4567-83e6-dc8aebaa67be" xlink:href="bdtx-20200930.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b307499a-a5be-4b32-92d9-87edd79d7f44" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_df72d656-1b9a-4567-83e6-dc8aebaa67be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d75a26a6-110d-4f22-a29d-2ae387ca74b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dae851ad-aece-4dcd-8dda-8011c32a2ccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d75a26a6-110d-4f22-a29d-2ae387ca74b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d23674cc-b552-490b-a453-44bab0829605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d23674cc-b552-490b-a453-44bab0829605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5c91eecb-2e5f-46d1-8ba0-655f09f5bcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5c91eecb-2e5f-46d1-8ba0-655f09f5bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641ba917-67c3-474c-8031-f6d45fd38fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_641ba917-67c3-474c-8031-f6d45fd38fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc18158c-83da-4730-b669-1ed6a1eeb60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_30d17571-9fd5-45c3-9c67-92e1d335ff15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc18158c-83da-4730-b669-1ed6a1eeb60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_fbf883b6-5dd0-419d-9701-480622356090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_fbf883b6-5dd0-419d-9701-480622356090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ad63d1a2-d39e-41f1-b825-c1b8a298d517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ad63d1a2-d39e-41f1-b825-c1b8a298d517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0c6da217-011a-429e-90dc-05ca10e70583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0c6da217-011a-429e-90dc-05ca10e70583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7eee4551-29a7-46ff-8624-68dfacd957ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7eee4551-29a7-46ff-8624-68dfacd957ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7138a1d0-d5d8-48d3-99b0-d4aed3b6a4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_97978f7b-f12c-432b-b79a-990babc97c0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7138a1d0-d5d8-48d3-99b0-d4aed3b6a4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf2b5dc-6eaa-4619-b2a1-b9501f2bad40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bf2b5dc-6eaa-4619-b2a1-b9501f2bad40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c13a5a17-5e86-4da0-b53a-b76ced5ad284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c13a5a17-5e86-4da0-b53a-b76ced5ad284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee4b16d4-228c-4a36-82b2-597d86f40a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee4b16d4-228c-4a36-82b2-597d86f40a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b96ea9b-8c11-457f-ba08-8010327f8323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4b96ea9b-8c11-457f-ba08-8010327f8323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c3dc26b9-2a06-4b89-8c5e-3f4034e0c59d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c3dc26b9-2a06-4b89-8c5e-3f4034e0c59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aba699bf-af46-494f-a747-0a4830df77e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0908aa42-e485-4920-827c-78fdbf6f99f4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aba699bf-af46-494f-a747-0a4830df77e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_00352261-fc20-47f5-aba5-5db8dc177df0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_019923ce-2b4e-433e-9356-476ce87fa010" xlink:href="bdtx-20200930.xsd#bdtx_DeferredOfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_bdtx_DeferredOfferingCostsIncurredButNotYetPaid_019923ce-2b4e-433e-9356-476ce87fa010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_f7771779-acce-401f-b2d6-3ab3d4eb5606" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_f7771779-acce-401f-b2d6-3ab3d4eb5606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0fd7c139-c59c-467d-bd84-ab7071ea01fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0fd7c139-c59c-467d-bd84-ab7071ea01fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditAssumed1_c7b05c94-a1f6-42d8-866e-4b1f104907f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ed299c-562c-447f-9792-0468f3e9f064" xlink:to="loc_us-gaap_LineOfCreditAssumed1_c7b05c94-a1f6-42d8-866e-4b1f104907f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_53f019b2-ff2d-4a1d-8cff-288eb3146834" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2d186035-d2e5-4ba9-8235-5e0b9c6b2c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53f019b2-ff2d-4a1d-8cff-288eb3146834" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2d186035-d2e5-4ba9-8235-5e0b9c6b2c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="bdtx-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_98cc9867-f9d8-4857-b4a4-fd9df20b8474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_98cc9867-f9d8-4857-b4a4-fd9df20b8474" xlink:to="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_42bc9a94-8a5c-4c27-9e47-b10c27643e68" xlink:to="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cb26cd54-122a-4c36-b157-fd421f3c152a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_CommonStockMember_cb26cd54-122a-4c36-b157-fd421f3c152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5f0ed13d-075c-4542-85cd-59f86fb66806" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5f0ed13d-075c-4542-85cd-59f86fb66806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb29fa51-8eef-4b6b-850f-8894aa59bcdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb29fa51-8eef-4b6b-850f-8894aa59bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c1fa1a50-902d-4208-9528-d7b350e97990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9368de44-5670-4132-81fd-72d9d36a132b" xlink:to="loc_us-gaap_RetainedEarningsMember_c1fa1a50-902d-4208-9528-d7b350e97990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7d5ea9df-bfbb-4804-a5c7-34b7d4cb9708" xlink:to="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_426a6f90-dace-4cbf-9f69-623ef914f221" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0e03e65f-566b-4a03-8df2-b876cfc24946" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_426a6f90-dace-4cbf-9f69-623ef914f221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dab59a33-2c9a-4140-a5de-782846bbd575" xlink:to="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2be7cd97-d4bd-4dcf-b5a4-05e57a771c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2be7cd97-d4bd-4dcf-b5a4-05e57a771c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_74282277-8a94-4348-a752-77641f33c1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_74282277-8a94-4348-a752-77641f33c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3a30ef0c-63c5-4e47-a735-653be1639f0c" xlink:href="bdtx-20200930.xsd#bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3a30ef0c-63c5-4e47-a735-653be1639f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_25319d22-9ab0-4a05-b796-7723deb2c543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_25319d22-9ab0-4a05-b796-7723deb2c543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_ea3f024f-f42f-47f8-86bb-38e4a49c8d6a" xlink:href="bdtx-20200930.xsd#bdtx_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares_ea3f024f-f42f-47f8-86bb-38e4a49c8d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_1b34ff15-4929-409a-a004-f34813216299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_1b34ff15-4929-409a-a004-f34813216299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_e586d6bb-cd3e-401a-b198-7f2c53213f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_e586d6bb-cd3e-401a-b198-7f2c53213f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0797e39e-b8d4-4abb-abd0-b7ddb170b71d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_64661588-b8c9-4949-9902-acdd314d62b7" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0797e39e-b8d4-4abb-abd0-b7ddb170b71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_613a7475-2bc7-4d92-b32c-93f7290dafcd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64873152-8228-43a8-9902-5c3aa5a3926b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64873152-8228-43a8-9902-5c3aa5a3926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_571a426a-b02c-4529-bb22-5d36bdd30d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockholdersEquity_571a426a-b02c-4529-bb22-5d36bdd30d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_83535188-65de-4546-b742-601fbce501d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_83535188-65de-4546-b742-601fbce501d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_79dd9d8f-74cc-4f59-bb5f-c949b354abc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_79dd9d8f-74cc-4f59-bb5f-c949b354abc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9b95fa2c-dab5-4b50-8539-4705b9282e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9b95fa2c-dab5-4b50-8539-4705b9282e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_61a88ce0-f928-4a92-a642-782795d1ca66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_61a88ce0-f928-4a92-a642-782795d1ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c70f1ff-28d4-4af0-ab67-b16a9a5bf161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c70f1ff-28d4-4af0-ab67-b16a9a5bf161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_57760039-ace4-4615-9a6b-9463554b7de8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_57760039-ace4-4615-9a6b-9463554b7de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f85a0a0-d51c-456f-b4ca-63ed69a6021b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2f85a0a0-d51c-456f-b4ca-63ed69a6021b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2e546-76e9-4ede-8c41-4757d6a83197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9e2e546-76e9-4ede-8c41-4757d6a83197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_261d0c1b-5101-4c08-9fd1-dc18ce2dfc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_261d0c1b-5101-4c08-9fd1-dc18ce2dfc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_71db0928-3d83-42a8-bedd-fd7ddd92cb68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_71db0928-3d83-42a8-bedd-fd7ddd92cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_416e04d6-ff5d-4842-806f-d03159d6b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_416e04d6-ff5d-4842-806f-d03159d6b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e270af0e-2277-41e5-973f-be896e043c70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e270af0e-2277-41e5-973f-be896e043c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_782fb4a5-6515-430a-aec8-982596069c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_782fb4a5-6515-430a-aec8-982596069c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81abb371-263e-4093-879e-05522008e895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_NetIncomeLoss_81abb371-263e-4093-879e-05522008e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a496daa7-d644-444f-a1ee-aee950e9fd79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a496daa7-d644-444f-a1ee-aee950e9fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b020f6b3-608d-4dba-9b37-b1a2ead77e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29d24edd-7f07-49c4-b9c6-95c0b06f604f" xlink:to="loc_us-gaap_StockholdersEquity_b020f6b3-608d-4dba-9b37-b1a2ead77e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_403532bd-0c32-4732-b13e-6c3054bb2239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_42fabfd6-7710-42f8-8279-61c1853c740a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_403532bd-0c32-4732-b13e-6c3054bb2239" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_42fabfd6-7710-42f8-8279-61c1853c740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7209a2a-44b3-4c56-88aa-e1952b9947e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7209a2a-44b3-4c56-88aa-e1952b9947e5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e3ebcab-8a67-42fa-ba28-213f7d7ea37d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_15f5afc9-db47-4105-b4dc-efaa657a9667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23935975-2409-4d06-aa79-e18c175b85ee" xlink:to="loc_us-gaap_IPOMember_15f5afc9-db47-4105-b4dc-efaa657a9667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_25e109b3-8e2c-4794-9d95-91ee85339622" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_aefad231-a961-4659-ba6d-56300bf82a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_aefad231-a961-4659-ba6d-56300bf82a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_08fa687c-a76f-483c-9de4-46e5f0dd7643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_08fa687c-a76f-483c-9de4-46e5f0dd7643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d79c1385-4ca3-417f-b749-0d0140db78ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d79c1385-4ca3-417f-b749-0d0140db78ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_88c9578e-910c-4951-a4ac-d875bc19612d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_88c9578e-910c-4951-a4ac-d875bc19612d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a0c99b73-faae-4c5c-891d-010ae7627bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a0c99b73-faae-4c5c-891d-010ae7627bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_81d38dc1-07c1-4cbd-a8fe-5d12239d7196" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cd8ee539-d903-4a98-96c2-e65d95a0ad16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_81d38dc1-07c1-4cbd-a8fe-5d12239d7196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9e67581-426a-4ab1-9529-a681a875b4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bd30d906-0952-45a6-8d40-c8449ced48a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9e67581-426a-4ab1-9529-a681a875b4e9" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_bd30d906-0952-45a6-8d40-c8449ced48a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9ed0c972-7549-4545-98a9-d5644fd908b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9ed0c972-7549-4545-98a9-d5644fd908b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_76507a7d-92ac-4509-9b9f-011630429249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_76507a7d-92ac-4509-9b9f-011630429249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ed02dd42-029c-457b-911c-dd71b1a2b929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_UseOfEstimates_ed02dd42-029c-457b-911c-dd71b1a2b929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_b72efdc1-0080-413f-adb5-57c02c47792b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_b72efdc1-0080-413f-adb5-57c02c47792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_47450c14-bfcc-43c5-9807-77dc7e1694d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_47450c14-bfcc-43c5-9807-77dc7e1694d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_667fc732-0c62-47d0-95ea-9fb86718c668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_667fc732-0c62-47d0-95ea-9fb86718c668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e88c8d91-f711-4a73-99a0-b8b97ebc0422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e88c8d91-f711-4a73-99a0-b8b97ebc0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8c4f1e8e-ee45-4bd5-8e9e-9df63116271a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8c4f1e8e-ee45-4bd5-8e9e-9df63116271a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b1d399b7-6867-4c47-98e1-7b711cfa31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b263e21-9fbf-4f9e-be60-135782e3be60" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b1d399b7-6867-4c47-98e1-7b711cfa31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4b944db2-8b34-4a90-8a31-933dc337a15e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_39516129-f0ae-4445-93f7-a7526ae274d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b944db2-8b34-4a90-8a31-933dc337a15e" xlink:to="loc_us-gaap_DeferredCosts_39516129-f0ae-4445-93f7-a7526ae274d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_470fa876-a270-42bf-bd5c-e2f48c244e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8e95c959-9d24-47cb-a1e7-045230f7ed0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_470fa876-a270-42bf-bd5c-e2f48c244e2e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8e95c959-9d24-47cb-a1e7-045230f7ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cd14477e-7cf2-498d-baba-45f6ecffc1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aee943f0-6a04-4b74-8a32-39638efa3637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd14477e-7cf2-498d-baba-45f6ecffc1db" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aee943f0-6a04-4b74-8a32-39638efa3637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f5b5aaad-de7e-4325-a42a-51bf0e5ff207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd14477e-7cf2-498d-baba-45f6ecffc1db" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f5b5aaad-de7e-4325-a42a-51bf0e5ff207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbbdcba1-0028-4b9c-afc9-137915f9a676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbbdcba1-0028-4b9c-afc9-137915f9a676" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6cd6ad7d-74b5-4674-81e7-5c0c81ee6bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c38e59ec-90a1-48dc-b717-af88cd3e6b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_34e6d236-7e42-4411-9080-9c1cf80cbcdf" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c38e59ec-90a1-48dc-b717-af88cd3e6b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fe9c43d-2256-4911-966b-4bd060b1403f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c70d3d25-0f4a-467a-a3ea-cf9b1bd99a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c70d3d25-0f4a-467a-a3ea-cf9b1bd99a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_da0c01e1-5fd9-4e13-a340-3ddddd05b519" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_da0c01e1-5fd9-4e13-a340-3ddddd05b519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8328dc3d-5d00-472d-a98c-7c882aa0e8a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cee0a6c2-eeca-403b-8a31-3079517709c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8328dc3d-5d00-472d-a98c-7c882aa0e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0babaa-6763-4046-beca-be5a043ca2e7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cb5f1023-ba4b-4f45-9d4e-5334a5caab3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cb5f1023-ba4b-4f45-9d4e-5334a5caab3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a689b255-3e33-4abd-ba95-6b25c0a24fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a689b255-3e33-4abd-ba95-6b25c0a24fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_73050156-b8ef-40eb-9e16-07d6cbe899fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_73050156-b8ef-40eb-9e16-07d6cbe899fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f24f5a1-3134-42ea-a4bd-7e19ace7ceeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bf096c55-edb2-4b46-8eab-a182ebce538c" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f24f5a1-3134-42ea-a4bd-7e19ace7ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c1752f13-bce3-41da-8760-714292cecab8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_630036c1-1ecd-4179-8b2f-110a09d9118e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_630036c1-1ecd-4179-8b2f-110a09d9118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a00a1ddb-1e34-487a-a461-3c0b347c17f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a00a1ddb-1e34-487a-a461-3c0b347c17f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90ad49f0-aefb-4b1a-ba94-1fad0d21d0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_951554a4-3018-4bde-84d1-641772def100" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_90ad49f0-aefb-4b1a-ba94-1fad0d21d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eedbf2d-b4ca-4885-a0ce-d486d2ecf512" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_79c4f18f-f854-4584-a870-0da7a0d4be75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:to="loc_us-gaap_DerivativeLiabilities_79c4f18f-f854-4584-a870-0da7a0d4be75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_40a8d900-040b-4308-8910-77e7e77d56e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_54883142-1ef9-40cf-b965-7a8cf70f4ba6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_40a8d900-040b-4308-8910-77e7e77d56e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_530b3d5b-f4e1-4583-b6b3-d2ee77787f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_530b3d5b-f4e1-4583-b6b3-d2ee77787f0b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_407c9205-2dc1-471e-ad45-53534127b7c4" xlink:to="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_982fca69-b299-487d-9a88-40144c90fb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_021d75f8-f0e8-4c12-9b1e-9977c8079b00" xlink:to="loc_us-gaap_CommonStockMember_982fca69-b299-487d-9a88-40144c90fb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d9d0fbdb-22d0-4b30-94da-f4ae306052bc" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23877028-1806-47da-bb72-3525133aea85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9a4b661d-9e0e-4c57-b4a9-e4a5c828f8fd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_23877028-1806-47da-bb72-3525133aea85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0e49e9a4-89d9-41a3-ae95-d25c2651137f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9bc9d0b-ba93-4965-a6ff-e4dc1cf2cd7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0e49e9a4-89d9-41a3-ae95-d25c2651137f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9bc9d0b-ba93-4965-a6ff-e4dc1cf2cd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e051e18-13ef-4ee7-a2f6-5b41bd930a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9bc9d0b-ba93-4965-a6ff-e4dc1cf2cd7b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e051e18-13ef-4ee7-a2f6-5b41bd930a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_427b26b1-d1eb-47e3-96fb-1507d3ded7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9bc9d0b-ba93-4965-a6ff-e4dc1cf2cd7b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_427b26b1-d1eb-47e3-96fb-1507d3ded7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2050d112-08ad-48de-ad43-9c4c33dd4b07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f9bc9d0b-ba93-4965-a6ff-e4dc1cf2cd7b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2050d112-08ad-48de-ad43-9c4c33dd4b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24d62daf-6899-4da6-b9bd-27433b490065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_243b3bb2-7ff3-41e9-bd9f-ce789ea27b05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24d62daf-6899-4da6-b9bd-27433b490065" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_243b3bb2-7ff3-41e9-bd9f-ce789ea27b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a96f43a2-af3a-4122-af8b-be7b9242a28a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9077d807-c7be-457d-aa89-84db6d5931e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a96f43a2-af3a-4122-af8b-be7b9242a28a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9077d807-c7be-457d-aa89-84db6d5931e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56a8bfa8-8aa8-44b8-849d-7a4d80977793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_56a8bfa8-8aa8-44b8-849d-7a4d80977793" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78c4d4d0-ce26-40ee-af47-839c841c5c25" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f3877670-e85e-4745-bdb9-cc50bde4a804" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f3877670-e85e-4745-bdb9-cc50bde4a804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ae024e07-d34b-41fa-a5ff-46d436bb4727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ae024e07-d34b-41fa-a5ff-46d436bb4727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d080e134-cd1d-4e64-856c-e020b20b41ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_511d53e2-fc7d-4d6f-a977-bc975ed54ab5" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d080e134-cd1d-4e64-856c-e020b20b41ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bc70490f-eac7-408d-a36c-697ceb075c1d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ae202fc-d33f-42d7-af23-016e75b39a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ae202fc-d33f-42d7-af23-016e75b39a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2e268cae-e8ed-4c62-b333-1ba02ba40471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2e268cae-e8ed-4c62-b333-1ba02ba40471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6af6aa86-6bf1-4916-9253-f162e1715323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6af6aa86-6bf1-4916-9253-f162e1715323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5376d157-5bd8-40eb-97ff-4628c2ee1fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_927b27bd-0a9a-4fde-9e81-e2aec410c5ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5376d157-5bd8-40eb-97ff-4628c2ee1fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b1b57a89-146b-4206-9015-4847654159ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6c99a3e0-923f-46ee-9738-bb7a620db786" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b1b57a89-146b-4206-9015-4847654159ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6c99a3e0-923f-46ee-9738-bb7a620db786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e885a8e1-48f9-42d2-ab2d-600457ad15a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78fb512b-ac0d-4521-9127-c280de334e68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e885a8e1-48f9-42d2-ab2d-600457ad15a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78fb512b-ac0d-4521-9127-c280de334e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8432f0ce-ea6b-4a40-8a1b-21bed5f2799d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8432f0ce-ea6b-4a40-8a1b-21bed5f2799d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fe90e60-144a-4e6b-aa13-738ae6b90220" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_19795511-ba25-4b1e-84cb-8ac64d7c0a55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_EquipmentMember_19795511-ba25-4b1e-84cb-8ac64d7c0a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ee0e13b8-b308-4e5e-95e9-595a97b6e1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_OfficeEquipmentMember_ee0e13b8-b308-4e5e-95e9-595a97b6e1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f2cd3c88-afdc-4df1-9488-20e2e5f7cdc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bd96fa9-a4e0-42dd-9391-619ddc280842" xlink:to="loc_us-gaap_ConstructionInProgressMember_f2cd3c88-afdc-4df1-9488-20e2e5f7cdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0c67ffe-9323-46b8-af19-2690f678d37d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_98339f5d-85c3-42e7-ab76-cc9c2583256a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_98339f5d-85c3-42e7-ab76-cc9c2583256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562d8bfc-1759-4d09-a0ce-5ab672f030d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_562d8bfc-1759-4d09-a0ce-5ab672f030d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3b9721ca-df9a-4b76-95fa-0af35cc05dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3b9721ca-df9a-4b76-95fa-0af35cc05dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_30b7899f-3728-4044-8895-564d3901b891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4fdbb26c-f5cb-4cb4-af95-95fb251a7aef" xlink:to="loc_us-gaap_Depreciation_30b7899f-3728-4044-8895-564d3901b891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d14f6235-1e54-49a8-bc63-c2ee8e8ab916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_dab915bc-4e26-4447-9f45-f1e017757d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d14f6235-1e54-49a8-bc63-c2ee8e8ab916" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_dab915bc-4e26-4447-9f45-f1e017757d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_afac2b8c-63a6-402b-95af-851742009639" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d0372164-917d-41f9-9290-e89509e8850d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_afac2b8c-63a6-402b-95af-851742009639" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d0372164-917d-41f9-9290-e89509e8850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_436feaaa-e8bc-46b0-8be3-e142e32f4eee" xlink:href="bdtx-20200930.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_436feaaa-e8bc-46b0-8be3-e142e32f4eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d70becac-ad75-4833-a7c3-eabff6dd6218" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d70becac-ad75-4833-a7c3-eabff6dd6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1e17a047-2ed8-46ca-80fe-f1ae4dbc2128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1e17a047-2ed8-46ca-80fe-f1ae4dbc2128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedLegalFeesCurrent_6ed33032-dd9b-470c-9e77-86c66bdce2fd" xlink:href="bdtx-20200930.xsd#bdtx_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_bdtx_AccruedLegalFeesCurrent_6ed33032-dd9b-470c-9e77-86c66bdce2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e4aee2ba-a9e2-4955-a538-acc57b34b3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e4aee2ba-a9e2-4955-a538-acc57b34b3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c56fb0e-2642-49c7-9afe-55a0f4acd92a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fa72aaac-4a5b-4df8-8024-16a8bc1b0bd5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7c56fb0e-2642-49c7-9afe-55a0f4acd92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0b256597-6976-4e94-bfbc-1f521b9362e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b3900a79-20e6-4ff9-bcfd-758b3cc69306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b256597-6976-4e94-bfbc-1f521b9362e5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b3900a79-20e6-4ff9-bcfd-758b3cc69306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_23dd9f93-4be8-4104-95e0-393f9877a572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23dd9f93-4be8-4104-95e0-393f9877a572" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4574a20-54bf-433f-b1c0-767c5ec82882" xlink:to="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4a43bbd-0a0a-4049-ba97-9adbcedabb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_464fe299-f1d7-4aaf-a92b-956dab18c17b" xlink:to="loc_us-gaap_CommonStockMember_a4a43bbd-0a0a-4049-ba97-9adbcedabb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6d5615f-2294-44ee-a637-7227bef09fe6" xlink:to="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_61883345-8ede-4807-b7e0-12b82c7aa296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_61883345-8ede-4807-b7e0-12b82c7aa296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SharesAuthorized_b1ceda10-68d4-4dd0-99c3-f4cf7c5e7789" xlink:href="bdtx-20200930.xsd#bdtx_SharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_bdtx_SharesAuthorized_b1ceda10-68d4-4dd0-99c3-f4cf7c5e7789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c4443b3c-d16b-4275-afcf-d4d124f205e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c4443b3c-d16b-4275-afcf-d4d124f205e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ff3bdd3-9c5d-4024-84b6-9da736226a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4ff3bdd3-9c5d-4024-84b6-9da736226a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_45922ec0-5d3a-44c8-ba92-b07c3f67ff5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_45922ec0-5d3a-44c8-ba92-b07c3f67ff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b188c68-8ccf-4005-ac19-d866aa886b12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b23afb45-1639-4bb4-b417-383a9e55051b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b188c68-8ccf-4005-ac19-d866aa886b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc2cf28e-d6ab-4865-bd9c-819f2e9f14f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_486d5e0a-5d24-4307-98e7-4e08cd7d7a69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc2cf28e-d6ab-4865-bd9c-819f2e9f14f0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_486d5e0a-5d24-4307-98e7-4e08cd7d7a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236c1553-7996-4368-9d3d-966952ac3c15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_365d1491-437e-41d7-8830-63b567843182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236c1553-7996-4368-9d3d-966952ac3c15" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_365d1491-437e-41d7-8830-63b567843182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59b49ab-53b7-4098-8953-0175df3b1de3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59b49ab-53b7-4098-8953-0175df3b1de3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:to="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a20ecee4-80aa-4ede-a031-524a2cdc533c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_383f49c1-858f-47c3-93fe-cf243889e159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_383f49c1-858f-47c3-93fe-cf243889e159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7eb78af0-86da-4aac-a776-7c865a24c680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5582d68-50d9-4158-b42d-08d6260b757e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7eb78af0-86da-4aac-a776-7c865a24c680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:to="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_769fa9c6-8928-4f0e-a6f2-8eee40837e14" xlink:to="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020PlanMember_18a1f1fb-14f7-48fe-b0ba-a107e8ab64f8" xlink:href="bdtx-20200930.xsd#bdtx_A2020PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:to="loc_bdtx_A2020PlanMember_18a1f1fb-14f7-48fe-b0ba-a107e8ab64f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_c893c976-850c-4f5d-bc93-8432b5679ce6" xlink:href="bdtx-20200930.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_71cd1b43-2008-4405-8969-7fafbd2d6e0f" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_c893c976-850c-4f5d-bc93-8432b5679ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1537d80c-c783-4b36-851d-4c3cf3e0c26e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ff0f21c6-07a7-4ff7-8fb7-b43b6e1e7d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ff0f21c6-07a7-4ff7-8fb7-b43b6e1e7d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_d1c0093c-2800-4ef3-be45-06d3fac182d4" xlink:href="bdtx-20200930.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_d1c0093c-2800-4ef3-be45-06d3fac182d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a62cf128-a500-4fb9-9d47-d2b979e10a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a62cf128-a500-4fb9-9d47-d2b979e10a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d58f082a-b015-4719-8bd2-ded2b6d4ebe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d58f082a-b015-4719-8bd2-ded2b6d4ebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5adfc58e-eb18-4023-9240-b23e9472967f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5adfc58e-eb18-4023-9240-b23e9472967f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d8b436d2-df95-4f9d-b2c9-f3529282ba4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d8b436d2-df95-4f9d-b2c9-f3529282ba4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_009cc487-b32d-4022-a391-177ae405fc61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_009cc487-b32d-4022-a391-177ae405fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1eead00d-aab4-4b1c-9c01-7598b2e23f81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1eead00d-aab4-4b1c-9c01-7598b2e23f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_adb19674-33d0-48d7-b705-5fafc3708ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_adb19674-33d0-48d7-b705-5fafc3708ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ad80029-afb8-4ece-ae6e-7da9e1954390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ad80029-afb8-4ece-ae6e-7da9e1954390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2c824bad-ea17-485c-899d-90500e2cbcc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2c824bad-ea17-485c-899d-90500e2cbcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dad81d71-a043-41c5-a6a3-054cb2d8b182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dad81d71-a043-41c5-a6a3-054cb2d8b182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd51ec3f-2850-41f7-954d-9a786b08f181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd51ec3f-2850-41f7-954d-9a786b08f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f43e7e8b-3c69-4395-9e65-3e1771628da4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f43e7e8b-3c69-4395-9e65-3e1771628da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e66e2cd-e00c-4749-9560-9f23891e4d79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e66e2cd-e00c-4749-9560-9f23891e4d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3f90465a-2043-4451-9ec8-fe81dfeb2209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_562d4a1c-df1f-470b-b85e-4afbbf6dfd90" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3f90465a-2043-4451-9ec8-fe81dfeb2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85a95587-0ab6-4c1f-9538-e0a9d991a612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85a95587-0ab6-4c1f-9538-e0a9d991a612" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4b445400-f741-4196-a90f-527ce2793a6a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a5b82e0-8175-4fa9-87d7-d08d4c3788fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a5b82e0-8175-4fa9-87d7-d08d4c3788fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8df48c34-2b84-4e82-b1aa-03032248c198" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a823fcd3-a5de-47f0-8b35-915b64a755d9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8df48c34-2b84-4e82-b1aa-03032248c198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd454638-94c8-4c61-9826-71ccde524310" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9909d8a8-ce3e-4af9-947b-8c24de3a6428" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3edfc59-96fb-48d7-97cb-52460b4059ba" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9909d8a8-ce3e-4af9-947b-8c24de3a6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9bbba196-b038-4cad-8272-6b595d8e1136" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ba600870-244c-493c-9d97-c61d3fc78c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9bbba196-b038-4cad-8272-6b595d8e1136" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ba600870-244c-493c-9d97-c61d3fc78c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_05418fac-6edb-4a97-b5cf-c3aae5628cec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07c509e6-87fa-4e27-b09e-0ce61b38dbc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05418fac-6edb-4a97-b5cf-c3aae5628cec" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07c509e6-87fa-4e27-b09e-0ce61b38dbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cb14a853-29d1-47ba-a02b-da7a504a57a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05418fac-6edb-4a97-b5cf-c3aae5628cec" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cb14a853-29d1-47ba-a02b-da7a504a57a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51831e17-2e40-4d55-8c4d-05904fc16b59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_310929cd-e0d2-43cd-84fc-be77cf7ed02c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51831e17-2e40-4d55-8c4d-05904fc16b59" xlink:to="loc_us-gaap_NetIncomeLoss_310929cd-e0d2-43cd-84fc-be77cf7ed02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb4a6a3d-e999-437f-9c43-3ef80f94c225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51831e17-2e40-4d55-8c4d-05904fc16b59" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb4a6a3d-e999-437f-9c43-3ef80f94c225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_dd55050c-42fc-47df-a3d5-679bdf317f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51831e17-2e40-4d55-8c4d-05904fc16b59" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_dd55050c-42fc-47df-a3d5-679bdf317f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8f4b0396-a0a7-4967-a228-0c331922b63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f4b0396-a0a7-4967-a228-0c331922b63b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_68369942-f889-4dfa-90e2-bc338da0a43f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_914a1a2f-3fe5-4bec-a1f4-765b61ee304b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_914a1a2f-3fe5-4bec-a1f4-765b61ee304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_cbf04268-e3be-4625-ac86-1f0247eade29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_RestrictedStockMember_cbf04268-e3be-4625-ac86-1f0247eade29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_81849657-d2b8-42e8-8ebb-6a5c636b3041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_81849657-d2b8-42e8-8ebb-6a5c636b3041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_babd99ee-eac7-4578-bc35-df223efa05db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_471fee03-1a88-4f0c-a525-6f4d1a6a9f91" xlink:to="loc_us-gaap_WarrantMember_babd99ee-eac7-4578-bc35-df223efa05db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b6e3a30-581c-4eeb-8166-efb5633d2458" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e9231596-b8e4-4194-8c64-64f3d58c82b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f5f6e32d-b412-48d6-8e62-68cf354b2d99" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e9231596-b8e4-4194-8c64-64f3d58c82b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3575c543-4e8c-4c64-a118-bb5553cffe94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_33eeac1e-565f-4588-b114-82f511a5cc22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3575c543-4e8c-4c64-a118-bb5553cffe94" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_33eeac1e-565f-4588-b114-82f511a5cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b005641b-a0ff-4b51-92de-3deb36bc895d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_88c84c29-9662-4688-87b0-f53cf93c99b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b005641b-a0ff-4b51-92de-3deb36bc895d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_88c84c29-9662-4688-87b0-f53cf93c99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e75b6700-221d-416b-b846-89c5f2f38ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b005641b-a0ff-4b51-92de-3deb36bc895d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e75b6700-221d-416b-b846-89c5f2f38ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_f05f7e3e-2bbb-446d-9244-cc4c0cb1893c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b005641b-a0ff-4b51-92de-3deb36bc895d" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_f05f7e3e-2bbb-446d-9244-cc4c0cb1893c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_de0293f8-ee01-4262-9497-fb5b9aa04ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_de0293f8-ee01-4262-9497-fb5b9aa04ec3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:to="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:href="bdtx-20200930.xsd#bdtx_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseContractualTermAxis_535cf1e0-c8cb-41d9-ac42-1777b2a22e0a" xlink:to="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_c8c71ace-93af-45fa-8ed7-ff2243815771" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeOneMember_c8c71ace-93af-45fa-8ed7-ff2243815771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_2150bcef-c8a3-44cc-958c-1d3c083038f2" xlink:href="bdtx-20200930.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseContractualTermDomain_721d3d1d-23f2-4552-9c13-44a97d9489df" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_2150bcef-c8a3-44cc-958c-1d3c083038f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e14ed6ba-a8ec-416a-8007-9834722c5199" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_5c64b325-5d9c-440a-8d1d-69cdba504234" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_5c64b325-5d9c-440a-8d1d-69cdba504234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_749c5707-65f7-4f61-9d27-1fe3a6c08ae8" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_749c5707-65f7-4f61-9d27-1fe3a6c08ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fbd9b1aa-d715-46f4-9aeb-ada1889c60a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fbd9b1aa-d715-46f4-9aeb-ada1889c60a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5398f4a3-6f10-4255-be80-cca47a724444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5398f4a3-6f10-4255-be80-cca47a724444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ebc80b6-f227-40d7-8598-e8f853874ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ebc80b6-f227-40d7-8598-e8f853874ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_00150213-bd7b-4065-be99-7a315463e867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19dcb246-8377-4316-be67-3655ba936205" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_00150213-bd7b-4065-be99-7a315463e867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ca29206e-3908-47af-a372-c7582fe10f45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca29206e-3908-47af-a372-c7582fe10f45" xlink:to="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a6fed60c-cf92-45d0-b980-136d1a2e6c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:to="loc_us-gaap_OperatingLeaseCost_a6fed60c-cf92-45d0-b980-136d1a2e6c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_2ee47d66-4787-435d-9fd0-4c642406b831" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:to="loc_us-gaap_ShortTermLeaseCost_2ee47d66-4787-435d-9fd0-4c642406b831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9ff7fbdd-9030-4d0a-8f53-5d52700a2be1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:to="loc_us-gaap_VariableLeaseCost_9ff7fbdd-9030-4d0a-8f53-5d52700a2be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9f794654-b2ad-457d-aae0-cdad6b1cc477" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d2752e05-fe2f-41c3-9408-2b23d1da07d0" xlink:to="loc_us-gaap_LeaseCost_9f794654-b2ad-457d-aae0-cdad6b1cc477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract_66a079cd-3236-4be9-aebc-8cf649b88bda" xlink:href="bdtx-20200930.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca29206e-3908-47af-a372-c7582fe10f45" xlink:to="loc_bdtx_LeaseOtherInformationAbstract_66a079cd-3236-4be9-aebc-8cf649b88bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f492a8c6-ae2b-4c79-8d3e-57650900517d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_66a079cd-3236-4be9-aebc-8cf649b88bda" xlink:to="loc_us-gaap_OperatingLeasePayments_f492a8c6-ae2b-4c79-8d3e-57650900517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a082d24e-a92a-45dd-beff-b81df1494075" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_66a079cd-3236-4be9-aebc-8cf649b88bda" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a082d24e-a92a-45dd-beff-b81df1494075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef9c3e33-3d6e-4073-ae08-300755467588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_66a079cd-3236-4be9-aebc-8cf649b88bda" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef9c3e33-3d6e-4073-ae08-300755467588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_682d2dfc-0ddb-4e66-91d7-8b1b8f55bdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d2dfc-0ddb-4e66-91d7-8b1b8f55bdb4" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_04160fe3-0f01-4a98-9548-7afbc283ba93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_04160fe3-0f01-4a98-9548-7afbc283ba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bed9f16b-cb17-4a7e-8faf-09bdbe37a117" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bed9f16b-cb17-4a7e-8faf-09bdbe37a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b2ff611b-7b52-400b-907f-f54c8a3623d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b2ff611b-7b52-400b-907f-f54c8a3623d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc88337a-2258-49bc-99a1-2ec052bae131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc88337a-2258-49bc-99a1-2ec052bae131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50c1f62d-86d0-4cf2-b50f-5df865a24dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_50c1f62d-86d0-4cf2-b50f-5df865a24dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_87842dda-db1b-498b-b944-8018eedca110" xlink:href="bdtx-20200930.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_87842dda-db1b-498b-b944-8018eedca110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2299cdd2-22bd-415e-96c6-2117b92c85a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2299cdd2-22bd-415e-96c6-2117b92c85a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46de343d-d94b-4a69-a46a-9c886255fba4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46de343d-d94b-4a69-a46a-9c886255fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_04f16c9a-b1d0-48db-a5c0-024af98d6a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a2f38218-41ee-4095-898d-08c8af4bd1a7" xlink:to="loc_us-gaap_OperatingLeaseLiability_04f16c9a-b1d0-48db-a5c0-024af98d6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_682d2dfc-0ddb-4e66-91d7-8b1b8f55bdb4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_0708b7ed-6198-4a55-933c-fd1d77c8135c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_0708b7ed-6198-4a55-933c-fd1d77c8135c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0e955ee7-c3a8-429b-9268-5f8d41f6abc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0e955ee7-c3a8-429b-9268-5f8d41f6abc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_65768a32-c452-4941-ba40-310e44686b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_65768a32-c452-4941-ba40-310e44686b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e280f469-8c65-43c6-94d3-69b2a202a9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e280f469-8c65-43c6-94d3-69b2a202a9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f11fb5b1-e90e-4631-9cfe-598022d9cef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b027606d-ff4c-4482-b6a0-fc13dacda632" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f11fb5b1-e90e-4631-9cfe-598022d9cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20200930.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bdtx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca11c448-8b5d-4d81-9c78-07c3bd4fe6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c273dc14-9352-446f-ab8d-dd277d431179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ca11c448-8b5d-4d81-9c78-07c3bd4fe6cf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c273dc14-9352-446f-ab8d-dd277d431179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9d9a92a1-3d2b-4d10-b656-31fe21b45feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6727353e-9bc1-4b52-beff-ee76426a2d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9d9a92a1-3d2b-4d10-b656-31fe21b45feb" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6727353e-9bc1-4b52-beff-ee76426a2d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#BENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30017e9a-74ec-4d46-81a6-fd750bfe3996" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_ddb18e10-b6a4-4020-a734-794f951951f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30017e9a-74ec-4d46-81a6-fd750bfe3996" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_ddb18e10-b6a4-4020-a734-794f951951f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7cc96c55-2f4a-4c5a-8a68-b81e4332e9de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_30017e9a-74ec-4d46-81a6-fd750bfe3996" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7cc96c55-2f4a-4c5a-8a68-b81e4332e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0151051a-a0bf-47c5-a4b8-ec2ee50d4b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_77c07b3e-5a8a-4854-8f7b-bb1e3c0c08c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0151051a-a0bf-47c5-a4b8-ec2ee50d4b06" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_77c07b3e-5a8a-4854-8f7b-bb1e3c0c08c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bdtx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c21a495f-0f27-452c-b474-459bb3ae2a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c21a495f-0f27-452c-b474-459bb3ae2a1e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a655aa3d-82c9-4fe2-89f2-be677764a6b6" xlink:to="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_5dd1cb85-25ef-4dc3-bb88-4a64178a7706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2aa2878c-2d3e-4c07-8985-b1a40f661421" xlink:to="loc_us-gaap_InvestorMember_5dd1cb85-25ef-4dc3-bb88-4a64178a7706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_acdb51bf-4ce5-418a-8be2-a86f0a5bffc6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ServiceAgreementMonthlyMember_c309de9d-aafe-4c02-9eee-f6218f364a0d" xlink:href="bdtx-20200930.xsd#bdtx_ServiceAgreementMonthlyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_40635be5-1835-4293-a35c-b1d74fafa304" xlink:to="loc_bdtx_ServiceAgreementMonthlyMember_c309de9d-aafe-4c02-9eee-f6218f364a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5acb048f-93cf-4319-b9fc-e0f28d6766ce" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_59c360d9-b4ee-4b63-89a3-a1e8d22d4526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_59c360d9-b4ee-4b63-89a3-a1e8d22d4526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2059be46-9ff8-4077-a378-2e0d7589d53b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2059be46-9ff8-4077-a378-2e0d7589d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PrepaidExpenseRelatedPartyCurrent_a6ea7c58-3070-410d-8fda-7a59d9b5d700" xlink:href="bdtx-20200930.xsd#bdtx_PrepaidExpenseRelatedPartyCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_bdtx_PrepaidExpenseRelatedPartyCurrent_a6ea7c58-3070-410d-8fda-7a59d9b5d700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa100b87-5031-4952-a82e-7bcec0d3fd28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6f6845c6-3b02-4ffe-92c3-baaccbf5c6d7" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fa100b87-5031-4952-a82e-7bcec0d3fd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>bdtx-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bdtx-20200930.xsd" xlink:type="simple"/>
    <context id="i922f12bc23d04883ba291d428df17336_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0b08c5e6ad442e2b8cbbc86f2eb975c_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="i784f5ca30047442983dcf65beeb93bee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a81c80297be401c9d24d2691c346ef2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id21232485659451988f7d0eeb28e97ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia0b21f1f0f004ece96252d4ab23c11ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia58633b5da934b49b8b50a4c4d972181_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6e7217cdda7640e7ae1b034817463336_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9d9f23bd51f0443f93921337df5f73f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibad83db20b2549b4b55cf677334915d0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i124cb79a827443e2813493747649bbc9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id3dc3b2779764af18308733d70c4f62c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i074869ac335a42f5a7f196856849e937_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i54576d77d11f4bc98d78e4d4bec9b2b7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idd5a3ed127c341afad5d8cdcd796de26_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1c3505c54f434cd3bf526b9ed482b76d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id0cfe23a39d04b45981404b0cafafc1e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i492b70942c8c464bb7b030c69dcd3bd4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8ad6d2688d764b80aded6ed0d00e934f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i38b6d873955e48209a6a418f35b7fcd3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i59e65f12447a43acb33a821020f9863e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9b38575d385a49a3b26c1c87ac517877_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic8555adf1567478096f826df6313d2d6_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib2357a6951c74f2696398526a038572d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i66353e29adac49abbe387f172d904c62_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie8c0efe4132343138143e5551a0f9837_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife57cf6f9104422ea61f7f4857babf83_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id1b3f11fec2b49a0af040ad809ce33d8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37a8909a627e42b38848dbf90108399f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i36492d9410124470bd9c2fd1f4212068_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i95b4a20b72814524a27c1406bacbb3ef_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i565b73dece054891910461129ca95434_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i207c218d1bd04cf780603f54f79e1863_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2476fa9c3754d8db2e83fb8bfd68fb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i454902132c0642799fb3ab69cde52ed3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ied582ee35a564838b1ea295d1176b312_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7bcac3d2e867465e96341db5f2240c0c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibd34c9b0a76740898aeb60ac87424dd3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia81af7b765594d60a9350f6f9fedee1d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7af9b7ab721f42c2bcba0cfa7c44b81a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9841212013b649f2b1befa1e22e66032_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i648406fe2dd641c9affb2f4fc7fe5632_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieaf864a6a53647a3bd5644df4cb8cf9c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7d47962149b433f8c6ea96b2b55b0d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifd76357b0ab74e2fbe8275e5146d131b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3fdc57f4648e450bbfed378e5fcdd3ca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib846e7133d394e7ca2eedbf3f8d57752_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5b55a68c910849e8aa744b2a08ef3db2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifab225aa474040e399399aa03538e02b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f9728ed0168479192af535918a672e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida314bb8f6ce422595b08aa880542938_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ica9f2958722341e9b1508549506b903c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i906e723b16b14714b27adf1a70d6337b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9d945985182a46d29e60d5b0adecc88e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="i064d8550b5f14a5fb7683f439ba8a906_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic5c8de7312dd4239bea9f029a69bf4e5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iae70735391d2461e94a96257903690ce_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i366d53aa80e440bf8d38fbbdd6303468_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id3553eae519643458d423ae9f2a413fd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i49bf379564304e5d922780e8f420a712_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idea11d544c35426496604cfa84c025e0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8bb0fe716bc64955bf8206a8eae54346_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1dbfcd5ae7574f13a33d7c0efca4e952_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i70ec4550d4d24650a1470219051050e7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2a424b1ba33e48f98265d6336718bb87_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1dd312051b8448829439a465edcd48dd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib1e90e33c2994557a44434862b43372d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20d3a820d1414559b9b3240726cf7b3d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4f321b23d52a4820b45efe5d1c94f118_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if11983767b7d4dad85f031fb6de73cad_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i897a00dbb83a405db5ed163d9aa4a3ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i802ddccf8c754eb68a0e9690f6a2f763_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9b02127f61304cda9eba1d4bcae89e8f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2780cbca4e684d8989e0b46f32e55c05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f9324e281d648bcb6c60d03c062a4e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73a5f286773d44689501ab785a4633f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i320d8fd71f63489eb502ae104503decd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81cd387e3c1146338b053867f9d31021_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id054160055b645cf8264647b7eacebbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74e7964618df467b897aff2a1719ffed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6f8a8b906244beea5072e056d82cd69_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i2796d34b9fe24cc0a43d330adcfe578d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib092073e7a104302a2a7a6e648beb09a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5e7e3ae08f09416bac8565a02b39cc9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i654506ca5bb54d9ba365a4051bde05bf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i475fec1b34ae4ddcb54ac9b6e28c06b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2614ce618414bc8b1620a813fef8f2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90f6ec00451a46b0808c3397c1657e45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i761759e947174f6ab451d27b4f158f63_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="i12d92be850134e31a71d7e87905cc175_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="ia1021664df9e453ca21007fd9e2c51dc_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="i85cf12dce2d34ce8b9fb13d1c6a7cd12_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iacebca6e78b94922a7d8f7456173f057_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if7a892af05d144f6950d2aaa62a4c297_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9413c1bf291b46ef9b03d54c13c6aee1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab5948b654d548159e4cc0ad67cf5a7f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84e014cca6184bdca2ca8de90a9a1b01_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i088778d5e9cd4a59b544a5b80f5d24ba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i995c252df7d4498e9caa9cfcdce34d17_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6fc2768ca441464d88c7b71c6c9bf982_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib645a438e6804745bd7f89c819800c30_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d3791e4cc2d4bff830aac311516f572_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3abe3620951f41a29d7581f1d9a8baa5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2dcb5e81a97143b0afa64625ea7745ff_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia99613d35727440abf965ec6cdb33b89_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0db89b0e05b542d5acd609d84363f0fe_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib4613097211945d588002788a6d88b08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62b4a0d7d7f74e5980d1e7f53a4c1d3e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie55196c9d5d44810bf624b67d74cf207_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i978c35a69f6244fb9664243bcb241cbd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icfadec1e666b4412980e25adc961a5c1_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bdtx:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="if98ef25099314086a82b8992bf03ca26_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bdtx:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i516d9585532d496ea7567f7c7e177c98_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">bdtx:ServiceAgreementMonthlyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="contract">
        <measure>bdtx:contract</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV8yLTEtMS0xLTA_84f3b50d-08e8-4df7-9d18-f76389f93140">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV8zLTEtMS0xLTA_a6337762-e9cf-4f46-b554-49a1a6b62ae2">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV80LTEtMS0xLTA_dc0c2e12-4177-4c3b-a340-20f4525c8140">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV81LTEtMS0xLTA_1e014cea-9a5e-4c5d-9efa-e7f032a08596">0001701541</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180L2ZyYWc6NTc1MTk1ZGQzZmNjNGJmM2JhNmI0NmU0Y2MyMjI3YjMvdGFibGU6OGFhMmJhYjQzYzY5NGE2OGE3OGNiOWJjYTdhZGM5MTUvdGFibGVyYW5nZTo4YWEyYmFiNDNjNjk0YTY4YTc4Y2I5YmNhN2FkYzkxNV82LTEtMS0xLTA_96d1da06-96b6-4b40-8aa3-2d8fdff09561">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="icfadec1e666b4412980e25adc961a5c1_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNzQ0_ab6c24e2-8031-41b8-b38c-ee6a9db619f1">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if98ef25099314086a82b8992bf03ca26_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfODUz_2dbf53ff-d133-4eb9-bc06-8e02afa3e25d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xMjY_6a83003e-bca9-4add-966b-985fda80231a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6ZTQzMGI4M2FjZGIwNGY0ZGE1ZGJlYmNiNzAzZWQ5ZTcvdGFibGVyYW5nZTplNDMwYjgzYWNkYjA0ZjRkYTVkYmViY2I3MDNlZDllN18wLTAtMS0xLTA_c3b62874-018d-4819-8fbc-82b5b4647684">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8yMDY_7d51b7af-2096-43a1-b80f-f83250b73295">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Y2QyODJjZjhkNjAxNGEwZGIxYWEwMDMzNGJkNzdhMjIvdGFibGVyYW5nZTpjZDI4MmNmOGQ2MDE0YTBkYjFhYTAwMzM0YmQ3N2EyMl8wLTAtMS0xLTA_ee4805db-6bd3-4f19-b9e8-6f7252f6a459">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8yNzU_76521fb1-d9f2-4b1c-a8c1-64b08e949699">001-38501</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8zMjI_bea529ed-0d32-46d6-b640-153c9dd235ac">BLACK DIAMOND THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18wLTAtMS0xLTA_315495e5-363a-4b20-9213-7edecbb6ed22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18wLTEtMS0xLTA_37791982-f19f-46e3-8b6b-23f82eed2108">81-4254660</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF81_0e10a185-8ef1-42e7-9327-c46324255bb3">139 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF85_446dbac5-c330-4b4f-8fec-1f7d29bfdacc">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YzFiYTAzMTQ0MmU0Y2E1OGZlNjk2OTg5OWI1ZWU3MF8xMw_1722d17f-8d6f-4225-83a2-71c17be242fd">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18yLTEtMS0xLTAvdGV4dHJlZ2lvbjoxNDdjYTIwYTVmNGE0MGMwOTg4OWNjZWE1ZWQzZDdhOF81_45914b5b-d621-4eed-a5f6-508890ac328a">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4M2IwNmVkNWJmNWE0MGVlOTc4MGUzMzUwNjg3MDVlZV81_70372194-7057-4ce2-a4bd-cb89f879a395">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6NjhhYjVkOWE5YjRlNGUxYWIwMmQ2ZGZhZjFmNzQ0YTMvdGFibGVyYW5nZTo2OGFiNWQ5YTliNGU0ZTFhYjAyZDZkZmFmMWY3NDRhM18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo4M2IwNmVkNWJmNWE0MGVlOTc4MGUzMzUwNjg3MDVlZV84_ed7b8541-9f44-4058-bb78-33566619fc8b">252-0848</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTAtMS0xLTA_ba10a116-5530-4d10-9dd8-4a385bb143a4">Common stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTEtMS0xLTA_4d960b73-21c7-4d61-8a9a-b9a099ddf0a3">BDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6Nzc2MzBmMTg3MjFhNDdiMWFlOWNlMDg3YWNhNjQxYjcvdGFibGVyYW5nZTo3NzYzMGYxODcyMWE0N2IxYWU5Y2UwODdhY2E2NDFiN18xLTItMS0xLTA_ac2c6a63-1aca-442f-a011-057d746177ab">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF84Nzc_1a5c778e-06b8-403a-b8d7-3dd8904ff0fe">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xMjA0_398648fe-266f-40da-9661-2ba4842a5944">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF8yLTAtMS0xLTA_a8ed2881-9379-45d9-87a6-96eebcf4cbdf">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF8yLTMtMS0xLTA_95f56237-2d91-42ed-bab3-a9f83134ec8a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGFibGU6MjkxOWRjOGVkNGU4NDY4ZDg0MDJiNzZhODU1NjA1NjgvdGFibGVyYW5nZToyOTE5ZGM4ZWQ0ZTg0NjhkODQwMmI3NmE4NTU2MDU2OF80LTMtMS0xLTA_c07d3329-6b1b-4d9e-9688-5d8de36ee09f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xODIw_eda93470-e188-4ecb-a516-80eb7169d4c3">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xOTQ1_390f42f6-5d96-4b79-97b2-59b30977da15">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib0b08c5e6ad442e2b8cbbc86f2eb975c_I20201102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xL2ZyYWc6OWVmMjgwZDc1MzVkNGJjNDhmNzU4ZDZjZjNlNDhkNjAvdGV4dHJlZ2lvbjo5ZWYyODBkNzUzNWQ0YmM0OGY3NThkNmNmM2U0OGQ2MF8xOTg2_184f6a50-45c6-45a8-b95a-8a68d8a42464"
      unitRef="shares">35995660</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNC0xLTEtMS0w_e56dc0d0-eb56-4661-aecc-699ef4bea9da"
      unitRef="usd">56197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNC0zLTEtMS0w_fb028563-c2d8-4108-9f2d-2ade7225dee5"
      unitRef="usd">154666000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNS0xLTEtMS0w_4c04bc65-0038-4701-9c27-092d1d650007"
      unitRef="usd">276875000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNS0zLTEtMS0w_875deb27-aceb-4c7f-8a58-c3888db77e4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNi0xLTEtMS0w_8dcae985-4e58-4fb2-b2d9-a255a905e9f4"
      unitRef="usd">3356000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNi0zLTEtMS0w_8c633f64-d48a-40a5-9e5b-b22f375269c6"
      unitRef="usd">1048000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNy0xLTEtMS0w_22a5fc8e-1825-414e-a171-4c550a41cb16"
      unitRef="usd">336428000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfNy0zLTEtMS0w_429c5539-7e7a-4be9-bcf2-b68dd39fa295"
      unitRef="usd">155714000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOC0xLTEtMS0w_8b5ca9d4-8d05-4864-80f6-ba3ed58e745f"
      unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOC0zLTEtMS0w_c0b9390e-000b-470a-a723-8cc3d37c0413"
      unitRef="usd">164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOS0xLTEtMS0w_49e3f606-f5b7-40c8-83cc-07d6945ec233"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfOS0zLTEtMS0w_b78c1adb-3ea1-4cc8-844a-75c8741e5758"
      unitRef="usd">55000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredCosts
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTAtMS0xLTEtMA_ec4d08e8-0b25-4ac0-82e9-bc7cdc396fcb"
      unitRef="usd">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTAtMy0xLTEtMA_acd2069b-ad31-4f4c-af2c-e19ec0227ff0"
      unitRef="usd">2303000</us-gaap:DeferredCosts>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTEtMS0xLTEtMA_01a423ca-2cfb-4901-8131-0ea116394399"
      unitRef="usd">8463000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTMtMS0xLTEtMA_fe5ff0c1-31d9-447a-b310-6bbafb5ba0b5"
      unitRef="usd">92000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTMtMy0xLTEtMA_21bb7362-b19b-456b-b801-2cded5ce3d01"
      unitRef="usd">59000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTQtMS0xLTEtMA_3f85d60e-4df2-4b96-a7e9-a804916c95c2"
      unitRef="usd">346435000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTQtMy0xLTEtMA_7fe07f19-0761-40d0-8729-fabca8946bab"
      unitRef="usd">158295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTctMS0xLTEtMA_2bb55bb4-e431-4c15-af7b-b5fcbfba79af"
      unitRef="usd">2932000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTctMy0xLTEtMA_fde09411-e599-4d9e-bfe1-0b7fa8698cf9"
      unitRef="usd">1964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTgtMS0xLTEtMA_fa1a4c15-4db8-4a68-911e-ab39d1291034"
      unitRef="usd">190000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTgtMy0xLTEtMA_0fae3891-94e4-4542-a776-d666e72d0873"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTktMS0xLTEtMA_007a3f0b-f259-446a-90ed-3df8ad7cb922"
      unitRef="usd">8219000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMTktMy0xLTEtMA_9a5e22b5-2aaf-49af-8771-4839f91409b3"
      unitRef="usd">2899000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjAtMS0xLTEtMA_fca478be-d84f-4fd9-ba76-e99c9c4d54b8"
      unitRef="usd">11341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjAtMy0xLTEtMA_79ab6ffa-51c9-4e78-ab5a-6f40319c46a6"
      unitRef="usd">4863000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjEtMS0xLTEtMA_19f25aaa-8efb-48d4-bf2e-43782de33d93"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjEtMy0xLTEtMA_1b599247-bd3c-4ab4-9b2f-257f939d8de4"
      unitRef="usd">16000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjItMS0xLTEtMA_1578405f-6299-4714-8ea1-d2efc8fe6a46"
      unitRef="usd">7749000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjMtMS0xLTEtMA_747102d1-cbb2-401e-b6d6-08bb7b84b373"
      unitRef="usd">19090000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjMtMy0xLTEtMA_3473c184-d672-442b-95aa-33c8dc1a54a8"
      unitRef="usd">4879000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjQtMS0xLTEtMA_b6e76a0b-4ff6-4163-a93c-9a235671560f"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjQtMy0xLTEtMA_016da72c-4731-4594-b214-2827868fa60f"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjUtMS0xLTEtMA_09face2a-1a14-4ab1-9abc-0b02b2b463e8"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjUtMy0xLTEtMA_bccbfecb-3478-48e9-9e29-08134c31bc24"
      unitRef="usd">200573000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzE5_2866c6d1-5eef-4668-a3e7-491c6ed3a1ac"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzE5_fb8c9da0-61ca-4556-8f7d-175043bb3695"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzMz_9884e0d2-f207-41d2-878e-5cd7d5843edb"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzY0_b4c165fb-5fd6-43f4-982b-195fafab0ef5"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzky_ecd1adef-1e4f-4d57-ac8d-5b9701eb7070"
      unitRef="shares">35963447</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzky_f40252ef-d3c2-4704-be80-bb67b9dd737a"
      unitRef="shares">35963447</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzEzNQ_0aa13540-58ba-46db-9890-2e89515db2de"
      unitRef="shares">2236672</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjRlZDVhZWIzOWI4YzQ2YzBhOGUyNmY4Zjc4MjEzZmEyXzEzNQ_5ebbc3d7-fa46-45c8-b724-f9affda1cf4c"
      unitRef="shares">2236672</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMS0xLTEtMA_adc66d9c-b577-4c38-b181-a1f3dc2a6ce7"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjctMy0xLTEtMA_6dd636d2-8167-4e46-bd96-6130e24a04f2"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjgtMS0xLTEtMA_64683e29-208b-4b40-b26a-7782242bfeca"
      unitRef="usd">422063000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjgtMy0xLTEtMA_7d039435-bd96-426f-9f76-a16e854bf758"
      unitRef="usd">3812000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjktMS0xLTEtMA_ab788d5c-65c6-4888-9606-ab60142308e2"
      unitRef="usd">875000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMjktMy0xLTEtMA_e703aa6f-be05-4a58-b4ac-36aae97653cb"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzAtMS0xLTEtMA_a3cef8c3-4cbd-4679-93e3-35828d7c6ce2"
      unitRef="usd">-95598000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzAtMy0xLTEtMA_ba79a5df-8cad-4509-a6ca-5d3f34cb4ef9"
      unitRef="usd">-50970000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzEtMS0xLTEtMA_c1eb7677-243e-4b47-a0e9-5ef8f8522bf9"
      unitRef="usd">327345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzEtMy0xLTEtMA_196be1d9-baaa-4d7d-9948-08195e9b9cc1"
      unitRef="usd">-47157000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzItMS0xLTEtMA_0bdc6bfa-1379-484c-88e3-b340653ec397"
      unitRef="usd">346435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xNi9mcmFnOjdmZjcyYTc5ZGZiMDRlZDA5ZTIwMjg0MDdiZWRjNTk0L3RhYmxlOjNkNjNlODc0YzkwNDRjZjVhZjllMmJhYmUxOGU5MDI1L3RhYmxlcmFuZ2U6M2Q2M2U4NzRjOTA0NGNmNWFmOWUyYmFiZTE4ZTkwMjVfMzItMy0xLTEtMA_86f00c17-31af-48b7-9dba-8f7169c8c88f"
      unitRef="usd">158295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNDM_035c2cb0-a895-45ca-a146-f077f69590e3"
      unitRef="usd">190000</bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty>
    <bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNDc_5ed1943e-fc2a-4f4e-a646-cefc5004b961"
      unitRef="usd">3480000</bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty>
    <bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNTE_b3b8ee6f-a51e-4f7c-b25a-c72d3200a501"
      unitRef="usd">2293000</bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty>
    <bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0wLTEtMS0wL3RleHRyZWdpb246MDYxNzZhZDdmMzljNDMyZjgwMTc5OGJjN2U2MWIyYTVfNTg_fd04aaca-ccae-49c3-b2b3-6c6b24bcd93f"
      unitRef="usd">8497000</bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0xLTEtMS0w_e873b9bf-cbea-406d-b084-76b95d7cfb40"
      unitRef="usd">12929000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy0zLTEtMS0w_7ea780cc-29e1-4108-bc54-45bbc314d8f6"
      unitRef="usd">5634000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy01LTEtMS0w_93b5ca04-f789-41f4-adbe-b786ded17cc1"
      unitRef="usd">30453000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMy03LTEtMS0w_22c94ff2-0a52-482e-a25c-63688b5d0a23"
      unitRef="usd">14293000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNDU_01afddf3-90af-4d34-abe4-92c341bedd05"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNDk_fb6e8fb6-d034-41cc-bb35-4ccd7431a979"
      unitRef="usd">176000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNTM_f43431d4-3908-4a73-93f6-29f86cd772e4"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0wLTEtMS0wL3RleHRyZWdpb246NjAwZjI0M2NjZDNhNDBjN2FiNmZlNmRjNjIyZDg1ZDRfNjA_39452ecf-17a3-4338-b349-f76a49e718af"
      unitRef="usd">357000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0xLTEtMS0w_dcb77505-bcb0-42fe-b8f3-255894b49763"
      unitRef="usd">5551000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC0zLTEtMS0w_b317218c-c57b-4c51-840d-677794f01aa7"
      unitRef="usd">2514000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC01LTEtMS0w_dbdc63e3-4bf8-4143-8a6d-a4e7fcd3fc5b"
      unitRef="usd">15934000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNC03LTEtMS0w_47a48eb4-5718-4a91-b664-d8e88f80229f"
      unitRef="usd">4695000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS0xLTEtMS0w_e918eea9-e99e-4082-8162-0d86ce42a352"
      unitRef="usd">18480000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS0zLTEtMS0w_ac85ea4a-14cb-49bd-9664-e4804d40b241"
      unitRef="usd">8148000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS01LTEtMS0w_1cc782b7-b36e-4f27-afcb-9f4370668abe"
      unitRef="usd">46387000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNS03LTEtMS0w_621a4907-bda8-42af-af86-d1b45df7d971"
      unitRef="usd">18988000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi0xLTEtMS0w_5adc7aab-e295-41cf-beb7-eae959b21761"
      unitRef="usd">-18480000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi0zLTEtMS0w_1c1dc70e-9f36-444b-a754-b7922e8be0a1"
      unitRef="usd">-8148000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi01LTEtMS0w_57d48783-1a0e-4d1d-9270-8558335cc461"
      unitRef="usd">-46387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfNi03LTEtMS0w_571700dc-e513-4b3b-a84d-91dde423e885"
      unitRef="usd">-18988000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC0xLTEtMS0w_1a576122-bebe-472b-a0df-cda533864abe"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC0zLTEtMS0w_7d274b12-b4fb-4af1-8bed-49a8665f7af7"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC01LTEtMS0w_6c3ce32a-3336-440e-98df-58bbadeb05ed"
      unitRef="usd">1000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOC03LTEtMS0w_bf2ca670-1b34-47b5-958b-74275ea7bcb2"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS0xLTEtMS0w_d1d6aaa2-8440-4c18-a0da-aad3a7294b1e"
      unitRef="usd">1162000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS0zLTEtMS0w_3d535d8d-1aad-4bf4-a0b4-c9ff8ed61370"
      unitRef="usd">1000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS01LTEtMS0w_506453c1-07ae-4d10-97d7-ea22e7f60af0"
      unitRef="usd">2787000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfOS03LTEtMS0w_69c7f02f-9aa5-4e8d-99b4-3b6078f699b5"
      unitRef="usd">21000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtMS0xLTEtMA_19415489-9e2c-4a64-a1c6-074ce5bd1237"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtMy0xLTEtMA_08e8cfc9-18eb-43fa-b5af-0323cef48b3b"
      unitRef="usd">-1116000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtNS0xLTEtMA_a64e42de-bb1b-4acd-9fe9-8f767c9b7091"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTAtNy0xLTEtMA_790f57aa-cd1f-4349-94e0-b9083b9ed486"
      unitRef="usd">-6416000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtMS0xLTEtMA_304515c7-1dc4-424a-9800-14b00f670535"
      unitRef="usd">-594000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtMy0xLTEtMA_833f4719-bdf0-470c-b170-0699a7c7ee65"
      unitRef="usd">-5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtNS0xLTEtMA_57f0a169-affd-4350-9b98-8bba4b63a9f1"
      unitRef="usd">-1027000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTEtNy0xLTEtMA_c40d8e9f-9ded-4cc6-8100-e8d839d9a3f6"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItMS0xLTEtMA_bcf6cfeb-151d-4ec5-bc16-7d56d20f993a"
      unitRef="usd">568000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItMy0xLTEtMA_0f1cc754-c8fa-40f1-8ab4-b407a3e417ff"
      unitRef="usd">-1120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItNS0xLTEtMA_f338202e-5168-4e75-8e6d-f66828014d0e"
      unitRef="usd">1759000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTItNy0xLTEtMA_c5e46040-b970-4c37-b120-004e2d946c78"
      unitRef="usd">-6395000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtMS0xLTEtMA_2886df3f-ca93-4420-b4f6-379158f2b4c3"
      unitRef="usd">-17912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtMy0xLTEtMA_6f958e42-c364-4cac-818b-ad0e53f0a647"
      unitRef="usd">-9268000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtNS0xLTEtMA_4131c25a-06d6-4efb-b5d2-fc7025717bd5"
      unitRef="usd">-44628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTMtNy0xLTEtMA_62466c99-5cd0-4ba7-8078-cf77f15f2b0b"
      unitRef="usd">-25383000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtMS0xLTEtMA_7f7f676c-a6f9-43ce-a36d-2a3444e365a5"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtMy0xLTEtMA_6ca40f0b-2073-43a8-8292-b3e4bc704ec6"
      unitRef="usdPerShare">-4.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtNS0xLTEtMA_42f6a046-a155-4adc-a9dd-b14481934808"
      unitRef="usdPerShare">-1.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTQtNy0xLTEtMA_d33a7341-eb73-4bcf-8df2-83974ec45d10"
      unitRef="usdPerShare">-12.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtMS0xLTEtMA_4f6c69d6-5a03-40cf-b870-5b1dd81c57d0"
      unitRef="shares">35927485</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtMy0xLTEtMA_fcad5661-727f-4195-a725-d41a666d19f3"
      unitRef="shares">2065676</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtNS0xLTEtMA_80ace4ef-aa45-4b10-b1a8-d502382d91c1"
      unitRef="shares">31860716</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTUtNy0xLTEtMA_40f845c1-14f2-4bf3-bb11-f8bc5bc5d336"
      unitRef="shares">2054115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtMS0xLTEtMA_1153429d-b9d9-4805-88bc-e4619285b846"
      unitRef="usd">-17912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtMy0xLTEtMA_666468ea-cefa-446b-ad04-3cd89cf985b9"
      unitRef="usd">-9268000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtNS0xLTEtMA_3e82a2d7-35b3-4fa9-ac52-0d79b92a72e6"
      unitRef="usd">-44628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMTgtNy0xLTEtMA_033fbddd-b8c3-4d35-ab08-8f6050081067"
      unitRef="usd">-25383000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtMS0xLTEtMA_4908e453-9691-437c-9bf5-da8d10817c2f"
      unitRef="usd">-137000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtMy0xLTEtMA_4f5370e8-8fe2-4814-a6f1-1c06d26603ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtNS0xLTEtMA_26efb099-4590-4316-8a4d-9b51d434cf00"
      unitRef="usd">875000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjAtNy0xLTEtMA_e7d4cebe-8389-495f-b430-7c3d4220f820"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtMS0xLTEtMA_fa04628b-4d43-4806-9845-8f4683a6bf6e"
      unitRef="usd">-18049000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtMy0xLTEtMA_39f023c2-b426-4d8e-a84e-7ca363d92c09"
      unitRef="usd">-9268000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtNS0xLTEtMA_1104fe48-0223-4517-bd93-5def537094c3"
      unitRef="usd">-43753000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18xOS9mcmFnOjA1ZGI2OGRjMTg4NDQzNjFhYmIwZjk1YzVkOTM0MzAwL3RhYmxlOmUyZDBjZmZiOGI4MjQ3MjhiMGIzNzhmMzZiNDcxNTcyL3RhYmxlcmFuZ2U6ZTJkMGNmZmI4YjgyNDcyOGIwYjM3OGYzNmI0NzE1NzJfMjEtNy0xLTEtMA_df780a97-a247-4c85-9b60-1cde37920129"
      unitRef="usd">-25383000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMy0xLTEtMS0w_b5bab496-f13c-4239-8439-188935b26d25"
      unitRef="usd">-44628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMy0zLTEtMS0w_b63bcf5b-8370-4317-b849-ea6d416a1d61"
      unitRef="usd">-25383000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNS0xLTEtMS0w_677fd0dc-97da-41b4-aaed-ad9a160ce4b2"
      unitRef="usd">5295000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNS0zLTEtMS0w_019ab72b-e699-4f79-a3f5-a183cdf22692"
      unitRef="usd">1133000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNi0xLTEtMS0w_4aceec0d-7989-457d-b07a-3fe84b2ac55d"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNi0zLTEtMS0w_fc0c35d6-f2b7-4894-8fa4-ef40f0be4ce6"
      unitRef="usd">-6416000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:Depreciation
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNy0xLTEtMS0w_6f94f07d-46aa-4df5-885c-5852c2c30136"
      unitRef="usd">37000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNy0zLTEtMS0w_9719559e-cc41-464f-9c8e-2a5e3f43cbc5"
      unitRef="usd">38000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfOS0xLTEtMS0w_7d45ec03-db8e-4f57-91a3-53b30b6a8c7d"
      unitRef="usd">990000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfOS0zLTEtMS0w_77aebf43-d199-4010-85c0-97f693f927db"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <bdtx:RentExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTAtMS0xLTEtMA_842ff830-4713-4e3f-a3ac-e6e386692364"
      unitRef="usd">287000</bdtx:RentExpense>
    <bdtx:RentExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTAtMy0xLTEtMA_6e59befe-101b-4583-8fed-0d3ea19de336"
      unitRef="usd">0</bdtx:RentExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTItMS0xLTEtMA_5820d570-ae08-472e-88b9-c82c157393f4"
      unitRef="usd">2308000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTItMy0xLTEtMA_d07f5b51-01aa-42fb-91d8-58438fcb9b24"
      unitRef="usd">270000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTMtMS0xLTEtMA_04e23f09-8c56-4207-aeca-b7edbb38bbdf"
      unitRef="usd">33000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTMtMy0xLTEtMA_84a89833-0ee5-405c-b2f3-552f921c1b59"
      unitRef="usd">25000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTQtMS0xLTEtMA_0d1183e9-cdbb-47cf-89e3-5445b78a0abd"
      unitRef="usd">1528000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTQtMy0xLTEtMA_c5a2ab14-3d74-45e6-b5ef-4bb962ec4b7c"
      unitRef="usd">496000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTUtMS0xLTEtMA_3214c3db-d605-4957-94cb-b9ca50c8ca46"
      unitRef="usd">190000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTUtMy0xLTEtMA_7f71b356-d48e-44ff-9d08-740554a6429b"
      unitRef="usd">-453000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTYtMS0xLTEtMA_9f7d4d31-c524-419a-b8a3-a1563f4a2648"
      unitRef="usd">4551000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTYtMy0xLTEtMA_88584c40-b4b2-4302-8e6a-7865608455c0"
      unitRef="usd">860000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <bdtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTctMS0xLTEtMA_bd0a990f-2624-4143-b6e3-abe80b6a3cbe"
      unitRef="usd">-301000</bdtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTgtMS0xLTEtMA_9d36c416-67ae-42bc-937c-5ad056df6498"
      unitRef="usd">-36372000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMTgtMy0xLTEtMA_26fb6d81-e712-49cb-a87d-fdc6ecc5db15"
      unitRef="usd">-17188000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjEtMS0xLTEtMA_5fe16bfc-95ba-4193-b23b-98814c24f37a"
      unitRef="usd">33000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjEtMy0xLTEtMA_6f235ad3-6aef-4eda-876b-e01cb1db630f"
      unitRef="usd">19000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMS0xLTEtOTM5_77b3bd50-3327-4c22-9084-9ba1be5e533b"
      unitRef="usd">17765000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMy0xLTEtOTM5_add776a0-44ca-4d82-b542-052da28146f9"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMS0xLTEtMA_c5a139e1-d1b1-4bbe-bc40-0b3cbd6a91eb"
      unitRef="usd">292775000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjItMy0xLTEtMA_02c21f77-bb93-4d0b-a7ec-19c576456ae4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjMtMS0xLTEtMA_70dd9b5c-08e0-47dd-88ed-54716c77a0c1"
      unitRef="usd">-275043000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjMtMy0xLTEtMA_48f281f1-46fa-4a00-b98b-1739c8ee3d1d"
      unitRef="usd">-19000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjYtMS0xLTEtMA_8195a22b-f76a-4f69-914c-068525a714f0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjYtMy0xLTEtMA_f4892df4-9941-452c-bc5c-b904249fc436"
      unitRef="usd">44669000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMS0xLTEtNzk_89c60de5-0cc9-4fe2-94e0-94f30ccd35a0"
      unitRef="usd">270000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMy0xLTEtNzk_b05de4b3-742d-4f35-9386-edac6e791dca"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU4MzljMWY2ZDVhMTQxMmI4NWE4MGFmNDZmZjFkNzBhXzY4_5b669f2f-a234-4086-873e-9d5bb2a69670"
      unitRef="usd">1275000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMS0xLTEtMA_5700fc19-e6e6-42f2-b6c4-0e097021361d"
      unitRef="usd">213844000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjctMy0xLTEtMA_40837560-4036-44b0-8405-ba184767187b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjgtMS0xLTEtMA_37dc642c-c190-4809-8292-b7b21c9a817e"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjgtMy0xLTEtMA_ed128d4c-4861-428d-b263-59baf834cb8c"
      unitRef="usd">408000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjktMS0xLTEtMA_505f9d7e-ad52-43c5-8d60-0eb629a0a056"
      unitRef="usd">214114000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMjktMy0xLTEtMA_e9983867-721c-4be5-a6a3-522559cc38fa"
      unitRef="usd">44261000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzAtMS0xLTEtMA_499c0726-d6dd-4252-a9b6-db7cf8454642"
      unitRef="usd">-97301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzAtMy0xLTEtMA_a2791ff4-a9ac-40b5-b23e-ff0b1d44ed94"
      unitRef="usd">27054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzEtMS0xLTEtMA_473507e2-1955-4e7f-b9e4-9cfe4fef4ede"
      unitRef="usd">154721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzEtMy0xLTEtMA_7dd89c69-54b5-48cf-8ceb-4f3fc5216a0f"
      unitRef="usd">51660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzItMS0xLTEtMA_d79d8329-08d0-47f0-ad8f-dd491c6499e2"
      unitRef="usd">57420000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzItMy0xLTEtMA_7789c2d8-5af6-4c45-8935-5f5e9c149b81"
      unitRef="usd">78714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzQtMS0xLTEtMA_9216f64f-78f1-40c6-8e85-84ef35a99b2b"
      unitRef="usd">56197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzQtMy0xLTEtMA_c6912d81-b097-4013-8edf-52bd2910b6d9"
      unitRef="usd">78659000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzUtMS0xLTEtMA_748d393b-566c-4007-8830-47e1a5f1b3ff"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzUtMy0xLTEtMA_78a6fc7b-ddb0-48ac-9a8c-2ce570ef593d"
      unitRef="usd">55000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzYtMS0xLTEtMA_b5de4655-c892-406f-b01a-d0092f32be14"
      unitRef="usd">57420000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfMzYtMy0xLTEtMA_8b875c79-42a2-43c3-8eb5-146a0eb43112"
      unitRef="usd">78714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdtx:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDAtMS0xLTEtMA_b6f566bc-7f72-4948-9f5f-ab07098ef6c2"
      unitRef="usd">0</bdtx:DeferredOfferingCostsIncurredButNotYetPaid>
    <bdtx:DeferredOfferingCostsIncurredButNotYetPaid
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDAtMy0xLTEtMA_c60d9f49-1864-4876-8f98-fdb375ab274d"
      unitRef="usd">1169000</bdtx:DeferredOfferingCostsIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDItMS0xLTEtMA_6491fcd9-0c26-4a16-acd2-eae58c5d2c97"
      unitRef="usd">200573000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDItMy0xLTEtMA_9fd8dbe0-ea76-4b35-ac7c-a5542f0d6a32"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDUtMS0xLTEtMjI1_3a850a22-cb64-4a8b-bc38-f610a0a72445"
      unitRef="usd">8274000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ia0b21f1f0f004ece96252d4ab23c11ea_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDQtMS0xLTEtMA_3ebbfde3-851f-44fb-a360-4b4dfb00a7ef"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ia58633b5da934b49b8b50a4c4d972181_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDQtMy0xLTEtMA_bf514ae2-2db5-41e7-ad8c-f97e840fe7a8"
      unitRef="usd">6393000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:LineOfCreditAssumed1
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDctMS0xLTEtNDI4_d4ab5fd5-88ac-4155-a7fc-2aeb30e48b36"
      unitRef="usd">1168000</us-gaap:LineOfCreditAssumed1>
    <us-gaap:LineOfCreditAssumed1
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yMi9mcmFnOjg2YTc4YmRmNWNhYzRjNzA4Y2EyNGI0MWM5MGRjNmFkL3RhYmxlOjVhZTU0NWFkZTIwMzQwNDdiMmRiZGE3NmUwYzQ2MDVjL3RhYmxlcmFuZ2U6NWFlNTQ1YWRlMjAzNDA0N2IyZGJkYTc2ZTBjNDYwNWNfNDctMy0xLTEtNDI4_91b683da-547a-46e5-9208-aeb8fbd8c98c"
      unitRef="usd">0</us-gaap:LineOfCreditAssumed1>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xLTEtMS0w_0b13a0d2-bc2b-43d1-b6d7-afb589fd1fc9"
      unitRef="shares">33668075</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0zLTEtMS0w_e6706b8e-3d3d-4b48-a78c-c9a3807b1dcb"
      unitRef="usd">60770000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6e7217cdda7640e7ae1b034817463336_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi02LTEtMS0w_45a03fa7-44d7-4fd9-a018-30340e472fa1"
      unitRef="shares">2173684</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6e7217cdda7640e7ae1b034817463336_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi04LTEtMS0w_5f5a67fd-94e4-485b-ac1f-072c7876e744"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d9f23bd51f0443f93921337df5f73f3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xMC0xLTEtMA_a0917fe2-cf09-42a4-bfb7-4ba26db8427b"
      unitRef="usd">169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibad83db20b2549b4b55cf677334915d0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xMi0xLTEtMA_8994b80b-d632-461c-ad34-601e594b5068"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i124cb79a827443e2813493747649bbc9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xNC0xLTEtMA_4ca624d5-ddb9-42fe-a709-f4d7378b3143"
      unitRef="usd">-15712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a81c80297be401c9d24d2691c346ef2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMi0xNi0xLTEtMA_2e633528-6dab-4117-952c-1ce5f7a58178"
      unitRef="usd">-15542000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="id3dc3b2779764af18308733d70c4f62c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMy02LTEtMS0w_a70f2b3c-7ec1-422b-9498-4e495018af03"
      unitRef="shares">46416</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMy0xNi0xLTEtMA_eb288c30-a1a8-4287-b944-4bdc81696b69"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i54576d77d11f4bc98d78e4d4bec9b2b7_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNC0xMC0xLTEtMA_2a49dd9b-9567-43a0-aab2-3b313b17379d"
      unitRef="usd">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNC0xNi0xLTEtMA_a63e56e3-2681-4895-9a64-5087782adf1b"
      unitRef="usd">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="idd5a3ed127c341afad5d8cdcd796de26_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNS0xNC0xLTEtMA_8a67d60c-59e3-4744-ab99-6599bc483bd7"
      unitRef="usd">-3828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i074869ac335a42f5a7f196856849e937_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNS0xNi0xLTEtMA_3305d845-c268-4386-b232-6ff6d6121c79"
      unitRef="usd">-3828000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xLTEtMS0w_76307930-e017-459d-b424-8345409549d4"
      unitRef="shares">33668075</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0zLTEtMS0w_ded41b1b-8a74-4c0b-8059-b0d0eae15f7b"
      unitRef="usd">60770000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c3505c54f434cd3bf526b9ed482b76d_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi02LTEtMS0w_e5e5860c-5bba-44db-b32b-ac96ec46ddae"
      unitRef="shares">2220100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1c3505c54f434cd3bf526b9ed482b76d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi04LTEtMS0w_a61124cb-0700-4843-b6c6-ac41a991fa6e"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0cfe23a39d04b45981404b0cafafc1e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xMC0xLTEtMA_9c002978-d91c-4816-a4cf-1f621a285bf5"
      unitRef="usd">260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i492b70942c8c464bb7b030c69dcd3bd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xMi0xLTEtMA_3043feb4-1a5f-4c4f-8df4-925bf3e1b6b2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ad6d2688d764b80aded6ed0d00e934f_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xNC0xLTEtMA_2bdd6ecd-4c79-45a9-9710-36d554df4682"
      unitRef="usd">-19540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d600a77ccbb4becbddcf4e85cd1e08d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfNi0xNi0xLTEtMA_18a91458-2a64-4c48-9208-24bf0eaa61c8"
      unitRef="usd">-19279000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38b6d873955e48209a6a418f35b7fcd3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOC0xMC0xLTEtMA_6d7eec74-f25a-466f-af7d-038d122fbb0b"
      unitRef="usd">192000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOC0xNi0xLTEtMA_c561155e-40ea-4792-bf90-997b88dfd1c8"
      unitRef="usd">192000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i59e65f12447a43acb33a821020f9863e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOS0xNC0xLTEtMA_f663ab94-9c2a-4d02-8b93-506eca573107"
      unitRef="usd">-12287000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic112d91ceee4466dab41f8cf8f9db3aa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfOS0xNi0xLTEtMA_67dd4ce5-4575-405c-b718-2ab6b461334f"
      unitRef="usd">-12287000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMS0xLTEtMA_93749ed8-1b6f-4156-bdb4-89c9ffdc6844"
      unitRef="shares">33668075</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMy0xLTEtMA_8cd1da7d-c167-45c8-9562-20de88db875a"
      unitRef="usd">60770000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic8555adf1567478096f826df6313d2d6_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtNi0xLTEtMA_c51bd6f1-e71e-486e-ae52-49d82a00aee5"
      unitRef="shares">2220100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic8555adf1567478096f826df6313d2d6_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtOC0xLTEtMA_ef4e5d9a-7ec8-4534-8ff3-011b69ee1296"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2357a6951c74f2696398526a038572d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTAtMS0xLTA_3d8e654e-6e00-4eae-85c1-064f8b78ed04"
      unitRef="usd">452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66353e29adac49abbe387f172d904c62_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTItMS0xLTA_1ed88791-1275-440e-a6ad-bebe5bcf7a32"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8c0efe4132343138143e5551a0f9837_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTQtMS0xLTA_86c4666a-eb92-451f-ae74-c37e2da69be7"
      unitRef="usd">-31827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b38575d385a49a3b26c1c87ac517877_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTAtMTYtMS0xLTA_20afb3ea-c27e-466a-8e4f-a7840e0f405a"
      unitRef="usd">-31374000</us-gaap:StockholdersEquity>
    <bdtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMS0xLTEtMzE3_a03b49d4-f2b0-4c17-a393-7b55179b6468"
      unitRef="shares">11751154</bdtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ie59d3ecd53b841fa9d9370c430179696_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMy0xLTEtMzE3_609fa4ba-9145-4b84-baea-9c87ec125777"
      unitRef="usd">55070000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ife57cf6f9104422ea61f7f4857babf83_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTAtMS0xLTQ4_f18eac4a-1e26-4845-a3d7-308136232cbb"
      unitRef="usd">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTYtMS0xLTQ0_f8ee3b63-3dab-4a74-ab38-9d90db865db0"
      unitRef="usd">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="id1b3f11fec2b49a0af040ad809ce33d8_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTQtMS0xLTUy_ec1582bc-585b-4bb2-b7a2-e4117c4f6685"
      unitRef="usd">-9268000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTYtMS0xLTQ0_52d4c1e8-a05f-4e87-befd-3d3f94c19ce9"
      unitRef="usd">-9268000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMS0xLTEtNDQ_2fabc085-6644-4cfc-8c21-9421ca838830"
      unitRef="shares">45419229</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMy0xLTEtNDQ_d1ddd1bd-cb10-433d-afa3-726e2496495f"
      unitRef="usd">115840000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i37a8909a627e42b38848dbf90108399f_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtNi0xLTEtNDQ_1178761b-6e3b-49a0-af70-4d89408fa012"
      unitRef="shares">2220100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i37a8909a627e42b38848dbf90108399f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtOC0xLTEtNDQ_72aa1abf-690c-417c-ae28-fdb80dfa0a0c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36492d9410124470bd9c2fd1f4212068_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTAtMS0xLTQ0_9e865918-b923-49fc-bde6-26459d3ed482"
      unitRef="usd">1302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95b4a20b72814524a27c1406bacbb3ef_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTItMS0xLTQ0_b4fe2bb1-8e56-46a5-b279-26534d945e96"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i565b73dece054891910461129ca95434_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTQtMS0xLTQ0_00df11fd-5dc6-422e-915b-2da7dcf9aecc"
      unitRef="usd">-41095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id21232485659451988f7d0eeb28e97ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTYtMS0xLTQ0_6c7c74d2-bd6c-4313-b136-bd0fad3573d8"
      unitRef="usd">-39792000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMS0xLTEtMA_de06fa1d-4109-4b0d-937e-aee117335185"
      unitRef="shares">64839353</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMy0xLTEtMA_faefaaea-d303-4f92-9b90-693ec71e83b6"
      unitRef="usd">200573000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItNi0xLTEtMA_ea257c8f-0ce4-42b1-894e-9380e4d08e9d"
      unitRef="shares">2236672</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if2fc77cd345f4e0daa0df20f350cd9bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItOC0xLTEtMA_44ae2801-a383-4505-8df6-ef0e1b3d58ff"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i207c218d1bd04cf780603f54f79e1863_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTAtMS0xLTA_087451bc-bd79-408b-ae8d-57c291415bc0"
      unitRef="usd">3812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2476fa9c3754d8db2e83fb8bfd68fb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTItMS0xLTA_1b009ccc-f65e-41bf-a4d5-87f1e4722b26"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i454902132c0642799fb3ab69cde52ed3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTQtMS0xLTA_42427f8f-4e87-403d-bac5-deba3c818014"
      unitRef="usd">-50970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTItMTYtMS0xLTA_c9caa250-a913-43c2-b887-8facfbddb21e"
      unitRef="usd">-47157000</us-gaap:StockholdersEquity>
    <bdtx:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMS0xLTEtMA_4158e109-041b-460e-9d1c-a776b20ea2de"
      unitRef="shares">64839353</bdtx:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMy0xLTEtMA_007dafef-1084-4e0a-af38-716caae626c5"
      unitRef="usd">200573000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtNi0xLTEtMA_66c77359-4b08-4074-9db9-35f6e4d9e9fa"
      unitRef="shares">21499770</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtOC0xLTEtMA_7c2ad85a-b4a5-4d20-a5be-aa8757096f8c"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTAtMS0xLTA_242086ff-dbd1-4fed-9e73-f0100d561644"
      unitRef="usd">200570000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTMtMTYtMS0xLTA_c3d0ee65-d3a5-47cc-b8c6-c446db6ade17"
      unitRef="usd">200573000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtNi0xLTEtMA_092d1b7d-99ec-414a-bfbe-c4d13f67940b"
      unitRef="shares">12174263</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iafeaab3d05f042e0bf7fb8d0ce44f74b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtOC0xLTEtMA_71d38bcf-01c3-40f9-a519-0b15ebb5e72d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTAtMS0xLTA_5e8a6f79-9ec0-4a6e-9cf8-bee6ceb42155"
      unitRef="usd">212100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTQtMTYtMS0xLTA_ed82175d-c0e5-4af2-850c-c4a1c621c6bc"
      unitRef="usd">212101000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTUtMTAtMS0xLTA_33f63800-8fba-442c-abf4-1d5080cf7bb2"
      unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTUtMTYtMS0xLTA_0fe77df3-be4b-45d4-aaa0-e2aa168b2e36"
      unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if8611c5d8aca4f559d67683bdc869388_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTYtMTAtMS0xLTA_a2900481-6bcb-4aff-8620-9d7b31e44720"
      unitRef="usd">1877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTYtMTYtMS0xLTA_0891c737-a8e9-4025-a5ae-1f314fa3ae4d"
      unitRef="usd">1877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ied582ee35a564838b1ea295d1176b312_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTctMTQtMS0xLTA_24f552b3-0723-4208-8408-e012212f6892"
      unitRef="usd">-12145000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id17eb0e4a58540ad8610a6c6c345ecb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTctMTYtMS0xLTA_56f5704f-0d8b-425c-9877-49fe357d4071"
      unitRef="usd">-12145000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMS0xLTEtMA_b85f2a33-e71c-41c7-ad80-8a333bec65c6"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMy0xLTEtMA_e697e09d-d8a3-4b5e-90ee-46872d14b2ca"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7bcac3d2e867465e96341db5f2240c0c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtNi0xLTEtMA_10eb8180-6c64-4eef-ae38-e51d96029042"
      unitRef="shares">35910705</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7bcac3d2e867465e96341db5f2240c0c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtOC0xLTEtMA_3dbb362c-f04b-4136-81b8-3136fb3b9c4d"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd34c9b0a76740898aeb60ac87424dd3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTAtMS0xLTA_5f5a720e-b566-47e9-8b3c-c078e2decc22"
      unitRef="usd">418375000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia81af7b765594d60a9350f6f9fedee1d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTItMS0xLTA_43c8c14a-e353-4a03-ba38-b358e5370242"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7af9b7ab721f42c2bcba0cfa7c44b81a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTQtMS0xLTA_54c7d153-5a1e-49fe-b569-3aaa4e78bada"
      unitRef="usd">-63115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia82f5e77b7de4ea3b8268e9acd6f0b4f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTgtMTYtMS0xLTA_a58f8d84-83fc-4663-a5b9-74b01392e532"
      unitRef="usd">355265000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9841212013b649f2b1befa1e22e66032_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTktMTAtMS0xLTA_f20ecc20-3616-4674-a47f-7f46d9a3cea6"
      unitRef="usd">1419000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMTktMTYtMS0xLTA_b4520cbb-ba3b-4911-9d50-3c46677051a5"
      unitRef="usd">1419000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i648406fe2dd641c9affb2f4fc7fe5632_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjAtMTItMS0xLTA_dd1d3907-2afb-4e29-b617-4d65e7a98c0f"
      unitRef="usd">1012000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjAtMTYtMS0xLTA_dc0c202b-9610-4407-8a25-924fe12da189"
      unitRef="usd">1012000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ieaf864a6a53647a3bd5644df4cb8cf9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjEtMTQtMS0xLTA_0a868d3c-b256-4d1e-b8bc-712efddc89a7"
      unitRef="usd">-14571000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6faab6233a964e19be3d66b76d81adc1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjEtMTYtMS0xLTA_b4648180-3325-4776-9019-c92c45656c26"
      unitRef="usd">-14571000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMS0xLTEtNzA_8594192b-d34c-483c-aa09-626aa30b7dc6"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMy0xLTEtNzA_509ea7e4-efa9-4e34-bac8-1dc2ee88c01a"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifd76357b0ab74e2fbe8275e5146d131b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtNi0xLTEtNzA_11f20f0b-2378-485a-9db1-8f39060ad42b"
      unitRef="shares">35910705</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd76357b0ab74e2fbe8275e5146d131b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtOC0xLTEtNzA_292c31d0-2119-4e00-b8b6-a496a45a3d70"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3fdc57f4648e450bbfed378e5fcdd3ca_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTAtMS0xLTcw_0f143734-7f94-4edc-a2ef-032f1c883981"
      unitRef="usd">419794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib846e7133d394e7ca2eedbf3f8d57752_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTItMS0xLTcw_23830033-380d-4c7b-acb4-63658bee3f54"
      unitRef="usd">1012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b55a68c910849e8aa744b2a08ef3db2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTQtMS0xLTcw_d67bd985-b4dd-4f54-ac87-88bbe5fac0bd"
      unitRef="usd">-77686000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7d47962149b433f8c6ea96b2b55b0d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjYtMTYtMS0xLTcw_8768c49b-5a26-48ef-bd7c-e11b5bf14f95"
      unitRef="usd">343125000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctNi0xLTEtNzA_6fc7835b-7e14-4a40-aaad-f9ba813bb3dc"
      unitRef="shares">51076</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifab225aa474040e399399aa03538e02b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctMTAtMS0xLTcw_0643c788-c218-425e-828c-83ddc5ad70db"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjctMTYtMS0xLTcw_6ed224ea-64dd-410c-b315-4f3b1da810e1"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia09c721c03504852b09cee83c676d4d1_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktNi0xLTEtMzc1_9126bfd6-1a5a-46bc-bf95-a61992b5e66d"
      unitRef="shares">1666</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTYtMS0xLTM3NQ_24892caa-5404-49bb-9dd6-485fb233cf03"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifab225aa474040e399399aa03538e02b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjgtMTAtMS0xLTcw_1fb1d8a0-7083-4c1d-b8cc-6e482e2d896c"
      unitRef="usd">1999000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjgtMTYtMS0xLTcw_489e9632-b1f7-4448-b161-4750d1fa7ceb"
      unitRef="usd">1999000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i5f9728ed0168479192af535918a672e8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTItMS0xLTcw_29646563-d141-4b9d-bbbc-53359889b195"
      unitRef="usd">-137000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjktMTYtMS0xLTcw_4bb3e641-083f-458f-bb4f-2e9081bcb82a"
      unitRef="usd">-137000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ida314bb8f6ce422595b08aa880542938_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMzAtMTQtMS0xLTcw_005659b0-0424-41c8-81b9-8a26c11b7385"
      unitRef="usd">-17912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMzAtMTYtMS0xLTcw_5c7c0ac4-467c-433a-9bc6-3f0d699cfcfe"
      unitRef="usd">-17912000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMS0xLTEtMA_32ed8db9-69ef-46d5-bb66-ca3b23365d00"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMy0xLTEtMA_2583c2ff-0968-454d-990c-0f9ffa485347"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItNi0xLTEtMA_c4bde409-63ca-48ed-baf7-28d7b7996bec"
      unitRef="shares">35963447</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6588ba54d4c74d56b3f1e936e0f30d06_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItOC0xLTEtMA_792b5c62-b34f-49f1-b012-b11653da886a"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica9f2958722341e9b1508549506b903c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTAtMS0xLTA_b6f3ec3f-ddab-451f-b2c0-f400caf472d8"
      unitRef="usd">422063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i906e723b16b14714b27adf1a70d6337b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTItMS0xLTA_9e008451-8818-4b23-8fda-c25770c0af4d"
      unitRef="usd">875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d945985182a46d29e60d5b0adecc88e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTQtMS0xLTA_fc310d9d-4d46-4438-98cb-53f0f2820e28"
      unitRef="usd">-95598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18yNS9mcmFnOmNkNzJjNTdhM2UwMjQ2NGI4NTllMDk3MTY3ZmRmNmRiL3RhYmxlOjg0MDYxYWQ0MjQ1ZTRjZmE5NTY1OGJlYWI4MTQ3YzI1L3RhYmxlcmFuZ2U6ODQwNjFhZDQyNDVlNGNmYTk1NjU4YmVhYjgxNDdjMjVfMjItMTYtMS0xLTA_571dc507-1dd3-4dcd-9ee2-659ec3ef2339"
      unitRef="usd">327345000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfNjk4Ng_48508508-5949-4056-9a63-0580267332ce">NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of BDTX-189 and its earlier-stage pipeline programs as well as its mutation, allostery, and pharmacology computational and discovery platform. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers including a related party Ridgeline Therapeutics GmbH (&#x201c;Ridgeline&#x201d;). Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;On January 21, 2020, the Company effected a 1-for-3.01581 reverse stock split of the Company&#x2019;s common stock. All shares, stock options, warrants and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Company completed an initial public offering (the &#x201c;IPO&#x201d;) of 12,174,263 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231,311 and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#x201c;BDTX.&#x201d; The Company received $212,101 in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Upon closing of the IPO, all of the Company's outstanding shares of convertible preferred stock automatically converted into 21,499,770 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of convertible preferred stock. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of November&#160;10, 2020, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital requirements into 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The ongoing global outbreak of the novel coronavirus disease (&#x201c;COVID-19&#x201d;), which began in December 2019, was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries worldwide. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &#x201c;essential,&#x201d; work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of the Company&#x2019;s business, including how it has and will continue to impact the Company&#x2019;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#x2019;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#x2019;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#x2019;s third party service providers have also experienced shutdowns or other business disruptions. The Company does not yet know the full extent of potential delays or impacts on the Company&#x2019;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 ultimately impacts the Company&#x2019;s business, results of operations or financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain the pandemic or treat its impact, among others. In addition, a recurrence or &#x201c;additional waves&#x201d; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. While states and jurisdictions have rolled back &#x201c;stay at home&#x201d; and quarantine orders and reopened in phases, it is difficult to predict what the lasting impact of the pandemic will be, and any prolonged material disruption to the Company&#x2019;s employees or third party service providers could negatively impact the Company&#x2019;s ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Company&#x2019;s business, results of operations and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfNjk4Nw_8ad3e397-7277-4397-89b0-03677e77182f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of BDTX-189 and its earlier-stage pipeline programs as well as its mutation, allostery, and pharmacology computational and discovery platform. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers including a related party Ridgeline Therapeutics GmbH (&#x201c;Ridgeline&#x201d;). Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K, which was filed with the SEC on March 24, 2020. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMTgyNQ_afca3e09-f5e9-45d6-8dca-1d9043e33f19"
      unitRef="number">3.01581</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjI1OQ_f514283e-0bcf-4159-bee8-28f54c812123"
      unitRef="shares">12174263</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjM3NQ_de458481-c653-4e8d-aaf4-e8c8c93a2fd4"
      unitRef="shares">1587947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjQ0NQ_a81952d7-a85a-4ffc-8917-2af18b0dac7f"
      unitRef="usd">231311000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjU2Nw_7b89f620-f3a9-468c-b3e9-613e7bd9c952"
      unitRef="usd">212101000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6931db1b4b1b48bb85867ff8b8283f80_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zMS9mcmFnOmIwNjkzNzAyZWNkMzQxYTI5NzA2NGNmYWU5MjJiNTE4L3RleHRyZWdpb246YjA2OTM3MDJlY2QzNDFhMjk3MDY0Y2ZhZTkyMmI1MThfMjgyOA_a6a273c3-5fac-4715-b753-27bdd1d55186"
      unitRef="shares">21499770</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODA_a6f03cab-864e-4d77-bf34-b3462746e466">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K, which was filed with the SEC on March 24, 2020. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred offering costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company recorded deferred offering costs of $2,303. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. After consummation of the IPO, which closed on February 3, 2020, these costs were recorded in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments consist of marketable securities with original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders&#x2019; equity. Amortization and accretion of premiums and discounts are recorded in other income (expense). Realized gains or losses on debt securities are included in interest income or interest expense, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company&#x2019;s statement of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. Restricted cash includes amounts held as security deposits in the form of letters of credit for the Company&#x2019;s leased facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Company adopted Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-02&#x201d; or &#x201c;ASC 842&#x201d;), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases (&#x201c;ASC 840&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company has elected not to recognize leases with an original term of one year or less on the condensed consolidated balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on our financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzA_8a4494a3-7aba-4eed-81b3-9cf6077d5e1c">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODE_147545bc-31bb-447d-be6c-bf60bb189f47">Use of estimates The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</us-gaap:UseOfEstimates>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzI_be8e0838-5010-4bf2-8e2f-5c91211470ae">Deferred offering costsAs of December&#160;31, 2019, the Company recorded deferred offering costs of $2,303. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. After consummation of the IPO, which closed on February 3, 2020, these costs were recorded in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMzM2MA_392302db-dda5-4c62-9844-d79b1141494e"
      unitRef="usd">2303000</us-gaap:DeferredCosts>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0ODI_61bc4bf3-767a-4294-85f3-2d1cc0c0e139">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments consist of marketable securities with original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders&#x2019; equity. Amortization and accretion of premiums and discounts are recorded in other income (expense). Realized gains or losses on debt securities are included in interest income or interest expense, respectively.&lt;/span&gt;&lt;/div&gt;If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company&#x2019;s statement of operations and comprehensive income (loss).</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTA5OTUxMTY0OTIwMQ_b78ce543-9405-44b4-99f1-46c099d5ee54">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. Restricted cash includes amounts held as security deposits in the form of letters of credit for the Company&#x2019;s leased facilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzQ_76f69c4b-ed01-4f7f-9cf5-e9e0bcdb4dea">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzU_b94ec207-cad9-4686-9b7f-f2d1e9e5e726">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Company adopted Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-02&#x201d; or &#x201c;ASC 842&#x201d;), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases (&#x201c;ASC 840&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company has elected not to recognize leases with an original term of one year or less on the condensed consolidated balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNC9mcmFnOjVkYmVmNjQ2OTMxNjQ1NDBhMTI2NzViNmM5ODlkNDYyL3RleHRyZWdpb246NWRiZWY2NDY5MzE2NDU0MGExMjY3NWI2Yzk4OWQ0NjJfMTE0NzM_7ed68c97-6c66-477d-94bb-1be76db7a54b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on our financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxMQ_cb4880ce-e9f1-432a-8f3b-953a5ec54bd5">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Fair value measurements at September 30, 2020 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;328,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Fair value measurements at December 31, 2019 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;There were no transfers in or out of Level 3 categories in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of derivative liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liabilities related to the warrants to purchase series A convertible preferred stock is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Upon completion of the IPO in February 2020, the warrants to purchase series A convertible preferred stock converted to warrants to purchase 10,757 shares of common stock and the fair value of the derivative liability was reclassified to additional paid-in capital. As a result, we will no longer remeasure the fair value of the warrant liability at each reporting date. Derivative liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Balance - December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Reclassification to additional paid-in capital in connection with IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Balance - September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxMg_bf1d2f93-1c04-4e57-ab78-c368da3bc712">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Fair value measurements at September 30, 2020 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;52,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;328,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Fair value measurements at December 31, 2019 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i064d8550b5f14a5fb7683f439ba8a906_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC0xLTEtMS0w_524da71e-7354-4e18-b552-baa068fc58d1"
      unitRef="usd">52018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5c8de7312dd4239bea9f029a69bf4e5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC0zLTEtMS0w_6d547194-3940-452b-a6cd-5460c046deb9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iae70735391d2461e94a96257903690ce_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC01LTEtMS0w_5b96bf16-c0e6-4096-9d16-e5f3585bd531"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i366d53aa80e440bf8d38fbbdd6303468_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNC03LTEtMS0w_b6ed09c5-3448-4fa3-9b77-46245a5b0c71"
      unitRef="usd">52018000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id3553eae519643458d423ae9f2a413fd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi0xLTEtMS0w_bbff8ea2-abb8-4259-9bf0-aa4441235f6a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i49bf379564304e5d922780e8f420a712_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi0zLTEtMS0w_536c30da-56bf-4976-8687-a459d46d7120"
      unitRef="usd">69968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idea11d544c35426496604cfa84c025e0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi01LTEtMS0w_529f83da-c86c-470f-9504-ef9eec793114"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8bb0fe716bc64955bf8206a8eae54346_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNi03LTEtMS0w_5ca87db5-40d4-4960-8efd-8a473fe58676"
      unitRef="usd">69968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1dbfcd5ae7574f13a33d7c0efca4e952_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy0xLTEtMS0w_df34cd64-f82d-4f11-8c1b-f123748bc62b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i70ec4550d4d24650a1470219051050e7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy0zLTEtMS0w_9f3684bf-70db-4a9d-8958-82ac75f3f1e1"
      unitRef="usd">186863000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a424b1ba33e48f98265d6336718bb87_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy01LTEtMS0w_1b06177b-70ce-4059-b6e4-bd687ecd325a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1dd312051b8448829439a465edcd48dd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfNy03LTEtMS0w_7bef29ef-366f-446b-92ed-7191776ec712"
      unitRef="usd">186863000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib1e90e33c2994557a44434862b43372d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC0xLTEtMS0w_28b252db-6dc9-4291-9797-b3721e817527"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i20d3a820d1414559b9b3240726cf7b3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC0zLTEtMS0w_9573e2ce-a97d-4bc4-a89a-ae7f9a13bed5"
      unitRef="usd">20044000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4f321b23d52a4820b45efe5d1c94f118_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC01LTEtMS0w_61edfbc5-eeb1-46a3-a226-b1a2a26ce762"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if11983767b7d4dad85f031fb6de73cad_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOC03LTEtMS0w_7cafec1f-0e76-46d2-8a00-0375452469b5"
      unitRef="usd">20044000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i897a00dbb83a405db5ed163d9aa4a3ef_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS0xLTEtMS0w_6ce1126f-da54-4e3c-bc48-215dff06d2bb"
      unitRef="usd">52018000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i802ddccf8c754eb68a0e9690f6a2f763_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS0zLTEtMS0w_4f5c1f66-02b0-4199-ba4c-e0d7c9ab1705"
      unitRef="usd">276875000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b02127f61304cda9eba1d4bcae89e8f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS01LTEtMS0w_29d20f28-21ee-4c5b-a398-f11cf8dbced0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjNjNjQyYWZjNGQxZTRhYzdhMTM2YThkZDc1ZmY1ODViL3RhYmxlcmFuZ2U6M2M2NDJhZmM0ZDFlNGFjN2ExMzZhOGRkNzVmZjU4NWJfOS03LTEtMS0w_9cf3c884-04ab-4029-a1fe-a37c748e79dc"
      unitRef="usd">328893000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2780cbca4e684d8989e0b46f32e55c05_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy0xLTEtMS0w_b61ffe4b-c270-49a0-8d92-2adb71105810"
      unitRef="usd">24157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f9324e281d648bcb6c60d03c062a4e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy0zLTEtMS0w_071da8c7-a504-474f-abb2-ba35743ccf9f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i73a5f286773d44689501ab785a4633f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy01LTEtMS0w_c90e0594-426d-4974-b6e0-0130f68aa283"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i320d8fd71f63489eb502ae104503decd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfMy03LTEtMS0w_e417241a-a22e-4fbd-ad19-ec10490ff2a4"
      unitRef="usd">24157000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81cd387e3c1146338b053867f9d31021_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC0xLTEtMS0w_1c32132d-8b6f-4eb6-9e98-2bec7070f3d8"
      unitRef="usd">24157000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC0zLTEtMS0w_c55fe759-1967-4198-9dff-380a59427074"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id054160055b645cf8264647b7eacebbc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC01LTEtMS0w_d70302ae-d632-49d9-a969-7d78b7424721"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i74e7964618df467b897aff2a1719ffed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNC03LTEtMS0w_65bc3e4f-f20d-44a3-9849-1c8171ca82f3"
      unitRef="usd">24157000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i81cd387e3c1146338b053867f9d31021_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi0xLTEtMS0w_fc97c51b-9b45-44a6-8b4c-7ff08e38bce7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi0zLTEtMS0w_be4b3ea6-e929-41aa-8390-fb331803b3b1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id054160055b645cf8264647b7eacebbc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi01LTEtMS0w_318314f6-96db-433c-8b31-ec1478ae687c"
      unitRef="usd">16000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i74e7964618df467b897aff2a1719ffed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNi03LTEtMS0w_f8361202-821c-4051-bab8-ea6cf3f0aebf"
      unitRef="usd">16000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81cd387e3c1146338b053867f9d31021_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy0xLTEtMS0w_b999ce12-92a5-431c-90be-9a9e9774307b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3d8c9d8373aa4848b9a5fbc175b436bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy0zLTEtMS0w_9f290f69-d1ed-4227-a420-4b3a79ca58d2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id054160055b645cf8264647b7eacebbc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy01LTEtMS0w_72fa931a-92a6-45a7-82df-aac25e1f6e0f"
      unitRef="usd">16000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i74e7964618df467b897aff2a1719ffed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjI1ZGZjNDUzMTVkOTQzOGU4YjNhNGRiNjBlNzUxYzBiL3RhYmxlcmFuZ2U6MjVkZmM0NTMxNWQ5NDM4ZThiM2E0ZGI2MGU3NTFjMGJfNy03LTEtMS0w_9380c81d-c037-4e70-b6bd-4fa8b3702222"
      unitRef="usd">16000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie6f8a8b906244beea5072e056d82cd69_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTYzNA_acd5499e-bb15-4fe5-b530-f8c8c40b0602"
      unitRef="shares">10757</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RleHRyZWdpb246ZWUyYjZlOGUyNGE1NGZiYmFhMmY5YzdiOWFjYTE4YjBfMTkxNA_b6163775-d254-4bda-a82b-d67e8917142c">Derivative liabilities consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Balance - December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Reclassification to additional paid-in capital in connection with IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Balance - September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfMS0xLTEtMS0w_0d1d08df-7e0d-49d1-bf69-af1a681a7fac"
      unitRef="usd">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfMy0xLTEtMS0w_29096ec7-cca2-4037-bb44-3ab212da2d9c"
      unitRef="usd">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N18zNy9mcmFnOmVlMmI2ZThlMjRhNTRmYmJhYTJmOWM3YjlhY2ExOGIwL3RhYmxlOjYyODk0ZWIxNDQ4NzQ3YmU5MjZkOTM5NTlhMzFlMTVhL3RhYmxlcmFuZ2U6NjI4OTRlYjE0NDg3NDdiZTkyNmQ5Mzk1OWEzMWUxNWFfNC0xLTEtMS0w_95b4d1e0-ea9a-4f47-a022-4b7f114792bc"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjI1_423b3c42-c5d9-45df-9012-63d45064e1ba">INVESTMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, investments were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2019, the Company did not hold any investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjI3_79fa7622-5647-4f91-9566-d5828e29c3c4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, investments were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;186,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS0xLTEtMS0w_92c8ffe6-4a9c-44de-9be9-d1d3f59b0c88"
      unitRef="usd">69860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS0zLTEtMS0w_32df8cd1-477e-4065-8755-e28b2b25ad6e"
      unitRef="usd">108000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS01LTEtMS0w_e61d5468-9ffa-41f5-88a9-61524705a234"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2796d34b9fe24cc0a43d330adcfe578d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMS03LTEtMS0w_f94ffb1d-491e-4b5b-bedd-f03bf1358dea"
      unitRef="usd">69968000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi0xLTEtMS0w_832b582d-58f1-486a-93b1-843c749a1343"
      unitRef="usd">186098000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi0zLTEtMS0w_96e9b11d-ee10-4011-a664-9b4b4c744d76"
      unitRef="usd">765000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi01LTEtMS0w_2d6b958c-6098-46ac-a180-45303d923511"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe186d8b23bf44b396dfc3495f7a7f57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMi03LTEtMS0w_3b7e66ca-bda9-4519-8615-1467204ac692"
      unitRef="usd">186863000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy0xLTEtMS0w_2358e26d-3138-4dcd-a2d8-7c155990d84d"
      unitRef="usd">20042000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy0zLTEtMS0w_44a3c05e-ff83-467c-bef6-50e04e2856ef"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy01LTEtMS0w_8b330697-b6e3-4456-a62d-542da55af490"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0bd08402d9ee449aa7ea0e5de2f00901_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfMy03LTEtMS0w_1ba9222a-6cbb-427c-a679-03b10ef2b02f"
      unitRef="usd">20044000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC0xLTEtMS0w_641a9d1b-1527-4e73-aebc-08dede16f255"
      unitRef="usd">276000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC0zLTEtMS0w_2546a0f1-213f-4aba-932c-e8cfd329a726"
      unitRef="usd">875000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC01LTEtMS0w_1aecd954-0b56-4b30-8612-1263ab4cb1be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RhYmxlOjJlOGUwZGViZWI0MzQ5NTRiYmUyNTIxNmVjZThjZGQzL3RhYmxlcmFuZ2U6MmU4ZTBkZWJlYjQzNDk1NGJiZTI1MjE2ZWNlOGNkZDNfNC03LTEtMS0w_9e087bab-f234-4963-bcf9-50381a23b538"
      unitRef="usd">276875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180MC9mcmFnOjI1N2NmNjllZDg1MTRjZWI5NmIyOTRiOTc1NWJiM2ZmL3RleHRyZWdpb246MjU3Y2Y2OWVkODUxNGNlYjk2YjI5NGI5NzU1YmIzZmZfMjAx_4609f413-6632-45fc-975b-901047b0c65d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTU5_3fc7686d-7152-4b6c-b89c-33c4e161cb05">PROPERTY AND EQUIPMENT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 was $37 and $38, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTYw_87f5e057-efaa-42f5-a545-3eb029901445">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib092073e7a104302a2a7a6e648beb09a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMS0xLTEtMS0w_954db7ef-79c8-45c0-9db8-92072bc47a98"
      unitRef="usd">226000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e7e3ae08f09416bac8565a02b39cc9d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMS0zLTEtMS0w_f36e74d4-86c4-4dae-9c17-f0c9808af18d"
      unitRef="usd">218000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i654506ca5bb54d9ba365a4051bde05bf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMy0xLTEtMS0w_ea4f3608-c043-4b13-b134-0efe978ae874"
      unitRef="usd">83000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i475fec1b34ae4ddcb54ac9b6e28c06b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfMy0zLTEtMS0w_34020679-ab16-4649-be5f-5358ae1afa28"
      unitRef="usd">58000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib2614ce618414bc8b1620a813fef8f2d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0xLTEtMS0yMTA_c8326cb4-319a-4507-bfb5-7a5ae2722749"
      unitRef="usd">69000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i90f6ec00451a46b0808c3397c1657e45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0zLTEtMS0yMTQ_1c120dc0-96ad-41aa-a878-9e01aee72c7b"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0xLTEtMS0w_9f9ceebc-225c-4438-9ed4-e55422086d83"
      unitRef="usd">378000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNC0zLTEtMS0w_695f080b-ed07-413c-b9fc-05095cb3781c"
      unitRef="usd">276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNS0xLTEtMS0w_3ea834e0-5558-438e-8ba2-641ed268f3bc"
      unitRef="usd">149000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNS0zLTEtMS0w_99d80051-5be3-4e67-b5a6-869a6e03fd88"
      unitRef="usd">112000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNi0xLTEtMS0w_50b7b555-9f98-4d8c-baf2-fd01f5b7d538"
      unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RhYmxlOjRlMmZhYjIyY2VlMzRiOTBiMmVjNTkzN2M1NzEwZmU3L3RhYmxlcmFuZ2U6NGUyZmFiMjJjZWUzNGI5MGIyZWM1OTM3YzU3MTBmZTdfNi0zLTEtMS0w_324f5509-8f2d-4815-8a7a-44bae0039127"
      unitRef="usd">164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTM2_69c55c78-38f0-4cdb-b909-38308218b910"
      unitRef="usd">37000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180My9mcmFnOmM5NzFmY2VlMDM4MDRlNGQ4MmVhMWNhOTgxN2RhNzEwL3RleHRyZWdpb246Yzk3MWZjZWUwMzgwNGU0ZDgyZWExY2E5ODE3ZGE3MTBfMTQz_6ebbba3a-9f82-4d43-aa82-a31724f4ebf1"
      unitRef="usd">38000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RleHRyZWdpb246ZDVlYzFlNTk2YmFjNDdhNjkyZDJjNjY5ZGRiMTFlY2ZfMTMy_aea2c839-b62a-4c1c-b5e3-5964621b4451">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;8,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RleHRyZWdpb246ZDVlYzFlNTk2YmFjNDdhNjkyZDJjNjY5ZGRiMTFlY2ZfMTMz_df176717-fa0e-4dc9-8170-43cd62548be9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;8,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMS0xLTEtMS0w_899d94ec-6e17-43a5-b02a-ef017b4c6679"
      unitRef="usd">1088000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMS0zLTEtMS0w_784a39a1-31ed-4e3c-832c-c484d9cd52b2"
      unitRef="usd">434000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMi0xLTEtMS0w_c3460246-a354-44ed-8a56-1fa8049f766c"
      unitRef="usd">2733000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMi0zLTEtMS0w_e49dde01-8b68-447f-86fb-ca59d21ffc6d"
      unitRef="usd">1182000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMy0xLTEtMS0w_941e33e2-e24c-41cd-8758-b79b7bb0526d"
      unitRef="usd">3141000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfMy0zLTEtMS0w_8e5bc619-47a1-4cb8-b531-b72bb239365d"
      unitRef="usd">984000</us-gaap:AccruedProfessionalFeesCurrent>
    <bdtx:AccruedLegalFeesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNC0xLTEtMS0w_696140c6-ec03-4328-977f-84fd265a3fa9"
      unitRef="usd">320000</bdtx:AccruedLegalFeesCurrent>
    <bdtx:AccruedLegalFeesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNC0zLTEtMS0w_3564029c-7c77-4a38-a861-a839a9bccda4"
      unitRef="usd">299000</bdtx:AccruedLegalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNS0xLTEtMS0w_59b20c37-7ca7-4a9c-9c10-c4b865047398"
      unitRef="usd">937000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNi0xLTEtMS0w_9574b6c8-39f5-4e55-bf1f-9b196443682c"
      unitRef="usd">8219000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180Ni9mcmFnOmQ1ZWMxZTU5NmJhYzQ3YTY5MmQyYzY2OWRkYjExZWNmL3RhYmxlOjczMGFlMmI1ZTlhNTRkMjhhOTM0MDE5ZTMwNWYwYTI2L3RhYmxlcmFuZ2U6NzMwYWUyYjVlOWE1NGQyOGE5MzQwMTllMzA1ZjBhMjZfNi0zLTEtMS0w_33164e66-e7f7-4645-8f3d-25c54a330a59"
      unitRef="usd">2899000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfODIy_88467691-b252-4e7e-ac18-213237c5b2f3">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Upon closing of the IPO on February 3, 2020, all of the preferred stock converted into an aggregate of 21,499,770 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, in connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 510,000,000 shares, of which (i) 500,000,000 shares shall be a class designated as common stock, par value $0.0001 per share, and (ii) 10,000,000 shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i761759e947174f6ab451d27b4f158f63_D20200203-20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfMzU5_6cbc0c8d-c952-4100-89b7-c520d78b4aae"
      unitRef="shares">21499770</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <bdtx:SharesAuthorized
      contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNjE3_ba1a30f1-504e-4abf-a97b-e71ebe45870a"
      unitRef="shares">510000000</bdtx:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNjQx_96fbc022-be37-4fdf-951d-3f15cc1c318b"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNzA2_51625d01-7b10-44c5-9bb6-80a8d9bc23ff"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfNzI5_ac6a6844-2ef9-48e3-8019-ab9f2aef83ad"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0029fbb6eac7454c8620a6bc05d2acb2_I20200203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N180OS9mcmFnOmJkMjQzMzNlMzE3ZjQyZDZhYjA2NjgwMjVlZDcwYmU3L3RleHRyZWdpb246YmQyNDMzM2UzMTdmNDJkNmFiMDY2ODAyNWVkNzBiZTdfODEw_4ce6000b-ea5f-425d-a99d-b3f6d583aa16"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTA5OTUxMTYzMjQ1OQ_4a5c8b37-aedc-4f50-876c-fae7ff4bbe58">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#x201c;2017 Plan&#x201d;), provided for the Company to grant qualified incentive options, nonqualified options, stock grants and other stock-based awards to employees and non-employees to purchase the Company&#x2019;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), no further issuances were made under the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The 2020 Stock Option and Incentive Plan (the &#x201c;2020 Plan&#x201d;) was approved by our board of directors on December 5, 2019, and the Company&#x2019;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#x2019;s IPO was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2020 Plan is 6,665,891, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#x2019;s board of directors or compensation, nomination, and corporate governance committee of the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was approved by the Company&#x2019;s board of directors on December 5, 2019, and our stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#x2019;s IPO was declared effective. A total of 326,364 shares of common stock were initially reserved for issuance under this plan, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 1% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#x2019;s board of directors or compensation, nomination and corporate governance committee of the board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, the Company granted options to purchase 1,351,593 shares of common stock. The total fair value of options vested during the nine months ended September&#160;30, 2020 was $2,043. As of September&#160;30, 2020, there were 3,639,228 options outstanding, 39,763 options were forfeited and 51,076 options were exercised during the period. The weighted-average grant-date fair value per share of options granted during the nine months ended September&#160;30, 2020 was $14.47. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested stock-options was $26,283, which is expected to be recognized over a weighted average period of 3.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The fair values of restricted stock units are based on the market value of the Company&#x2019;s stock on the date of the grant. Under terms of the restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. During the nine months ended September&#160;30, 2020, the Company granted 61,000 restricted stock units during the period. The total fair value of restricted stock units vested during the nine months ended September&#160;30, 2020 was $50. As of September&#160;30, 2020, there were 59,334 restricted stock units outstanding and 1,666 units were vested during the period. The weighted-average grant-date fair value per share of restricted stock units granted during the nine months ended September&#160;30, 2020 was $29.65.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested restricted stock units was $1,631, which is expected to be recognized over a weighted average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i12d92be850134e31a71d7e87905cc175_I20200114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTIyMA_f913fe8c-7a7e-4d9b-8e17-0472b8ec13bc"
      unitRef="shares">6665891</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="i12d92be850134e31a71d7e87905cc175_I20200114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTMxNA_5c83eabd-1d51-4d91-a457-a5df9b25d0ff"
      unitRef="number">0.04</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia1021664df9e453ca21007fd9e2c51dc_I20200114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTk1Mg_bcb8e5bc-23fe-4a39-b61c-32d07fb13e28"
      unitRef="shares">326364</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="ia1021664df9e453ca21007fd9e2c51dc_I20200114"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjEyMg_cfa3e68e-befc-4a22-a793-04d9e556b0a0"
      unitRef="number">0.01</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzE3Mw_80f8fa07-afd3-4d5d-a231-5dc94327dfc8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85cf12dce2d34ce8b9fb13d1c6a7cd12_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi0xLTEtMS0w_6ebb0721-fad8-407b-a486-d7b4eadd44f4"
      unitRef="usd">1044000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iacebca6e78b94922a7d8f7456173f057_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi0zLTEtMS0w_012d38b3-95a3-44ab-97ad-9f3d85e3031c"
      unitRef="usd">738000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7a892af05d144f6950d2aaa62a4c297_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi01LTEtMS0w_acf9af4f-4020-475f-b425-9fa6a3433b6a"
      unitRef="usd">2263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9413c1bf291b46ef9b03d54c13c6aee1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMi03LTEtMS0w_c7f642a0-442e-4518-a938-77dfac512f5d"
      unitRef="usd">984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab5948b654d548159e4cc0ad67cf5a7f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy0xLTEtMS0w_301cd060-4f3b-416b-ba33-eb74b3bb8e4f"
      unitRef="usd">955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84e014cca6184bdca2ca8de90a9a1b01_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy0zLTEtMS0w_484de958-50e2-47b6-b081-060f77107a4f"
      unitRef="usd">112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i088778d5e9cd4a59b544a5b80f5d24ba_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy01LTEtMS0w_b754554e-2386-4a07-a9f9-58572d62ea82"
      unitRef="usd">3032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i995c252df7d4498e9caa9cfcdce34d17_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfMy03LTEtMS0w_675d1568-1d53-4fb8-b647-fcfb8e5d37b1"
      unitRef="usd">149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC0xLTEtMS0w_16bc5469-7278-4917-a702-6617ec22b416"
      unitRef="usd">1999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC0zLTEtMS0w_0cec7634-b19d-4423-b51b-c0376c3c770e"
      unitRef="usd">850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC01LTEtMS0w_9ae0b935-69fb-42e5-8ffc-d5dd0904f5de"
      unitRef="usd">5295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RhYmxlOjg0ZDExZTk1ZTJmMjQ5N2VhZGYwNmE0MDdjZTE2NDI5L3RhYmxlcmFuZ2U6ODRkMTFlOTVlMmYyNDk3ZWFkZjA2YTQwN2NlMTY0MjlfNC03LTEtMS0w_4ab58354-9b38-4581-809e-22fd7263d555"
      unitRef="usd">1133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjY4Ng_bc89d2ea-358b-499a-ba71-48e3d87a2674"
      unitRef="shares">1351593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjc4Ng_d0ed14a3-067d-4259-b24b-cbe6d287c501"
      unitRef="usd">2043000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjgxMQ_e83add27-7708-4d6b-810f-a51fc84dcb8a"
      unitRef="shares">3639228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjgzNQ_5be2a62f-54bc-44fd-8e7e-18d823e652f2"
      unitRef="shares">39763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NDg0Ng_f28d6df4-7285-464a-bad5-b343ea8dae32"
      unitRef="shares">51076</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMjk4Ng_38cc90e8-1603-4d2f-9ab1-2775bebce751"
      unitRef="usdPerShare">14.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzA5OA_b886ec0a-9720-4a56-8007-023b48a6386d"
      unitRef="usd">26283000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6fc2768ca441464d88c7b71c6c9bf982_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMzE3MQ_88a054b0-f7d1-4081-bc7a-e927e5c7cd27">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NjIyNw_feb2e514-0133-4395-a6dd-1ce2fe0d0bdc"
      unitRef="shares">61000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzc4Mw_627f0ba1-4b4e-42cc-87c8-be4a02146b7a"
      unitRef="usd">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4d3791e4cc2d4bff830aac311516f572_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzk2OA_58559df2-be5f-42fd-82b2-82948af999c2"
      unitRef="shares">59334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1Nzk3Mg_d6ebcf8c-43a5-447b-8ee2-82c9b08a05f3"
      unitRef="shares">1666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfMTY0OTI2NzQ0NjM0NA_38939a91-46a6-4723-8720-9639d60eef4d"
      unitRef="usdPerShare">29.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4d3791e4cc2d4bff830aac311516f572_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1NzY1NA_def57d8c-1aed-4315-9988-6c5c278ac9f3"
      unitRef="usd">1631000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib645a438e6804745bd7f89c819800c30_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181Mi9mcmFnOjFkNzYyNDgxZGMyMTQ2MmU4YWY0ZGJkMjc0NjU0ODQ1L3RleHRyZWdpb246MWQ3NjI0ODFkYzIxNDYyZThhZjRkYmQyNzQ2NTQ4NDVfNjA0NzMxMzk1NzY1OA_7a90b12f-e940-48e7-91ac-d6dca84414d4">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMwOA_c6246e69-7375-4366-997c-e80dd2ef02da">NET LOSS PER SHARE&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(17,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(9,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(44,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(25,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;35,927,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,065,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;31,860,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,054,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(4.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(1.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(12.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include options, unvested restricted stock, convertible preferred stock and warrants to purchase convertible preferred stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,639,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,608,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;59,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;125,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Preferred stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;15,060,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of series A preferred stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,698,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16,805,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMxMA_a8ec5633-c734-494a-b193-6fc3582394a0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(17,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(9,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(44,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(25,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;35,927,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,065,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;31,860,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2,054,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(4.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(1.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(12.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi0xLTEtMS0w_ba39c338-ea8c-4e30-8b8c-e8b5e004468a"
      unitRef="usd">-17912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi0zLTEtMS0w_3c577418-2a36-41cd-a60a-c5c837109016"
      unitRef="usd">-9268000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi01LTEtMS0w_f9c8c92f-bdac-4687-865c-c7ef6ea936a0"
      unitRef="usd">-44628000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMi03LTEtMS0w_aaea5f0f-3eaf-44b9-8128-9ae44e547388"
      unitRef="usd">-25383000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy0xLTEtMS0w_9847e8e9-dbf7-4ac4-94fa-38edfc9dcf5a"
      unitRef="shares">35927485</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy0zLTEtMS0w_5a1585fc-6194-402e-9f6d-f925177ec642"
      unitRef="shares">2065676</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy01LTEtMS0w_12fcf720-6621-4e6e-98a5-5b2a9c63106a"
      unitRef="shares">31860716</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfMy03LTEtMS0w_cbbd73ba-7dbb-428f-88f8-e9f21e6de41e"
      unitRef="shares">2054115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC0xLTEtMS0w_1838f4b5-4ca6-44fa-b0f9-959373d0b72a"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC0zLTEtMS0w_8ebe27b5-257c-4fa9-9ece-cc7927979842"
      unitRef="usdPerShare">-4.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC01LTEtMS0w_da2412c6-24b7-4767-bbed-7b6e958918ac"
      unitRef="usdPerShare">-1.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjIxMzk5NzY0MmEyNjQ3M2E5YjY5NDI2ODc5NzYwYWRhL3RhYmxlcmFuZ2U6MjEzOTk3NjQyYTI2NDczYTliNjk0MjY4Nzk3NjBhZGFfNC03LTEtMS0w_10379daa-0d6f-41f3-8a1d-703b77d35c9d"
      unitRef="usdPerShare">-12.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RleHRyZWdpb246MGM3OGYwZGI0YTM1NDAwZWFiNGExM2RlZWQ0MDVjZTBfMTMxMQ_950a4015-e2f4-4a94-82d8-f60c06773238">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,639,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,608,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;59,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;125,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Preferred stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;15,060,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Warrants to purchase shares of series A preferred stock (as converted to common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;3,698,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;16,805,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3abe3620951f41a29d7581f1d9a8baa5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMi0xLTEtMS0w_8c4e0bbb-2ee3-4511-a81e-f661758b85ab"
      unitRef="shares">3639228</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2dcb5e81a97143b0afa64625ea7745ff_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMi0zLTEtMS0w_48d078ce-68da-4793-bafe-d620137c5d0e"
      unitRef="shares">1608411</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia99613d35727440abf965ec6cdb33b89_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMy0xLTEtMS0w_7c474a4f-2226-488a-9417-73b9ef47ac74"
      unitRef="shares">59334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0db89b0e05b542d5acd609d84363f0fe_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfMy0zLTEtMS0w_1a66896d-1274-4f15-9a71-328e90f0f790"
      unitRef="shares">125497</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib4613097211945d588002788a6d88b08_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNC0xLTEtMS0w_fcb15c5b-48a9-4b5d-9418-4d63dc5ff406"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i62b4a0d7d7f74e5980d1e7f53a4c1d3e_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNC0zLTEtMS0w_26cc359d-ed50-4bd1-8e98-f37d58eda5eb"
      unitRef="shares">15060346</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie55196c9d5d44810bf624b67d74cf207_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNS0xLTEtMS0w_54226051-af8f-4978-83d7-5c75fc62ac31"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i978c35a69f6244fb9664243bcb241cbd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNS0zLTEtMS0w_2fa1a56f-e2f4-41d6-92ee-6f0d0d4908e0"
      unitRef="shares">10757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNi0xLTEtMS0w_b2c839c0-c4ea-44be-9f8f-7468a00a55d4"
      unitRef="shares">3698562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181NS9mcmFnOjBjNzhmMGRiNGEzNTQwMGVhYjRhMTNkZWVkNDA1Y2UwL3RhYmxlOjU3YTk4M2RlY2YwYTRhYTFhYzczNzAxNWM1YzdkODllL3RhYmxlcmFuZ2U6NTdhOTgzZGVjZjBhNGFhMWFjNzM3MDE1YzVjN2Q4OWVfNi0zLTEtMS0w_2a0c5ac8-6f6c-481f-981d-dcdd88eb0aa7"
      unitRef="shares">16805011</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTA5OTUxMTYzMDI0Mw_c6fcb21c-a11f-4849-a4ea-ce594b5729d3">LEASES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company has historically entered into lease arrangements for its facilities. As of September&#160;30, 2020, the Company had two operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#x2019;s leases generally do not include termination or purchase options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company entered into an agreement to lease approximately 2,357 square feet of office space for its principal office, which is located in Cambridge, MA. The lease expires on April 30, 2022, subject to an option to extend the lease for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNzQ0_ab6c24e2-8031-41b8-b38c-ee6a9db619f1"&gt;three&lt;/span&gt; additional years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a seven-year agreement with an option to extend for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfODUz_2dbf53ff-d133-4eb9-bc06-8e02afa3e25d"&gt;five&lt;/span&gt; additional years to lease two floors totaling approximately 25,578 square feet of office space in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the Company currently expects the lease of the second floor to commence in the fourth quarter 2020 when the landlord delivers the space in accordance with the lease terms. The Company recognizes the respective lease balances on the condensed consolidated balance sheets when the lease of each floor has commenced. Under the terms of the lease, the Company is required to make up to $17,048 in total minimum payments during the term and is required to issue a $1,168 letter of credit as security for the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three and nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The variable lease costs for the three and nine months ended September&#160;30, 2020 include common area maintenance and other operating charges. As the Company&#x2019;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of September&#160;30, 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September&#160;30, 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;4,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;10,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(1,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, future minimum lease payments under the Company&#x2019;s lease obligations under ASC 840 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bdtx:LesseeOperatingLeaseNumberOfContracts
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTIz_a694d3e3-3f40-43c3-8fa8-6be3e2e5280d"
      unitRef="contract">2</bdtx:LesseeOperatingLeaseNumberOfContracts>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="icfadec1e666b4412980e25adc961a5c1_I20190228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNTcw_bc56e300-5756-4896-9214-5018e59167a9"
      unitRef="sqft">2357</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if98ef25099314086a82b8992bf03ca26_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Ng_99309740-1ca0-4fda-a5c8-7b643f1b8979">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="if98ef25099314086a82b8992bf03ca26_I20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfOTE2_a7339453-173b-4f26-a3e4-04636e654664"
      unitRef="sqft">25578</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if98ef25099314086a82b8992bf03ca26_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTQ4Nw_6f17066c-30c4-4265-b141-11d49ae3f376"
      unitRef="usd">17048000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="if98ef25099314086a82b8992bf03ca26_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMTU1OQ_4f2c312b-35d7-4c7f-8bee-e2d64b9bbe47"
      unitRef="usd">1168000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2MQ_6fc12780-c98a-4cea-903a-f5889c09de93">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three and nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMi0xLTEtMS0w_cffb0f9d-4fa6-49f0-b824-fe75bf81f988"
      unitRef="usd">274000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMi0zLTEtMS0w_3ac7d197-bc38-40c2-be06-cf9bb0b49deb"
      unitRef="usd">386000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMy0xLTEtMS0w_0d6214a9-16dd-4f28-9ed8-61620ec57aaa"
      unitRef="usd">211000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfMy0zLTEtMS0w_6577bb7b-1998-4e9b-9168-acff55ffd415"
      unitRef="usd">476000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNC0xLTEtMS0w_236256bb-c250-4410-9116-da7998042fcf"
      unitRef="usd">9000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNC0zLTEtMS0w_17ea9123-f7c7-498d-92bc-86be2306efdc"
      unitRef="usd">31000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNS0xLTEtMS0w_0126e95c-5a0d-48e8-8554-845da8c6f999"
      unitRef="usd">494000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjg3NmY0YjZhZjc5ODQxZWJhOTJhY2M0NDQxMDlmNmVjL3RhYmxlcmFuZ2U6ODc2ZjRiNmFmNzk4NDFlYmE5MmFjYzQ0NDEwOWY2ZWNfNS0zLTEtMS0w_bfc68c90-ba51-49fa-84a0-575769eb6392"
      unitRef="usd">893000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMS0xLTEtMS0w_b8728de7-f5c1-4f69-b774-a74b3cb28ea0"
      unitRef="usd">167000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMi0xLTEtMS0w_d40814f7-5690-4a2f-a012-1a026107d55d">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjE5ZTg3ZjI2NTZmMTRmOTM4MGM2OGQ0ZTY4YjkwYTJjL3RhYmxlcmFuZ2U6MTllODdmMjY1NmYxNGY5MzgwYzY4ZDRlNjhiOTBhMmNfMy0xLTEtMS0w_472e7e9f-e1ca-4745-8b2c-73456843d726"
      unitRef="number">0.054</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Mg_d4d74193-11c2-4a1b-98f2-39f7bb16f036">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of September&#160;30, 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September&#160;30, 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;4,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;10,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;(1,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;8,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMS0xLTEtMS0w_fa4ce2c7-077b-48ce-a79b-f347275daaf4"
      unitRef="usd">266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMi0xLTEtMS0w_bd7ae29c-204c-4b35-aabe-3234ef5c7757"
      unitRef="usd">1485000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfMy0xLTEtMS0w_2d8b1a9b-1ed6-41a1-94c5-48e728507ae3"
      unitRef="usd">1351000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNC0xLTEtMS0w_2c434f02-d6f7-4b62-8f31-37205af8569b"
      unitRef="usd">1306000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNS0xLTEtMS0w_49032c50-3d34-4f80-8004-861090c2332a"
      unitRef="usd">1339000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNi0xLTEtMS0w_e277be6d-d9c8-425b-a80d-acf5182650f5"
      unitRef="usd">4829000</bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfNy0xLTEtMS0w_e8dced25-f373-47d8-82c1-51986ce339c1"
      unitRef="usd">10576000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfOC0xLTEtMS0w_238359b8-684a-43ad-a100-30359b8cd90a"
      unitRef="usd">1891000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjMxMzIyNjc2N2UzMzRkYzY5NjgxYjZlZmNmMDc3NGJhL3RhYmxlcmFuZ2U6MzEzMjI2NzY3ZTMzNGRjNjk2ODFiNmVmY2YwNzc0YmFfOS0xLTEtMS0w_01e2941a-0f09-48bf-8b00-5ea2ac34e2ee"
      unitRef="usd">8685000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfMjQ2Mw_cf3774ea-3953-4fe1-9fa1-917185345b82">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, future minimum lease payments under the Company&#x2019;s lease obligations under ASC 840 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMS0xLTEtMS0w_f31f94e9-a167-4925-a22e-2918f422753d"
      unitRef="usd">223000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMi0xLTEtMS0w_046b433c-94cf-4918-a592-2530e9364165"
      unitRef="usd">228000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfMy0xLTEtMS0w_477fec9c-b5ca-461f-a538-f5c4ff76a72d"
      unitRef="usd">77000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfNC0xLTEtMS0w_ad460aac-d0a7-4e06-ae41-e385aa2d0960"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RhYmxlOjZkYzBiN2JjM2YzODRmYTFiYWJhZjJiMzQ4NzYwN2QwL3RhYmxlcmFuZ2U6NmRjMGI3YmMzZjM4NGZhMWJhYmFmMmIzNDg3NjA3ZDBfNS0xLTEtMS0w_20eb6756-cc11-4fcb-80f4-b3c9b589b7b1"
      unitRef="usd">528000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182MS9mcmFnOmE3ODBlZGUxOGI2MzQ1OTNiZTY5Y2I3NTY4ZmI0OTdiL3RleHRyZWdpb246YTc4MGVkZTE4YjYzNDU5M2JlNjljYjc1NjhmYjQ5N2JfMjI1MQ_caf09ef2-cd79-4f75-8a15-9f020959a54a">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September&#160;30, 2020 or December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDcw_bebc474b-8c45-4cd7-82b7-b203d79bc023">BENEFIT PLANSIn 2018 the Company established a Simplified Employee Pension (&#x201c;SEP&#x201d;) defined-contribution savings plan. This plan covers substantially all employees who meet minimum age and service requirements. The Company provides contributions of 6% of each participant&#x2019;s salary. Employees are immediately and fully vested in the Company&#x2019;s contribution. During the three and nine months ended September&#160;30, 2020 and 2019, the Company contributed $161, $428, $64 and $125 to the plan, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMjU4_f9c154c6-c81d-4554-bcfe-f7d1b35bbef2"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMTY0OTI2NzQ0MjE0MQ_e41871df-0f6c-4618-b27c-72f714834a93"
      unitRef="usd">161000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDMx_8b7dd4b7-5437-4bd0-9ab1-c425516b7cbf"
      unitRef="usd">428000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfMTY0OTI2NzQ0MjEzNw_0c17ff62-27ee-4b4e-a18e-9e70d4219243"
      unitRef="usd">64000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182NC9mcmFnOjg2MGY4ZmZmYzZmYjRkNTU5NjIxNzNjNTliNWZlMmJmL3RleHRyZWdpb246ODYwZjhmZmZjNmZiNGQ1NTk2MjE3M2M1OWI1ZmUyYmZfNDQy_5e3b2de5-315d-4881-bdb4-c0cdf41269b3"
      unitRef="usd">125000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTExNA_e2c6ee71-467d-4ee2-bfc1-6cee3db0872d">RELATED-PARTY TRANSACTIONSThe Company is party to a services agreement, which was entered into in March 2017 and amended in November 2017 and March 2020, with Ridgeline. Ridgeline is an entity owned by one of the Company&#x2019;s investors, whereby an individual who is a Company director and was executive officer until September 2019 and other employees of Ridgeline provide the Company with scientific consulting services. The services agreement is effective until December 31, 2020. Under the November 2017 amended services agreement the Company paid Ridgeline $950 per month, which was reconciled on a quarterly basis with the actual expenses incurred by Ridgeline on its behalf. In connection with the March 2020 amendment to the services agreement, the Company transitioned to a more limited consulting arrangement whereby Ridgeline invoices the Company for services performed on an ongoing monthly basis. Total amounts due to related party were $190 as of September&#160;30, 2020. Total prepaids with Ridgeline were $916 as of December&#160;31, 2019. Total service fees incurred were $190, $2,293, $3,656 and $8,854, for the three and nine months ended September&#160;30, 2020 and 2019, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i516d9585532d496ea7567f7c7e177c98_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfNTU5_1aa914f8-5c93-401e-830c-67f06e6ea0c1"
      unitRef="usd">950000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i784f5ca30047442983dcf65beeb93bee_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfOTM3_1346d97d-0bd2-457e-9ccb-6525380a55ce"
      unitRef="usd">190000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <bdtx:PrepaidExpenseRelatedPartyCurrent
      contextRef="if2368ce4e94440adb39d1bb4e7c7d03d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfOTg5_e8f16d75-1ac1-4c5b-8622-af46f528f91c"
      unitRef="usd">916000</bdtx:PrepaidExpenseRelatedPartyCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTAzNQ_35330ab0-c9c0-4f9e-9425-8cfdd898ed3c"
      unitRef="usd">190000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i922f12bc23d04883ba291d428df17336_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTAzOQ_717b4d2f-40dc-411d-bba5-b6f2b5880a67"
      unitRef="usd">2293000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ieb38167c58ba43af9e61c1130992de35_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTA0Mw_43959ce5-a1ea-4ff6-a5ba-aa8ce2ab44a6"
      unitRef="usd">3656000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i5ca0e44fa0eb4f7dbaa6b184d07bf156_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N182Ny9mcmFnOjBiNGM1MWFkODM5OTQ0OTFhODlhZjRiMDQ2ZWU4Yjk4L3RleHRyZWdpb246MGI0YzUxYWQ4Mzk5NDQ5MWE4OWFmNGIwNDZlZThiOThfMTA1MA_84cd6780-e8c9-4730-8b21-ea61cfe666a1"
      unitRef="usd">8854000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391876616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BLACK DIAMOND THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001701541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4254660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">139 Main Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">252-0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,995,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391923288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,197<span></span>
</td>
<td class="nump">$ 154,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">276,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">336,428<span></span>
</td>
<td class="nump">155,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">346,435<span></span>
</td>
<td class="nump">158,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">1,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,219<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,341<span></span>
</td>
<td class="nump">4,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">7,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,090<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock (Note 7)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value; 500,000,000 shares authorized at September&#160;30, 2020 and 80,000,000 shares authorized at December&#160;31, 2019; 35,963,447 shares issued and outstanding at September&#160;30, 2020 and 2,236,672 shares issued and outstanding at December&#160;31, 2019</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">422,063<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(95,598)<span></span>
</td>
<td class="num">(50,970)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">327,345<span></span>
</td>
<td class="num">(47,157)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">$ 346,435<span></span>
</td>
<td class="nump">$ 158,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391427112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,963,447<span></span>
</td>
<td class="nump">2,236,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">35,963,447<span></span>
</td>
<td class="nump">2,236,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391454296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (inclusive of $190, $3,480, $2,293 and $8,497 respectively, with a related party)</a></td>
<td class="nump">$ 12,929<span></span>
</td>
<td class="nump">$ 5,634<span></span>
</td>
<td class="nump">$ 30,453<span></span>
</td>
<td class="nump">$ 14,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (inclusive of $0, $176, $0 and $357 respectively, with a related party)</a></td>
<td class="nump">5,551<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
<td class="nump">15,934<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,480<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
<td class="nump">46,387<span></span>
</td>
<td class="nump">18,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,480)<span></span>
</td>
<td class="num">(8,148)<span></span>
</td>
<td class="num">(46,387)<span></span>
</td>
<td class="num">(18,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,116)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(594)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">568<span></span>
</td>
<td class="num">(1,120)<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
<td class="num">(6,395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (17,912)<span></span>
</td>
<td class="num">$ (9,268)<span></span>
</td>
<td class="num">$ (44,628)<span></span>
</td>
<td class="num">$ (25,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (12.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">35,927,485<span></span>
</td>
<td class="nump">2,065,676<span></span>
</td>
<td class="nump">31,860,716<span></span>
</td>
<td class="nump">2,054,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,912)<span></span>
</td>
<td class="num">$ (9,268)<span></span>
</td>
<td class="num">$ (44,628)<span></span>
</td>
<td class="num">$ (25,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (18,049)<span></span>
</td>
<td class="num">$ (9,268)<span></span>
</td>
<td class="num">$ (43,753)<span></span>
</td>
<td class="num">$ (25,383)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391554200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty', window );">Research and development, related party</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 3,480<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="nump">$ 8,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">General and administrative, related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Research and Development Expenses from Transactions with Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391276040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,628)<span></span>
</td>
<td class="num">$ (25,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Accretion of discount on investments</a></td>
<td class="num">(990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_RentExpense', window );">Noncash rent expense</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in current assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,308)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">190<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,551<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Non-current operating lease liability</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(36,372)<span></span>
</td>
<td class="num">(17,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">17,765<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(292,775)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(275,043)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs of $1,275</a></td>
<td class="nump">213,844<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">214,114<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(97,301)<span></span>
</td>
<td class="nump">27,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">154,721<span></span>
</td>
<td class="nump">51,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">57,420<span></span>
</td>
<td class="nump">78,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">57,420<span></span>
</td>
<td class="nump">78,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering and stock issuance costs included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock</a></td>
<td class="nump">200,573<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditAssumed1', window );">Line of credit for operating lease obligation</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of line of credit assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386429272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571308469192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series B preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">33,668,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 60,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">33,668,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 60,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(15,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (15,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Grant of restricted common stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Grant of restricted common stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="num">$ (19,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">33,668,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 60,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">45,419,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 115,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(15,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">$ (39,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,095)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">33,668,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">$ 60,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">33,668,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 60,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="num">(19,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="num">$ (31,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of series B convertible preferred stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,751,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of series B convertible preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">45,419,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 115,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,268)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="num">$ (39,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,095)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">64,839,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 200,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)</a></td>
<td class="num">(64,839,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock upon closing of the initial public offering</a></td>
<td class="num">$ (200,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,236,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (47,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,499,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock upon closing of the initial public offering</a></td>
<td class="nump">200,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">200,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,174,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">212,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">212,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrants to additional paid-in capital</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,910,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 355,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">418,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(63,115)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">64,839,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 200,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,236,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (47,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">51,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">$ 875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">35,963,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,963,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 327,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">422,063<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="num">(95,598)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,910,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">355,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">418,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(63,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,571)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,910,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 343,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">419,794<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="num">(77,686)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">35,963,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,963,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 327,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 422,063<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
<td class="num">$ (95,598)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of Temporary to Permanent Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386496136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of BDTX-189 and its earlier-stage pipeline programs as well as its mutation, allostery, and pharmacology computational and discovery platform. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers including a related party Ridgeline Therapeutics GmbH (&#8220;Ridgeline&#8221;). Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 21, 2020, the Company effected a 1-for-3.01581 reverse stock split of the Company&#8217;s common stock. All shares, stock options, warrants and per share information presented in the condensed consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, the Company completed an initial public offering (the &#8220;IPO&#8221;) of 12,174,263 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231,311 and its shares started trading on The Nasdaq Global Select Market under the ticker symbol &#8220;BDTX.&#8221; The Company received $212,101 in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Upon closing of the IPO, all of the Company's outstanding shares of convertible preferred stock automatically converted into 21,499,770 shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of convertible preferred stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of November&#160;10, 2020, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital requirements into 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing global outbreak of the novel coronavirus disease (&#8220;COVID-19&#8221;), which began in December 2019, was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries worldwide. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures. Such orders, restrictions and recommendations, and the perception that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &#8220;essential,&#8221; work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of the Company&#8217;s business, including how it has and will continue to impact the Company&#8217;s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company&#8217;s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company&#8217;s third party service providers have also experienced shutdowns or other business disruptions. The Company does not yet know the full extent of potential delays or impacts on the Company&#8217;s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company&#8217;s business, results of operations or financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain the pandemic or treat its impact, among others. In addition, a recurrence or &#8220;additional waves&#8221; of COVID-19 cases could cause other widespread or more severe impacts depending on where infection rates are highest. While states and jurisdictions have rolled back &#8220;stay at home&#8221; and quarantine orders and reopened in phases, it is difficult to predict what the lasting impact of the pandemic will be, and any prolonged material disruption to the Company&#8217;s employees or third party service providers could negatively impact the Company&#8217;s ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Company&#8217;s business, results of operations and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388496760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March 24, 2020. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Deferred offering costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company recorded deferred offering costs of $2,303. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. After consummation of the IPO, which closed on February 3, 2020, these costs were recorded in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments consist of marketable securities with original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders&#8217; equity. Amortization and accretion of premiums and discounts are recorded in other income (expense). Realized gains or losses on debt securities are included in interest income or interest expense, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company&#8217;s statement of operations and comprehensive income (loss). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. Restricted cash includes amounts held as security deposits in the form of letters of credit for the Company&#8217;s leased facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-02&#8221; or &#8220;ASC 842&#8221;), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases (&#8220;ASC 840&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company has elected not to recognize leases with an original term of one year or less on the condensed consolidated balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on our financial condition and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386486504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at September 30, 2020 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">328,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at December 31, 2019 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Valuation of derivative liabilities </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair value of the derivative liabilities related to the warrants to purchase series A convertible preferred stock is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon completion of the IPO in February 2020, the warrants to purchase series A convertible preferred stock converted to warrants to purchase 10,757 shares of common stock and the fair value of the derivative liability was reclassified to additional paid-in capital. As a result, we will no longer remeasure the fair value of the warrant liability at each reporting date. Derivative liabilities consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reclassification to additional paid-in capital in connection with IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386407768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, investments were comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, the Company did not hold any investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571387821160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equipment, net consisted of the following:</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the nine months ended September&#160;30, 2020 and 2019 was $37 and $38, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386517432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571387755336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon closing of the IPO on February 3, 2020, all of the preferred stock converted into an aggregate of 21,499,770 shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, in connection with the closing of the IPO, the Company filed an amended and restated certificate of incorporation, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 510,000,000 shares, of which (i) 500,000,000 shares shall be a class designated as common stock, par value $0.0001 per share, and (ii) 10,000,000 shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571387750920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the &#8220;2017 Plan&#8221;), provided for the Company to grant qualified incentive options, nonqualified options, stock grants and other stock-based awards to employees and non-employees to purchase the Company&#8217;s common stock. Upon the effectiveness of the 2020 Plan (as defined below), no further issuances were made under the 2017 Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) was approved by our board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2020 Plan is 6,665,891, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 4% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation, nomination, and corporate governance committee of the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was approved by the Company&#8217;s board of directors on December 5, 2019, and our stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. A total of 326,364 shares of common stock were initially reserved for issuance under this plan, which shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by 1% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation, nomination and corporate governance committee of the board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted options to purchase 1,351,593 shares of common stock. The total fair value of options vested during the nine months ended September&#160;30, 2020 was $2,043. As of September&#160;30, 2020, there were 3,639,228 options outstanding, 39,763 options were forfeited and 51,076 options were exercised during the period. The weighted-average grant-date fair value per share of options granted during the nine months ended September&#160;30, 2020 was $14.47. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested stock-options was $26,283, which is expected to be recognized over a weighted average period of 3.0 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company&#8217;s stock on the date of the grant. Under terms of the restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. During the nine months ended September&#160;30, 2020, the Company granted 61,000 restricted stock units during the period. The total fair value of restricted stock units vested during the nine months ended September&#160;30, 2020 was $50. As of September&#160;30, 2020, there were 59,334 restricted stock units outstanding and 1,666 units were vested during the period. The weighted-average grant-date fair value per share of restricted stock units granted during the nine months ended September&#160;30, 2020 was $29.65.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2020, total unrecognized compensation cost related to the unvested restricted stock units was $1,631, which is expected to be recognized over a weighted average period of 2.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388122024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17,912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35,927,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,065,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,860,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,054,115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.42)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock, convertible preferred stock and warrants to purchase convertible preferred stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,639,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,608,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,060,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warrants to purchase shares of series A preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,698,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,805,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391798408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of September&#160;30, 2020, the Company had two operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In February 2019, the Company entered into an agreement to lease approximately 2,357 square feet of office space for its principal office, which is located in Cambridge, MA. The lease expires on April 30, 2022, subject to an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfNzQ0_ab6c24e2-8031-41b8-b38c-ee6a9db619f1">three</span> additional years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiM2E3OTc0Y2YyNDRlNDFiNmVlNDEyMDVjOWQxNTk3L3NlYzo0YjNhNzk3NGNmMjQ0ZTQxYjZlZTQxMjA1YzlkMTU5N181OC9mcmFnOmJlNTJkNmI0MmFiNjQ4ZGJhYjZiZTgzMmQ2MjE0M2QxL3RleHRyZWdpb246YmU1MmQ2YjQyYWI2NDhkYmFiNmJlODMyZDYyMTQzZDFfODUz_2dbf53ff-d133-4eb9-bc06-8e02afa3e25d">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the Company currently expects the lease of the second floor to commence in the fourth quarter 2020 when the landlord delivers the space in accordance with the lease terms. The Company recognizes the respective lease balances on the condensed consolidated balance sheets when the lease of each floor has commenced. Under the terms of the lease, the Company is required to make up to $17,048 in total minimum payments during the term and is required to issue a $1,168 letter of credit as security for the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three and nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.435%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three and nine months ended September&#160;30, 2020 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of September&#160;30, 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September&#160;30, 2020)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2019, future minimum lease payments under the Company&#8217;s lease obligations under ASC 840 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388116072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of September&#160;30, 2020 or December&#160;31, 2019. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386549976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">BENEFIT PLANS</a></td>
<td class="text">BENEFIT PLANSIn 2018 the Company established a Simplified Employee Pension (&#8220;SEP&#8221;) defined-contribution savings plan. This plan covers substantially all employees who meet minimum age and service requirements. The Company provides contributions of 6% of each participant&#8217;s salary. Employees are immediately and fully vested in the Company&#8217;s contribution. During the three and nine months ended September&#160;30, 2020 and 2019, the Company contributed $161, $428, $64 and $125 to the plan, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388925304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED-PARTY TRANSACTIONS</a></td>
<td class="text">RELATED-PARTY TRANSACTIONSThe Company is party to a services agreement, which was entered into in March 2017 and amended in November 2017 and March 2020, with Ridgeline. Ridgeline is an entity owned by one of the Company&#8217;s investors, whereby an individual who is a Company director and was executive officer until September 2019 and other employees of Ridgeline provide the Company with scientific consulting services. The services agreement is effective until December 31, 2020. Under the November 2017 amended services agreement the Company paid Ridgeline $950 per month, which was reconciled on a quarterly basis with the actual expenses incurred by Ridgeline on its behalf. In connection with the March 2020 amendment to the services agreement, the Company transitioned to a more limited consulting arrangement whereby Ridgeline invoices the Company for services performed on an ongoing monthly basis. Total amounts due to related party were $190 as of September&#160;30, 2020. Total prepaids with Ridgeline were $916 as of December&#160;31, 2019. Total service fees incurred were $190, $2,293, $3,656 and $8,854, for the three and nine months ended September&#160;30, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391613048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of consolidation and unaudited interim financial information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;) is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of BDTX-189 and its earlier-stage pipeline programs as well as its mutation, allostery, and pharmacology computational and discovery platform. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers including a related party Ridgeline Therapeutics GmbH (&#8220;Ridgeline&#8221;). Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K, which was filed with the SEC on March 24, 2020. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">Use of estimates The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text">Deferred offering costsAs of December&#160;31, 2019, the Company recorded deferred offering costs of $2,303. The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. After consummation of the IPO, which closed on February 3, 2020, these costs were recorded in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments consist of marketable securities with original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders&#8217; equity. Amortization and accretion of premiums and discounts are recorded in other income (expense). Realized gains or losses on debt securities are included in interest income or interest expense, respectively.</span></div>If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company&#8217;s statement of operations and comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash accounts that are restricted as to withdrawal or usage are presented as restricted cash. Restricted cash includes amounts held as security deposits in the form of letters of credit for the Company&#8217;s leased facilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on investments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company adopted Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-02&#8221; or &#8220;ASC 842&#8221;), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under ASC 840, Leases (&#8220;ASC 840&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company has elected not to recognize leases with an original term of one year or less on the condensed consolidated balance sheet. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company is currently assessing the impact of this standard on our financial condition and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388548856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at September 30, 2020 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">328,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair value measurements at December 31, 2019 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Fair Value Liabilities</a></td>
<td class="text">Derivative liabilities consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reclassification to additional paid-in capital in connection with IPO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance - September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391798408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, investments were comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386435096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equipment, net consisted of the following:</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386466648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386416648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388091240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17,912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35,927,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,065,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,860,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,054,115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.42)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,639,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,608,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,060,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Warrants to purchase shares of series A preferred stock (as converted to common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,698,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,805,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571399045160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost and Other Operating Lease Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three and nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.014%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.435%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of September&#160;30, 2020 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September&#160;30, 2020)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2019, future minimum lease payments under the Company&#8217;s lease obligations under ASC 840 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388821880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.01581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="nump">12,174,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="nump">1,587,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="nump">$ 231,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from stock issuance, net | $</a></td>
<td class="nump">$ 212,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued upon conversion</a></td>
<td class="nump">21,499,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386202712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571389599800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 328,893<span></span>
</td>
<td class="nump">$ 24,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">52,018<span></span>
</td>
<td class="nump">24,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">69,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">186,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">20,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">52,018<span></span>
</td>
<td class="nump">24,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">52,018<span></span>
</td>
<td class="nump">24,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">276,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">69,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">186,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">20,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386544936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares into which the warrant may be converted</a></td>
<td class="nump">10,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391784664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Reclassification to additional paid-in capital in connection with IPO</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391286488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 276,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">276,875,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">69,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">69,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">186,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">186,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 20,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571389553640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Equipment, net</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571395783896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_AccruedContractResearchServiceFeesCurrent', window );">Contracted research services</a></td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">2,733<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting fees</a></td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_AccruedLegalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,219<span></span>
</td>
<td class="nump">$ 2,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_AccruedContractResearchServiceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Contract Research Service Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_AccruedContractResearchServiceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388399656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_SharesAuthorized', window );">Total shares authorized</a></td>
<td class="nump">510,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued upon conversion</a></td>
<td class="nump">21,499,770<span></span>
</td>
<td class="nump">21,499,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571389532616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,351,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">3,639,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited (in shares)</a></td>
<td class="nump">39,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="nump">51,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 14.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="nump">$ 26,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020PlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,665,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units granted (in shares)</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of units vested</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="nump">59,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Units vested (in shares)</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 29.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391519448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,999<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 5,295<span></span>
</td>
<td class="nump">$ 1,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571386218056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (17,912)<span></span>
</td>
<td class="num">$ (14,571)<span></span>
</td>
<td class="num">$ (12,145)<span></span>
</td>
<td class="num">$ (9,268)<span></span>
</td>
<td class="num">$ (12,287)<span></span>
</td>
<td class="num">$ (3,828)<span></span>
</td>
<td class="num">$ (44,628)<span></span>
</td>
<td class="num">$ (25,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">35,927,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,065,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,860,716<span></span>
</td>
<td class="nump">2,054,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (12.36)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391191288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">3,698,562<span></span>
</td>
<td class="nump">16,805,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">3,639,228<span></span>
</td>
<td class="nump">1,608,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">59,334<span></span>
</td>
<td class="nump">125,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Preferred stock (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,060,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase shares of series A preferred stock (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571396348872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseNumberOfContracts', window );">Number of leases | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payments due</a></td>
<td class="nump">$ 10,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember', window );">Principal office, lease one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember', window );">Principal office, lease two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Minimum lease payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571391784968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LeaseOtherInformationAbstract', window );"><strong>Other Operating Lease Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571395544696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>ASC 842</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September&#160;30, 2020)</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">10,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 8,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>ASC 840</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571388955016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution, percent of each participant's salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140571384123896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdtx_PrepaidExpenseRelatedPartyCurrent', window );">Prepaids with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expense, service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="nump">$ 3,656,000<span></span>
</td>
<td class="nump">$ 2,293,000<span></span>
</td>
<td class="nump">$ 8,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Ridgeline | Monthly service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party transaction, monthly transaction amount</a></td>
<td class="nump">$ 950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_PrepaidExpenseRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_PrepaidExpenseRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=bdtx_ServiceAgreementMonthlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=bdtx_ServiceAgreementMonthlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M,*!L .ZOI31[QPZQ_IN5_0-02P,$%     @ +CIJ45/JGU:L!0  5A8  !@
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MPNQ4[25F^Z'DIKFE>Y5*R:)Y306'744#X/^5E&K_H3OHKY*G_P%02P,$%
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M<<MHP:06@/]OA&CV+WJ!PZWSU=]02P,$%     @ +CIJ46H<C]TK @  BP0
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MA\*)!0<.33")0A&ZE'4._DU=<!P,;KA-6<(8YLR<?;8=,\<"L."((B(,NSO
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M_Z8I-[N?;_E:-DVYWKU<I?$RK5H#]?UC638O;]I?A#G^C-'5?P%02P,$%
M  @ +CIJ45U7%.T6#@  PB,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6RU6FMS&S<2_"LHW=4]JBA*E.383FQ727XDODILEV4G5W5U'\!=D$2T"S#
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M 'RG^['I@3;(?_7Q^K\ 4$L#!!0    ( "XZ:E&1>X)*%@8  ! /   9
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M-RVILZ.R!G1>2&E>%M9!_Z^8_ )02P,$%     @ +CIJ47R,4Q-R P  O@<
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MUA9J?BI;4XH:%PIT6U5</5Y@*;=G7N#M%F[$IC!V83P_;?@&EVB^- M%L_&
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M0),IL&Y#D\8B:-VHLGO=IV6ATX(TLC3 /GBE"U7-K<X6>/WN/&(2W?)U U(
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MZG!_>M"+-YOU@S=-N,S/C<>G05@6^!9C*P)XGQOCUP_B8/-U=_8?4$L#!!0
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M/.39 -\+AU)T+QQ@^ UU]B]02P,$%     @ +CIJ47-<IVS[ @  2 8  !D
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MAD:H6Z;TSX+*"M!Y+*5I-]9 ]Q>T_@=02P,$%     @ +CIJ45.NR6M $P
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MD&'.#L*LY?$&VWHN+5\JA7:_<&QB+]][D!ZTD64+)@4EKYJ5/;9]. ,DP3.
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MC<H&T'LNI3D=;()NYD]^ U!+ P04    "  N.FI1O[YSH=L"  #G!0  &0
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M6=PHS=&XV+DUA*<7E0V3-$KP@ER<!$WNYKPC]0OM%0PPV6AJ+%T9[Q"$,F8
MRU(COOHE<$\)OMYQCTU#-SNQ'BE5IO/2,Q>XHYY2^R?[ -U.E*8T7R=]&N-.
M?)70G/53^(J2(A(>PPJJ(>Y>US4#R'H]Z'9C2#I1$D,WS3Q1EKFYWXMH['7B
MK.=WNTD";_V'\*3X*M0;WV+<76VE;>JPW6V[V*0IWO_N30N\8WK#Z=X$K@D:
M75[W M!-6VD65M6^E%?*4F/P9DF=&+5SH/.U4O:X< )M;Q__ U!+ P04
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MD$'$IOZ8A9,(?.;&$8O',00>F\0N&WNQ68Q"YGG1-_Y]5%[#(V+N,');LMW
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MY.:D$+(BVKARZZM:(LD=J&)^& 2W?D4H]^*!VYO+>"!VFE&.<PEJ5U5$_GY
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MWXE9,=0/(Q F0/<O.%>;BKD8RZ?6\#=02P,$%     @ +CIJ4=V4&<W.!
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M!%E"\U_\7"2B8H"Z#0:H,$!O#&"GP2 H# (3:$YFPKK $H^&G&T!UW<K;_K
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M4^Q(7HU*U4:R4L\"MTSB9*&7"8Z7P)4!/E\R)I\VRD$SL(Y^ U!+ P04
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MC(%>GW.NW@9F@_KU-_X#4$L#!!0    ( "XZ:E&DM'CM) ,  'L*   9
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MWPY!F 7Z_9)SM9N8^T=SWQS] U!+ P04    "  N.FI1M2Z*(: "   ]!P
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  N.FI1F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M "XZ:E'?DU1[304  /H5   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  N.FI15B4#Z*P%  #^%0  &
M            @(&/#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ +CIJ40@I  >0 @  OP8  !@              ("!<1,  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "XZ:E%3ZI]6K 4  %86
M   8              " @3<6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  N.FI1_'&LO],"  #H!P  &               @($9'
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ +CIJ4>6_(@X[
M!P  @1X  !@              ("!(A\  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( "XZ:E%J'(_=*P(  (L$   8              "
M@9,F  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  N.FI1
M%PO5G00+  #22   &               @('T*   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ +CIJ45U7%.T6#@  PB,  !@
M     ("!+C0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M "XZ:E%3OZ)ZD1$   $R   9              " @7I"  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ +CIJ49%[@DH6!@  $ \  !D
M             ("!0E0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  N.FI1644\EL8"  #5!0  &0              @(&/6@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "XZ:E&-5M*=P (
M .$%   9              " @8Q=  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ +CIJ43ZYMX'8 @  -P8  !D              ("!
M@V   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  N.FI1
M?(Q3$W(#  "^!P  &0              @(&28P  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( "XZ:E&V6E\_* <  ',6   9
M      " @3MG  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ +CIJ45[?I!!H!   #@L  !D              ("!FFX  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  N.FI1LDY#BM0%  #I#0
M&0              @($Y<P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( "XZ:E$"!42.K04  $\-   9              " @41Y  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ +CIJ47-<IVS[
M @  2 8  !D              ("!*'\  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  N.FI1MI"J\_\#   1"0  &0
M@(%:@@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "XZ
M:E%3KLEK0!,  .LY   9              " @9"&  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ +CIJ41I;ZN?[ P  J0D  !D
M         ("!!YH  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  N.FI1\."P!\H"  "[!0  &0              @($YG@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "XZ:E%/E 5IK (  )(%
M   9              " @3JA  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ +CIJ4>8>:W#G @  _P4  !D              ("!':0
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  N.FI1O[YS
MH=L"  #G!0  &0              @($[IP  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( "XZ:E&7?+L@$00  *()   9
M  " @4VJ  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M+CIJ4=,7#YT'!   ,PH  !D              ("!E:X  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  N.FI1":$KJSP#  #)"0  &0
M            @('3L@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( "XZ:E'$&E'_)P(  'P$   9              " @4:V  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ +CIJ480ER]2:!0
MV!\  !D              ("!I+@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  N.FI1C\P)L3<"  !P!   &0              @(%U
MO@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "XZ:E&B
M,7H6J0(  /8%   9              " @>/   !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ +CIJ4>77$^UY P  "@X  !D
M     ("!P\,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "XZ:E%*P2=80@,  +P*   9              "
M@4K6  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ +CIJ
M46=Z2@V- P  = L  !D              ("!P]D  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  N.FI1FB5![6 #  "<#   &0
M        @(&'W0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( "XZ:E'?]_X-8 ,  &4+   9              " @1[A  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ +CIJ4>5*E)TK P  "0H
M !D              ("!M>0  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  N.FI1I+1X[20#  !["@  &0              @($7Z
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "XZ:E&U+HHA
MH (  #T'   9              " @7+K  !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ +CIJ40CMR8P@ P  80H  !D
M ("!2>X  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  N
M.FI1ZHW3I$,"  #$"@  #0              @ &@\0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( "XZ:E&7BKL<P    !,"   +              "  0[T
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "XZ:E$8Q6-O0@0  '@?   /
M          "  ??T  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  N.FI1
MN2/:-[(!  !4'   &@              @ %F^0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  N.FI19>&9M;<!  !E'   $P
M        @ %0^P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -P W /@.
(   X_0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</Role>
      <ShortName>BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2138113 - Disclosure - RELATED-PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables</Role>
      <ShortName>INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/LEASES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>INVESTMENTS - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails</Role>
      <ShortName>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails</Role>
      <ShortName>BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bdtx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439418 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bdtx-20200930.htm">bdtx-20200930.htm</File>
    <File>bdtx-20200930.xsd</File>
    <File>bdtx-20200930_cal.xml</File>
    <File>bdtx-20200930_def.xml</File>
    <File>bdtx-20200930_lab.xml</File>
    <File>bdtx-20200930_pre.xml</File>
    <File>exhibit311q32020.htm</File>
    <File>exhibit312q32020.htm</File>
    <File>exhibit321q32020.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdtx-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 13,
   "contextCount": 135,
   "dts": {
    "calculationLink": {
     "local": [
      "bdtx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdtx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bdtx-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdtx-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdtx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bdtx-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 351,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 7
   },
   "keyCustom": 14,
   "keyStandard": 277,
   "memberCustom": 5,
   "memberStandard": 25,
   "nsprefix": "bdtx",
   "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - INVESTMENTS",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS",
     "shortName": "INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - NET LOSS PER SHARE",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - LEASES",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - BENEFIT PLANS",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS",
     "shortName": "BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138113 - Disclosure - RELATED-PARTY TRANSACTIONS",
     "role": "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED-PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - INVESTMENTS (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables",
     "shortName": "INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - LEASES (Tables)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i7185da688aa847c2987adeeb176d4fb5_D20200121-20200121",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "ic9b7e547f4fb4f2d95ba8f0d3911059e_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "ie6f8a8b906244beea5072e056d82cd69_I20200229",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "ie6f8a8b906244beea5072e056d82cd69_I20200229",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "if2368ce4e94440adb39d1bb4e7c7d03d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Reconciliation of Fair Value Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "if2368ce4e94440adb39d1bb4e7c7d03d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails",
     "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i0029fbb6eac7454c8620a6bc05d2acb2_I20200203",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:SharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i0029fbb6eac7454c8620a6bc05d2acb2_I20200203",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:SharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails",
     "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails",
     "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - BENEFIT PLANS (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails",
     "shortName": "BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i784f5ca30047442983dcf65beeb93bee_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439418 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)",
     "role": "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED-PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "if2368ce4e94440adb39d1bb4e7c7d03d_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bdtx:PrepaidExpenseRelatedPartyCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i958d95565a0b49f0ad33cb795dc938de_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i7a81c80297be401c9d24d2691c346ef2_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "id3dc3b2779764af18308733d70c4f62c_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20200930.htm",
      "contextRef": "i922f12bc23d04883ba291d428df17336_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "bdtx_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_A2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Plan",
        "label": "2020 Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "A2020PlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_AccruedContractResearchServiceFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Contract Research Service Fees, Current",
        "label": "Accrued Contract Research Service Fees, Current",
        "terseLabel": "Contracted research services"
       }
      }
     },
     "localname": "AccruedContractResearchServiceFeesCurrent",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_AccruedLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Legal Fees, Current",
        "label": "Accrued Legal Fees, Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedLegalFeesCurrent",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_DeferredOfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs Incurred But Not Yet Paid",
        "label": "Deferred Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred offering and stock issuance costs included in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Non-current operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LeaseContractualTermAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Contractual Term",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdtx_LeaseContractualTermDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Contractual Term",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_LeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Other Information [Abstract]",
        "label": "Lease, Other Information [Abstract]",
        "terseLabel": "Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseOtherInformationAbstract",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdtx_LesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area",
        "label": "Lessee, Operating Lease, Area",
        "terseLabel": "Area leased (square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseArea",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdtx_OperatingLeasePrincipalOfficeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Principal Office, One",
        "label": "Operating Lease, Principal Office, One [Member]",
        "terseLabel": "Principal office, lease one"
       }
      }
     },
     "localname": "OperatingLeasePrincipalOfficeOneMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeasePrincipalOfficeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Principal Office, Two",
        "label": "Operating Lease, Principal Office, Two [Member]",
        "terseLabel": "Principal office, lease two"
       }
      }
     },
     "localname": "OperatingLeasePrincipalOfficeTwoMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_PrepaidExpenseRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Expense, Related Party, Current",
        "label": "Prepaid Expense, Related Party, Current",
        "terseLabel": "Prepaids with related party"
       }
      }
     },
     "localname": "PrepaidExpenseRelatedPartyCurrent",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassifications of Temporary to Permanent Equity, Shares",
        "label": "Reclassifications of Temporary to Permanent Equity, Shares",
        "negatedTerseLabel": "Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdtx_RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transaction, Research and Development Expenses from Transactions with Related Party",
        "label": "Related Party Transaction, Research and Development Expenses from Transactions with Related Party",
        "terseLabel": "Research and development, related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_RentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rent Expense",
        "label": "Rent Expense",
        "terseLabel": "Noncash rent expense"
       }
      }
     },
     "localname": "RentExpense",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ServiceAgreementMonthlyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service Agreement, Monthly",
        "label": "Service Agreement, Monthly [Member]",
        "terseLabel": "Monthly service agreement"
       }
      }
     },
     "localname": "ServiceAgreementMonthlyMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "terseLabel": "Increase of authorized shares, percent of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdtx_SharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares, Authorized",
        "label": "Shares, Authorized",
        "terseLabel": "Total shares authorized"
       }
      }
     },
     "localname": "SharesAuthorized",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of series B convertible preferred stock, net (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20200930",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r24",
      "r116"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r145",
      "r147",
      "r166",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r123",
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of warrants to additional paid-in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r147",
      "r161",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r239",
      "r248"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r35"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r98",
      "r109"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r95",
      "r99",
      "r109"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r97",
      "r109"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r148",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation and unaudited interim financial information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r79",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r22",
      "r68"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r7",
      "r69",
      "r74",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r188"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares into which the warrant may be converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r140",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r121",
      "r243",
      "r252"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note\u00a011)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, number of shares reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at September\u00a030, 2020 and 80,000,000 shares authorized at December\u00a031, 2019; 35,963,447 shares issued and outstanding at September\u00a030, 2020 and 2,236,672 shares issued and outstanding at December\u00a031, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r144",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Preferred stock (as converted to common stock)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r10",
      "r238",
      "r247"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution, percent of each participant's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r114"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r36",
      "r37",
      "r185"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r26",
      "r78",
      "r212"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Amounts due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r78",
      "r212",
      "r242",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r175",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r176",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r179",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r176",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r176",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r176",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r180",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Fair Value Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "negatedTerseLabel": "Reclassification to additional paid-in capital in connection with IPO"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSReconciliationofFairValueLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r182",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative (inclusive of $0, $176, $0 and $357 respectively, with a related party)"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Amounts due to related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in current assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r50",
      "r92",
      "r189",
      "r190",
      "r245"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion of purchase discount on nonoperating securities.",
        "label": "Investment Income, Amortization of Discount",
        "negatedTerseLabel": "Accretion of discount on investments"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r236",
      "r246",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Ridgeline"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r207",
      "r209"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost and Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Minimum lease payments due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the nine months ended September\u00a030, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term, optional extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r240",
      "r250"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditAssumed1": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of line of credit assumed in noncash investing or financing activities.",
        "label": "Line of Credit Assumed",
        "terseLabel": "Line of credit for operating lease obligation"
       }
      }
     },
     "localname": "LineOfCreditAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r45",
      "r47",
      "r51",
      "r67",
      "r82",
      "r244",
      "r254"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r200",
      "r209"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r196",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r205",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "ASC 840"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax",
        "terseLabel": "Change in unrealized (loss) gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedTerseLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r148",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs of $1,275"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r57",
      "r58",
      "r96"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r164"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r24",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r23",
      "r115"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r117",
      "r251"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Equipment, net",
        "totalLabel": "Total Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r125",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "negatedTerseLabel": "Conversion of preferred stock to common stock upon closing of the initial public offering"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r142",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party expense, service fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Related party transaction, monthly transaction amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "General and administrative, related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r142",
      "r213",
      "r214",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED-PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169",
      "r257"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development (inclusive of $190, $3,480, $2,293 and $8,497 respectively, with a related party)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r4",
      "r10",
      "r73",
      "r256"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r135",
      "r249"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from stock issuance, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r147",
      "r160",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r147",
      "r160",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r24",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r75",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r148",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r31",
      "r76",
      "r124",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B preferred stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "terseLabel": "Number of options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r151",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r146",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r201",
      "r209"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r33",
      "r128",
      "r129",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Number of shares issued upon conversion",
        "verboseLabel": "Conversion of preferred stock to common stock upon closing of the initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r128",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r128",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Grant of restricted common stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r13",
      "r14",
      "r128",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r128",
      "r135",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Number of options exercised (in shares)",
        "verboseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock upon closing of the initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r13",
      "r14",
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Grant of restricted common stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r128",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r94"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Convertible preferred stock (Note 7)"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of series B convertible preferred stock, net"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r140",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "Change in fair value of derivative liabilities",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r202",
      "r209"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase shares of series A preferred stock (as converted to common stock)"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6445032&loc=d3e90193-114008"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r261": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r262": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r263": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r264": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001701541-20-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001701541-20-000032-xbrl.zip
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M]F)(]MSNP<Q*&U.3),92QE/FD%4*V92@E')DK-3F^4H;7XQ2FE4Z(D&)(5B
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MF/K4O[(LL@I73$0YAACA0QC^LB^+;%BX"GZ2'WJ6.^."UX1)(_01*!J_P?T
MB1K% "S_XKCGZT :9:,Z^([J7W^+"S4]53_/\LO5B_QSM:&ZMO$;F7A;#: &
M@_2)ER?X4A@/W_13J6[F2XR+,),P4U7T&Q(UK+HJULK[W/SWR;<]WPSR'*95
MUCM[XZ2O^H-B*='WAVNH&"#V5]\8-DF$BU"LP9Q&%&P+89.(@G4M$4O]N0DK
MZP?N1M;!%+DJQ)Q5X?S#9'34FN51#Y\I3-S%OZW>(BQ/# \7OS^PKG@I@-8C
M#H!-)^OW :."$L][76]'MJ\:#FS*J\:V-R]]?]%SU]A4?=7P!</7(7A\C\F8
M\>X 1C+$/<#NNJ-!N\S&W8OV&[]Y2B:_$TK6J@']XRQ4UYWYZKJGAN)ROB-P
M=<4_YP>=$POLU[="TE\+.OWST5<J1<Q$ZB(2^]PM9)5O=@=KIQ43C"@N&:NQ
ML\;.Q<!.@"O5:,.\74,9 ]B9^Y[, 4YR;]C=^FD#N#:Z]4+1 ="%I^1#$PJ@
MI@.+<+7J[5BX'=A]?HV.&D=Y[Z)_/+R\!F:M"W.S+LVZH>U,2 3TV\0$7O..
M&8;+^/?AL.\.N'M^PX'>EJT&WS'7X<BL6^H&P,Z(#*WS29-\[2&,LIB;TUBN
M(3S[W4:&UWA"9GY;2M<(_;&&4_>WL8J3F>QA+D"OGH?%O-Y[,2LA=D*4R@^"
M/,VY,='/ SD:Z3GV^YQ?9J:4V_C%R/7XE)C'I[R\U/N\%+1Z^@A]<&V")'F+
MZJB77]U6,>-]R?Q--6 I79XR5M\\.;W<^;)[LO/.C__$6IL',/8(-3?_SEK?
M#H]W-C]A& __'5V/U5_M[&_QPW=-=OC%S^\(M4Z.3W<V/UXT.]NTU=EBK?U/
MI+GYB>R\G2J4^:J$LT0('$F:R(AQ*R.1J!A<)N>T29G1-EU9;]UF;RY8T[Q9
M@EW\HG337FETEWII9'F7?U8V]<N@W?R:=I9 %!;ZKT$!$RN6,VS]W$#4' &1
MY"F/"4TB8F6H/K:15II&2J:"8LJ<\24W#VG\79LF3VZ:3-SPH4T=5F;U!L_S
MP(4']:W;@R,UD,\"R(>+^RZL[9MR:6M _QZ@HTE -RBQE!(9Q1KKB%GIP*@4
M(N)66$?!O$0R?02@/R0S@<XOZ)O>$USU%36WQH2S]+:MM+"!!D9VMQ?VOP9%
M&9@% 7!=ZW>>1HW!AYM5?A/+/ZM]Y1]^D<&CX;&-+KQ;S\=:S[,B&.U=U369
M:OLXKN^!YP?[PQBMRFW1\#T),GM7P0;]3?WSUAAK8SY[ 7-'B,MQ?_;R_(>E
MA(<?WVO;V=R^^.JLDI0E*'(8)!ML-!TICN-((*<3'$O+#/U^D_67LHU3'+MV
M>RCTC=] E,-F2MGV]?ZMBKMWC@]<,?^=MWE+VYY?V656PS\A9_L?\5<J4<J(
M;T!@_0DK.I&13#2)N-04R22Q"O/OREF]G7SO;OMBPM!&V(5M]<XGCLXAY<DY
MJS>-!SLL5'^;EX?Y-ORQY$%."W]2?+$R+;L::20,=[&R#%QNHH71VH@X)4[+
MA)ORV&N,$5D!+#-91[6+/U>V6V^GCTGJ#CJVUZ\&W)+6%PI ]GS]1SBOOM@9
M](/= 30$KP1<#1B.?CFY/B)?L6!IK#B*&#<@UUR)2$NN(J%B885BA,5L99WR
M52GYZD1OTB%YUQLE63V/F*DRFZJX9J+<YLP?=NU'KS9ZX_6_>X]\\@#CLUYI
MZ;S._9G1V;F[\TCCRAU'XZ\H7?3:@_[=7[G]%.3;_/8?^M+UXWX?=JXS9_'*
M\%O'^=AU/G*1SITZC53:=_EKU;Y05\7*J_KXYV4__OD:,9Z^8\,##]_8&W1@
M:E=#H[$))FD>?+BN;>P$4W0W*TZ+QD91],"Y\XYC< !W!GEC&(J^NRGC@UEP
M1N]XNY+S<]7#N6;%9.9ZUQLQO4$!UO?$BY<MA_/PXO[O0=>XO*^R;DC+#[F;
M5[V!S^D<M*U/+0T-R1NAK6_#>3Q4P?OM33QXK;%_[,#7+N]:]L  K-2#OF^#
M$;SQ=M;)^B'WL]2]:0\LU@L?2WOH,4%5[*VL[J*C@X.RKF\U^SKRAYC,B08A
MJ^JI<@\?,H7IM<%L#7._&%]<6/Z01>Q4WK[R)/1TL^[<M7MGOHZAX=(TU'1X
M7O"C@8&\@NMG(079NC,7%MB77/NOMAU82F=YSPZ R8Q7A/Z@Q]6&K]@#&LBU
MQG;:N"@?/.@&, %65/9< 9^-1I49=4$R_4U+GKQQ5\^.P,!'OJ5 %I*B)V<.
MNEA[OO5FG,]L[L%;JC,?BJDX?=#N9Y[UX36\@G>Y#^# FCYV%B'_SUWZ@)'S
M+U$ L(76QK J%I3ZE6?YANV%F%!O=4HR %# KP4I&LH@3 8,B8ZS:P]"EIKQ
M?X3Q-S/?;Q'H'SC>=7, &T^=,X"N4+MC K@%XGGBGN7 5D#-$9OU/:F*(6/<
M9(FUQA=/TBL?&+2-#/A@^$3/[>4#QT^KI*X'HA2UE7;MQH=C!7")7Y%KCPSA
MR!%[!F7DP?+(=5T_,XW.H*_*]-* TZ.!F0^7>+8LD^O[/A6N7S/8TS&8U[HV
M*TPO8*L'&U\D<0M(>=*D/3/P061 T#)+>'PUM L%WZ_P_B: 0F8\:@0N&'%/
MX(** RI,+B-CQD-J#O!4ML((<;1<G64VE([TVN>C-E3PF,($\"H+WOPT E3Z
MIAH56/?5:2CXZ(U>+ RM9MNP^> H&!A=N%3BJ^?_KJ]1*94"?+,3RD\#Z%<R
M4SPHD;AFPA]EPA$5O=A[YIIBRANL=D/! D$'7:\S7;=DC8L2U[S)%LJ*C $M
ME@[:0Q ;F@O5[HK_"JC&8%C"U>;&A\89Z&(?X0B528,,<%8USK(SY]_JCED$
M%A_KZ-+KKCGGR3AGY-QXP\;TNKT.*!=@G7QP5E4OY(VCLK#\V*EV((['FNY0
M<_K)@&=1&3/WVI3@#0 $ :OX0:975!][>ZI;N!H?GA8?AFX7V!YYZ;<=9T4P
ME;V4=]2IF[9>O.;Q[I^W8DI?K]Q!K8!@:!&-S%NO+OR8H%7 SB^*, J&I(/^
MP#L?F=)9.^M?U81^2C_O6)T[+VJ^=M%.>2CMGJ<)?.1=%_]/$/$1V'LY+,,%
MX=O#X4'_>\)W8>U!W.%/ (,K\"*+L>XO=<3(QS/'F3L/QQH5@Z+RS$"O#%Q1
MVMB]-.M7S."U28@"!":I6>/)6</3RMN090ZR=WHKVC32O->YP\NY9N5I-R)B
MNZ;9D](L1 VZSHOR.!S3\*.]\'H_<5!N0=P:;<E5!OK6@"O0AZ$7QZX;[N7L
MJA][,0SL^=UVUVZ7/F/PA5>!*X '@@P[KSJZX9RR">:8U/+PV5&N.D&Z)P,L
M99%Y90/4?/)D?#(FO9?N(?'+H%B(694Y4GDY9ARI*D? _5;')?FWQ-!*-_1V
M9"@9*3#IM!*8"K2%20P#8.'Y93['Y* PC;L>,G0KAEH#'C $L1%^W1)@RSIG
MRK]5S7M/:EM>CY:%>)C*VB6<=,"/Z =**0M<5L9A@RFI4M<O_5/GS4YE0@1V
M(A![*[^%&$>)7<-P72^O0GAW18!OH%+-$4^IM6POP($I&V@ N7L7X?A'6-=V
M9KR[%ZB<%<7 YTJJL+_8*/?%R]#3'7:([[3DS'$7WN_H:K+)^OV[#M7^0&G%
M9-WP1_G4B9TP^-PK0=,? -/ L\%1 NZ$7_I5_N9D2';U9I1CB%%W[F$$UVAB
M]L--A[O&3[WL,!Y3Z=T)6&\4!N9:[LM]YPW*=?#86P0"%0,O=UE)(YWWE%VM
MO',P"/H9R-$X0EY&_ZX+TSB^=^WUP,\ AE-YF&<X S( 1*#L[8#^G:V9AZV2
M7R*OA2S8J84'&I6F(1.X%OBG%'@0@FXP./V2A_!VEGO!SLN]9$_<;B!<*=?C
M"'G1!_FM9..:&@FBW _;R=.WJ]"E9/!VJ4#&\4F_R:=RO]D_",V'LCRD:_ED
M'R\6=A#N 5S3<:Y?>;W.,[BR_GU+B^86K_:>/4:OK?)K_'O'=E'-A4_(A<'N
M\%#L(P_.G39"SQ%=9<($HI>6R%%F?!O#S.^;E+%/GYSB\;,WZ5N5NJK</,E]
MEG%GN(LW#EG<");GKF0 /T2#C0IN<HB6A0Y7TQ-:G9[$[8^K6>:ITR*.8=QM
M&0ZG[LHG_!6];K?:Z/+NMS_1K^^_%-JB^?*0J7&3!DBI8B<W3E0_ %&@<=<[
M6Y4#-IP#F,?M+,V\432\X5UX-(5XX.BT7;F[,QF4K;C]GI#K2TQ0K%,-YSZ7
M9TTUK,'O1\!O/S1TS(P;.MLAZ=E[!N<]+_[M2K7Y3:#2!VCWO-_6;H<@/MAB
M_HM7_IM9]]P5?0\_M;)Z^KV=X$P%'3%*Y[P A/. [T8I1MX5S+T-$VS?7KO<
MQQE7+XXZ6-P1.'8^!Z7:\RO<;4\:>J 7HRE=3=I.=\QM;#CYKP>G[L+'J(?A
MHI%[KD+@V)7=3HNKHN\Z0Q=W\KWN-->5,8.\C#5Y#Q'(T[ZJWKK<E1PMA7=-
MRDK04.=9#-JEP5;ME 8[K0PZ^<=<]RRGTU]K]G^R3#[?\-:;SU4H W#JR/-T
MMVPX#G0#K['DEGS4X'8X9MC =E  J(%7Y@VGH0UF\EY11&6WPK(L.(5??'I*
ML,"4M]O*.ITZ;/B4!'X3ZCA+D%"7C;:ZJ-3.O1(72'B++->$>FI'6T^G=8\B
M^U6XL=)"(\FI,+PHMYG-E?;@VE?F=(2N);5+ !ZJ"I_%!F;'H*P[ .JFI:Y1
M[2J3 "P8\*'RJ\E'3<:%1T)L 3]6X=^..BJ#,Z +JB3:U2J"5-9+#$*\:C)Q
M8J+F'\:UW5$XT?TL3.LQ[5'GP43>RKNSZJ,(93%P-Q RW?-Z=E3KD9>)G$=E
MH?8H_]C+QK"*QGN>X4:@O$T(%6O7[EU4N5YAR#"P/L$%+J06P>W"$$#QCP/E
M>X8#YY1'%DQ2KXQ%=\/!&U7/M"$I"J!=%8\9)K(&M[7L^1#V# LP#6"*JC2*
MPE1LSPS*+X6\Z8ORR(KQ^^UMO0D&D8\XAX#-(RIFR@"CMS>\Z3&=_1^T3N%#
MC?#K;:9'&0VXQ?:HQ&)Z7S/$(FZ&N'WQS5VD#5MDA<DS76Z]!NI5!*M"%8%B
M76\FA5N,5D@9M];8&)MV=RW ]);/:==O^H3LT& J#F\W'F&=ZU1=Z[/.:*&#
MD=4N>E/O>Y\*^/&UO45X'U;8F*Q\1^#Y/<5OWXEYU!&9.B*S[!&9>_G_V8L_
M/VR]V=YXWVCM[&\U=K?>;>QN;K?>-=[N['Z!7Z/W.SO_Z__>V]_8WVINM?;W
M%EZEWZ(U?<SZK=_ZP"CZV/@M:-:J _SUH57K]W^N!A\:P#OD]URHW$;M7N^T
M:F@T5*ZE;>951 >,O*F^1L,<#I_ZK4MS[#P4L 28'78](LG&+:<^C0][HD%3
MJT[9E^DW/ZZ:^/3P\;0]GH_NCK<>>*;4G8^9'#Q\".B[]I2-T:L:U@1RCS]-
MJRSJL&WIS:!BN*C.WFGAA-6\>\G! (&']#H^<2_$64($#AX\"K/<0RYPA>%1
M@)_5)KRW8=2(%4"W5F^X.OS(9TU=_ZPT Z]_6FZ5%M<_]A&9KKWQL=\1OO'A
M>/_DQB4P17S2\(W/P:\/M9LW'Y#[*JF;\SGK]4L/X?H%3YBL.W##HP]ZP[SF
MHZ!:*S;RN\VP@,4H/%7V(LI+3V>\M,-*YTD[M+*CCH#>\*:N;"E11;M&!D@X
M'2<8Q#X/NS26?8W65,'M73;6FA?RNVA_)[]]MPY[\B5T;W#+4?*U]SPC[]FS
M7#@;I'(]^SZY]FBUS*$=!C0FK=7@JA9.Y5Z2KY5R#1-O5V_+J5@-7LSUW+R*
MX;Q8':G*H/>;F+ZLSV<TM'W#KC+H":RZW=I<G71]QLD/X=RF(J#][W5]Z9.Q
MR[4<J=L2V6[+2)FJ'KZMN+WRPORU"J!N+;HO73;ODHV43V]4X573_6GI'M+^
M1UG\-W/^P7$&.KO@5/OMDE$!SR@U>J*\HPJ\#:E<J+:K!??Y!'=LN]TI;>$8
M4?",^\,JW0F*6^  7SI9]4"M4?=9B3=,?@WAR HX[R*@#Y).$O%<A0+988U^
M3;6G-:WR80VJ=6!.!:.^[$40SET[ZX^,[I%=-.B7=$XK-?D@S3B=C%T3]6F)
M6B8"#!OTA<QT[_N'J#W8QD.U]],&S[4]@RZ84F4,7H_9(NPWEC>8S)(?I5W8
M0='/KVJ.>&(/:ICO6.XJC3*8ALF](?HP*EL;[Q1XMOBN.(^K$R;K.VJ2/IN^
MG4IM'2K?LB6TI[;-U%&W!PZL*4GLVX\$+)C4S_?)>4W*IR7E'75(U<[4Y ;O
M5/G21*%2E9 V3"]PA2\USXKCU<D$,=MP?F?9A&#J'0_-_7Q]4/;<Y<,=Y3M*
MLVIAGXNP#X]F"&E9SHZ"7F60#$@Y ,H;^#0M*0BD]SN&97!BU%/&WZ%LT7LS
M*;4FYK/'IV[&*H:Z>#JK<J(AP1@4AE_I.J\%?')/61T(*K_OTT[R,I5C(@YZ
M:XGO?47$65K%ROR3JY8UPQO?T<7JH3W.:R;Z(8NNS-<U(ZM]M._CXYLJ#PPQ
M;!6U.MY4";&MU5&+BZJ-P3@OJ!L@)?AV$SQ9)HETCVJ:/BDPC)-QKF]Y78.-
M4:9WVU?P=H<I>N/M0EN=!E1#^=-2[#:IZX<4PA!#Z9WY_41_'$+F[NL*4I/I
MV33NN%(CT.\R*T)UX6WE%Y6>>W2)Q7Q0<L-/_V62,)0B5#VI0X\:,TJJ';JO
MII>#JCK/\D'1\.:(ZV3F6L>(JB&C.\N&5[O7HAV]F[U95J<WE,<;R.7=3&C\
M765J5^'LJO]CV1[R*F31@.76:[O?/4?5@OYD@AZH/!+D.S)"IKUI7Z'G<^8'
M15$F('WP=7K;VZN-;2_=>&.4#>,//&B\+1.WAQDQ=R60/#;)?4$S7.>0D7A;
MDN;*.JLS9>M,V;GGD6YT[\TDO#.;#%:G/<S!'ZJK\\Q=%#<V9"HO+?3H*J'K
M^HB)_K"W.@NK4PER94E!"8'E[P$45Z\78HSRE8:%*2%6Y"/\1@VJ!L15.Y@J
MTVIURD/Q:K;L85K5BO2NU5_X-KDNO'A(JO Z>3K-[_[[@1_K4[U\-]X\;&5D
M91%CF7YX7V;HV]M?:/IERM;M?H:3<R[KKBIZE;DBU>[6*#U0=7H^1%JENOK#
MX5:'.F54.A+D9%JME >J?4>WA'!MNW 7H0_AG9JF\0YT0+=:B6N*;N(TFM#_
MIZV,'V,'H?0G*Y>Z^X!5W+KT6\'>DAFU/835;ZN+4$RLBF+0\3F2C9YN5TER
M(5!Y%AH<CPZ#_>Z#1EO*/D3IX]Y>$'SHR>?;319%:8 A+]CJ7&7M@">/[XH[
M3R!IMX=1FWL6(\3SBZ&=6RYE>@?$^"JDD ;M?$=[GP:]>IW'PW[=[4P>DIZO
MSV2RB->?V>$SIHZRT! W4#P/[!/D*GQ_2D)Z][Y9:#P9@HD54H!2R9T_UG>C
M6Q:#Y>&XF+)-E&>(<5596=C4J#+0_2YR-[!8IY</,Y*G:^QZ=Q>@ 3"[T/4Y
M]'"^:VGSH;S;T7$D96NU,LX^KK@L4Z#'U\,!O3"B+**?2) >%]7Y=<K\ 2M%
MJ*NK\#YLQ>7=K#BN3B693M;W+S+*P??'')9II:M#_V-OZ\UJ507WG1*X696%
M?0<@JOYC 0G[OG&ZS^FN&J#= (E1)>$]#!3<^%*I7E=+9EP5'?:T5TMX.JLB
MZ.-X35E_<5+NGTUFKV<Y4*?HEUVFRG4*C__.G$J^#47RWOK\OM".X2W<^L8;
M]*[/9=ASWK3!%RTE3]UBDDP"Y62CV:K/EO52=C7DWLD7R*=X&>@W*,:'C=TA
M':5>!38O$UTKW[Q*)BE/*[MSQ1Y0^#%N@>NC-B$8,WI6,?"URLZZ<OT>8(D]
M[%R?.2J&84LV#\J^ T<0?O^S.B9]S+ZK4\P[V9-S3/SJY(GA+NXPU69U=#"2
M;TP_Z@O@NN=9WNN6YX,-*X3+,&:IF"OD'*963CG2=X5!1[4EC2+T^$LK\VAX
MW^%SAM\/AU[XU,\J[.W[U:KV4!D,9Q".^YF$IE "-'[Q<J<36%A5AP=-+)M/
M  ;]V)]>P=5AP'84Z/$,5C7D[#B8M/5%+%EY[DO6/7952>[$H8'7C*^ MR4X
ME?;\ZC5QAB=T!_Y\W:F5''9=K/)7)Q8@GV@L'^9:A$;1]^CULG1BO"X59MXC
M<&N-3]UV.(=BU&BFLKW]NWH)*SNAC_JBAKN,.6M\GN)D=X%JOF5'@8DWFIS;
MF(7]L'+^E>)<'5,%H.G<716KC<DVF$,ZA2_"[<]4I7^NTS3-?)W2^$E373)7
M)UYCR&!^Z%!02L <[L26;5+"7FKY6I,3*4#<3'G'B;JT4"QR-93&X)B--5/5
M+4^UKXIL[*VL7F^=6!I-H?:\5W8WT@YTR+!WS^*UK5N8$!*?Q?F\/GY1QYT6
M92Z_[O&\^QM_O=]J[+QMO-EI[3^R KL\9&XDX+Z+4Q2ZK)X5[O7PE]]!_X#Y
M?/4ZZX:GAR_]#I 7NE)72P W';.Q/_C;LW(_A__L\/[5Y;5PZ57?WKPFR1IF
MR9V7T1J^\]I]M^5K,:</NNNK,.-RUO#Z?AW_7*$K8^D.6PVO40.'Y;NYMA5(
M>OZ86.WO]'JH9G7/ \G9I7_D),^%W+SK5"@?__RH&LC] ;!O]&:/6,U;7L[O
MY=SY;H]8]<<(Z1/BU@(@9;?W.)"D0,^-W?W&MD?&1M1XN]W::(5.$-NMMSN[
MS8W][9W6@_FX@I: /&=@K/J61(TA1\Z #Z[+Q?-3N02\YZ0R/'$65$YN47U/
M*[RU!#Z4-N6V\YJW4JS/W;/^MW$_K[>CN-S>.-[QVZ>N G<(KO_S#LH^&1K/
M7PJ7EM+/+X77;E&F3\1H3E[&$E(M7EF_0R[_4NVP'[)W[-RMKL4+E\+EU(5Q
M+85+*(7R3BG<F^HTM3/N">FC:V]ZG;/<'?L30\Y=XWVOJ,5T2<04""YJ,5TR
M,27D@6+Z1A7'C;?MWD4MC\LACYZRLI;'99-'_D!YW//'FASWVM:5R6@X^;VQ
M]9^!+Y_X;=/YXP_[OZ";N9R2"C3'J!;591-5L;+>ZH6&<KW&*+;SF)!0+9_+
M(9] :(SG)I\/W,"JQ?4[S>U1%;8E:XUF*,;U,EBISJ*Q6987#9-<-H9)'J!J
MQZ+[9BK+<G><93EV8FN97@J9]MQ :"W3RRW3,JEDFJ[Y)+EN/^N73:^]>'[T
MAXY6?V].I,R&5M   2'KS-=TU"*[%"+KB4U9+;+++;+ "97,LK!]&DKQ@[Q^
M\)V2K!?16B"70B #*1=8(NL<HQ\F["C):)AEM+/_KZW='\HPJN5S?O()9*1Q
MG4:TH$(6C_.(WH?3%S^4O0)]H6&M I=$Q.):Q!98Q.10Q#;6&I/E^[5X+8EX
MR5]#O):3.IB,0ZJ?NKD[R@HPLOU6I3^&Q<=%JQW):V7QGXI0XE.INUH8EXC<
M&#W_1DA-GH>1AX^#H9LN56%OXM-9KPOBU\UZ^804UA*W/"3%B"QLA*6.ISR0
MCF(<\VS"S4%!I@[TXL2V1"V22R*2HA;)ER"2!%<BR=<:.Z'/Q$1ODEH8ET,8
M/1'G(8PU>1Y&'E;)6.Q[CQUG.JMSWI:)=AC-+T-F.BLUGH=B6U+")2OK>]OO
M6AO[GW:W]FIQ6QZJ873O7OJKT-YE^/GMW6,(?FBW\MN_=,NJ/74KO= ?*YS0
M[FSH8#<\6K:?*^M\<[#QB=V#<%:P[RC7'9ZHYCMQ^MY;HSZ7PYZMPR9G:XW]
M6YL6^HYLJEWTA@T.)YZWVH#7.<],V0&OZG_GKS:ZJN.J9J]33<DNCC-_CGT^
M.O.K/*:M[*Z8Y</>T#X5K7?1=3G,:F=0'O%7-G3T;7QNW'=8UW'GS%:GIS4Z
ML^2>-M?PF6],YD_#Z-K0K+'LBF9[KKK2.?.=1QMEV[%>MSC.SL(RA\ZE\*5>
M7KA.=19A<>9SW/,P)K2B7&OL]=J^=6GH1=CKGKMNYD+'Z_((X8<N\8.:O@82
MGIWY/IM^@CZMSS_EO_^!$_;[:F._Z:>XUVP45QW=\X=$Z&I$KVK&ZE>\:NL9
M&E^;LG/@M04:'D_M0J,WWS7S0H7^C"53CKIWJ@+>J;\Z[ 7KSWETA6]*[1M9
M51VF Z.;T-PI]%T-QU9X@:C.I5#E!">&!7ZI.*EXS!+^U+S 4JOFM>AMFM]>
M;\.Y.CSW=-@3_<+I(BN[U_H_WV?=4V>WNUY8?#O?AB?CQ<5:.WR>===,K_.J
M/);SZI5N*W,:V<SW$+>1]Q/5F1N$,SI#._*BGV? 5>,VZM,=F7>FCHL:]S2\
M;;3GO!QX&-ZP'8Z5[)?<5[:H]&?&98$?REZ#V^$<0-\ZN:B@L,*]ZFU7)]IN
M5R\8WJ5ZE<DW\2^\-G%##V,@"W S=51.P3?]!6H]Y+F^ZW=HWEX1P;_'[:\[
M; $:OC5L!NKY==S5$M87L ;6KU^VBAS<T4)TJD=M.#5/^?;CU;*%!IBPLD?'
M][.#/Y]K)/V@R<^\,@_WO &2?@J D1ZGX?U7'WN^R+SZ/-[7Z^S'6BW2E>&7
MZE:+<Y_+K]MJL3RXX6'=T&Y_G7L]S">=>XB0;/]$+ZGK+_= T8U7[E\1N4#T
M_<NKKL9FJ;O H!\KKU50".:>EN&+\@8/ZDAT/UT7[(U^"W8Y>&J@&7W/_O)P
M@>(XG(CANX*#G5/^Y7LOW_T^"]_\-,%K0HB9-S_%9 WC'[OM_==HPIYDLN3N
MRXO7JE4^)*I5RL]"]6K=\.&%'VG6^FRM;W^T9>CMBPVWF=-*[P%<.=_9OT'1
M:E@"@@B:6OJ?6( A.7Z!A=QTIEI'/%Q'+!_#PAJ4^Q$X:.!A5W,&O\V!#?VC
M >EG5H>5X!:AI^#WV>>NMWT47SV]F'^/*/.?R;P6[-'LG(;_+2@[WR[4;ZHC
M]51@Z]<_Q-?77GN.#/,KS61&8-L(/\FBLZEO2U=&_. 7?ZI9.+;F)A _YNU1
M8QDD]+]^ZA47^\2"/[)+OX7Z-E=EC'G0S?J[/K8U*.Q*"/?"[,,'62)8RHVB
M"+&$,2(%M2:-N79.2PK_?MWV9AV2%*TTK#-91[6+/U<B$(@RC@RWN.R_[@XZ
MMM>OKJ^$'13_L.A(J;/7GLDVNM;_V!ISV$;_C<IS?U309]4>.! P6#P71"U$
M8"S]?*4W>^?OR>[Y 6T.[,G6^>$[>;)SLILUR1;=V3?H@!Q<M39WVZW-MUFK
M\QE^;ETU-S^?['SY>-G:/Z7O::M]\*V'#DY:QZUOI[3UKM5IGGQ$A_L?+P].
M#MO^9_-D Q]\:Y\V]S_Q%A:7K4QV3.=M=^?$=@Y/S-7!ON&'[PZS)CSG<'.#
M'^YO7S1/CE!STV:'7W9/X#GH/=T]/NA<MG=.6J>MDU9[9Q/F]NWT N9V<GCR
M^?CPI-UN=OZ&,9\N=]Y]XLW-;3S\#CQK<$@^Q4WRD33))];ZMGNRL[^!_%Q;
M7]YV=KY\NCKHO,T.][?8X?XI//MSVGJ#+M_O;_6;>^CBJ^.Q-<BBR&D>1RR.
M<:2<,5$LI4N9=DI:M;+.XU4LDS]>37/&>GE*Z\^(PA#K'B$2BV<VU?#V0N$M
M)306QC$G&6-(64VEQ5HSEYC$(FH]O&&)"<4UO"T2O'T;P5NJ$1$\II$A5D0,
M(Q')E-B(*.L20KAUSI=Y<+8:Q_$"X=N,O)SEL"/+;>W.;9;CZ-W)X][]5IA=
M:BQZ!E-K8YBT\+:7^RK2<<W:IM/]\5^5>UJCTF-0:6_"Z&(&,6UB'B%$ 942
MA"-I2!(A22RV,0>F2U;621*OBH3_+"K=@PQ/977=X6?70OTT!L8WE_<L&!"U
M/#^K/(^M#)!2ZS0(L#).1\PD:204%Y&A0@BKD\0QL[(>,DK)[PLDS[]4M.J#
M/_8XL_ZT9I\+,'G*L9F*M_Z0#?)05V^IX>H9;)"*2ELED< S"O6!Y?Y.C5,_
M@%/9A-TAK%%."AXQ!^C$4DTB3:R,%.%<2<2=3-G*.EVE?)%\H86*]=1@\(S!
MD1H,9@X&$T:+B2E-8Q99)E0$%.21=%P#(I"4)IS$TL0KZW@5,;% 8##+P AA
M"VZR[/?ZJCT+ZZ1:A <GO;P\M'J.\$F-2S^*2U<31@HABJ=&N @+ I8*9BY2
M.,'@5G&.%,-&^^QI2N-51GX:F1XK&'.*G,S!AJDAXQD,G!HR?@(RQJ8,X#F
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M:ZU2S;5"FJ^L2[) MG/M-"^DB,\J&%^+^$Q$?.PA$Z!"0F,2:0QN,N.QCK0
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M,Q3%ZT/P*NXK[E>:<ZBX7Q#WTRP#]5YIYA0X+DNC+E-@4V8 DY K(J6V+N;
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MK'W^>&6DI3/2U._VTE!6!L\[8E1F),HS(X4$@KG #"5.!M/XW=G&;6&DC3\
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MP=Q>,*?L[E,O@K;>8A+"!*FDYBYX+0W7>IG>?\7Y:F7HIV4G#!G1,B4(+E#
M% .8J#BD;%@2A*02\2(<J'OWNL&]3NZI9JIF>@RI\Q6FSNKF^3@S7/;>>U[T
M:*2 P(N7K+P'I[T$CRB#DS9$JI;6T58GN<P%U@((V_>Q'/'-GO]U._TX+C_L
M7?R"'XS&]YL[O+Z]='6.?353[7U=GX6PKJGW?/O-2S7%?M\1".7(SK! G<J1
MN8E%)1TMN.1B=C,"Y4DJ@\3M[%+6I0J[3&YR[_R6H?N14^S7T5NCA/F&')14
M.@U<.Y^ 4,\!23)@!35 '!71.1$5"QO97%I!V[94>L7SXE,,]MZ+J*U,RD#>
MC0F@E1&,3QI<C-)'AXR*4D%3]N.EC2.JL*XA5S53-=.ZF6D-4^9UDUQ< 7SO
M?0P9GTKD)4RBR)MD8J %\3EFM=1+EO_O_,4FV2;?=QOZ9;ZNM2[9\,]V.+3]
M\:BTRY1;*3\O#3&V%Z#7[WA[TAO;HRUKB*GGLM5,M4"]+H2*UVJF[3/3:A-<
M5QWTO?#Q=#0^CMDC>3/8N_1'?LWNR'[_Z<09^6/BLDS<^.JLS^6L_WXEH\5Y
MDEP3 CHY"XC,@W4)@09!-/%).5?&<LH6E;!4"%>FK6:J9FKIAKB$9%;=$%>]
M(4ZS5R1%I4+BX"(Z0!$0K+4$8IE7+[5CD<N6;8C;4-/9I&W!V5$L]WA\$ONC
M)H%5BS?KV4<U4RW>K NAXK6::</-U-*ZJ[LXZ$U-=..^/)WQ7E[%_W?:&_7&
M\74<?NKY.#F+?A7]X$._^93F6+KZ\W/Y\V^O)+@L,X2@IB"==^4T.H&6C( )
MRG$:$14CV9_O:G5=MK'R0;OYH-)V-5,UTWKFN.KNNKZ[ZTRV3!OJ%5=@=2RC
M:Y@ *VP$FCC%9+F-&-JWNVY#I==!''>.!J/[=3>O;Z*^GJ=4,]6ZK;H0*EZK
MF:J9JIFJF:J95B&8'X/0+$8NK)"HN78T6F9$H%1)QRF[0T0\_XB?[./O]_W@
M./XG._HUCITKCO579HVQ<D; ' >B&(<BC D:\Y=(*,M035(;-M'90+&9RO@5
MPDM(:E4(KQK"TU24D$DH@@E(T"Y#6'@P6BE DS(MJX!$T79!>+/JMM2- /QI
M[S][!T^?=Z#SP@[]88?3;J>@9Y&ZK?- >CPX^2J.7D>&FE/>2[,DHE).A8C1
M<J>9U-%8'V0B#E,9('@'5:_;IBI?SMV9G:?U\G0\&MM^>;!5RFLN@OHP.UK+
M:9&8Y1RBHD7*RRO(>PP!G7_&7?12^*6/6+X;4M;H6.W6&]HT]-\@_W4OZ-]U
MGOI7R']JA\.S_"SWCK,1QGOC\;#G3L?6'<4W@U\S*?3'U5>9EPJF@[BB-"H2
M$R!D\ ,Z$<&0& &E5BQ0=,S;E5%!6]F@%26G6\,W-WH;RGGK>6!12X521",Y
MTN#R/L:0>.+OZ&U\,P!ZV@@T-^7]U=U8E&-FE$,IB:[,2(<<P99A?S&!C5Q#
M%#0829@AR'9VN>@:2KJ*7 ^)MH1F*@E\R^FX'P/<(C5:AY$O@NT975$>G..2
M>4BD]*A1+D%3IX'G[Y+CSOA2=5,A72%] Z1=X.B-(U9E2!-MM(U.$NNU0H8A
M\+O%$=_76*MH7RA:F%4=3<(J1B(X(26@B@:TXQX\43JR; //\E:.5'>YJJ"O
MH+\Q>4!M4DY)(0R&#'?#!4DRF11#C#0LECRH>%\"WO<O\8[<:U^D_B,7'- 2
M#LYFU]UQH:/@BK#BNF]Y>F +\3[/8::RR3AEG6(T(?/,>6>)3U9YQ!P7VML!
M/_\99H7_$N _K440Z%6@&?G"TM@<7Y:-WP"WUF)4VME@=W8E[U*ZR$%F!?[:
M '_EIP05[@\-]VG=@A4ZZ: 1-$\>4$I>YFT;4.@(Y8;E';])U(DNDVOCW6]#
MA\U2)6G6M\2J%K-6,]6.F[H0*EZKF;;/3'.XYD8CS2;-3IV3.:ICCKJ8<HC'
M6)22\(L6 ;RH+Y:<U*;YS?#X_[R2ST^,E)P] 2ZIS!Z_0K"H$JB$,AC+?;1%
M8K*+U+1(9;+R0:7M:J9JII;NKC)9ZR3CW!J)D1H7>9#2*1DTM<'3NKMN].XZ
MS:<Y%(QXY\J9F0,TE(()(F^V'J54B@AJ1?MVU\WJ!;H9S4\/;?]#[/0*CH<Q
M7]"7&#H?;/YWAG:O_RF>8ZIJ.E=YM&JF[2BPKPOA\1="-5,U4S53-=.R(C'4
M2&2*+ 2)U!N;DF,)DU<I"KG</.?+\6$<E@!K& ]SC-7[%*=J"GN?;.^HM"S^
M/!B^SN'4Z^A/ASG(BJ-I_/93S'\J?CT5=R:^.XCCE^F-_:N&9/.$9!_WKA0T
MAD #-T0!LRF'9)$9<)(JP"!%5-9H3U()R0AE+5()K<10^7MCS-323%KE[_;R
M]S2E%CSQV=0.C*0$$#.3:\L$&(8I4A8LU:9]_+T--6A5Y;D>WU0SU9JSNA J
M7JN9JIFJF:J9JID>3N79)BW12BNX1&6Y"T(BAH3>:9^,OT-H7"5B5QG'/K_2
M64FLECIP#XX)"1AH!*>=!T593"%X;:S*<2QVA:+MD(BM$%XVA)>0W:H07C6$
M9ZN[)#:R9IPS :B4!$.H 6^81R&%]$RV"\*;5=GU/97G?Y_V8X>3!Q1Y_KI%
M=4TX:C[EQ:0"*B,91>.0\Z2]C)FP''-".!+(>1OW5^14=9X?AZ+>7NH\'WS9
M>Z^%06J8@R*T!:BSOV$M,2"9M)83I\(*A9Z_1LL:G;)M#0/<,+W\7O"O6L^M
MH8.S*1T(8J)5$2$F:P C1\A+7@,-GL6HM2>TBCVWHA9U:PCG9I<C*,F%<L0Z
MA9$E%S53(@J*,E!.W1U=CBKVO"J2N1![+B1#:6(D$0>,*YU]#F'!!$=!)VZ(
M)#8@<U7MN;+ =]R.>U% 57M^ '!?J#T7<#/#/*>! *.T>!"$E+2E!(M&6A26
M!T6JW'/%](V8YBEX490%4$<4Q+D40]XCHD@^!.[MW4*)*@CWP '#I3R$__R>
M)(I<Y3A!)5-&-P0/EL4$A+-$O=;<:%KTGDU7&:RHKZB_0>1=HXR*<AZXP:A\
M7C\QN,23#D(IP2KJVX'Z_2GJ&=>\"',"UR0 >N7 >H<@N13:Q<B3P.46V5;,
MMQ_S\QQM"B>$E=KG&$^CB=I:A>B8)3HF'MPW0%\UGQ\%_;]-T1^D<L%H 0Y#
M1G_&.I21'*"U<]E7LYZXL+.K5%=J646?MP'Y*S\NJ'A_:+R_G>)=JTS4V5P@
M+).08[,$+B@/D5(G7 X DA$[NQQYE[+_S]Z7-[61;'M^E0K/FYCN"-(WUZK,
MOB\<@0WVHZ<EV@;: _\X<@5A(7&U&,.GGY-955))+ 8;C QUWVL,4BVYG//+
MLY]?1K-_#ADWFU_]R/;&/AN&6/7Y9!A' +R1#4_CUK29.&V$7+M-;2;.JA+"
M'=O-8V4+2BQF G,IJ(&_O9?,YD7NN*N#)8LZ6%+]B',PB1A;X_'4NXWI"-:U
M+(Y7.@K3E]LEQ-80[%J7X9U$$+O@,LR#+203!A6><,0UQTAK[5!01DO"C&'.
MOG@ER!HN+FL<3P=(GB:;/SF\?YK;=!<=3QM*A=:\X)ACSY2"_]<:D)E)CZGY
M!A1?XZ2]#+>I .G-:-LJ?+=#VT6G3LX9 *Y$EA*).!4>22HMDLPY*[0KL#,O
M7M$"MUC[BS%QB[7M-K7;]!@--81T2HA<:&RX"E@[QJPIE'!6,>E\>R2NX)'8
ML('FWE'*O49Y\GD0;)%A1" >F"$.E!#LR:H=B4\KF^MJ%OS'CR<PUFCA!,U[
M,NK9B7>5E3.R8UN@NRUQUV[3,TF*^ 4)X5>U<7Z8@6VZ;/U,CURJ7_AV. J^
M-YFFP;<FSSM(')]G)L_.A26?%*&Y"2Y'1 N->&Y X@A*()T3I:@1/L]=C+'*
M\Q\V>:XPKCQ-KG]R\-]N4[M-[3:UV]1NTR^_33_7J'6;&@ WF;KN)(>VEJ_;
MR:%SRU>'==]_HEPJ:K5&@F..N#(&*>=B)* (AL*6!\SNNRI &^)W.VY-5(]2
M[\88XC=KWMB&]K4.DW:;VM"^EA!:?FVWZ8EOT\\-S6I;3_^:<OWA8I 7"88X
MJ3$JL&2(6^*0D=:BW'-)/752Y3;:EY5:I=[3+2"TN-UN4[M-*WJ\WK-%K#U>
M?ZWCM1$PQJ7R*F<4&1(*Q#F7\%M.$"\$=B3HPGJS>L?K<P@9>W.D!X<^ZT5&
M'GD8T(5WJ3%=!KS=&WSQ%5.UD6.M>Z;=IC9RK"6$EE_;;6JWJ=VFQ]^F.Y48
M"ZJ@TCM,<LD+113503"AB-1Y0;V\A2XVJS76=@+_%52PSTM5"E7.<Y$SY @'
MQ<LHAXPQ%@D&5""E,B36+2*L^/$B92T"M$#=;M-W O4]&,U:H/[E@+II*S.&
M^1PP&DL6$!<R %#S@*A76!)CC:1ZA8#Z.<25 6$GFU@;1]9Z9-IM:N/(6D)H
M^;7=IG:;VFUJMZG=IGM7@9UF!+0@&7+K.:5""8.EUE)BP2DHP7=1@=M.[P^O
MP5ZL+[9$P%CD0AF,,*<<<6(E L55(:EI;@DQ!9/1U%BLJ2LZHCQ*J_>6AU?9
MC-7R\$_BX8852MC"8FV!??/"(LZ81LK8'+& 7:Z4#3;XU>+AIQ6M55S)@:_7
M_UKOOMG,4+;C3R?^Q/A1QO!:%EGH1R*T*G6ZG-L?#'; #:>F[Y-&_7P:M%Q9
M9JB0/ BK&<:\X"!_2.9LR(7QWB@&/ZL>+=^J+G3+GNYM=^4?,Z;7'L_-26?]
M$Z/>20>21ZY\ "1S AF3YPAV,Z9JY\)A_$ =W'^4E1[9(?>8@+%RYO__>B0:
MN,/>KQ2,7I8&OP]#;UL28PE"W^C1Z!S6</T$MF:R/IF,>F8ZB<[-W>'?@*Z#
M22L:WA53SV>82H5DEH: L,HEXH([I!2V" <5@N92,%ZTF+KZ0;ZMR'>]R)<+
M*8T&TN:VX$[DA@7B%<L]#@P[G-]2Y+M15WV36I"EBB6MS/>C^#2K%;G^R7+C
M/,<@\S&K8W\^AXP.!:+2%:90*C?>OGC%Q)K*V1KGEZ,HGC-$M6)?*_;=H]CW
M?3AZ37G_MH?ICR#D]IL90A:Q8*[-*3*,@U:L D$&DYB;27+!G)8RUR]>W7/O
MTA886V!L@;$&1JM5H$K(@E+& 1(-$5@*K@3.C<+,WDX?;OL^/[#6.ZL0L_[)
MY(%YRP)R3AM0>TE AEJ, M""U8$7U,D7KSBE:SAG+72VT-E"YP,5%<&Y+R@S
M)#>$%X0;6F@7B"ZPRQDK3"M3_D1\W)KAH_(82X!%)&7LDF@H0S(XC2P518$M
M!HAT+U[)HA4K?P(VML!XRZ59;52\4[R-4UPH*8BDFN>.*I]C)PS6@(%6RAL\
M+'</LVFA\QZ@\_T,.H-E!#OE$'<\1YPSB92T!@D6<*"28D]!M%1B#?;WQW.^
M[H-OGB9JML#Y/"7*^W%.MXCYT(BY/T-,41!G!2X0<8X!;%J'E/<4Y4*!CNX#
M94R]>,5HL<;X$Q$X4W3COU(4 _SK>E]>_3?\J$?=>);U0-JCG\]U-'+=[I'/
MM(VM%_0@AF!D@^$$GJY'\'$L)S?QAR/=ST[U:!*;E$Z._-@#:^JIZTU2SX:!
M\X.R>\,@K:&.'X?>0 ]L#VX<3^"#E&O^<K9_RVM1#XB]%##FT^$X%7'\8^3[
M>M+[XO]]UG.3HQHE&O=5.XOGMV@#8YA.KK_E1(\.>X-RU^GB.?% VT"^M0U,
MP1@)7ER=YL\X_ 0XW#!=J(+;0#GWG)C<PT^*A56."%5\BE)'==/1J)["J3[T
MR(R\_HQT@!G^H?MG^GS\XE^+"P.K4HV(QUVXY0)>OUPA/-ARE;L&P#T<I8(&
M?P#O^U&\"H:C5V8LV=$HGE;_Z]O[1C P8@2*R&)OXDF7ZC?J5U<1Q4\%D>4E
MN!3DG$#D=1\P.-OHZ1. @PP@9:1/_12@<;R6;0WLR^Q:UE^5&72W=S=WLMWM
M[,TV'-'=G<V-^-O.]E];&^N[\,?;K>YZ]\W6^E_9SBY\T-GL[NYDO^W5./C[
M(T[PFW'H:8*_E;%UXU@W='(TG,*S'.R._VI]//V.2L!WV:D?U7^5-UPQM=N!
M$2,OKEB/6^/'@VXW 9(L98SN] 0>89=4<TH#H<92YC"7DAE-%7&<2A=(P5A>
MI<*0A5281?GQ]70,;QV/-_S8CGJIE_WZP+W6X]YX._P]@E-T,$F L0MO?=T'
M8?-QI<J+SDRJW (I[_-%]V+]_.!C]W/G N[9W1+P-TT2W\<]T3G^L]?=W>0@
M(?;]_WR Z]RIH3S?/UZGV[L=UMD 29*^OX#Q'76.01+=V(<Q'QP=['X^[YQL
MD<[N48!W\.[A)RZC'PU+)!17B&.1(Z5SAK"0F.:PV-3Z4OKO#:;>K4?9W7A#
M>$X]4<IPAG-=:*,L:-V!6"$P7 ^+#@@$W#>:PIG07=_=^["9;;_-7N_M;'4W
M=W:R]>Y&]GI]9VLG?OKWA\T=8.CUW:WM;BU[5G2QA,#P7364M'?ECGU[.(O#
M=[B0%":=Y[GCS'F9&TFE#YH0KPTW,U7HP6BSI,)U$/NF<6"'?X/@9L_+G\^:
M'L\^2>V89ZI !2T*Q.-O,B5&LKPH?%$02</RA@IE2"#&%D1;KA31P0N@9(&=
MTDH59)D>'Q,/K]8"OGF _P:"?Q9#A"G^]YM264A_D7__GO5 7<A.1Z!'CR-/
M# =QU(?GV8EW/0NORBKM(CN%K[V/'1"C'I&YWM@.084Z3P>/\U]\?W@:584H
M!8U!)^]G)\.^M].^7\LFTY/A".G#P7 ,PXKWPQ![?OPRCC:KAI2=Z7$V!-T,
MU(]^_QQ^/=2#5!];QS'V>R=):>GWM.GU0:6?C0P.Q0UOR^PLB@G/DA271AE9
M)UO?V=Q=6);LK[_>O(2E:61UP7WY6KJE.1J@E*@EPELG0Q@"B(FGE:38>$=?
MGXTK[2K;B0I3_&,#U)^S>!!_:RS5%C77P:8:X2[KP8&?;H*7?W./81'^U(!L
ML"$P%_DRV^D-K$_/B+^D,VQQ@D<P0=BW89S>>&IB,.RDEU8^;A[,(=[K0QB.
MX%\8PD@#B<#NV[*Z_UHV-!/=&\2/*HUQ<+B6J %>.!TE2HE'I1[9HTM$8H$2
MQEE2$LO5332U2$6O-W;_'R)2E<^,@]$@FX/:#T,]]$"0ISXR U#O$-3<DW&D
MDS,/8X=_X^4GT_*07HL3@O<!L9;C.P41Z417A!ZIJ+H0--XTSAEIG\+PHM'I
M!AEX-2"@23[ T;"=Q]Y.TJ[UQI_':5I3((-1W+%89BY.&T@I7A%7]3PKU[1D
MJ?A]DC1]9GI '_9H4*Y5;^"FX\GH/-$K$+>%F1J@;&".\7@ZTI'B)D=ZTJ2S
ME)I0_'M\/2V<]6#/X#'CJ;4@=(5II,$XDKX'XE@KGZB=_\\T,A?L-HPH\2!L
MS95O:HRX?G9)J_.G14 ;#=W43L;U6( .T]7EI=G Q\%$?CJ,Q#!(0QWYPRG0
MQ##"WBD\X N03!K$TC/7LEZHKHCOK$<1%]V/;,EE7WI1:5QD?1@%X$NY_+"V
M?O"E-QH.:H:(H.GFLXO&*[AP *-(RQ'7M<'(94O.2:]<JM'PI*;[A!L5K3?W
M-WTXHX $D+KJ[+&('+VX9J<^&H\FV?1T6)+*N.SG,9Y!!VS@\-Q[6(QH7IKV
MX[A*4JPNC<OUI1>-M!$R^M-HM0.8K5$AFJW.LP\]=UCR^0*$OSLQ_Y/]5AUJ
MLVOJ8^UEMOG%#^(F7$4?U2XM$&$-=!&SYX0(^SB)TYWQ3G9VY =I=^'>T=*)
M$7>Y:NJ0W'RI:&.B&AC,U%>;4+U\K/MQD9>,!$ORZ\H!S7;CF"%E(O3B(L Z
M^M@1&?:1(%A2=*UG8#"-)^^R<X!(X70N8_T17EBJ9 &<#S)Z >)V,*(6D&DE
M(,,OEW)"ON4+Z +)EXD@IR!'O$EG?!1^/D0V(JN2#/+39>C.[N%Y]_TG':QF
M'BL4A >=3K@<26<U(DYA#M(U"R0:^U]B(B2Y9.Q/M#X: _W'!<[&<85KX6B9
M#:LC*%WY,EL'YBFS@]:JFX=):($_09 :S;!C;N/H#4J'4*2JTU(ICU)3B49W
ML&V#)/0%3CKO(][%ZJJE1#+RH9\.47C:E;,:)*R:C(9Q[O$)43-+AU(4H$Y3
M7Z/Q?&3UH1D%2S@Q[:P33'P!8%WV)38^NM5BK;@T B#QUIM10@EV%4C,#O?2
M3=%+Q]7IU( *"_,/I9;1U%JV_MZ>:2RP0'=,+U.,.$- .8?_I#%2R+P(04;%
MG06)*TRAF*'ZE^_/,XO5?+=#@I=N CCX(PVJ["&_-=@%4AZ7XWZ^4'.\1;;?
M?PJ"<-@"C["Q 7$B% (NE(C*(+B5@.V4O7A%Z!HI^!J](LZW HQ:XFCRR%I#
MI(B$Y+]&P6N<&"Y*F)DY3Y\G_>QL!*KEJ-;B>J,*>B(*G$Y!9-71;78:_UQE
MRHO3+JEL8QHYJ.RL5E)?^G*[!-3-:BG<,Z:_#H.CSGDN))<$V5PPQ+UT2.O
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MF6(_GL"25T.:R5.U_/0R>U/==LVBW#R,!)>Z/QY6;_7E8AQ-)R6ZS237&4'
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M60!4?23"W3"64GLIEWPMIK-%D3^RX3+XQQBL$M1+7:R27QJ@>P8,/JZEF.9
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M49!66HX-SG&4N_%:<45Z8E;N>B1)(-"3R,.)CN*I?/ETNP9/SH'2(J+8N)'
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MNSLW&\JO-(9_\VVO'IC<(H4UR*D.'GD['.W H; ;?W_&),0^%2KH(@=0%SG
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MNY9Z)LD2@I7*,)J8J@?4?1FE+-)W _$,U MTA3+6*L=L*A0:P0(:A'[9J9C
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MOALE@96$0?#FK>UO" OU'&H9.X;S4AG.W7+!.H9S_PRG+BIP&/=C*_1)Q)V
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M<S>(&'58$@K/XI;EF&%HQ\)Q\="M4-][^*,[]$>Y]U>#BV\FM_PD\6QB^T(
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MJ)>X=I"$%@?^:BTZA#4QK,J14;10AA@2T62A&U/"O7M>5PAA3252!C<MEZ]
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MT$.B]OP\&Z'NM'S7M6+8Z-";);K6=\?8A2V67I("QY&%HT6YM!'[V3YI59
M1B!0^MS!JM*1TUGI3\-NK<I@DF-B$K'^@Y6%VIH0L:6R[/,%=#6IBF2Q"KBU
M"-VD##/\OT]@/[;>_M$%/T@*6%PVSB98"5267M8+GRZ]R9G,:P9U&O7^*G>_
M;IQ;7\YA=E'VT)26!NKMS:R'\DUS-J@^@&9O3O4.=/B!087W0??55>;I?$==
M724)*O@4NZ$FRKDKTYS83./7ZR ]D/RY+.QB)446I;5<=54% DD$RM!13U,*
M7,!1AF'@LGG;8O?;,D429X '+,XE-Y4-C[!B1'9DTWEY8@)2)INT@"_*O9FT
M=E<7]2C_97.K0;_7!3Q9V1GNLH$%4)7J-%A+;='I\OFRE>_E8N]J+$#(M;M2
M\KP5L- U1+,*.JGRL,46LF#*2<L%?3.3(3* >)Z;JB(>%>(M5)UY)%/5"F7#
MJ*I*,!2T15[Z>B3>1>E[NF9)58:IKHJ1E7*ZWR_:M'E:HU*427%)UC"KZIJD
M=_IGFDRO?ZTJ6\):._46H18_G$T5+ZWLM^K,0?G(9^>U=U;7/Y7\1I5 S+#!
MUL^ISNJJW8B*+4N'EZ2H8IZD5-+>8MW1;,E2>UKR(2A!%8G2VW@ZRB+T7L!V
M9N/+RK6@S&]];-C>L>&TJ_ME2]4M570ERZ&J^5>[T-JAUI8<3!KYHVKFC03=
MZGB7EZJH0EXX:V2$LH!7>TR$F!:M[%D-7X$DAH]+J5.U8&8Q-CV3I;IRF]'/
M\%56O-U8Q%*WOLP%^ASE"4UE;4JS&&9EK4NOL5LEMR8-CZIRNI8A DT/=:4[
MJA+Y+*VK/<Z!42""QDB[N;"?<5:YA.2^]N;H197%+J%AS'S*RY-2H]<M-A$O
MNF3P*ND9!+H>7J^ZXGER(*"=VN.9J,KQ.2\L1D"D.VJW8G2C2T436 97.V=1
ME%P:?*CRMF3>,?#V4U$3_?_+QN?_7AHH58IO7:58ZX<KA&)3EE4D,Q&GK"SO
MUC13'G(E:W'DZDS+,LOZ2K>NP98K'7^4OCPQ)]O*7%,E)30/@Z-4MDBE?R"D
M^%@U;JLX68N-+6_KW:Z5Y1525#/U'L-0*NK=..W*'%2WTAC"6N#=5>"BU%VU
M=U'SM3*" 2]*,$.3BQI(1SKV9CEKLH#2"NL!.5RT OV5WQ:4\OQ4BBEX\Z34
MTIH<L[;I%"NNVA<HVDLJY48I(]K_CVMH_1*+N21VO-K?'GH[4>E%RIY7;S!H
MJQB7B@5HHZ&A7ER G*MP:9J3E)WF6X@RZNXTC)0R?J8M^O*\U7%)17QBE!@Z
MB:XOR%5=,GR&)P5\JW3TR@*Z2F.IA;,TJ?&L+L!0D9[LR2DP@!ZJK64H-Q>Z
M!ET+:CE28Y%+6!XPB1%L6].0;%S3:\53]0-=<*GE$5,DJL-<6O(T)*H.V%2,
MI8'#@YV-:S:C@!5D+%3;^?@+I9#4;96U*%NA@6YXSY;D'ZR)O^-M+_X.:K+9
MI(S^:$UI<4^>GB%OV$?\L\IO>/IY7X^,E^FFWA=BK=I^_*#*F:@MIF5)'%II
MU0IVG<91Q787!F]F<%0X!/KZ B^'.RJD:J+DBV1)4A=I:!5E7M4U&<E2W:X+
MPI0S24*6P:N6@ )(SV:5D5FG16@$NP8'K()5U1++Y96+4()Q&4K"?TH^*6'Z
M2B"=2:8B;3*>QPHER5486LK<.K-F)H6K?)M*I-9I'UUT:65TR>VB2UUT:0LE
MQ^%"2L/3"Y$- 5<_KPJ75TD:OTKA4:B.954J@(8+:[4;^FW;C;&;%XMPK6F!
M-B]87;F&'%.YKU75=RFQZDR#1DEO+6DKX[L&]6OF$J];E%B7*$^*AID^OX(R
M/[>:9JGM:@](5U'\H#4(<ZW)&A:.S 04J,.@^WU5S?%\?7'EA<?@J"RX6Z;P
M=(4ECWFH"OEV7J^4/>R91$#05S-K1*%59N^[SX<R&H"JGH0A*)F+LKU+R%X#
MN42!$],A\,I#?P,O64)5\[[*,JJN)UN#9ZG\T849]V^8L4Q$51THFV]OT;*<
ML4YHYZ*L#Y5K6N2A*ZHSUB-QJ:YV-+YQ*:].DB\DR+62Y#(;&)E/":;7)I72
M7U*LPKG8C$R7,+_Z%4UIVIZ%AE;$%T=LRH?2BL4J!AFA;7CP2_#*BOS1?&1X
M>37 <^V&6H@%K9JNKB.HRS!;X%ZZB6/'FA^.;,_9I6+ 8Q9+BUUF*V-IA"PF
MT6%?Z>F<Z7ZU8/L3%9I4_@&5CU,7%ZB#5<DH-8?O#O$!Y:N.F5?QG5+@MLK&
MV(CEY;V+Q$0DZ;3.J5$QZHQ_)RHA',-G,(2NV],:,TJ:.C[?$+@K14^)7ML=
M_Q.H5S+A9;&)]%P'TR.)@"MF"!YN?!A'_Y%*2_5]=W /B=\RIRW(H'4J-3QY
M2@T[I5G'T=55/W!=]0ASLV27F:KHO>*M\M"PR%+V)&"UQ&L5V,ZY#(R\S(V
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MQXV&@[J,4IEG"I5,ZP_M:-/<7>P.[&$9J=)+>BH(=*XDGP*[TUK$THX*4@U
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M6X;8HEIY+)P!?B_S'D?I=X%C7K2HBTU:Y'+.+E$S;5;PK2JFGD^-TUD LD(
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M8/3&-1V8-3S7<S]K?G7:LD'^=7#>O6L> J"F6S9M7DJ,5&!N2Q)+IX9>:K!
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M 9YR[V:*(4.-'/D"_Q94!=ZB[1JGKRQKDH/R*\::]$RSARI4X1_# 3>L99L
M)6:#-C@D_*?^S]06$.K0I6S54(XG<0R_N8T[4$',@$<W+33>,=;1S/1,:-SK
MZ8AM':DUN#59$AFJ90 ;H.J\]K&0C^BQR>B]_1OBB*27(+/.EC\65740$@AV
M*&].XW["2,7I4$0O^U&T&B:AH@0PP*["2][2(+'IF;B.?V9OWFY&3^U[2CI]
M\3_.8%^.=QO]M-E<+/,=SN5FZ_S[VED_<Z-"JI7%&KL"NW8=&]4&@@I]C1GZ
M029YI%-# )]G[?S^<&L6)-&<!>VSM]^_7-3=[K<LCJ_/=W&\)+^ .ZNT16EQ
MJ/R[:XN51:;\O5M?1Y$Y@5THVN'<5])/D-RA. A-\/[T(:X?I(4B!A*] ?**
MM9,<%Q,,T #5:RPA'"V1H\+_A3!CZV0,_3)=%8<=$US0<OU;6=!WWK9<M_<6
M[D\O7OS,C5Y\G^ 55P]]U'(=H$&DH;.K&K@C8KD;/U5<V?0^3Y@N_"K.*'MZ
M[-]Q%I>J&6X=M%%)BZEI'&T7PT>2:;=<N3;-:[\R!(U;;<(-_<MM"VI]PX*C
M;]<%N9G9XEWIW=R%/T[I^,*E;L*+W7AOBA ]?& )<"78>872Y3B7\Z;BPY%W
M,?*51;WJ]A2^K)P0ABCTPK\1AWO0TZ6_0.@6I3GQ\LR*7U8=C\S*VXXC_1%4
M+69@\+AF;&1,:U;,\D^WAO+C@9:4WTU,/&/5NS!P#JY(VQ\\%A.*^#T@?T([
MI2CTTAK/.?>I+TF'^+J@:"KTY#=V%?!(\3>0K;7WX&58B/[7'V&#GS1G-059
MC?_.,AAZFE"2B*4O(D/Q[-L? P::/KCZZMMF\<IOJ@Y25)B'%][7.M)*\5/_
M0]B0+W6H\)TW<9']% )A7/#YMXM@=5_$Q_S96MV_L6W]7J<)CW;UK1+@O"A+
MFN,WCJ'6Y>('6L%7SR[^*W";D"B:]&^_<BM10KD*G=N<YO#GWJ;8*1:.?D:G
MG;_>CW!GGW_.V%<?S,5CUWN7CMNG'D ZT0K,$'LA=FJMA"Q(O.V3LR>KMV)G
M#O);B'QA[MSZ@T_G;Z[.]W1^XU8LU$VM\/T#IBJK3GB/SOWL?2'[[J G7'W?
M%S,XY8H2+M)<OC_D@CF/!Z)67^0X#-O/Y*'\E@T+AO;27_TU>:D^#VOP(>?N
MX> XUG>[QC&4%J>]O\__[GS0Z:C+E'?IK*H[773Z[/=0U?WF\UE5][]II>H)
M+?3W>T>/<:T,==*1Q*'3WALK5XLK+;@B_)5LB'=IS]QJ4V3RG]X9]$_KO0QR
MK[X3XCV*8NJV.S3>@0&HW'L5SRD@WQ=P@]65<N.CH]Z,9ELY/$%*%OW[:,N'
M]BNGV<FU:'V\+O:= W]I53BH?&M)@-H:T-HF/5'(^5_G];JQ83WZ0DP360%?
MF(HB[&/$'_5323F0GVC!X))%N$!LP'$$0>"4&?G^,AS5@<ZL5E\?/0M%P]0Y
MZEQF%J^?A5Z9?$T_OM<[MDISZ(9/*-=!J\2=U^)T"KH-*A^BR/"$FE&(P5R!
M(.:3XM-%4?OK533"1QX#&H')M\>E3LQP11?U5_4NX\Y'.OX>:"3=<$^#7QSC
MR^OL(Y5?.5[-=WY0<QV>26NA [9W><E.N$RQ9"\#8RCD2,$1NW4[$#$1^LW'
M]#X>1:SGUYHA]_,&+:C:*BPYY\!",]P4()A?7)E?F$3<OFK:Z-%%#>2-=[5$
MGAD[@[PXZ@ NRDX;SO(31I(JDG%E_0XO_/R+^/BZM![SI4,U[O>;*%L'.#5V
MU@A0-1=M03+DD_LF)/WM)-5"(N3>.TT+,(R/FZI,OBGM4@JYC]@S2"#9B2>&
M\7PKY3AR\<4,3K^A/FKL\N,TL'_6'3,IM[>5G24[,YRTZ=;%I&M_=Z -6]T4
M?F)RU!7&!Q4ILA-OS<<%%U)L\LX6_JASQ)MC[@P%N.[&)330'Q[[?G6^L>]K
M/Q6+SRXID/*KL64F9-I1_QMD OSO5W' 7B!!]R-OM3=%\^X/<@B<VL6Q+.%M
MQ)O.[Z&KY\N+Y]KM^/U[(8]^(=#TF&N,)3LAYL,/"H)5[CG/'+ZCB3!O=/Q^
MV(^=GO=;3=Y2GOER^OP2$49=[3C-]C.Q ZTI5WXVBV4BS."DL&1/S*H_]]>9
M3M5&JHDLIA^9"I!ZQ4TIY.6V<!N_V-7T_>0/RI7CXY7_%I.P\K<LI-'Y!'8H
M;/@?(WJ1ZQIKN[+#> C#N/C$;$%_)/ 6_"R_N/KB$_?IV#;\E#:M?(X&72O^
M#IA*S;MY/$FT^ Z=^P0+H//3A6G//G0DZ-6 EUGS)>_YXK_E+33/V\9A!Y31
M%FBHS%"CF+:C>KSRO+.W)-GA6Y>_*YF\"W35_F.F9V02&7H*<WA'\QES_$NW
MJVZYQ/8R.M-(Z=]G#+A>4%R7J24=?0V!)HW85W:[8M[1#UN'-^(GCK4L2L63
M8]IT2Q]'FP)%8N<19J$!@J1+UEF@."-WI-L3%_,_W5J2H%+#H_TE94B."Z5T
M+@ H7MR2_@\CA*(WKD,OU0"&RDZSCQ6[?<?U1FV5[ZB=44)>N[5C>]T';^6\
MX>8.'\WZ.V1T!W]B5K=X%ZD!<'7&NDIA_.-,<V%2*H;LH(;5Q'0WF90G_%);
M;/T=(-00U@"B)&23:;!7/FZHVK J-/W:7Q,TK-7R[[P/PJY*;XNEMG<M(QC\
M([C$WH<%2JC,N^Y'8@IZ=637E9M$:J!H@ZR]\QL;=&1YY,'Q8!(1Y[Q[[UID
M,LX'?#9QO*MUD -Q\1-9A[B8WJAU.)OWF-)P& ,#C(8HM-$(RL(E;1-ZR8]>
M__P3(CJ:0D)GZ0DP85^UT>9^-M:]+QK #3@BEMCJ^;.KK\3R$-3=FS!ZIC7S
M;>2GZ'4N%R^&#T9V+L?Y2UQA*T',)@#B\,?B@:>$8#UUBU+EIDF/J$/E;8HB
M1ME8A"?<^YVE,X%8TB9K8#TEJ:"D='6Q'Y]%Y-<$]*>;C>&#P$"P,Y"KJ9,Z
M_P,7\9AXVER ,@6HS^>NI[F6].2V_Y<)Y]?;< *2M^RI,=(I\$"1]6<')788
MN5)I\_/2^.!J$EUY4]15"=L%"&Y)#D3K(DO[F,5/28K27)U_PEV^>D=/Y\WJ
MADUR*UE1M9'><=DXN&E$]XI[^<<SGIV$ O38L1A!T+"=6U^3WU=SLV@ FS%\
M#/Y@O I!K B?\T^7B9.L_ SPO^VUV=%KU+B*/!7&0OYY&^&G_4'F-BYQS"C_
M5R*8R-=^G- TXZ[)&0T'50=(F+A:4X.\Z<J5T*6JV]SV\(%\O"I_S-_]E>BX
M\V-<_Q'DP:;6.$:20/UQ55/WACEBA0!:@3\"'!&/ V?MV/G:7ZE3 2;7VS@0
M<G5-$$.9)K->F-5C;>9K4J<M$RDY5##]-ZG)0-\DU;*HR)<@#@F_R%P"I*1V
M9;]?-M(\?>XN^!MQ]6B1OOBC:"A%L)\/>AJ.>< .0Q; E=?^CVN.U>7E9$?F
M2V)-C)F&D37%>8=-1:$J&U!<8J?=1B;*HM)W4EWZ!Z=43L/J9LJVQZ,I)RSR
MM9\)BIJ2R$CQB#'OTAB3G/ )K6OO)XJ5"/#L:M71:N-M@L"CVLR4%8\VD85Z
M($C?+!!E>#^A<8&Y=''8^?,#N ?.Q1@NGW?N: &&R83KV3^W9S_J!,;*>L_3
M#3,;7*Q^[ ^WS%^TYE(ZW&9WPUUER@ZJI>XUNW!D[]4-;AM*LQ$*U'L&N61<
M:#6 #E>N-]S4YW-,3WM@LI(Q:#J,[%B;<&',/Y4M4C22.?5#1[T9W+;'69)>
MTXDA_V4SF3,H:!5U8JVD:\!,>,^]]*[12GX5J!--\")?KJ0'-VE5BKS$R$>+
MOYZ?>BG.X#?1@R=#X*>TV1REJS%X?:8I=_&"^^4-9")T<.#Q@&J3$Y_X?O=,
MN/R@=%M 9@A&+C1\F@OK0M=K)9DQZFBIUH2<4MR&Y*%KX[3M7<Y]0]&M@9MS
M[BLZ2>JK:Z8C@_S:TE0 Q[RYL8B@-P@:#N)Z=K;7[J9J$\Y=KK$@FFR!6:>3
MOI+.F^ %2JLK>XFC(1'7%Y9L@[PMHF*&R:<J6M%96&.X?+"!4K#@X,5&YPJR
MV\3GW:?><*]TR"\0JV6$4HF<Y3J^N^/YK)>)GL=H>@9E@^J/63:@-51 KB$N
MVR+ <,<C,\45RO*NDW66&UWRAU4&1DKFC=;,-Y]BF5U]L99_C5;0U[;9B/KW
M-1H"T/CY,UZ-M$ -!0:W+E)=CAA;FIC(/_JP_)W;";=K[_O9PUYN;N*8SJ%_
M\7LT<5P]^VSNXOAOG'E_@N4\?D;\_.+-+XO7KQ<7BY]^^?/W;Q:O__K#3V]^
M?/'+ZY_^^N'PN"_/'!YW=;GX"PF6,I#,431V[OF['] 5BFZ$2IBL G,)B->%
M10AG$=1856081"BYCP29-I)Q&@0=(6;?%2A!-.VLP0FKF0BVB0B"&/R=W\(5
M IB"J\KV%E2S!NWDH&<=KB235!0EV((Z'$V@'&/'[IIK"$1C8?0-F8])7*X@
ME"@/:26=0O>VL"$-6R(_&#I\]>R;<U_-+RZ! U[\P)P!3[^2<<4QF>CQM?W2
M+ZM-MPMN&3MP0H_KPX)KPC-JM<3DF>F=C<!'B!?UJ\PY8+%JC6LI/FBWD^VK
M F20WVK"HX==LUWDN+/"F,2;>VF:X])]]1K*2;(3N0TW,HKI'J:DP]:/CW<O
MB1(,:57_KNB)$+;@X4B,BL" (H%V&E7[FJRW?XC#E@CM)K;2='OQ2F?&^ID4
M!O8(U-R:H[ZIY^O!^'IXQF"!6.PP( S=^VW>-0$FK]_"C)=HXN!:LE\:[G+Q
M(B81IAZ#T6WHJO _%XX.8J,"XY-,?#2#:T>9H7W$R'@CC!8GZM8NZM]ID"\7
M+R6#D79K3*S:&H&O-]#KBUU5O9/VME <_'F'SA@\9N,X?]"(9CE%[BV1(T@4
MA4*B?TAJ&O?75YSA#W+YO\CEW\;+2X3U](;G=-T.TS^ % PTDX=L6V?S8J/Y
MY!,N]N"5QS0[GO[M)L^+\8D4Y\3;FJ,(7(LQG1(BH6\;;D_L8<JD<AL5?NKW
MQWHX\UE0.QLGIAL(H:=R&),LJ@.]]$0X4J1?QP388+QV3);"[7A&_/6!3X$,
M@H&7V,P>^.]@;];@W6FJ]/ (Z49S FSS>D\6_^G7TWWZD>ZU>BX7/U)CW0D9
M/EI9+8U%44YJXM"DH09>$O.L5,)=(RB,;;>G0>@ G59NHTC@&<AI>X2TC=%9
M%!XXH:?%U.#$%X8GOQ30#&C(;ZVVVM;E-P4W/^)8"/K3H\LSTE9U.,A&Q./"
M.H3_4SK.RM?NK@79XP_%G)#@N;U[8)ZD%);;'W:J/]<SY-)X2+VL17Y=^EDL
M5F'(T(_6-+3"P>G8<,U+P&?'/ER+NG1P[^I &Q+MJ2_'KJ^&YN_2$"X[&.=\
M$W1V_),6*RFN[KTC0X^_9UY&]*UBK[NU3)[*/BRYV?.'5R\0:6EU@\G"_.!2
MN=!:C&NIB"P=_35VO"9JT:.+FGTV608GUGY/GZ^AE47HI('D7NJM_L>]#,2@
MB$PEX[F(?!><P^Q=KB<'/<=HFIK6SXIKOIWGX='FP0JXOO[K*Z;:PS8B#(8;
MR!5:KMB>8-H\2X\V2V1+F=-28<2@0N[\676A-CTY5X3$^3A/RD<Q87XCM$5L
M#ILWQA/,@?H^KJS] 8Y=4*@6KSU@YMEYBMFYC].+LX<XC$/7PX@.ZSQ=CS==
M^<:UA,BO=MX_EL .010A5/(5E.DIK6R\A F^=X070&K!QSYJ$DN" @A>CX0"
M7;NM:LA0)!%%$)*;)__1)A_R?0?1(^\/_,D)1]ZJ/$[M:2H')G"HP73/+O['
MDE.2BFAHQ#_X2;H83C>"[Z(-3<WS]#VE?)G*,R:-;H51<RS!U+=&G:1F$8Y6
M*B9]J.[[U:YK"&UV/+&C3\SF#*KZ<FY,GN%1LSW[<'LF.@X3RE 7Q#=U-.+?
MKI;RC\HV<IMPH@V>'TR7)]DU;W!,R4H)<53CN*/CS)U(&"L/RU0=11/?\['W
M>,LDF6^2Z6LRZYAR_WA4';-K@%4_H/1>)-+Q?)VAOC5F>\UJ6SJW5(%QK,BU
MD\I07R54XE3ZTNP!/6:.>I#YO&OJED=-!XG C%:TA!=+XEIK<0[YL9JG\5%W
M=.Q'8:Y4[.2XA\C*KIA?K<X/<U3Q1%&%W13@%:0&3,;,21=>[8K]DM"X='@S
M"=T\48_G+L6I"1V>S Y/1I$<6,[;:7*N;R,-^E+C^[-'OORB]%]EM;CN<M*=
M=(:\+\ 0L8@9G"*HQ['Z\4(BW>K@R@M_?+O=XN<M@0RO_OUYKQR0@$(4.60Z
M]$B29AKSE"8M.3TB8),-6"09B)ZZE)=^T*Z9K43?2[#F(XB_<?!7"NP4&1Z#
MS#GQR)H%F(9>">.[\!CZKRLW86@C7@/FOZGS/5 <J[QK"!Z_\^]/T+%);!FW
MS];7KC5J9X2[7ZD6+8T"!W>0=PO:KT<J3[>$ELYZL8#V43-*-T'CK(2_CG6?
M]])_N=M-QP&74 ,#J!3\YXM-7NPZEA0";*UT"O/A*8AB??<;?0AF2..J2+OA
M"71-!@S1ICH%1OH!\+B<JEQFW$U?PU(Y;(6R9[!#PM;RCQ! Z$$.3+/W3,.R
M: H< F1_N+-/.=?-@-+7"1!&A>E]UPH<6V")/.EZ^(!R ] ?/,#6[>71Z@X!
MX'!/\H9D^OS"G$S<4HAM%AY/GPF?AB?)&)VL\K[< .YOB*F-)D$0\/8!PCL&
MY"*Z(O%&Q#JC=R! 7NTJ%G#W4WR!:CT/88$(]\@DM''A+USNGU&N&/_ /VR/
M!P:+$S #+$81R2_V(C5E $?QP&: P2WBNM!K'/PIWF%GI5""43B=&07>F?Q@
MWF@=*N)&DC<B/#Q!#,7_9@>OH<8?]N\:+A0(#R]'3_2L,AU1=IOXP7AS&&[)
MT<?!I*0WY,YH.W1^J?T[&>BP&(7@N"@M/YJ^^-*OW4W1$@QO%[@$F,HX/@(W
M< ,P"/UE9-05>0<PDSZ3?$>[7N7JH"K H=[X!<S"FSU![-)=5VT1J."TA@;(
M'JV6(,5.TXDF7X6Q50<"W^Y&,($9MOW14G?0X0QT:;UF3>9IHZ7ZO8)0Y#E#
M/2'!Y1I*A,C\P%9YEQ^5^%AV%_I+>D"C'H!8NNKE$90GMPI])E,6_,P]G01'
M*F<GK0',ORZJV(X!/FR_8:JR=/V!A3SN+H>$O9V)3;7J&L7,WMNG""O1+_+K
MBB7+:>+89/"/0<E#X;3RZ"G*DP%B4\5A0L+6:G,K?E6_C/&I2=8$>4%&&@=V
M(&*:9@_!/]*J8)9I0$8Q>$QR0B<UCE<?2;:"(2T7-P4<9GL3]9)9']YO2GQ#
M9<CM&_)C-(0BQ;*-/B<8N56)7H3G1QP0/LH!-;YCF. M"DN>]8C"@74L2*9&
MJJ[R+GZ3R/M-7EA[ P2&;:@5 T,*.P'#20#^F)TU&1RV?JP/T.'XG[AM6$JU
M=T?*?Q#Q'I1WN*!(FX'5QJ#R=6KM2"N"S<&1]/'*E6@9#3Y271V]%W1,<\QT
ML.?"K,RFB\P[^L,B[1OL=% \(R(=QJ2PP>4FIVKG!C#S(;H\OA<\CQ-3,E,'
M_[X5NJ_F"MU<H3O#9K!7!;F9'1DF\O4!4Y0R/CN)W*S*QVSD&Q\BL*>='9%T
MVU!05'!4C3LRE1K=,-Y->HGZ21$FM!S)C) A-&&8.*/#& ]'?/ABT22"'7R"
MG+]7)OTU&J**R&$R6R0_$K1QTK@QY)TF.U+\L 1I;9$Y%K D][1$US@%KR:.
MLMZ&.UL:CKI8% TYCH.C/&$;NZ](K,('QC7Y;R?>(X2]$\51X=VBE6::\F(C
MWI@W7\#O\%\DYEZ1M\?2%)6 B-H-JUBHMK2#43#6FBCAI$G_-B=@:L5(5R0<
M2<YNR_9(^+C*#B+M?MR]XW+-[, GAHU#3HE>FHBR2ANB-%DRCJ0*+(?TB[^5
M</_1O\P]9]';2J(%;JKV;CYG>7JQMSJ2@[V:]1.%,@C#M]787@(2)#IMK-[X
MJ!_DN %[#:%$>K20)NSEJ?!LE#R0%K286^"5JDQKTC]&VB]H$#0O)V0=2=[D
M@PQ2:)^'#&N8]7 K?B_I=,/=]/)I0FI3U:-Y/J9J /:*]S&ND:2D L&(-M7!
M)O<:#9%&43/ )33J8.-1J,IK=,".[8FI4*REL"MF1&VH0>(@)PQ G(9M-1#D
M)>X#74.Z)?N/10N()' H^I1UE^3>DL/.O*SH>?S!@WU-J8;XRL=@D!TT>1I)
M@/-(\AZE0X.ZF,/1,M&EA56YZ6J$0]BU<K>*V?R# BAG@H(E X5G$U@5-;&#
MM1)F'*LM6)75-J_S%3T5 WX##44>^"N!(6WXO_R 0.X,+ ]^,TIY 3V9=$!P
MR:!FHHPJ-*ZO^0@ ^2':4)&#Y\>WU!G**&_X5,D;BI@1Y#B3@YP6(B<C5E73
M[H[,*435E+%32#R#+!RD=Q\>]LQ0\MSQDUQ->E1W6[F"C$$D!)'489"M&A:#
M6*4,(\-C(;,]@N<7_\(I'PS7W3FB35=4&-7WM)B$1,5>UW;6\**B,D&P/C#S
M5#Q(<1G]2ZCUEGPH)[<C*X[)\W)NMR$5;+OB0F?T(!T<<_0CYZ!RW.K%?8SB
MZAKY(<K8BTC787ML_.SF)2=2PBW8J: =@W$<> :L+LQ3O)'" ;,A9D$!CJR%
MG!]85W:)9EH98K(4OA#R2*&*/UJ.W)CT34AT:>&!W+4_!@D"L^H8.FCFH,0@
M,YVPI&/N:"L:=TV](]6U*CUEKVMV?]+JIW?#9-#/)CKXQ?QJ/GZ=A'^%B3 >
MLE2GCE/O7/'MLE%'5RWGPW8%:F0<E=([0AC#]7W&QKEW/950_W[>V0W"6Q0D
ML+"SJ*1,Y49M)_YWE)O1E-\O,$W'Q2MX;E%UY8>\:1>_^"WZSOXI"YE ."-X
M0#J!_!SNF*%BDB[";"/=E.?O5OP"3=#@>=L31UT #1&)4QK-5P/J@YGLX'$[
M<.+1V?<(TC0+3LT9^?:XDR&53U7^3&9@'OM'1!VF1X>ZT+TM4##UX'6.V#:<
M5);HAKU6(8Y)Q<?F^?MH\R<@@42 33UH@!J\B9NGXS%[=HWJF:C24; /PES#
MU6@@$@/V@QF]^]B'#=A?TPQ*R">.9+R8K,I;.DH%CQ]1@2NK9SACK6"N*O_>
M5>6OYZKR7%5^\E!O0#LX:CW$.TIZ:QY0%,AKK6=Q58 3@ZZC[$!.>:N[:@.2
M-^"4?2B2U,Y_V=D2"[X+<*:-B6)RFJF--2F*XD=2=MC3R$CQX]"J8IB6$NXJ
M.OB?I#_(^_9TZ;A_$+DW+N2A%7!0D[A<O"W*]-W\E[AJ7-CT?.K:^E&2BAJ*
M7L**R:!P#&Q2[^GC(TW=9BR&Y+F<JA@!HB^%X?')L5-"@XW&US U4U6=7%)I
M8T]D(=$ATSU>K/6>#=-<0VV>LDM4/ "7""!:3$:^.RY0\MR[=ENM>5%K$QD5
MMD):1^^V/\V1RM2G2/D-B4_UT,UL4C6L6<X?%R!BQP!+FI7R*X74&CO6:B)0
M!P-C0\8]XT$C@:>MVU?\.=48<FQ>U%)'\!O(Y(R1\?4K(G:T!S/&NSW-#-+1
M?O!#^^\U]74PA0^/;&;SY/QKOX59S%>M!JA.&T+0:9G"U'PX6DBA _(GY %9
MD)I*D8'Y&/,^97"DGQPUH:YT 5@("]?5WO4(3]%?E9SQHQ(7ZD,1L3SD$CO[
M)" #.T?Q& +IC#"2C,ED:XH4PD< DPZ:H:9&O0\35>[XNUA8ET[8E[.@.7 /
M"F%A$0K]%LTH0#20_4MMPX"HSJ/0\7#V<+%(=EYS;AE@W096/-?2T* F\/2O
M?%=MYS>^H$!BTL(I':M4$B"<1;CL!*P$AR1P<(*>&.N.TI4;E4^I@$\2-]3_
M)*&W5.+'?C]23]5K7J/I8O3BW.6 MKO+Q5^H3'/1^ L,@T%&7]S1A)'V$!A9
MP;2)@!((W&E?IIW HQY,QOIL.7:J -^K^CHO!07-U!TOW_PDCJ&1;KU<O''<
MU7?/.]%5^A?1!H65POX-P(S-7W!H%5<5?"'HR@6PV3*IED5Z[75\0P93Q0+_
M?9Z/ZE1<23I2$UZ!/@.=TQ_$A[J+T9^=0WHK=D>HEN4?NFF!FZB%HSLT N$Y
M<WH>0-S@ZA+#>E$WE*NY8!KW^^(^I8T,Q?4EMBJ0'#F[NUQXU_VAXQ>;EA@<
MT4+<!M*S1[LF[W@'CEQD]33^JE2#S6MJ^REQ?)GI->W0(HAR:N2?WBX^\"CX
M::)O<\RR8$](^\O:>Y,EDP$G79);[1H7;W9%_]'58P"1D_U5(8: "5+$<F@6
M2L0BIH!Q@]Z)<YB?D^?6=YQ].XF^X&BDYR81_\Q)VJ%8_K9[']S[=BJU+KYS
MY76[/69R>+P/I9"R =;FGBLF'((3?$>@4Z+UHHM#]:@CL * 1@%31A3AY>)G
M\PCIK55=JC$/C&_X^82H<I2#L, I/D@ @.I:UI,C)W?K1/,H""9Y^RK=VG1%
M5IF@_5]R:=]JFO;'Z3@R2E%K'D]P9P2;:YNX2'<@'.KUL&;<^\SBW=#10JZ8
M,&ORZ 9JS9(<0*+P,6!@*-R1!>NG.)^SWT2_6"*'4=Y_7FT8O7OW0%C4CK^D
M7XA8J4%;.]P/38@7/"L#M_*%]M!/W,#N18;%L!4(] T/>ALL@V._&;T::&23
M,!!P<8.>D!ZT.@#X:?U1$W CNFJ"#8R]Y4'>J^$D0QLUWR3ID73H9_U1Y,N'
M5]17,(V%,@DB'A/]<?4KB) AY _PC984LTFE!QL"B'_R@]N:<XD(!:'3(7L$
MBV<P35'P,5C+>YI#,EK#[H%2VE9C6N/4N=L07%V1!N2VW>NT5087_Z,#<2SX
MX$@X+9 6@>KWZ5?A)HG=\)7^4KQSA(;*> EF##:F'3 :4DSNHJ"G(Z0SM.QT
MC4)N"0,58Y5#<5.U8P_TPN09!4#G0K9B650'2A/D*V2=$0RL_2%82V,\>>'P
MAFVPT[AVZ<,^SHPI:KC_8M+TK_&A3(>\!F8A2QD!_#%A\*DCWZ?_]J'#@(ZG
M\&XR'19^&,F;)4FOM<SFT%[0I!1(6_+H0,QI*C\/AX+\[_N>[Q >Q/$1N@OR
MYCXGQ5SV^V8N^\UEOR?WE5Z BW24V&K4EP\:6EQ&4FN>AA#W# %#V'TWEY&R
M)DQTI[X>.&$V\589 H'[FS4?,57<6'7C!BUE#PES3S#!1L*$O7-M6DAPY?K@
M'S_TVA%VNFD'X8YW9_8NIUB1,.3QU**\9,@AUDYT$W!^T'NY&HU83;4JP+-U
M0AC#J&S'I'>(Q#EBB 'K".?[-$,9YUD;UNYN0,39:.@B:2%[#M_D?GKDR"2O
M=6("[!&J2V+IVELJO44'];YK01Q\5$.'+3%RZGN/P]4@=1@JOS'3%7L@,=[S
MI[__+!%C)G;URF]\_VM]S%7T7$"DHW7M ,L:4/!0YC3>D-D5MWPI7;C#\)-O
M&WI5U#4FK!!!A7*_N?LI\J2S"W1#0H!&5!B2*20RJW+%M&JD8DC#TG)MFOF*
MI#&R#NL+B51V^X;+DZM]/C*F#&^RTV6J5I*NOG&T2=C-!]E/XD21NZ+[E-:S
M=R:% );K/X'LPSX,+U244DMV5;/AG='/ 1H7WB!:"!-M9].JRT156DV<4BLI
M0NF)V9,X$[U"13/B[U/:'?JD3%MU)N)9[1<2VK'0KF%:-2\7K_RT7:AX;C([
M_&#H9A-VNMCB!/#M7A)VEK2._'Q%J(TVKZ%QI!96F-@%/.@V\DM(K[G:Y<6>
MEJ MXB$JE0W$K%?UOJ=*/25%'2N.QO90\]Z9ISU"F\[$?$N[#5,9E0@?>4/8
M61V!#1KIY,J_)&?BVNJ]W_SML9<?X(WS_9]^>$.9LV)IFHAC@+[VAUXC+=_<
MUH9K@7" S6F=-]L$.H"\F.4?Q"5#NW7HP>;<AHAXWQ:[]0592]'F7OA9J:6/
M+G:N:F),N^?CTV1Q*/0808H&MCEM50XTF8F6,%^PLFD1\Z[,6!6> V,B5'+6
M?4C4EX<30.:T6E*A@RK??.*? J&,-M5R2Q>CA 0RQ(E!GO9\Z2_"W ]%S^)H
M#[#]D/PURF*7>5U7MV2PX4\VW=(<4Y$LJ=V>6(_!&/>?FQYY1VD!->'>(./?
MTN^K>KO&\G.I'Q-^H2Q\1'DF#:0^-E:QH:JCEB8,C>0]*,^ZK6Y1AN5FM2+-
MOVI^"[EY@@BQ?@ @0TRYAB0/\#\;NCYSB %^9E^8X;S!S9HP\PJ\H N=@V%Z
M./Y@I ,:&2I(A?HQ]/_O_0Y_E.[-&<')"5/G&SAK9=+VVD3P6Q9$FTT;H]PY
M"T=SR)32R=W*@2L)OW,8Y[M #WZ/^>=FAP-#F'#K^"7[U^K&(3GV_-G5-Z'&
M1L (HG+N48J4BU<^1,/7KS[+Y"?4TWI[Q_S=Q?U[8I[Z7!X#-IB4E5>*\<%,
MR+_A+_I'N7!4>C?-S18IF, VA$, *$,_AHWR:<@X"I11_1$=HEP)L'6?#H+F
MBJ$8F1*!4(EY13P6UYW_D%-Y?'6DMVLR+?(8#<M*&S]R)-F9H/%T>0M1[:A#
MB5)X['TR5)T%#3EMM\ R.M8@D(0L/#IV*'NDVJ>>)+RU<@'C>!&T2:#60T(>
MX3L2^XQT))-9*YT(7-##@0E02[^7!C 67D2\.8 "2@R+>U^P[5;; Q@$7<A_
MP'ZE5@12*S6YB.4BTSF-N$5,6ER+W)UHVRFR3@B31O22;8&[QZLT@E-(8#]/
M;\L>>&;\$*<@-LT3,Z7_/:-:M%<_\A=,$I-/M_.?=)Y#%$'1[*@L,M_\((LS
M>H[G,."G$X&-(M"QZ1U!DXBO23:BA)$:/:7OBZ'-5UO8 6V*;U8U^3HP+(IZ
M0IVQ34'Y BI2D@#OY#L5P=E64A.M*0=GTESJO07X;J_G?Y!E^H6:]+=@+"<4
M7QHCC1 &,)F3HH1'&&['J3GIO!A=6W2L=MBR.%^5#.)H*$<!]G\YNB[)59&;
M2V=75?Z]*U=1*FB<UQV1=TRBZ/LJI:^?C;]+/E/V"4+@)FC:^'L2>NIR\3T3
M0J- Q0$#5WL(73#,B<&N&Y3USD02!ZE!B_\Z'"<!P !')RRX_O=X28)FV+S&
M*$E-)K!\7"9Y.H%"ABDCC^X7P_U\8O:HI@7^N_2F#'+#Z^(0BL&<I=H9C \"
M::2_*.1+6B'\\4'U6$[X]=G5S-8@@MF\,8L"B*P6_M-<<YNJN7W^;*ZYS36W
M)S]JIXW\N$4V(9D<._?,'0]-N6E,H9.:KH.HPN6,NZWJ: X/=<%N+/OE(V!*
M?ZJRR=7'VUIR2F_)I&R76%CI(ASWOOI"7<R8)NT<J7Z4.3<Y1)QD #5PMI3:
M*G$)6XDM1AZ-8X! GZO!0#C3^<'&3G1+(47.Y0F%G\G#9X*\MY_AUS3M>;(7
M/M#9'VMZC/4"*41#:X0&N(H47 ]58B*-&<(KI?@S^)5<[>G]6,+WT%*1!0)3
M.K;1XX!LR!:$N'PU\3S7 <$TPA06)2^V!9!T]#)N0X%V<T^AI?.<^+N:CC]@
MTC)-WQFAFEB0#U@W.\W(_5G=3YYM3BE2M8[O^SRLI30\6>[R]3KH"&94FZ_V
M3J@1Y#/R&)HV_/,Z)PW15?@W#6FI]HT>IZS*"^;E7#G_/[LNY(N1*_KKVY=_
M>9D930?O<Q5KX29DQU7&:@&JCIBP$:J;9J'Y?-.+W!WH']Y+&:CHQ(OS_D+.
M.GJ<3:(Q,RC-CND0!6FHT4H[94O(;V[ZW=?W8*I#3)FR[8;)'<PL9E2C(9WF
ML2$;'U0KF1.D+&(]9\V4G\UJZ];=CLF@X?4SR+!Z5_##4_V#EZ??F<3F>7WM
MJ&,8_93^/#GJE<@@=4N1V#'J16S_A:K:/+IIL0FOQ6\RV%7CK_W E9),C:%"
M-J,3JE>(4#AY*3WN<&]$D(ZUG6HX$'YX?GKSAH30E-B5'C%5@4()'1\1<I*E
M,.1ON,"KG][(>-FYT\ASB=Q<CB7!.?T;*KN86H+,3P+?P60AXP2]%LIW4J91
MZN-<0@_D?^MHDS41._(*X>$)FR^-,SQA$QP[P_X^VK ,LB58RF''X!#3ZYV@
MGQYJ7"547A<-L6+Q4#+BNB@WNXXKN,LCT#@$>5D6$#\906L$F!B55]G4]<\]
M?>+6,A9; #8,^_!EA791L>!K=RA$'V_C\A;8&OGQLJYRLMUC:E5\ZB)L;Q*<
M0N@8AKZ/=0WR55V1"F"X;A#^)1>B:TS7>'^4]1(CKL+H'.?J+0Q](-'WXBLJ
M8LIZ(M*JTAY-&GZL<YI!')(:RRW*C"J;!GO%]<F3W !!!$BG??J;@^,\XOOO
M?A0IPXA)!S!K1SXVEIF!R:5@.!7V"C#&2/%A!2?#J94 "J7 KEZF@N'OL;?.
MW@<+L)$!$]11(K\2&VK1M05V0Z[[4!-<?=(*L\5\_"8K6?C]1]QY,HKZYV <
MN<.ZHJ. R"JD84EJ^RE"X&3##A)M:,&%XG#P5U)LS_1&XZ<01G_* 5/BWRBL
MOIZ\.^E$(FT]!$1*[Y46+9N8()_$00 I +,[M94_43B78-<8? +8W:<+)++$
MV$:U/?N^EBW>[+52%62-E& $VK'UF9E>/PHCWVB*A]8XK>AUG=]&- [O6YLA
MF%@U,X?BD\Q85#^('BBW#I*N+M *?G;VS-"N+E*NN+9E]=ZM%=-VF]>E@-QS
M812( ,YY>A]O>B,H/F0\":04H Q^9J:--2IZ!64(EIV@Z?.U=_V+!EP,672A
M3F"=:GNWL'2FRD[S7G_:O9XOWGS_X]N0M"3LZS5%RQ#@T%"$#U;EU.?D/8S#
M=>>] ?^U(!2A<8?\G2[+G"BA9!^E4=!@#UXVM27^Z*;L%%PN78:(F)GO+#-8
M[FO\764AX%P ,DNK=:^%[[:J=O,"^RC69E@CHE47*6-"ANR:'-YRSVQCH+)A
MY )@ _-D/?YDD8;PFO'L;E^AN7C\- B-YQPKD-3R3#;^N/-C&G:D.V=+NL>2
MDZ&\7E'^O:N/&GA!Z<3/0;'NZ.PU42'4B]]-JQK.1-B/SQQ?NX.*W3'0D]+S
M,Q+F!!+F:D;"S$B8)\\]_DI ^)W ,H5"*;3P >:@N:8^-IKSQ!+XJD1$[#_6
MMI_8V"E-BJ, "8'5T'T(H4H$>X6PSJYJ=%MR,:.1@LPTZKK?X*VL&%S(37..
MQ?Y Y']]T2N+;4[@BI-\4.4ZTIL*K>E9E/X?B/EXJ?&MQ=EZO[;:,=!4*,D&
M3&0LQRAEZ,C2I2Q>F6">0CU-&5%LT_==Y#2C58R([99^I@A!,LO(T.4.JE^B
M=MOKHPE5LSKVQ4XT.L7"K38A)"#_D)U^ )M+U5HJ2E/[G$(MW<'BYX0:'2QI
M)IO!NZD>)Q:.K0\8),)R[;G2E]!I1NJV/CY[,N5Y#AOC-!!_%R!=X_2=D5C;
M3&L?FRZ]-#W2MZ)!4[Q?&&C#]Q:H:II"!E/YM&ZWKI1&TI-SR\!GQG-'-C'8
M.<HW1*(O?RUIG^**R,A"NEP,F _'B"3(\D^D6C:A',AG(3UZ6JR)A(=A5TUM
MC):&0+>A/Z7%UHPT=XT3G]R3 R2.$;%6F:(W.C&D@;5_TP'G8.#_DQ9407\(
MAV&/ "_ITY66U6DRO).4=W)2!<J[H7ECWC#JV=TGU&Y].RH<*,H'4QAR-VK2
M-X8V-N\=IN@? =D +Z]W68FSH2%/0!?Y35X?F8;./Y:_AH44Y?Y61Z5A9)+(
MR!\605'BL>@>&V.(<S4IRX*<K2T:Y@0IF,7^OK98Z*M+Y^^"BCXM#XDX&0LX
MLD$")?X8%O 4T^M$E7Y4J/3L+>BO)^FX[T7)J:M5^8<?=").@3&#@_,1&$K_
M#%+$L0,^O6/ 2K,Q&_:"9HR&-$SHH)3LH]6+ZPK\-V9(;"-GI$P-#+YW<J>.
MLZ2>_>I+.W)5)66LD]8@922W:_ DQ&^$U6DF1;X596-HY$:@%7%]%])L?0J
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M!Z]\2F?NGHT/\;9"_M$PC)_@&1Z.\$('-R90_ V^[VIOG3D825GWA;\R#."
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MWY!?K$'3,< =!4RX#-W L5YH*-%"\O@_[C4Y7U+"E!ZJO+[8N8T?N*\UJUD
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MJRUA.\MG> [#]G T'3H[W@>F*85K6@;. 'JQ"=5ABTIEQ<B9 4;Z  4%!;+
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M@8FP+9H@1!?XL6R$%NNKV,Y8009!97BX<(3MR;SQ&4?W"$#0&"CN\[]7?9)
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M7E%A5@OD&%TQ5%&]MN4'R8\E*SS@>:FNP'N Y>+XJ?73TGG3A*%*@O0H_B8
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MI!?MP)(-2!.<4Q<S6O"ZPI[?CZ<4-I[XYOLO?WW1%07AHM".+HOL\"] *[4
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M"UP/#+J*UXP,/<:D"\5W5B?@U4B2!=4,=5*W$ $[M C]FF:CT8M/SI=@)\J
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M2!HL+J=VMY%X3FC^AOZ2Y&EYEY/R$2SJ>#<B;,ZR(GMJ##B$SW\,(>BX42D
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MF:?W86:Y;UZ\HK:;([IC-)TOV*\R79]_^J2N==_+JN\@W.!,@21%SW5X5NZ
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MA%XZ2W]2VHC9&BAKC/\+3M$NI?>$ZN=N)S42[0,HCTFKO@D]*RPI,IQOE=)
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M-_K =,I4.K1*V'[K>LI0S\P\)T\2X:GT%ZB,T[N'%4O^VP@A-@KJ-M9VD_@
M:>G;[)W;V7,2FO#LYWK:8CWM#^=ZVKF>]L%/,QB]FDV>.W6R[,/,6'NR?S+/
M8=,JV-W96(7$:/^5>I?B\:BZ)&5T=A0T;Q+COJBCH99=['9')\4N."8#Z$2O
MR8176F0(AI%HT$>&"N@90D>M76O!?V//%]^V'E6-:!^>P 2J=R0'6_I&4U:[
M*:O*Q&""#@4^H*W5NG8--[-DVNUUCV" 6"$JFQ1V)'GL%AK6+(''.&4Z.*0'
ME*N/_/1Z[I]$0#J/* 3<VV?V_)72DKB+S8NBVO%19;!XI+VQ:BZ9DYAYFQ;:
M0_'"E!,Q]3RA"KX3J1*&7?)O)S[XE'Z$ZUP)..6V.#K%85#J*;[M^RY&/D$(
M_2-+8:FR4KKT.6:1SAS-!#&1FZHHQ>*TU2.)X*V+/<A)=26']QW: ]JH+'RL
MUV$;JYA:VOS\)$;WM!H<64O$=-SV"M7$5R]?E[@AG1E6N?>+U=_(@207W7C$
M2Z2 OCW-(2P+F5/0H>4^(1\L5T-_2W'Y-O7GD1 4? 4'J4SD.M@V<65P3!:E
M>5W-3]!@1^55SA[IR<_AMV4B1FLYT8&W6,%I7&(?T!&8<-""DM%)0DHN+K:O
MBH75R6)RC&#'F/^"N"/MY_IH@KO;A,V#\N(R@^3R@SM6>9Q0S$@]QF1A CP9
M[21@8H)YI/%# =@@*R2K"ZLLM=Z]TGL+';:OR:8Y$*&A>&QKLIZNII,63I!$
M"6ZQ<=C9>GM#;:HS @U71C*9:Z1W"[)QV/KV5\&$M%L1B+I7KU/-=>,;U!S$
M>F%2??UW1NIQ6KE'&V+UEEK"-YB*X_!$J(KJ% ^YU':TO\.H>D_.7U2%H!)]
MN_/6$%GCF2\:MD&(QRJ?%$8*3E=AS!Z2 Q>?-Y&@D!-P&T:T14;\BS3%G%?H
M(AE">]2%3S2$ZJ?&_M:K]J; 0>(RCU:U2MI7(UJ^1_;F:RD@(\?G/5;?L8@R
MP"9)>UL./6;/W9CT41]Q:$($(-DEG^J,%5-ZT'T?)F[:V:X2AEI4QBW5NV"(
M -?S3;GW-O.H,7SBI\9,^(.*G<>6A5(T-RCI51,,).>W/4YV<M""V#7XHD1-
MZW GI(I\V[Y?^8*V'-HC:>/-F0 :H'#B;;"*%(X =;JJ\*T">7.P@YHK5E'/
MQG5*"E^0,63;M6+BCJ>4"J Q754 ER?<!A>K[^#Q[QII1*8-S$]2!M*5GHW>
M0$O#)IM!<[,=:,]!-@< 1[+%L8;BD7NR 0NUV6#AQK[*WYHK\,0J<O\B5_(B
MHO=RY.27NW[]IM (KU*BO,FNPBMP_9BX'(Q;,"-(3%/[I==( (ABX>+S10-S
M[ZG1SWD*H):WW'D;B2 I3+-IY7[OL*PNP^L1JM;G'I0'W@W #(Q7".*>'-_+
MO>31#EA*DQR#(]YJ#_2(VC$OWP<7)/;?0T7#'X67#:LQ&Q* T@$*#;JBOH^D
M%ANV3,>,OE5T-XFZA)8J$B=',FI7LB!=I*#NX8/?Q&-W52@H]>3J(\J/+>O#
M&W/&0Q@)^*3S;^U$1J)*U0(0 OBQ8# WDVJ^M(0?^7=8TL'07KOQHG'7430+
M?W_3V[H^L!UHB^ ??DP,4!@R))Z$O.2R2<N*9C7I[(;-L/28]P9L^T_L=WJJ
MYV@Y?LILTGD2C:XHR8.41EA7J,Y2I_+#0W.<ADZ#44KDL?@ESSV+K#(UM0 !
M.[P<4\/8^E&OI6C_N*/@*+1HJ88U]2Q%>NGXQEFTM,@R, P]4]IP)NYDG.\7
MNWK=<L?_'ZSX8LJM9-F3--Q#[?RY_O7IN?YUKG\]P:STBW>6$331Q(4PU.1Y
MO8X+:P2HF&:?"6E"D"[1QF!87#^8D/HFK/X6;@X=NY?]QC6NS92N&.N9@J=$
M@?').Z6GR1H)HRR^WMH:>L-[MAR3J91:)-K7$E"*+/1]%J8Z8?/:-<OI3H[$
MN/14XU>0DW*T]U:)FE^X=$5074K>'MTBH)Q<%EV%8R97=MSXI:50I<\9B?G)
MB6FN^*PUI8KYS43O3:B;^P[)&\O>2JND4?)=#:RZ S"15(.302=W*3A*X33W
MMRW=THF!7*S^+M>%#F04UH@*7K;AZHY?C%BQZW8W#8TQZTGN8"156@+&A/&9
MA!(;/HLT>L0-$U[U392YQ"95=A=61ZWL*YH<V42UQOAA%R8?7(+])233V.\(
MKT)Z0PT<J_W\-;O"-&#D8HSIWM>I8E)6B-9O\%LZ[N)#5.Z("C,)&/H8=0'7
M]AE!698TB2(1J,G7!!O:-?6&@Z]P*2%=Y%J]NQWYRCGRDJL%-2$DE8);UN5/
MLG9(SGI-4$**AJ./WMAK'Z)\ZP"SK5 4YE(H9^V3D]HGI!0C>E/"*X\Z5(*8
M-3/L%'Y3]<7?*(PMBM7X'WXDTY5HIV1$@E'.!JLAK,2-*FR<D$]Y!Q4K:_1>
M!>_4 0Y" +CK@R4:V-0O!O^O'3Y^VVL^391"=7N/PI7AS/+<&,S1]2^BM/4O
MI++"X!TD-F>JX.\D:/,NU/0/UFPI.&JQ\)=K<KZ+BDM<CYPV>,\R+K%DD@7"
M&(5U>V BL]6"/-$H2CZQ3@(+GZ)D%BAUT ?E=*+B2>RN'_&I<6.+TMZ"P!#V
M4[P6T$G#\C.(6%%3T["._JCF<<^9HA8E:!^H:'>?XIQ2F2;S5-F?$RI4&<)$
MG^Z$[ESU$X7GCD]$7*ZP!R-DW6_"B]4/!9XO,XFJI%S!6;).G-O%CECV5M&H
M',>5'153N?6*<J7H@TEO)> PE5Q^578;J$[6<+H,"G@E9XB:.IQ7KGT<U%=!
MA>@>9=_T0)B?!R4W76EZ)647>U <5&).<!_9/US7![I1PJ@%_VX\XIT%A-8,
MU_5A9!3!\EQWB^??]WQX9CO%_?8TF(Z8,N9@.LOJ+;,#QY3SLL1A\J!//$2>
M>426.(_F*.^$D_J\('3RXKT=S=)RHAB(\*CUE=*P"%H!N5J1L?7M?E'FK5#-
M3&%_YI"D3@@;@FCQ%4;+^J1*O;($3"BI9!M89@[9225-E @(1 B;Y!D73] '
M/[$N?7L:WU-$^Y[S:MTBLSO7,*S^('&8 D*>&2+D'AD>-S"C?Y[8YY2 ?HZY
MJI3S8ZRV5^!-[+#E4-]3*U'0'>8[RO79-RZ<E8HHYG,1ZV1)^CM%Y/Z"Q^'/
MP+G]TRL2CS9:?_V?E\-O_WJN7"Q6+OYXKER<*Q=/L'+QK6'FO46/F@S>H6*
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MWG_ZP#H\S#\OOK]XK.LL<]$$KP-"8EL%7\:44+9&HIS6Y\3\_6H(U[5TE([
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MR+&K1J0EZF+5KS^8LK9QZ4CCIF8(MPM!EIN&4QW4?]( &>_6%W,7M:*(QX_
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MN1K,=P2I$'S.DEPQ$NZ1\%P+4U5$.@(N[%7G$\6F[&CJC:8BQY)KY <B"VM
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MVEC\Q^^]T^'_R']X$^[<^\N/\A#^XW"#_Y\T5,,S.+/](E*6_86ZIMFM<A?
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M 9X6YQ &[2;:B&O2KME(2QSU65PNJRF]E-L31=L#N_!(-L)@8_"HB@2Z(I6
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MX<GFA>Q6O!N<ZF,G>?\H:;?<G]U:KDWF=5W5H2(7#/I<"#;"?,'7\?E8)=P
M=1?H1\"Z3]_LE*^+2S">?]>=*^2U$ -0"9Y^/7Q(L!)0=DY/@N_LP.?V-RWU
M:@%W)BVUTZY@>8)4YBB/E&R4@HC/<IR<SM_K*._&IZ+G@*JU<69_IU@\WQ"L
M^9]$3BI<R65N6$9&([JP+1>2+S1"GD6@'S.+QM/K)/$[IN!TPHGI/ N0EK#(
M.?-6H9J,J"X03,7,;Z&8UT@\!W(57:3>(V$WZ9VM^#7C06W()R$4U$&+>O:E
M1"$AZL>(6SA.]A%R>5.4G$BBASRI&?M1@4UFFV%55M%><$KMS($.)XR$<<$\
M51-# T+FFNHS4=P7"%[%XR.>='ZL4>96PRNUBVMP*2/?Y[M5IE4D17FBRSF-
MX\SG4D='V_.D4FI[V/5I*42'NGPJZX&V=E.8X,?Q7+?3C;Q2XLGSO.R4(3U3
M^%J1]ZJ:2M<TV%Z%1&^&PTKWS4$<?K=OZKX.N1V_O^,P@*6*^63PT=9MME?7
M$S5& D>7@2T1CQ&]>2$7MUQ6^>$SP3]3!^P69P1I%^5D^JC@&=B@M*!$BLE<
M(.C]6'G515Z.3<0H_69$N(FC,:,#+A$%AW#*6;DU)![&TQON:&0.[7F==DA-
MP&MA& BM)[II1)SHH>5"T"[':682A2A_")2%+)PS)72DH'F.3_6B#E?4$E-?
M9L=G*BDY1DO)N$N!IK!G6LCLM\)D(?+97"CMA)?4G:#L&6.,!0\VV4G*G>AA
M%1A?_3T$5T'P8FK[YP$BT@^\K(K2&]>OJ-U!S$QR5WFZ'*2X;N>5>#Q4)-XQ
M=IJB-BK($+6*;N+ E L*,1I?=S,ARE8<C_25C":W['%KF>^8A:7F3P)IH%\J
MW)_\LDRW[; (/S63HIX>4RK -#RE>%ARRY!8E$2F(I*T]F 0YL$2D=6591S<
MR@+"F+P#MUHO(]>PW$2)J]ZD#H==BH[,70=S/UI*)-&Y-H76PAC+GW-0YCU>
M*G'B<]7M!$&EX=]5&G!5Y5)(G3ZQU!V2R:*Z)M79!&VTYA#SIYPOX&%QS38A
MBSZH9Z32P&#,G&$HI(TEUT@X-5WJYG?+*QQVS-R8^Y3<EKW23_,FLA CNLEP
MN@8^3SHN^X0?UN+YG:&E:]#?K U><GRN.<3R>U#MP\"9?\_WPY3Y9^\3:]Q(
MH&C4ZSWG%I5B<S2I>(Y,I8[G:%<%X#MWN]5N.L1/O5O'W38%&KFX[:V*R]__
M(]_2]WR1ME0@62H,HX=0\D1H5WE$5,K?T>W:$2F+6 G/3$O*5B?3J@;<AZ+.
M.??5>8"2,>^G]]=7LV>O[/U6(Q'WPR-$V7 &@%.E/M*$0C8P4K?D.#1B\+S"
M2EXZF['40,T[*E7).*1 N]:[CHV*391GPC&H&<S,,O'$O6%));P\R,JE5&$)
M_G#BUX71(S;+R"Z6C-9IB*T)QN:\\H[>5E)-W_UJ,S/^AXN<I"'Q^X16=P]'
M]]VO'C"(K6!8Z7_VZQV/]_<7KW].MC')N:__2#SNZ$QX3'73\Z]Y(.AG=-]K
M-V<G[G4O^?$GS<R=%YKTJLC)*XD6G_588T6 GLBJYM2BL1FJ!/A\Q#)5$*L9
M6QD6 U'/(8UTE<OE&"DLGG@CJ29%$.K0NVM>+Y0:OC=55#UL$@F?^*7]?N=D
M0;A.F%C\V)H2SX'=RYPUZ3PGZOA,@[16^;LE.[-1_-V<_=QT*1URO7$+#TC(
M/<VS(JE+S\)H6./[8$@$S^U3E-?<17N97K)-+.KLA$!T&WV72N%76 _PC77>
M>>L((W3P88<&$\^#;=]QHA_-)PQV[*]_^N37$LK<P'7)\ZMX@ ZSKG63@Y&
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M=+NLR/!N'F@8HN)<*/ST!CR 2G,8#6G#GBT7M#[0V^K#Y&&;W1JIKAE -F$
M6=--J>='[*[?J!H;(F)3MI<01GM;#9R\16QJUY$HW:>L 4$Q9I%)9<&O1Q=
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MSMSM:],>C=DT-SJS$_>JA*'Y:].MW*TWWQR0H7MR.OGNW:*8%NVAGSV_((?
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MDV%G-#8GYF!J3+O#P:'.D!-=PG=-4S4M6F/ U')]&A+$_HB P; #$FC L($
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MD(-!/JGGU0?C,4[&/6V\X#8F5K@@*PTYX4>,S'#'30[>0VCBIJT'=_N,;$6
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MP)-M$H7-FDGI:6,"99F743(37/:V: ZJ27BL0\)M663?]W0>N ?0DJ'VANE
MM//2)48;?8[%EA#*_LW59W,0NGT=-D@2N\)Y'QW9>Z/1-]K>_@/.+[&G8Z"]
M+$3F4[TP:5QA$;BOB4U<25=J2;M61'L2W?:)M /-S^%>MVIK<-!Y5P0W%TUZ
M2>4D;0Q, J?]*OHP*[VC:+57&GDR;>Z9+0+T$AG4B7(:'&9N9DS0XFW)WRP,
MBB;P0=-73CO&07O%<W$.FR1Y[=R8J)7\JA+IRYO([R#/<='K+?CSX?ARA-]Y
MI"5F&4)BQM:S =H&67!!,JZM+PI#X;:9';$)\&=A0FQ-<P\GJ]OH L+U;=3K
MT^GI8>/1;!W)KRXGQ\/)/W#R'OJY1^H/4B5D,FID6BED01F:H-5!\:X ;4A+
MW3]8_IV[6=.WI\QA>TTT, EF0=GQM!S'-)9V<%%O#U[%:C&+'BW1CB9-8)!J
M#GV]RAQEMDQ!5%EC-);;)FO14\A>"*'::*J!H?"AMKHY*1_'.+VX?!(G)--Z
M+'U](O=V.)I_-^=;CY?LDE"!D3&3:BN<S&)MA0/1<2>0)D&!)@;H^IA?&/VV
MI=T&YZ_5-#@IKVGI[=<[]9<7=;(D%[E)@4"(0JNMS.2%65NOGHDBN [<E28I
M'?/ O# J;:R/!D>FW^W(LYI7WDLF*IMC9C2:&ISCG(4"CLF"(A>+M$\W8<==
M&!WRXE:7JN9&] :RG&?A_#3K.?372D',?_MY,KK$FQ\.!Q/\8W)X/GWAWWX>
MXZ>'-W<VH,/K<QB/KS?</_KC7D9G=.3DC3LEF$;A68BTEAD=P/CL(+8I#+40
M48<D>:1MV".D64/+BPBSD;1;6,>W\+R9KJQ+(>K=ZV#6J5G\ %*7N\>B'FR/
MJ'\SG=TW<KL1^':HH, Y#*"9U!*8!IZ81^Z9%-G)HGPHHLTA_)8H<*>MW0X9
ML(J<&VC^E%QX'+^ZF[/\V]3 ZGFK3,3,F5)02WRA89[<]NK,<W*WLB;3M\EN
ML!C3#HS)#55V?S?H2-X+FT3\ZR_W1$-FSS]WV$6G?5.FI]ZY'_UUEF^UE *H
M:+(JP2F=<@21<BH\6*4-@%NB@]<*$FG,ARF]/P_/B:'C&H.8?'M#*DC]2=LN
M2TN\=A>L6%4:]XBAI8\6(ZID$SDM'+#H4-"#3E&D*)\FQA( .N_*9(6J03%#
MRUAR3&?RHZ,BMSJHXF3@&4IJLXMTWI7I85;>&5Y\&8Y@]&TFS _#\_.WP]'O
M,,H]JZT5QGL6?0HU-AAJ\JMD4)N]")VMW%:AM\4@]R*BM0H_GBZIU9%&&O1@
MNH=LVA-C?'(YJ2W$:VIG3T9T*0?'LB9/4].:SZ(A*X,;-(Y,#I%$DV/BIX#M
M0VFMKM0Z;*B3!M;Y/7S7^3:SX,C!9#+JQ\O)M!#F<+;#]QQM$E(ZQSP$S;32
MGI')()ES5HNB5!*I28[XRDA?#JLZUEJ'P:UI./?^'*@F0KT7AOG-90WOSC+2
M9U/C&'^?_FI,/I#B6,CSL2H9\E6T(\3*,&M41&%5H-\M%6-?Z_7/D#Q;TD6#
M"-1RH*<Y@C>8I5$B9"E9@,BK#VWJ!2%+C)<J8Y3)Z";'2^N ?89LVYKNNF]H
MDNJ!3)^\EMF5LY/R?0RTG.+H @:U)\>M_;R'H J7NK"B9:GAGAI]BY$ICQIT
M2#Y;6&JM6N/ESY [6]%#@]MZ*T'NB:AT+813$UU),KQ6;^5<LT*;LU!26!E"
MFZSA%5 ^0W:UUU:#>PU/^A%HO,V5ZRFK:?82L"B"9Z[0:DGX5/%E][[=-AP4
M[H+#6K@B^DRF+I!,(&9..TC.43@>G6AR'+2A@]+%:='#T[?;DT72EJHQ9^($
MKQV"DV8QI-I#*O'(;6U*UX0B*^)\AF=&W>FE20[KQ<5P!O'ALF*U=TJ0HTC>
MHR>_$?QL@:V=Y<" "K)-!^;'0.W#GM2A1A\DJG:DCA:QW >C[ADG0$M+NPVO
MF6R&-L<8R7(W6=E(FS#/ILFB\A#*\Z;%AJ)OT1O[L;.#F\M!L[R&.OY?1[5/
MO5=&&4$FFS69#!6C+>W,6C++18D)#1>YR?GA>G!? *G:JK#!<=!C9PB+0;N0
M<\BU-6(MN:V+J;/%%);(:8C*D)V8FES$6 OMBZ1=APILDN+\R%RY?;OD5J'&
M6Y6U0PRF *W3&2(YD=%PYHT*M4&TB4%ZB6WN"&\&^T7RL(5*&YPV/3:+G@9O
M!7B?D+,2JB4)Y." I37<>>F"R2*!W?IR^(..6U)H@P.J)2-),CE>1"E,S@YG
M"F<0K6-16 A@8A&V246\/T_4;T?+W7HJZO .]C*SX :D<<YRKNIE3=2U)IEA
M 6QD05MEC(XNH]_V\O6R:;2!@AZRR&_*HCO-U@]RGLH?SNN=\:/!5?>\O\-H
M!(/);"@]6;P!#K72HZC>M"TLU@:(5F&V!)U+T>2D:V6DSYM=;17WD&FAZ<8W
MO[YV"BBQ>LW.(IF+2$ZT3UJ0X6A<MN"5"(VN1ZX*]7ESK;'JYAS ;ISC^=CB
M.Q^QM"+S)"(SHO8$2-S7KBR"Y23(7)2Y))&VO5/^X%K'BIM#M6X.^U<Y'#S&
MR4DA617L3RY'T^+).?+JC:CL:X-K\"Q6\97L<LY!IFBW::0MC_Q%4K&18N=0
MLU7H8>$!XH,!:&&1ZVQ9*28S[<E/]B0UEKD2)F0;@]KZHOB#F%M5ZQQ>;AR9
M6,9XG4ZS"-,[5!=?<#">)A]]0)+DN#_!4QQ][2><C?P#IN&GF89G%3!1.DX.
M.;)I+K<62%Z54V3PH@]UZ(I\]UTY*9L,['GS>J]H,8?W&\=&3NIUQ8I[A)_K
M]?>OM9[\\ +?#<?CQ=U&;\3R"LMPA/<3\FZ);3K3S^"/GO.R1 TU];SFXBD.
MM3DY649>FF"Y#<DU.3_<V@B?]TS83Z+,F1(;1V<(R,W0>EY C,H))NTT.S,H
MYEU QHV1DG-/\[15<_@;%,^;6NL+?([Z-Z]#_E@6%^A@,X!CV6K-M*Y5?04B
M$12#X4A>GFN2^;U\4ETGJ6&12UYL5,QR7Z\V1F"!=,*B (F0:XF+=K&>1U+#
MUAG<G6)--=X;0"DF4P#:;C5G4#-A:,WQVL:8C6LRF_>FO-DFV;$;R'+ORIM=
M97K3?C8<3"N9U_(]FH02ZBU+#R8QG:1CH=Z8BX+3UU8K;'7J\0BJ/2ESMI*V
M%Q%G8ZDWR(R]A^FJCL\RH%I6.YN+:L<%SS;7WK"5Z+?&BZ"LSTA[O[&N=NQ5
MDGE1R.R1.61E@7[0)-:X13XL6_UL2W181>)M[UA<E>)*4=J4C69"UA)?25D:
MG7&L9"U%44D8V:06QP,DV_<*.M#0XCL3:XBW02F6!8<\5^!,X9B%RHR[2F]3
MCRE-RLR$XFV)UOHV->$?1?4<>-"=V!NL 0<I75Y<GM>*68N.06[(&PH8P3QB
M83K:2$!Y8=X'#6!"3+E)=&)IA,^"*TW4T:(Q ,YJQ1_":$".^O@:E2@@P' 6
MN"3O6M;PL)&>91=5/41P(30)!<R'\QP8T8&@F]QV650GUF6#$')AL<3(M.>:
MG"GRQU7-KM,I!L?;.II[6DN[$R=S(VFWZ"/VL$KL,HA>=BWME73V="7E=02^
MG5K:'#GY1*;0LD>[DP:NF,]%LNB=325)'72;+D/[7DN[8P:L(N<MU]*N-X%M
M"9QEJ.V+4BPL%!N8E0I+$+I(V>:T?<]K::^DLA5J::\B[]W4TCX^./OXX?#D
M[:N/IT?'AZ>G!\=O7AV<'IV>O'W_X?#T\/CLX.SHY/@NQN7*(R_YY 85D-<9
MT[TBQZB+TXHL.K((]?3:J$EDWO-@'9"%+WNKCVX;>GI3K=/S<3MU7;]@9UJ;
M.\)[RO/:*.64L4A6?A#!<Y&*T465HJS2>DGE7;]JP^7X,H[[-/#1MYJO<+7L
MW$3)4B8ZU0NA.="BHR&0XV"39+0:Y5"O+&31YHKEH["Z#_0>#R>S%.;3+^?]
MR<U-Q0\U.4/T@ RB+)5@$*Q@VM9[VV SK<>*\UB\A(97_E8 NH.Z0]WQY^ER
M(1UJJ<&!Z2T!'%]6J=$WTQ2%63KHT>!L!(,QI*J0'O<%K'>)@;.%C#J56,C3
M6V9H"L^Y1@B:,&H%D,^+3:VTTZI&T6J7>K(+2:C:<CP!B4;4OO).$P,R%YKG
MZ#QN,QM\K^YCM5ZCVFEJ>R6/[EU]]3X%0TA8$#PQ'0PMJAH2R]Z9F 2MKW*;
MI3YV?3=Y^PS:0!\M#G!O1EV[IO3SM,MKS>U.V/^*^>3.Z@D\A1"=8@6@NI4F
M,1]$)G5S0&>EB[%);N!**)\7B9KI9_^J$'F156U RKA+]4YAS Q\06:RD%*%
M[&@V;'VGV\.R+[O:];K58(NB0]\%<S*:^16_X>3S,,]:("/>$M>K;P\_?/VQ
M6:!&&A0\1,4\U@*&+FBR%(.A=1K1DY\?K)1M'>3-![&U+-R&C-R53O<FGW>>
M;*?A X4*8X+(/%C'M"Q 7K&LC1A5<=DA*-?&E%N$:&<AUIUQ9"%9-]%5"[_S
MEH\,%_3E+:OANJWG$@A;!FR?AKBC &XW.GWDT*)#A>R&.K2U*Q/JC0O- ].9
M6P;@ D/ADR WQAO$YT29IP*^NV+,*GIHP)2C]R=7X4=ABH&2:,./NE[YK2UR
M=$Z,R K6. C6MNG^>(U@!T9YQ^JY7[9_+=GN)K1[^O&WWPX^_./D[>G1K\='
M;X]>'QR?';Q^??+Q^.SH^-?W)^^.7A\=GJX3*USRR0V"A.N,Z7[_6JMCREHK
MYU%[SGV6V8(-DNQA%Z3LK3ZZ;>CI_?"\GZJ?VTQ?W]^P,[W-'^,]_65$J"T.
M#%JNG5,A125<2HKT:$P,2^IOWFBWH<<-0O2KO6!G6EPF1!]3R"A*O6'/M0RT
MYF:>@K/*E!QI;5Y2B7/&NID.WQX<??B/@W<?#W\[/#C]^('^[_ALK25R_H,:
MZ&0)Q/=DSX,-67(;P1:=, ,71OIB091,FI"])[$WD/'4Z5MK5CSVN&W)>Q[Z
M>U)/R8 O"DM"IY7B8*7@-2"EC)&DB?E2?SB.!K(_39\Q7Y[CL+R%_F@:&#D8
MCW$RAD%^UX?8/Y\>*_Z&,+X<89Z>>E^.ZK'D*QCWQQNL:"WA;$OW+:1WCSL!
M7,S"1Y\5:"[K\9V-,F*.4'Q0=CYW.@*VF3-R[]4'<U]]<O-J^L#Q<#"Z@^3F
M!-,AC;G(/"O>JKTW#'A"EK6W66(J1C0Y#.YT%!O?$9MB^ [I37]<ST$)P4$<
M3T;DZO2"$<9HT$QQX9F.M0"ISH)9+9R3-!MHY6ER-^PI9-OW!W?'OP=WR3I5
M6X/TJM<P_DS#K_]7#V2_DB<]F NX5].]E$V""4RY9E@$YJ,L3 @./.0@A&]R
MT+0TPNWSK&/MWK]ET$0U+<Z>IF?X%XO0 ><@<HZ$3FF:/PX8:$MZ3CPJ[9)P
MI4E1G,=A/3>V=*B$!OE1"\?>"QRR#K65!)9(8Z[M:6N!!U$@\RQ%YFW8L1#1
M<R-&-Z)OD/YT:T]^;.R&=EPEM"3FEMI?.146@S7,@4_%\:+)I6U!D.7@O63C
MIH$"&^Q.;W!$>^>D_Q5OX>VYD'01OK#B#:V'QFL&WG'&,SC@64=L4ZEM+IKM
MDZB%ZH9=R[T!&1X?=T]S\.1H$QS-8ZT-ZFL.'V?.(?W'96.QB0_U.*QG28\.
M-=' 7NEBD9VEM-3HHBQ"L9BP)J9G8-Y9&@C)+<B$"6*36@R=C6!;>6S[LZ_M
M1OG[DO/V??2OOEV-M3[U[0C_ZQ('Z=LTE\*F;"&[S)RN#2ZMT\P+=,PDGN@+
MM#$VN6>U!+9=Y<'MB#2+J-N1\AILP=\AS@-XE:VQ#,26^7!+8-Q-0ESG^EW$
MGXZ5LR,>*8VTVBO+')*5HK40+'#/64@B%<]33+D\*_X\D1VW#_1912=;HLWX
M^ZI\7=E+>30!$R$#0=9#3BPZX1@4[U-6) /=I ;G,N!V>.+0E5:78,U&*FD0
M)[DU<[Y_^>]]'-%+/G][AU_Q?%:?MB YN"HS*8UE.E0Q3*O+Q,PMCS7RWW;!
M>13>#]NH8Q6V]#QO3X:'>*^+62\!=MN&TD*T.S>9.E/[,@M8ISK;UD:X$'1"
MY#"]-X;5G^:JYM$KX@-WP0CG>$A-SDOW@&#+VU3[P:]55-625T>#+Y>3\50"
MXGH3=SRK+ WC14.U+8&!0F"IA"AB#@%,DWH:CV#:#W.J(VTNXLV&JFAI3]V"
M)J^@9>")"Q3,E%Q;*=-V#TISIG+]AYMH1)-*!X]@>FDL64<56UI+U!4TKR0Y
M ;2@FLPYTTYF!L$GYI+W$H"CAR;5PQ[!]-)8LHXJ6IC,_0$,4A_.CP;CR>BR
MRF"ZY7K@$2( L\Z2L\"U9;$./**!VOH2)#:Y";< SPOWOCI04H,DE.E-P8*C
M*I99*U4:\DF9@W9\1H\<S__5U?Q:9BPMO;$N![,C9ZT+E@SW3,4--L9.QQ0+
M#S89PS!'20X)C<DC1 ;"2Z2I;I1O8I7O/UV?<OWVG:VK:+8!2W\;#O#;;S#Z
M)T[>7@[R][X9T13!)6TCH,D!+MJPD#4RHY0FKP,@JB9\FP]G^T;;[E0\[%P_
M+:XD#"\N:EG'VJN)S)SC86W?>WZ9,?^]/_D\/RO^"CE8'Z(D82A4M=A1S#6C
MU3!+/TP<I"YM\K?6A_R"V;<E/3=IVC?Z,AS!!%\-JPRO2[!=@7.*&RX,K?F^
M=H7B&%E 81EWV::(/H32J('?(ZA>-,^ZTE8#W_7CZ:_#KS@:3&V'3SBHU0G>
M8)P\P!D*L=I U7J]P"&Q7N @WCL4 1(Z\NV;= 9=%N +)E@3'2[T=9N6CYE[
MI_@81J-I(G?7E[X?/'A;U[<?']&]B]@ J419=!;":QE=4,I'8XR ##ER/O\B
M]H-7=)5_ .?$83S]C#CY=32\_$*D_\[KFW9',"N0_>Y[0FP@IEDK,JUN?%J>
MUK&H(3"L)IV7OOC2I&#AIL [ZHGU]ZJ.P>1D]*'_Z?/D>ZWZ[S/T-9R?8W[U
M[>ISXZL/CGM2>>>X]$QX;IEVF=RXZ"131AJA%"#X)H'/#7'O\"AZ&PQ=T)%K
M*UINFUTT3WI7W0M#YB7FR*3,G+8HQ5G0!+1H0,4M-S*V#9X^ F[KEP1V0;+.
MM;0O*?]/]%SG+@7)#9.UNK1V AED;9A11FDA771)M^#=HZAV'DSIC .+^HQN
MK(L&CN_\UKK+@&H9]IB+:L<=1S?7WK"5Z+?&"RY%=J9X5CAZ6FN%9"$2PA"<
M2YZ[$-M4I-DB'Y9M/[HE.JPB\2;G8A?DB-WNA1F\+ EL8%&&4,M.T,8+GJ!Q
MH74*M$K*)C;+ R3[TH9\)0W-.3!=7[R[J4<[US?^@&3(I/YY?]I.Y5:ILEN)
M"5V?-:SRSFT=0ZPMAWLG%%*"\S&[>C]'6\4C%S)J:\BB16^RF7]"L:9$-N/#
MT?%_')Z>K5UA\_:?-]#20G3W!%Y\1@].I)"C3LJ%8M#)8!U:H5#%W@*<G<EN
M_<J9#Q_25HY+5,D$GJT6,5@"J4VVH#6"LD9(%9W3N?<HYLYD>E,Z<182A3O]
M=398CU9^1UN-K#'.^PKS' H468)4NI@4@K52&MISLC(63&_EMVWHOUZ]XZ0<
M?*7'U5>\'8YJ5?B;-]TZ B#+BOZ;&8< 3)=,NR]ZP5 ")BUX,MBF=<LJ*#<N
MN'7O%7?C$0<7P]&D_]^87P_'DVF"7R\ $FE+8EFIPK3,]6J=5#0.B\Y$%2 T
ML=16!;J#[@+-V/6@5%=+I34XMGP";TJ7%Y?GY 'E7T?#\?CC8(1P7@?P*XG]
M%9;A",_@CYY$:7T"9.@QDTEL)8M**28B<!E!<_*,=L"\Y="_8#HV4&\#GW3=
M0;RC[VX&8:%8 &^9C474VUN6!6D4*\)*%$X8)9L4/.D$_0^.=JG>%M4Q%PKI
M[G!Z1CF;A7',Q.RODE5<H97?2I\DHBBQR8V&90&^)*9UHJ0&-QKNS8![J&<!
MBE@[< 1>&$)R!-%G1@Y78C:XA)$[DT03$W@);%MKF[DUXG2MD'V)&B[*?G<^
MZ:PS9XEV_LI_)*-4.^952%Z+9))L<U5\OZY==:[V)2]4K2+^?;^9LLQ8?ERH
M6N="U4HL:7E%91T5[SMMC1#9*)2L)$<N3[:%07".Q10<;11&0VRR NX_7=>\
M4+4W;%U%LXT"K&M>F2@UP\TZ3FZX0::=-BSF&%A*AL>,&CQODL7S8J_&K$25
M[J[&K*+G)I>W'KML <BE1NY85O5FF2C P$Q=HZR5C5$[V<1_?<Y78S;C65?:
M:K#8+7VM(G//L=ZH2%F0!-!JY@U9T02?1_JO%FT".B_D:LPF!&NBPX4G<$TS
M6=Y_.'E_^.'L'P?';P[_[\>C]S6ZN4XT>.YS&D1\G\9[OT>R%C(%0_\XI*DM
M BKK;$A9\P3<JMY3R+N7[_II#H\\;4NR7B+Q(20;'=&;!.ZTQPSD[D=.(C<E
M%0EEKL2[SH"8]XX-DAT>>]R6)+],"D,RP0A-;D.AM<5%\" 36.ES+A@,V+FB
M[R9;X?UH2#;=Y-O[<Z!%<9"K#?>E+I WQXVZY!@E+7_%)-IY4]3D[P3#@BG$
M%@$.L$D9V:>A;;JI+WS#-#[3"UZI4$RFQ3^I>D/2,8C.DO4:2%=>26.;W)U^
M'-;V-_"..7)_6^Y0"RW2"FZB=F_PRPC3+$.1OC['J=@'^2H78OKSA8/I&2NS
MCR4QX4P@RX6'61,0 ]$Z6;CBN4UON8X&\.QXMQ/--G!-%@([QDE/Q4#64P*6
M2XT5U8E#L@'&H2B3$C<Y-<D5> S4LV-29QIH$,Z_3>V>XM'5(A),.5FCP9H<
M&T^#-%9G%;B(/C3);KH-XMEI?VT)-XBWWP22%P[ZJGHB3]:5@BPH2;NJC9X&
M3+J3-O!BG<_*-<X[?1S@MB+OC;G11!_[$G-?.*17W^I!SC188LB#X6@Y$[I6
M=D8;&8!0S"D/]$W@4C:Y=K<$MEW%XMMP8MDM:4W=;--NJ0"OC_N6@-@RYKX$
MQMV$TCO7[[+\V5 YN^)1S,$6(,-<(Z^YZ9DF51#,BI!SDIY[+9\5?YZ(;>\%
M?5;02:-KXE-(5X?^(KA@C! L@C2U 7EM:YYJ4?)$MIM+'$P3__P>CCTRC]?5
MU9S;X>L*NL&!SDDI_83W02'6B _ML+%V]]5H:-<U&)@)!H*+%D5J8J?,1?/\
M.+"YT)LDL$S#BZF*]JB>[WP:X?A[ZH),625?3:Z<F,Y%L*#I6\E1HBDNY3:$
M> S4\^-%9RK831CVX/7K#Q\/WQS^Y_O#X]/#TX/C-R=G_W[XX?7'#Q\.C\_>
M'1V\.GIW='9TN-;U\N4?WB"4M>;([@>VT$KG$B2)FI9V#%E[+I*I8?2H<^ZM
M-<8MZ6S]>.^JK]BE_I:(#"NNHJ79)Y( S<%'52/%%JU35J%=08M=AXN7?O$&
M,>25W[%+;2X3;?8)-9<E"Z.<]H)'GCPMM1RT]K2PJN75V7E!CM.SD]?_Y]]/
MWKTY_'!: ]UG_UA'8W.>TD G3V&])W61I)6E\.QBUD(YKX&\*!^SYR4$*WJ/
MH^Y:KAM,B,4/VXJ4EZ$X3RX7;HO1BFNR0GQ0PC@GB\!:' +F"+N;=(JKTI_3
MLD@W)\A1*BA1&R:L"N3Q1,VB%HXIKR"@,=R()N6RYZ+9O#XC/>UH/+[$_.:R
M]F1ZCZ/^,)]^!C+=R)[[BJ-Z!'%29E]/^G=J;/2L\%XIDH7'C(S, <>B([M1
MR.AE<@ RV":!AXU@;]_RWIQ)#XLY;DUQ';KM=?WIS3 >7$X^#T?UPG0OBH09
M!&?69TVN0>8LA*18T8G\ H/.^?#4.C;WR7]F16\NJK9E^!Y 2UIK%55B6=3F
ML](9<O5285EG(761W&"3</0CF/[,^N]:Y VR$6Y!>P^CD]&T)F6>%GJCU6B*
MMJ=+43%GQ4(RF9&IJIG7T;*0@1P.*2UHWY@5B[ ],W9THH(&60SO2:LX&F&>
MSV%M@I28.#-9 =,Z^=IP1[+(75*EADQ-D]R%QV$]!VYT*/B'M-#=TF(A>6TD
M2R59SWQ*M8D.IR4ND4*SM[6NBJ??-XKU+0/O^=&D$T4\I(OI+A=J"O/5MZD@
M9JD58+.QPA0F92"C2-<[O%8YYJ1T$0L/!=MX(8LQ;2OCJ8%CT9&@]R6OZ?%"
MV44;IT'2(J@CL;K6NB,3FS-GJS5=VS;X)LO+7G8@Z$SU*S4>6$4%6RLPOPRH
M'XT'5M7>4I7FUQ']]AI26%VP5D0O(CNF >J-51E9,#8#[9!)N":'?W^6Q@/=
MTV$5B6^E\0!H(*=[6K"+0TT*#]5N=BQ CO5P)D;>YOQW7QL/K*2A)QL/K"+>
MW30>F(8;7AV<'KYY??);C:H=G!V='*\=?'GXI%:1ER<PWX]Q2;2U0:5WNFA;
MTP?!>A^$-\9(KTOO:?0MY+Q^(/_1YVU-YLN$Z$WA-BB1=0 MG0!>K-7H/,E=
M&.0+)-]U/'[^6[IHV;GDD[>FDY6:=D;:V;1!]%8$#2:'!$*ZS(,K6ND("[33
M<=?.J5/^"L:U9O?%%]J[8;;TCV#P"6>YOS<?>0_?IF4R?H=1OO$2ZTU'#2*Q
M7 3MU8Y'%J>5?<AWC,7FDD.3I+C-H7>XJ;^&+_T)G,].QS[@&$=?,;\=CMY>
M3BY'6 -LM1-;KQ1>I$BU>3/0'E>*8[[$VN%/U<Q&=-DVN3:_,M(=U,G=+A,?
ML2 :Z+))[',=81T,!I>UA$X:(?WJI-P<Y,Z&^Y[<?/ILC?=^E\?)Y60\@4'N
M#S[U,EGAM/XF)CWG3&-1+*(VC-NL"B3A20/+QUAW,((70^P_#T\:N%MKC_MD
MUH[UUVGSW:/!+!MB5G,"K$Q%2,_ U"&5&%C(VK$L8W !!0?9I/)'@[&\F$FP
M+WQH$#6?XHU/#RDN&-)_X'B"^7I(WUNKB5XVOG O@44N3&WZ&)B/63(R766T
M62--Y&8\;S"@ETGV73.C11V##2?QK?UIUGB]9R"79#PRC*(69I"*!:DYBU)A
MT--^>4W,\<Y'\C(YOC,N-,ACV'1 Y)\4[%<'I9;4//SC2W\T?<+W3:N7/7DF
MMD[76JA"EY!I;"FPHHP,TM=.1VVJ>[0>V0_R[Y0K+;(T'LM*GOD:LY$<_E&+
M4-,H>^1MI*0]N=]*3K/3)(-ZX5 X!ZBY*<DV21M='>K+HVM;;3[DG]WU8GS7
M7?@[]C]])HOJX"N.X!-.?_D&)OC=LNH)1,B<9P80=;W]GEA(Q#5G@H\2I2J^
M#7FW.\Z7Q_P]YM'#:>,VSG6X^'(^_(8X*^B-\T=_7"^25 =C.M#QV7 "Y[=_
M7WN''@\G_\!);?_]:3 ]<[JU2/0@1T'&F&9*9?*[?:YW3KAAID!)RO%Z%:5)
M[L0V1O?BILC^<>;AQ/![.S&N7/3AZ.I']7.B%R![SF5@)/]:0B,A [3(7(:
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M?N(9VO3J^9V/VK8OY^&)[MY9V[[N^>H'_VI\QAO],H\PH:;K-P-0X@R@)"T
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MDQW0ACAFD*@X2Z@F9IP E.80Z"4K 5G&6"JX+!+LE!-\3-C02'==5U,3J>X
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MP(1VD7AN>@] +B#*7,.YMV0,C=R6L<I+/3L'<V^C>9RJ/&$4F(O<X>D4R7T
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M(Y4L36"XTG]KB>8\M+J>FAAQ*5X]S6]F\[_*^1T=BU'*F4@2DH(X3S. 1%(
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M5;]>G: 0R&[[2T%D=./O19)(&UMSW:8EU(&_HR)+""8% S$Q"6LX1GJMEL>
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MIW84UD_I1FRFM"Z=F*WPW^AX:DJCWT[?R'+\C1K?NAH)@@6DF ,ALQ2@),X
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M0 K\-7? Q^F3/H' &9_UH2?W]FF?,&W]\SYU:3<7_"_4G+;-VX1NQBB,(6>
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MSUT+L-J.E!VMA, _,-FLJ5RCV^(9HG6R*SI>ZXG9RNZWJI@C(CNUQ5SO[WK
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MZ9<KW:,F[V$@I_O[7XX7/N8_>\@'=]Y_\)R_,352LS):,_9W<.Y_=(Q^%P$
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M#][<7TCO*?TW8GI/7MRU68191=3[X<L&,ZO(CA'%-(5%04%&3#H#BW. $XZ
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M_VKV[#T&PWG7_0PGJMN,8?0HY5>MROB;;*)@Z\#Y>_IC6;D ,LJ98#%@A2@
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M3X!=)&SY;$EFAXS?5F0G9/;<@LP.@=W68Y;W^6M*^4%.Y?>F(NP(L3@3+,=
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MSS"#DE(J7=S%?M4?HLLI6K6CFG6UEV2V%^M_R)6ECNGO_;X3ELONP8YTX!G
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M<??M-)26VV^] 0J]_[;!IK8P1!G05@R\[K^=;FG8#;A6;X]VX-JO[CBC,>G
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MLKVOHP"\>6"UP_#^U:3%5[N0U<[#+O>^U"?9?'^[6>*D4)@S3#/ >)$!*(0
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MQ.G0->Z'T@)BY_6H6@@[ASW %A#IHV-M(=OJ&6!NTI&V98^Q8%)07 !1\ S
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MPU\QDY)GK'T;0!KEJILF*%"4G*RFST4&X_A=O0X& -!=U(S3JJT%</:6=0>
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MB[LK>+]/6,DV<>F!O&L2I+$98G:*-AC++$=:<"4TB8YVIWE\+W0TZ!Y*TQV
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M_.$T+J>DYL7WX\7&%_HKKC[/\V8&)V(]2SCK??KL^^U?/O^U39=+H9$S\IO
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MG".7*I< GJ& 2%IQF52E9),.S0UYZB5E]_!0O7EWW0ENNEU"5T:K*<L+(I/
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M$&Q,F%B6)8LF[U]L2?>PG9Q#.-<F$FU_I[[Z0?U/I-#@'W_['U!+ P04
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MO/T1@5??+N"-;F7IXX=FU=T_D#FT<M&A28,' <-#D[\!H0(,4C#S;!R!*7R
M\!Q'3(9ZN!X6(V%JTM3'/I->Q&6&\S25"AY9R*2">^#C:4EV$"$^(.0L#/HW
M7DB3*R =9*EA%N$(TQXT=F#73#7]@3[:7=3=5;CA"%V_7TDKF<YY6R!$MP="
MY3VS##V0J/LQ<:8*/9[LHBZ0'LWDTZ?H2C4&1$A^)UO[>";0 /+(A$G#3C@*
M$F-'*^4EKZURHX (OR J\^*WA$TQYTU]D2''H2^21\PW#W=D-I;,9U0P'0"S
M)=JP=:(M95*73;-QI*FQALNX!'1((7?J22FJ1^9E$=44C&$9)Y;E%V?88KZJ
M0?#;&/1 9$F<#_YF5MQ^V(ZW![9Z#7;.J:!7*+M#(]5TAM-,R$RS!Z83NU[4
M^*B9,(&G7)9)K59J5FO-CQ_J^P>U>JF^WVKN&8SJ"[56=7&A57-KN^\U2=[V
M)"GGEOZ$1IG9@'JG0!"@/&$32% ^K\N,10%[ J'8P\W*PQ +3D0RD%;?C'FF
M[O?@*91'%Z-!B[?@<>%-QG-9:$@2[$J@/P9=^@;O$&'^]B#,E"Z;N74$Z%8O
MER#FRD:8,?V@*[$"66>=Z#RNZ&9KR](\EB/N>9G0>5[A_@U68RX5GM>/T="6
M]-#07_;! ]FY9TJ @,6V[L[HW'%/DYCN4G4#FV0+OW:M5R&5BT*)=8D:@(-O
MBK19#RIY@MINAKWH-41YRWIG?/&;E^A^4+]OQ=_8+L"_3/&;9V'^?*\4E\RD
MB7(5KTN2THA[<O*+ZV)LX1I%0::XL(RJQY@3:#(V=1L>* -C3H7A6I^A?\;(
M#J(:65=J5L?_6A;.MR+\E3%TWVR[+/%,9[N[N8.8IW'US5K*[7O%MA68$UA[
MUS:?->9*\;CM+*?0,0K-3*U/>>3UG/T,Q7(;7$%IC%OVND0#7/LVC:9T)@NO
M_$KP_PW4ZXJ<3A01W=@PW'-:@.I&V&. FR07*HM&9HJIU<H#Y)S=;4MD'CG.
MG\<\:^OE/8?MZ3=0/?5QHH0%T]^[3<<L8LI,$?KU++*$D3\2M8_,XA@;I[_!
M!)-7V(U/KAZ7-FCH"@&<[Z&FWGA;B[0MZWDZJ&D"@?19Q*2#87R$C7D^G..K
M:"4!2R8\FH#6!0DRBGW,+?(B 7$:\1G@U6G(;66@M]"+:'L5T51^.@8>?(O_
M%+:Z;7'/6-0/M&#)V<('4<+<1325T)Y_.<"JF$9TUF:)R8"9=##1A12E6/Y&
M5/$T9]E6L^SL[VFB5>B-\N?F<PXN&PZN*'_]6KU6;CC[]UYVRNZ]UQXR6RLW
MG?MGOM1JO5'>;S5>9/;A6S9:+UN"AZWN.?>'LCJS8I)F$X< D"E-/A5JA3LE
MKUU-;X@[IR&+ +T)-Z#BGW_=:B+MX78WPH:<XN8S;R?=_.WD8H?D:_&\,.VK
M_[N!VEWU1K$>SVY+N!?%M2E];QJ5>=PDS>?:SP6>$:JC RT\?^CK;H0W7DEW
MS_GQX/'$H/*RAE341LO$/.XF<_]>&O&;_7;FWIWPMC_I.1>HT;48+9)NR" @
M_1OP,MTBDC/;9F^)HUJ=]_)6>4M<VCD7#'5ABL)P;=7N_#;P^_/=G;:_;F7B
MD\P\V%<_W9O_33-F^2M&6G]S-_!ML[;C@4_%_C3<_$C]Z+]02P,$%     @
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M]^MN*AMS%LJ)[]CVRY*>UVI&/)%H3*!P_C77L:9)TDMID)B-$U_'4\I%B^&
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MSIK%.70XHE7;S+X G[DQLU,BQDA=1UQ*/O7OBX<?(5734I*,8EI,&'&!+-/
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M2P$"% ,4    "  N.FI1S<7")&/( @"SC!< $0              @ $
M8F1T>"TR,#(P,#DS,"YH=&U02P$"% ,4    "  N.FI1-!)DTF$,  !"=P
M$0              @ &2R ( 8F1T>"TR,#(P,#DS,"YX<V102P$"% ,4
M"  N.FI1O1C9E>(;  !U'0$ %0              @ $BU0( 8F1T>"TR,#(P
M,#DS,%]C86PN>&UL4$L! A0#%     @ +CIJ476;30@<.@  Y6T" !4
M         ( !-_$" &)D='@M,C R,# Y,S!?9&5F+GAM;%!+ 0(4 Q0    (
M "XZ:E%4C>?5RIT  &2B!@ 5              "  88K P!B9'1X+3(P,C P
M.3,P7VQA8BYX;6Q02P$"% ,4    "  N.FI1DC4A<0A=    ,00 %0
M        @ &#R0, 8F1T>"TR,#(P,#DS,%]P<F4N>&UL4$L! A0#%     @
M+CIJ49E\HZ7P"   _RX  !0              ( !OB8$ &5X:&EB:70S,3%Q
M,S(P,C N:'1M4$L! A0#%     @ +CIJ4>DXK%[+"   62X  !0
M     ( !X"\$ &5X:&EB:70S,3)Q,S(P,C N:'1M4$L! A0#%     @ +CIJ
M4<3,VR)Q!0  9"0  !0              ( !W3@$ &5X:&EB:70S,C%Q,S(P
<,C N:'1M4$L%!@     )  D 4 (  ( ^!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
